







 
 
  



<HTML>
<HEAD>
<TITLE>
	
	Dopamine Receptors: From Structure to Function -- MISSALE et al. 78 (1): 189 -- Physiological Reviews</TITLE>


	
<script language="JavaScript">
<!--

function SymError()
{
  return true;
}

window.onerror = SymError;

var SymRealWinOpen = window.open;

function SymWinOpen(url, name, attributes)
{
  return (new Object());
}

window.open = SymWinOpen;

//-->
</script>

<SCRIPT LANGUAGE="JavaScript">
	<!--
	function startTarget(windowname,wid,hei) {
	
	var dotpos = windowname.indexOf(".");
	if (dotpos > -1)
	{
	var tempwn = windowname.substring(0,dotpos) +
		windowname.substring(dotpos + 1, windowname.length);
	windowname = tempwn;
	}
	var sizestring = 'width=' + wid + ',height=' + hei;
	window.open('',windowname,'scrollbars,resizable,' + sizestring + '\'');
	}
	// -->
	</SCRIPT>




	<!-- has inhead tag -->
	
		 
	 
	<script language="JavaScript">
	<!--
	if ( top != self )
	{
		top.location.href = unescape(window.location.pathname);
	}
	//-->
	</script>
	
		
	
		<style type="text/css"><!--
table.content_box_outer_table {
	padding-left:10px;
	padding-bottom:5px;
	padding-top:0px;
	padding-right:0px;
	}

table.content_box_outer_table_in_sidebar_frame {
	padding-left:10px;
	padding-bottom:0px;
	padding-top:10px;
	padding-right:10px;
	}

table.content_box_inner_table {
	background-color:#f0f0f0;
	font-family:Verdana,Arial,Helvetica,sans-serif;
	font-size:65%;
	padding-top:0px;
	padding-left:0px;
	padding-right:0px;
	padding-bottom:5px;
	}

table.content_box_pdfinframes {
	padding-top:0px;
	padding-left:0px;
	padding-right:0px;
	padding-bottom:4px;
	}

td.content_box_title_highlight {
	font-family:"Trebuchet MS",Verdana,Arial,Helvetica,sans-serif;
	font-style:italic;
	color:#ffffff;
	background-color:#003399;
	font-size:120%;
	font-weight:bold;
	text-align:center;
	padding:1px;
	vertical-align:middle;
	}

td.content_box_title {
	font-family:"Trebuchet MS",Verdana,Arial,Helvetica,sans-serif;
	font-style:italic;
	color:#ffffff;
	background-color:#828282;
	font-size:120%;
	font-weight:bold;
	padding:1px;
	text-align:center;
	vertical-align:middle;
	}

td.content_box_space_between_sections {
	padding-top:2px;
	}

td.content_box_arrow {
	text-align:right;
	padding-left:5px;
	padding-right:0px;
	padding-top:0px;
	padding-bottom:3px;
	}

td.content_box_item {
	text-align:left;
	vertical-align:top;
	padding-left:3px;
	padding-right:5px;
	padding-top:0px;
	padding-bottom:3px;
	}

td.content_box_pdfinframes_citation_cell {
	background-color:#ffffff;
	border:1px #000000 solid;
	padding:3px;
	font-family:Verdana,Arial,Helvetica,sans-serif;
	font-size:65%;
	text-align:left;
	}


font.openaccess {
	font-weight:bold;
	padding-left:3px;
	padding-right:3px;
	background-color:#ffffff;
	}
font.openaccess_open {
	color:#000000;
	}
font.openaccess_access {
	color:#cc0000;
	}
font.openaccess_oa {
	}
.content_box_openaccess_title {
	text-align:center;
	white-space:nowrap;
	background-color:#BABABA;
	}

--></style>

		
	<script language="javascript">
		<!-- 
	function popwin(url,wid,hei,fromtop,fromleft) {
		var winPref = "channelmode=no,toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=auto,resizable=no,width=" + wid + ",height=" + hei + ",top=" + fromtop + ",left=" + fromleft;
		window.open(url, "popwin", winPref);
	}
	// -->
	</script>

<meta name="robots" content="nofollow">
<META NAME="ROBOTS" CONTENT="NOARCHIVE"> 

</HEAD>
<BODY BGCOLOR="#FFFFFF" 
	
		
			
		
	>



<A NAME="top"><!-- null --></A>

	
	<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0">
	<TR>
		<TD VALIGN="BOTTOM" NOWRAP>
			<A TARGET="_top" STYLE="text-decoration: none" HREF="/"><IMG BORDER=0 WIDTH=220 HEIGHT=44 ALT="Physiol Rev" SRC="/icons/banner/title.gif"></A>
			<A HREF="/cgi/adclick/?ad=1947&adclick=true&url=http://www.jap.org"><IMG SRC="/adsystem/graphics/physrev/893942274.gif?ad=1947&adview=true" ALT="Journal of Applied Physiology" BORDER="1" WIDTH="220" HEIGHT="40"></A>
			
	<TABLE CELLPADDING=2 CELLSPACING=2 WIDTH=450>
	<TR>
		<TD ALIGN=CENTER VALIGN=TOP BGCOLOR=003399 NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/"><FONT SIZE=-2 COLOR=FFFFFF FACE="arial,helvetica">HOME</FONT></A></TD>
	    <TD ALIGN=CENTER VALIGN=TOP BGCOLOR=003399 NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/help/"><FONT SIZE=-2 COLOR=FFFFFF FACE="arial,helvetica">HELP</FONT></A></FONT></TD>
	    <TD ALIGN=CENTER VALIGN=TOP BGCOLOR=003399 NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/cgi/feedback"><FONT SIZE=-2 COLOR=FFFFFF FACE="arial,helvetica">FEEDBACK</FONT></A></TD>
	    <TD ALIGN=CENTER VALIGN=TOP BGCOLOR=003399 NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/subscriptions"><FONT SIZE=-2 COLOR=FFFFFF FACE="arial,helvetica">SUBSCRIPTIONS</FONT></A></TD>
	    <TD ALIGN=CENTER VALIGN=TOP BGCOLOR=003399 NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/contents-by-date.0.shtml"><FONT SIZE=-2 COLOR=FFFFFF FACE="arial,helvetica">ARCHIVE</FONT></A></TD>
	    <TD ALIGN=CENTER VALIGN=TOP BGCOLOR=003399 NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/search.dtl"><FONT SIZE=-2 COLOR=FFFFFF FACE="arial,helvetica">SEARCH</FONT></A></TD>
	    


<TD ALIGN=CENTER VALIGN=TOP BGCOLOR=003399 NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/content/vol78/issue1/"><FONT SIZE=-2 COLOR=FFFFFF FACE="arial,helvetica">TABLE OF CONTENTS</FONT></A></TD>




	</TR>
	</TABLE>
	</TD>
		<TD><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
		<TD VALIGN="BOTTOM">
	
	<TABLE CELLPADDING="0" CELLSPACING="1" BORDER="0" BGCOLOR="#000000"><TR>
	<FORM METHOD="GET" NAME="search" ACTION="/cgi/search"><INPUT TYPE="hidden" NAME="andorexactfulltext" VALUE="and"><INPUT TYPE="hidden" NAME="resourcetype" VALUE="1"><INPUT TYPE="hidden" NAME="disp_type" VALUE=""><INPUT TYPE="hidden" NAME="sortspec" VALUE="relevance"><TD ALIGN="CENTER" VALIGN="MIDDLE"> 
		<TABLE CELLPADDING="1" CELLSPACING="0" BORDER="0" BGCOLOR="#DBDBDB"> 
		<TR>
			<TD BGCOLOR="#003399"><IMG ALT="" WIDTH="2" HEIGHT="2" SRC="/icons/spacer.gif"></TD>
			<TD VALIGN="MIDDLE"  BGCOLOR="#003399" NOWRAP><STRONG><FONT SIZE="-2" FACE="verdana,arial,helvetica,sans-serif" COLOR="#FFFFFF"><EM>QUICK</EM> SEARCH:&nbsp;</FONT></STRONG></TD>
			<TD ALIGN="RIGHT" VALIGN="MIDDLE" BGCOLOR="#003399" NOWRAP><A STYLE="text-decoration:none;color:#FFFFFF" HREF="/search.dtl"><FONT SIZE="-2" FACE="verdana,arial,helvetica" COLOR="#FFFFFF">&nbsp;[advanced]</FONT></A></TD>
			<TD BGCOLOR="#003399"><IMG ALT="" WIDTH="2" HEIGHT="2" SRC="/icons/spacer.gif"></TD>
		</TR><TR>
			<TD BGCOLOR="#DBDBDB"><IMG ALT="" WIDTH="2" HEIGHT="2" SRC="/icons/spacer.gif"></TD>
			<TD BGCOLOR="#DBDBDB" COLSPAN="2">
			<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0"> 
			<TR>
				<TD ALIGN="CENTER" VALIGN="BOTTOM"><INPUT TYPE="submit" STYLE="text-decoration:none;font-family:verdana,arial,helvetica;font-size:10px;font-weight:bold;color:#000000;background:#FFFFFF;" VALUE="Go"></TD>
				<TH ALIGN="LEFT" COLSPAN="2"><FONT SIZE="-2" FACE="verdana,arial,helvetica,sans-serif" COLOR="#000000">Author:<BR></FONT>
					<INPUT TYPE="text" NAME="author1" SIZE="9" MAXLENGTH="80" VALUE="" STYLE="font-family:verdana,arial,helvetica;font-size:10px;"></TH>
				<TH ALIGN="LEFT" COLSPAN="3"><FONT SIZE="-2" FACE="verdana,arial,helvetica,sans-serif" COLOR="#000000">Keyword(s):<BR></FONT>
					<INPUT TYPE="text" NAME="fulltext" SIZE="16" MAXLENGTH="80" VALUE="" STYLE="font-family:verdana,arial,helvetica;font-size:10px;"></TH>
			</TR><TR>
				<TH><FONT SIZE="-2" FACE="verdana,arial,helvetica,sans-serif" COLOR="#000000">Year:&nbsp;</FONT></TH>
				<TD><INPUT TYPE="text" NAME="pubdate_year" SIZE="4" MAXLENGTH="4" VALUE="" STYLE="font-family:verdana,arial,helvetica;font-size:10px;"></TD>
				<TH ALIGN="RIGHT"><FONT SIZE="-2" FACE="verdana,arial,helvetica,sans-serif" COLOR="#000000">Vol:&nbsp;</FONT></TH>
				<TD><INPUT TYPE="text" NAME="volume" SIZE="4" MAXLENGTH="10" VALUE="" STYLE="font-family:verdana,arial,helvetica;font-size:10px;"></TD>
				<TH><FONT SIZE="-2" FACE="verdana,arial,helvetica,sans-serif" COLOR="#000000">Page:&nbsp;</FONT></TH>
				<TD><INPUT TYPE="text" NAME="firstpage" SIZE="4" MAXLENGTH="10" VALUE="" STYLE="font-family:verdana,arial,helvetica;font-size:10px;"></TD>
			</TR> 
			</TABLE> </TD>
			<TD BGCOLOR="#DBDBDB"><IMG ALT="" WIDTH="2" HEIGHT="2" SRC="/icons/spacer.gif"></TD>
		</TR>
		</TABLE></TD></FORM></TR></TABLE> 
	 
	</TD>
	</TR><TR>
		<TD COLSPAN="3"><IMG ALT="" WIDTH="2" HEIGHT="2" SRC="/icons/spacer.gif"><BR>







	
	

	





	
	
	
	 

	


	
	




				<FONT SIZE="-2" FACE="verdana,arial,helvetica">
	<NOBR><STRONG>Institution: Weill Cornell Med Lib</STRONG></NOBR>
	<NOBR><A TARGET="_top" HREF="/cgi/login?uri=%2Fcgi%2Fcontent%2Ffull%2F78%2F1%2F189">Sign In as Member/Non-Member</A></NOBR>
	
		
		
	
	
	</FONT>
	
 <!-- showauthstring -->
	<!-- INST -->
	<!-- INDV -->
        <!-- SPONSORED -->
	<!-- USER.PFA -->
	<!-- USER.PFABSAIC -->
	<!-- NOT GUEST -->
	

	


<HR ALIGN="LEFT" SIZE="1" COLOR="#000000" NOSHADE></TD>
	</TR>
	</TABLE>



















	






	
		
<b>

	
		
		<FONT size="-1" COLOR=003399><I>Physiol. Rev.</I> 78: 189-225, 1998;
	         <BR>0031-9333/98 $15.00<BR></FONT>
        	
	

</b>

	 
 

 

 
	  
		
	
		<table class="content_box_outer_table"
		 
			
				
					align="right"
				
			
		>
			<tr>
			<td>
	

<!-- beginning of inner table -->
	<table class="content_box_inner_table">
<!-- citation -->

	
		




	

	

	
		
			
<tr><td class="content_box_title_highlight" colspan="2">This Article</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr>
				
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				
				<strong><a href="/cgi/content/abstract/78/1/189">
				Abstract</a></strong>
				 					<img alt="" width="32" height="7" border="0" src="/icons/shared/toc/free.gif">
				
	
				</td></tr>
			
		
		
	

	
	
	

	
	
	


	
	
	

	
	
	

	
	
	

	
	
	

	
		
	

	

	
		
			
		
	

	

	
	 

	
	 

		
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
		<strong>
		
		
		
			
				
				
					<a href="/cgi/reprint/78/1/189">
		<strong>Full Text</strong> (PDF)</a>
				
			
		
		</strong>
		</td></tr>
	
	

	
	
	

	
	
	

	
	





	
		

	
		

	
		
		

			


	

			

			
		
	

			
	  
	

			

			

			
	
	

	
		
	









	
		
	





	

	 

	

	
	
		  
    

	







		
	
		
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/alerts/ctalert?alertType=citedby&addAlert=cited_by&saveAlert=no&cited_by_criteria_resid=physrev;78/1/189&return_type=article&return_url=http%3A%2F%2Fphysrev.physiology.org%2Fcgi%2Fcontent%2Ffull%2F78%2F1%2F189">
				Alert me when this article is cited</a></strong>
			</td></tr>
	

		
		

		
		

		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/alerts/ctalert?alertType=correction&addAlert=correction&saveAlert=no&correction_criteria_value=78/1/189&return_type=article&return_url=http%3A%2F%2Fphysrev.physiology.org%2Fcgi%2Fcontent%2Ffull%2F78%2F1%2F189">
				Alert me if a correction is posted</a></strong>
			</td></tr>
		










			
		
			
			
			
				
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
					<strong><a href="/cgi/citemap?id=physrev;78/1/189">
					Citation Map</a></strong>
				</td></tr>
		
	

			
			
<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr><tr><td class="content_box_title" colspan="2">Services</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr>
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/mailafriend?url=http%3A%2F%2Fphysrev.physiology.org%2Fcgi%2Fcontent%2Ffull%2F78%2F1%2F189&title=Dopamine+Receptors%3A+From+Structure+to+Function">
				Email this article to a friend</a></strong>
			</td></tr>
			
			


	

	

		
		



			
			
			
		
	

		
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
		<strong>
		<a href="/cgi/search?qbe=physrev;78/1/189&journalcode=physrev&minscore=5000">
		Similar articles in this journal</a>
		</strong>
		</td></tr>

		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/external_ref?access_num=9457173&link_type=MED_NBRS">
				Similar articles in PubMed</a></strong>
			</td></tr>
		
	


		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/alerts/etoc">
				Alert me to new issues of the journal</a></strong>
			</td></tr>
		

		
		
	

		
		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
			<strong><a href="/cgi/citmgr?gca=physrev;78/1/189">
			Download to citation manager</a></strong>
			</td></tr>
		
		
	


	
		
	

	


	
		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="#otherarticles">
				Cited by other online articles</a></strong>
			</td></tr>
		
	
		
	

	

		


	
	
	
		

	

	






	
		
<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr><tr><td class="content_box_title" colspan="2">PubMed</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr>
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/external_ref?access_num=9457173&link_type=PUBMED">
				PubMed Citation</a></strong>
			</td></tr>
		
	

	
		
		
			
				

						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="/cgi/external_ref?access_num=MISSALE+C&link_type=AUTHORSEARCH">
							Articles by MISSALE, C.</a></strong>
						</td></tr>
				
			
				

						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="/cgi/external_ref?access_num=CARON+MG&link_type=AUTHORSEARCH">
							Articles by CARON, M. G.</a></strong>
						</td></tr>
				
			
		

		
	






	






	
		

	

		
			
		











	




	</td></tr></table>
</td></tr></table> 

	











 





	
	
	
	
	
	
	
	
	
		<vardef id="TEXT">

<!--

   Pages created by the Electronic Press Engine from

		Atypon Systems, Inc.

   Visit http://www.atypon.com/

-->
<a name = top><!-- comment for mosaic --></a>
<P>
<!-- COPYRIGHT -->
<font size=-1>
PHYSIOLOGICAL REVIEWS &nbsp; Vol. 78 No. 1 January 1998, pp. 189-225<BR>
Copyright &copy;1998 by the American Physiological Society<BR>

</font>





<H2>
Dopamine Receptors: From Structure to Function


</H2>


<P>


<NOWRAP>
<strong>CRISTINA MISSALE</strong>,<WBR>
<strong>S. RUSSEL NASH</strong>,<WBR>
<strong>SUSAN W. ROBINSON</strong>,<WBR>
<strong>MOHAMED JABER</strong>, <strong><font size=-1> AND </font></strong><WBR>
<strong>MARC G. CARON</strong></NOWRAP>
<P>
Departments of Cell Biology and Medicine, Howard Hughes Medical Institute Laboratories, Duke University Medical Center, Durham, North Carolina







    
	
	    
	
	    
		
    
	
	    
	
    
	
	    
	
    
	
	    
	
    
	
	    
	
    
	
	    
	
    
	
	    
	
    
	
	    
	
    
	
	    
	
    
	
	    
	
    
	
	    
	
    
	
	    
	
    
    
	
	    
	
    










<P><P>
<BLOCKQUOTE><FONT SIZE=-1><B>
<A HREF="#SEC1">I. INTRODUCTION</A><BR>
    <A HREF="#SEC2">II. CLASSIFICATION OF DOPAMINE RECEPTORS</A><BR>
    <A HREF="#SEC3">III. GENE STRUCTURE</A><BR>
    <A HREF="#SEC4">IV. STRUCTURE OF DOPAMINE RECEPTORS</A><BR>
    <A HREF="#SEC5">V. RECEPTOR VARIANTS</A><BR>
    &nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#SEC5_1">A. D<SUB>2</SUB> Receptor</A><BR>
	&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#SEC5_2">B. D<SUB>3</SUB> Receptor</A><BR>
	&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#SEC5_3">C. D<SUB>4</SUB> Receptor</A><BR>
	<A HREF="#SEC6">VI. PHARMACOLOGICAL PROPERTIES
OF DOPAMINE RECEPTORS</A><BR>
    <A HREF="#SEC7">VII. SIGNAL TRANSDUCTION OF
DOPAMINE RECEPTORS</A><BR>
    &nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#SEC7_2">A. Adenylyl Cyclase</A><BR>
	&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#SEC7_3">B. Calcium Channels</A><BR>
	&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#SEC7_4">C. Potassium Channels</A><BR>
	&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#SEC7_5">D. Arachidonic Acid</A><BR>
	&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#SEC7_6">E. Na<SUP>+</SUP>/H<SUP>+</SUP> Exchange</A><BR>
	&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#SEC7_7">F. Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase</A><BR>
	&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#SEC7_8">G. Additional Signal Transduction Pathways Involved in Mitogenesis</A><BR>
	<A HREF="#SEC8">VIII. DOPAMINE RECEPTORS IN THE BRAIN</A><BR>
    &nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#SEC8_1">A. Distribution of Dopamine Receptors</A><BR>
	&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#SEC8_2">B. Function of Brain Dopamine Receptors</A><BR>
	&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#SEC8_3">C. Dopamine Receptors and Regulation
of Gene Expression</A><BR>
	
	    
	    
	    &nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#SEC8_4">D. Development of Transgenic Animals in the Study of Dopamine Receptor Physiology</A><BR>
	&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#SEC8_5">E. Clinical and Pharmacological Implications
of Multiple Dopamine Receptors</A><BR>
	
	    <A HREF="#SEC9">IX. DOPAMINE RECEPTORS IN THE PITUITARY</A><BR>
    <A HREF="#SEC10">X. PERIPHERAL DOPAMINE RECEPTORS</A><BR>
    &nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#SEC10_3">A. Dopamine Receptors in Blood Vessels</A><BR>
	&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#SEC10_4">B. Dopamine Receptors Controlling the Renin-Angiotensin-Aldosterone System</A><BR>
	
	    
	    
	    &nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#SEC10_5">C. Dopamine Receptors Controlling
Catecholamine Release</A><BR>
	&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#SEC10_6">D. Dopamine Receptors in the Kidney</A><BR>
	
	    
	    
	    <A HREF="#SEC11">XI. DOPAMINERGIC SIGNAL TRANSDUCTION AND HYPERTENSION</A><BR>
    &nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#SEC11_1">A. Human Hypertension</A><BR>
	&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#SEC11_2">B. Animal Models of Hypertension</A><BR>
	<A HREF="#SEC12">XII. CONCLUDING REMARKS</A><BR>
    
<A HREF="#References">REFERENCES</A><BR>
</B></FONT></BLOCKQUOTE>
</P></P>


<P>







<!-- Abstract
References
 -->


<a name = "abs"><!-- comment for mosaic --></a>



<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;ABSTRACT</FONT></TH>
</TR>
</TABLE>
<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Top</A><BR>
















<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">References</A>

</FONT></TH>
</TR></TABLE>

<P><B>Missale, Cristina, S.&nbsp;Russel Nash, Susan W.&nbsp;Robinson, Mohamed Jaber, and Marc G.&nbsp;Caron.</B> Dopamine Receptors: From Structure<SUP> </SUP>to Function. <I>Physiol. Rev.</I> 78: 189-225, 1998.&nbsp;<IMG SRC="/math/12pt/normal/mdash.gif" ALIGN=BASELINE ALT="---">&nbsp;The diverse physiological<SUP> </SUP>actions of dopamine are mediated by at least five distinct G protein-coupled<SUP> </SUP>receptor subtypes. Two D<SUB>1</SUB>-like receptor subtypes (D<SUB>1</SUB> and D<SUB>5</SUB>) couple<SUP> </SUP>to the G protein G<SUB>s</SUB> and activate adenylyl cyclase. The other receptor<SUP> </SUP>subtypes belong to the D<SUB>2</SUB>-like subfamily (D<SUB>2</SUB> ,&nbsp;D<SUB>3</SUB> ,&nbsp;and D<SUB>4</SUB>) and<SUP> </SUP>are prototypic of G protein-coupled receptors that inhibit adenylyl<SUP> </SUP>cyclase and activate K<SUP>+</SUP> channels. The genes for the D<SUB>1</SUB> and D<SUB>5</SUB> receptors are intronless,<SUP> </SUP>but pseudogenes of the D<SUB>5</SUB> exist. The D<SUB>2</SUB> and D<SUB>3</SUB> receptors vary<SUP> </SUP>in certain tissues and species as a result of alternative splicing,<SUP> </SUP>and the human D<SUB>4</SUB> receptor gene exhibits extensive polymorphic<SUP> </SUP>variation. In the central nervous system, dopamine receptors are<SUP> </SUP>widely expressed because they are involved in the control of locomotion,<SUP> </SUP>cognition, emotion, and affect as well as neuroendocrine secretion.<SUP> </SUP>In the periphery, dopamine receptors are present more prominently<SUP> </SUP>in kidney, vasculature, and pituitary, where they affect mainly<SUP> </SUP>sodium homeostasis, vascular tone, and hormone secretion. Numerous<SUP> </SUP>genetic linkage analysis studies have failed so far to reveal<SUP> </SUP>unequivocal evidence for the involvement of one of these receptors<SUP> </SUP>in the etiology of various central nervous system disorders. However,<SUP> </SUP>targeted deletion of several of these dopamine receptor genes<SUP> </SUP>in mice should provide valuable information about their physiological<SUP> </SUP>functions.
</P>


<P>


<TXT>
<A NAME="SEC0"><!-- comment for mosaic --></A>




    
    <A NAME="SEC1">
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;I. INTRODUCTION</FONT></TH>
</TR>
</TABLE>
<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Top</A><BR>





<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Next</A><BR>


<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">References</A>

</FONT></TH>
</TR></TABLE>

    
	
	<P>Dopamine (DA) is the predominant catecholamine neurotransmitter in the mammalian brain, where it controls a variety of functions<SUP> </SUP>including locomotor activity, cognition, emotion, positive reinforcement,<SUP> </SUP>food intake, and endocrine regulation. This catecholamine also<SUP> </SUP>plays multiple roles in the periphery as a modulator of cardiovascular<SUP> </SUP>function, catecholamine release, hormone secretion, vascular tone,<SUP> </SUP>renal function, and gastrointestinal motility.<SUP> </SUP></P>
	
    
	
	<P>The dopaminergic systems have been the focus of much research over the past 30&nbsp;years, mainly because several pathological<SUP> </SUP>conditions such as Parkinson's disease, schizophrenia, Tourette's<SUP> </SUP>syndrome, and hyperprolactinemia have been linked to a dysregulation<SUP> </SUP>of dopaminergic transmission. Dopamine receptor antagonists have<SUP> </SUP>been developed to block hallucinations and delusions that occur<SUP> </SUP>in schizophrenic patients, whereas DA receptor agonists are effective<SUP> </SUP>in alleviating the hypokinesia of Parkinson's disease. However,<SUP> </SUP>blockade of DA receptors can induce extrapyramidal effects similar<SUP> </SUP>to those resulting from DA depletion, and high doses of DA agonists<SUP> </SUP>can cause psychoses. The therapies of disorders resulting from<SUP> </SUP>DA imbalances are thus associated with severe side effects.<SUP> </SUP></P>
	
    
	
	<P>One of the challenges of the last 10&nbsp;years has thus been to discover selective dopaminergic drugs devoid of adverse effects.<SUP> </SUP>This effort has led to the development of a number of new therapeutic<SUP> </SUP>agents that, although they have not resolved the etiology of the<SUP> </SUP>clinical problems, have contributed to increase our understanding<SUP> </SUP>of the dopaminergic system.</P>
	
    
	
	<P>A new impetus to the search in the DA field came from the application of gene-cloning procedures to receptor biology one-half<SUP> </SUP>a decade ago, which revealed a higher degree of complexity within<SUP> </SUP>DA receptors than previously thought. The complementary DNAs of<SUP> </SUP>five distinct DA receptor subtypes (D<SUB>1</SUB>-D<SUB>5</SUB>) have been, in fact,<SUP> </SUP>isolated and characterized. This approach produced a wealth of<SUP> </SUP>information regarding the structure of these receptor proteins<SUP> </SUP>and provided the tools to precisely define their distribution<SUP> </SUP>in the central nervous system (CNS) and in the periphery, to express<SUP> </SUP>the receptors in host cells and characterize their pharmacology,<SUP> </SUP>and to evaluate the possible linkage of receptor genes to specific<SUP> </SUP>disorders. The application of in situ hybridization and polymerase<SUP> </SUP>chain reaction (PCR) with the newly cloned receptor probes made<SUP> </SUP>it possible to localize DA receptors to specific brain regions<SUP> </SUP>or peripheral tissues even where they had not been anticipated<SUP> </SUP>before. The function of many of these receptors, however, is still<SUP> </SUP>completely unknown, thus highlighting a serious gap between the<SUP> </SUP>molecular biology and the functional approaches.<SUP> </SUP></P>
	
    
	
	<P>A classical key requirement to elucidate the functional role of individual receptor subtypes is the identification of selective<SUP> </SUP>agonists and antagonists. Pharmacological manipulations have,<SUP> </SUP>in fact, partially clarified the role of D<SUB>1</SUB> and D<SUB>2</SUB> receptors in<SUP> </SUP>the control of various functions as well as the interaction of<SUP> </SUP>DA with other neurotransmitter systems. The specific structure-activity<SUP> </SUP>requirements necessary for compounds to be selectively active<SUP> </SUP>at each receptor subtype, on the other hand, are still unknown<SUP> </SUP>for the novel DA receptors so that drugs able to completely discriminate<SUP> </SUP>D<SUB>3</SUB> ,&nbsp;D<SUB>4</SUB> ,&nbsp;and D<SUB>5</SUB> receptor subtypes are not yet available. This<SUP> </SUP>drawback, together with the fact that the new receptor subtypes<SUP> </SUP>are expressed in lower amounts than the D<SUB>1</SUB> and D<SUB>2</SUB> ,&nbsp;has limited<SUP> </SUP>so far our possibility to understand their function.<SUP> </SUP></P>
	
    
	
	<P>Gene targeting using homologous recombination to inactivate a chosen gene has been developed in the last few years, and its<SUP> </SUP>application to DA receptor biology has provided an invaluable<SUP> </SUP>tool to investigate the function of each receptor subtype. This<SUP> </SUP>approach has been already used in the case of D<SUB>1</SUB> and D<SUB>2</SUB> DA receptors.<SUP> </SUP>Inactivation of these genes produced phenotypes in mice resembling<SUP> </SUP>those observed with specific pharmacological manipulations. Targeted<SUP> </SUP>inactivation of other members of the DA receptor family should<SUP> </SUP>thus be helpful, by overcoming the lack of specific ligands, to<SUP> </SUP>define their physiological functions.<SUP> </SUP></P>
	
    
	
	<P>In this paper, we review some features shared by the DA receptors, as well as those that make each unique. A special emphasis<SUP> </SUP>is given to their distribution, second messenger coupling, and<SUP> </SUP>function in the CNS and peripheral tissues. The pathological and<SUP> </SUP>therapeutic implications of DA receptor diversity are also analyzed.<SUP> </SUP></P>
	
    

    
    <A NAME="SEC2">
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;II. CLASSIFICATION OF DOPAMINE RECEPTORS</FONT></TH>
</TR>
</TABLE>
<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Top</A><BR>



<A HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Previous</A><BR>



<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Next</A><BR>


<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">References</A>

</FONT></TH>
</TR></TABLE>

    
	
	<P>The first evidence for the existence of DA receptors in the CNS came in 1972&nbsp;from biochemical studies showing that DA was<SUP> </SUP>able to stimulate adenylyl cyclase (AC) (reviewed in Ref. <a href="#B226">226</A>).<SUP> </SUP>In 1978,&nbsp;DA receptors were first proposed, on the basis of pharmacological<SUP> </SUP>and biochemical evidence, to exist as two discrete populations,<SUP> </SUP>one positively coupled to AC and the other one independent of<SUP> </SUP>the adenosine 3',5'-cyclic monophosphate (cAMP)-generating system<SUP> </SUP>(<a href="#B424">424</A>). It was shown, in fact, that in the pituitary DA inhibited<SUP> </SUP>prolactin secretion but did not stimulate cAMP formation (<a href="#B59">59</A>;<SUP> </SUP>reviewed in Ref. <a href="#B226">226</A>) and that although the antipsychotic drug<SUP> </SUP>sulpiride was a DA antagonist when tested in the anterior pituitary,<SUP> </SUP>it was not able to block the striatal DA-sensitive AC (reviewed<SUP> </SUP>in Refs. <a href="#B226">226</A>, <a href="#B424">424</A>). In 1979,&nbsp;Kebabian and Calne (<a href="#B226">226</A>) summarized<SUP> </SUP>these observations and suggested to call D<SUB>1</SUB> the receptor that<SUP> </SUP>stimulated AC and D<SUB>2</SUB> the one that was not coupled to this effector.<SUP> </SUP></P>
	
    
	
	<P>Subsequent studies confirmed this classification scheme, and D<SUB>1</SUB> and D<SUB>2</SUB> receptors were clearly differentiated pharmacologically,<SUP> </SUP>biochemically, physiologically, and by their anatomic distribution.<SUP> </SUP></P>
	
    
	
	<P>Concurrently in the late 1970s, by means of functional tests such as renal blood flow and cardiac acceleration measurements<SUP> </SUP>in the dog, the existence of specific peripheral receptors for<SUP> </SUP>DA was demonstrated. These receptors were named DA<SUB>1</SUB> and DA<SUB>2</SUB> on<SUP> </SUP>the basis of some pharmacological properties distinguishing them<SUP> </SUP>from their central counterparts (reviewed in Ref. <a href="#B166">166</A>). This<SUP> </SUP>led to a long-standing controversy concerning the identity or<SUP> </SUP>nonidentity of peripheral versus central receptors. However, subsequent<SUP> </SUP>biochemical and molecular biology studies in peripheral tissues<SUP> </SUP>pointed to extensive similarities between central and peripheral<SUP> </SUP>DA receptors so that the DA<SUB>1</SUB>/DA<SUB>2</SUB> classification has been dropped<SUP> </SUP>(reviewed in Refs. <a href="#B7">7</A>, <a href="#B307">307</A>, <a href="#B326">326</A>, <a href="#B336">336</A>).<SUP> </SUP></P>
	
    
	
	<P>For a decade, the dual receptor concept served as the foundation for the study of DA receptors. However, after the introduction<SUP> </SUP>of gene cloning procedures, three novel DA receptors subtypes<SUP> </SUP>have been characterized over the past five years. These have been<SUP> </SUP>called D<SUB>3</SUB> (<a href="#B420">420</A>), D<SUB>4</SUB> (<a href="#B450">450</A>), and D<SUB>5</SUB>/D<SUB>1b</SUB> (<a href="#B431">431</A>, <a href="#B441">441</A>).<SUP> </SUP></P>
	
    
	
	<P>Detailed structural, pharmacological, and biochemical studies pointed out that all DA receptor subtypes fall into one of the<SUP> </SUP>two initially recognized receptor categories. The D<SUB>1</SUB> and D<SUB>5</SUB>/D<SUB>1b</SUB><SUP> </SUP>receptors share, in fact, a very high homology in their transmembrane<SUP> </SUP>domains. Similarly, the transmembrane sequences are highly conserved<SUP> </SUP>among D<SUB>2</SUB> ,&nbsp;D<SUB>3</SUB> ,&nbsp;and D<SUB>4</SUB> receptors (reviewed in Refs. <a href="#B78">78</A>, <a href="#B159">159</A>, <a href="#B217">217</A>, <a href="#B401">401</A>, <a href="#B421">421</A>).<SUP> </SUP>Pharmacologically, although the profiles of D<SUB>1</SUB> and D<SUB>2</SUB> receptors<SUP> </SUP>are substantially different, the D<SUB>5</SUB>/D<SUB>1b</SUB> receptor exhibits the<SUP> </SUP>classical ligand-binding characteristics of D<SUB>1</SUB> receptors, and<SUP> </SUP>the D<SUB>3</SUB> and D<SUB>4</SUB> receptors bind the hallmark D<SUB>2</SUB>-selective ligands<SUP> </SUP>with relatively high affinity (reviewed in Refs. <a href="#B78">78</A>, <a href="#B159">159</A>, <a href="#B217">217</A>, <a href="#B401">401</A>, <a href="#B421">421</A>).<SUP> </SUP>In addition, the initial distinction between D<SUB>1</SUB> and D<SUB>2</SUB> receptors<SUP> </SUP>in terms of signaling events, that is, positive and negative coupling<SUP> </SUP>to AC, appears to apply, in broad terms, also to the novel members<SUP> </SUP>of the DA receptor family, the D<SUB>5</SUB>/D<SUB>1b</SUB> receptor being coupled to<SUP> </SUP>stimulation of AC (<a href="#B95">95</A>, <a href="#B169">169</A>, <a href="#B431">431</A>, <a href="#B441">441</A>) and the D<SUB>3</SUB> (<a href="#B75">75</A>, <a href="#B287">287</A>, <a href="#B360">360</A>, <a href="#B377">377</A>)<SUP> </SUP>and D<SUB>4</SUB> receptors (<a href="#B74">74</A>, <a href="#B80">80</A>, <a href="#B287">287</A>, <a href="#B290">290</A>, <a href="#B438">438</A>) to inhibition of cAMP<SUP> </SUP>formation.</P>
	
    
	
	<P>The D<SUB>1</SUB>/D<SUB>2</SUB> classification concept developed in the late 1970s thus is still valid, and D<SUB>1</SUB> and D<SUB>5</SUB>/D<SUB>1b</SUB> receptors are classified<SUP> </SUP>as D<SUB>1</SUB>-like and D<SUB>2</SUB> ,&nbsp;D<SUB>3</SUB> ,&nbsp;and D<SUB>4</SUB> receptor subtypes as D<SUB>2</SUB>-like.<SUP> </SUP>The mammalian D<SUB>1b</SUB> receptor, originally named on the basis of its<SUP> </SUP>high homology with the D<SUB>1</SUB> receptor, is now commonly referred to<SUP> </SUP>as the D<SUB>5</SUB> receptor.</P>
	
    

    
    <A NAME="SEC3">
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;III. GENE STRUCTURE</FONT></TH>
</TR>
</TABLE>
<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Top</A><BR>




<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Previous</A><BR>



<A HREF="#SEC4"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Next</A><BR>


<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">References</A>

</FONT></TH>
</TR></TABLE>

    
	
	<P>The D<SUB>2</SUB> receptor cDNA was first isolated in 1988&nbsp;(<a href="#B47">47</A>) and subsequently, in 1989,&nbsp;the existence of splice variants of this<SUP> </SUP>receptor was demonstrated (<a href="#B91">91</A>, <a href="#B162">162</A>, <a href="#B315">315</A>). The D<SUB>3</SUB> receptor was<SUP> </SUP>identified by screening a rat cDNA library with the D<SUB>2</SUB> receptor<SUP> </SUP>sequence followed by PCR extension and genomic library screening<SUP> </SUP>(<a href="#B420">420</A>). The D<SUB>4</SUB> receptor was cloned by screening a library from<SUP> </SUP>the human neuroblastoma cell line SK-N-MC (<a href="#B450">450</A>).<SUP> </SUP></P>
	
    
	
	<P>The D<SUB>1</SUB> receptor was cloned by using either low-stringency screening of libraries or PCR based on the sequence of the D<SUB>2</SUB> receptor<SUP> </SUP>(<a href="#B95">95</A>, <a href="#B314">314</A>, <a href="#B480">480</A>). The second member of the D<SUB>1</SUB>-like receptor family<SUP> </SUP>was isolated using the sequence of the D<SUB>1</SUB> receptor and was referred<SUP> </SUP>to as D<SUB>5</SUB> (<a href="#B431">431</A>), D<SUB>1b</SUB> (<a href="#B441">441</A>) and D<SUB>1<IMG SRC="/math/12pt/normal/scr/beta.gif" ALIGN=BASELINE ALT="beta "></SUB> (<a href="#B464">464</A>). It is now well<SUP> </SUP>established that the D<SUB>5</SUB> and D<SUB>1b</SUB> are the human and rat equivalents<SUP> </SUP>of the same receptor.</P>
	
    
	
	<P>The genomic organization of the DA receptors supports the concept that they derive from the divergence of two gene families<SUP> </SUP>that mainly differ in the absence or the presence of introns in<SUP> </SUP>their coding sequences. As summarized in Table <a href="#T1">1</a>, the D<SUB>1</SUB> and<SUP> </SUP>D<SUB>5</SUB> receptor genes do not contain introns in their coding regions<SUP> </SUP>(reviewed in Refs. <a href="#B78">78</A>, <a href="#B159">159</A>, <a href="#B337">337</A>), a characteristic shared with<SUP> </SUP>most G protein-coupled receptors (<a href="#B112">112</A>). In contrast, and by analogy<SUP> </SUP>with the gene for rhodopsin (<a href="#B327">327</A>), the genes encoding the D<SUB>2</SUB>-like<SUP> </SUP>receptors are interrupted by introns (reviewed in Refs. <a href="#B78">78</A>, <a href="#B159">159</A>, <a href="#B337">337</A>).<SUP> </SUP>It appears likely that many of the genes in the G protein-coupled<SUP> </SUP>receptor family have arisen from a single primordial gene, suspected<SUP> </SUP>to be one of the opsin genes, that lost its introns by a gene-processing<SUP> </SUP>event (reviewed in Ref. <a href="#B337">337</A>). Two main evolutionary mechanisms<SUP> </SUP>may have created and amplified the molecular diversification within<SUP> </SUP>the two gene families: <I>1</I>) gene duplication mechanisms that gave<SUP> </SUP>rise to different, but nevertheless similar, sister genes encoding<SUP> </SUP>receptor subtypes or pseudogenes and <I>2</I>) speciation that originated<SUP> </SUP>species homologs and the development of genetic polymorphism that<SUP> </SUP>provided receptor variants found in individuals within the same<SUP> </SUP>species (reviewed in Ref. <a href="#B452">452</A>).

<P><CENTER>
<TABLE BORDER WIDTH="95%" CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1><TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF>&nbsp;<BR><STRONG>View this table:</STRONG>
<BR><NOBR><A HREF="/cgi/content/full/78/1/189/T1">[in this window]</A></NOBR>
<NOBR><A HREF="/cgi/content-nw/full/78/1/189/T1"
	onClick="startTarget('T1', 500, 400); this.href='/cgi/content-nw/full/78/1/189/T1'"
	onMouseOver="window.status='View figure in a separate window';
	        return true"
TARGET='T1'>[in a new window]</A><BR>&nbsp;</NOBR>
</TD>
<TD ALIGN=LEFT VALIGN=TOP>
<A NAME="T1"><!-- TABLE 1 --></A>
<font size=-1>TABLE</font> 1. &nbsp;

    <I> Molecular characteristics of dopamine receptors</I>
</P>

</CENTER>
</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>
<P>
</P>
	
    
	
	<P>Analysis of the gene structure of D<SUB>2</SUB>-like receptors revealed that the D<SUB>2</SUB> receptor coding region contains six introns (<a href="#B91">91</A>, <a href="#B162">162</A>, <a href="#B168">168</A>, <a href="#B315">315</A>),<SUP> </SUP>the D<SUB>3</SUB> receptor coding region five (<a href="#B420">420</A>), and the D<SUB>4</SUB> receptor<SUP> </SUP>three (<a href="#B450">450</A>). Interestingly, the localization of introns is similar<SUP> </SUP>in the three receptor genes and in the opsin gene. The D<SUB>3</SUB> receptor<SUP> </SUP>lacks the fourth intron of the D<SUB>2</SUB> ,&nbsp;and the D<SUB>4</SUB> receptor lacks<SUP> </SUP>the third and fourth introns of the D<SUB>2</SUB> .&nbsp;The third intron of the<SUP> </SUP>D<SUB>4</SUB> gene has an unusual intron/exon junction in which the conventional<SUP> </SUP>splice junction donor and acceptor sites are missing (<a href="#B450">450</A>, <a href="#B451">451</A>).<SUP> </SUP></P>
	
    
	
	<P>The presence of introns within the coding region of D<SUB>2</SUB>-like receptors allows the generation of receptor variants. Indeed,<SUP> </SUP>the D<SUB>2</SUB> receptor has two main variants, called D<SUB>2S</SUB> and D<SUB>2L</SUB> ,&nbsp;which<SUP> </SUP>are generated by alternative splicing of a 87-bp exon between<SUP> </SUP>introns 4&nbsp;and 5&nbsp;(<a href="#B91">91</A>, <a href="#B162">162</A>, <a href="#B315">315</A>; reviewed in Ref. <a href="#B159">159</A>). Splice<SUP> </SUP>variants of the D<SUB>3</SUB> receptor encoding nonfunctional proteins have<SUP> </SUP>been also identified (<a href="#B137">137</A>, <a href="#B161">161</A>, <a href="#B418">418</A>). Analysis of the gene for<SUP> </SUP>the human D<SUB>4</SUB> receptor revealed the existence of polymorphic variations<SUP> </SUP>within the coding sequence. A 48-bp sequence in the third cytoplasmic<SUP> </SUP>loop exists either as a direct repeat sequence, as a fourfold<SUP> </SUP>repeat, or a sevenfold repeat. D<SUB>4</SUB> receptors containing up to 11<SUP> </SUP>repeats have been found (<a href="#B451">451</A>).<SUP> </SUP></P>
	
    
	
	<P>The D<SUB>5</SUB> receptor has two related pseudogenes on human chromosomes 1&nbsp;and 2.&nbsp;They are 98% identical to each other and 95% identical<SUP> </SUP>to the human D<SUB>5</SUB> receptor and code for truncated, nonfunctional<SUP> </SUP>forms of the D<SUB>5</SUB> receptor (<a href="#B169">169</A>, <a href="#B464">464</A>).<SUP> </SUP></P>
	
    

    
    <A NAME="SEC4">
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;IV. STRUCTURE OF DOPAMINE RECEPTORS</FONT></TH>
</TR>
</TABLE>
<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Top</A><BR>





<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Previous</A><BR>



<A HREF="#SEC5"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Next</A><BR>


<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">References</A>

</FONT></TH>
</TR></TABLE>

    
	
	<P>Analysis of the primary structure of the cloned DA receptors revealed that they are members of the seven transmembrane (TM)<SUP> </SUP>domain G protein-coupled receptor family and share most of their<SUP> </SUP>structural characteristics (Fig. <a href="#F1">1</a>). Members of this family display<SUP> </SUP>considerable amino acid sequence conservation within TM domains<SUP> </SUP>(reviewed in Ref. <a href="#B362">362</A>).


    
	
<A NAME="F1"><!-- FIG 1 --></A>

<P><CENTER><TABLE WIDTH=95% CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1>
<TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF>

	
    <A HREF="/cgi/content/full/78/1/189/F1">
    <IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=197 HEIGHT=200 SRC="/content/vol78/issue1/images/small/jnp.ja09f1.gif"></A><BR>
<STRONG>View larger version</STRONG> (58K):
<BR><NOBR><A HREF="/cgi/content/full/78/1/189/F1">[in this window]</A>
<BR><A HREF="/cgi/content-nw/full/78/1/189/F1"
    onClick="startTarget('F1', 583, 640); this.href='/cgi/content-nw/full/78/1/189/F1'"
    onMouseOver="window.status='View figure in a separate window'; return true"
    TARGET="F1">[in a new window]</A><BR>&nbsp;
    </NOBR>

	

</TD><TD ALIGN=LEFT VALIGN=top><font size=-1>FIG.</font> 1. &nbsp;
Dopamine receptor structure. Structural features of D<SUB>1</SUB>-like receptors are represented. D<SUB>2</SUB>-like receptors are characterized by a shorter COOH-terminal tail and by a bigger 3rd intracellular loop. Residues involved in dopamine binding are highlighted in transmembrane domains. Potential phosphorylation sites are represented on 3rd intracellular loop (I3) and on COOH terminus. Potential glycosylation sites are represented on NH<SUB>2</SUB> terminal. E1-E3, extracellular loops; 1-7, transmembrane domains; I2-I3, intracellular loops.

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>
<P>
<!-- /FIG 1 -->

    

</P>
	
    
	
	<P>Analysis of DA receptor structure pointed to similarities and dissimilarities between D<SUB>1</SUB>-like and D<SUB>2</SUB>-like receptors (<a href="#B78">78</A>, <a href="#B159">159</A>, <a href="#B217">217</A>, <a href="#B337">337</A>).<SUP> </SUP>Members of the same family share considerable homology. The D<SUB>1</SUB><SUP> </SUP>and D<SUB>5</SUB> receptors share a 80% identity in their TM domains. The<SUP> </SUP>D<SUB>2</SUB> and D<SUB>3</SUB> receptors have a 75% identity in their TM domains, and<SUP> </SUP>the D<SUB>2</SUB> and D<SUB>4</SUB> receptors share a 53% identity in the TM domains.<SUP> </SUP></P>
	
    
	
	<P>The NH<SUB>2</SUB>-terminal stretch has a similar number of amino acids in all the receptor subtypes and carries a variable number of<SUP> </SUP>consensus <I>N</I>-glycosylation sites. The D<SUB>1</SUB> and D<SUB>5</SUB> receptors possess<SUP> </SUP>two such sites, one in the NH<SUB>2</SUB> terminal and the other one in the<SUP> </SUP>second extracellular loop. The D<SUB>2</SUB> receptor has four potential<SUP> </SUP>glycosylation sites, the D<SUB>3</SUB> has three, and the D<SUB>4</SUB> possesses only<SUP> </SUP>one (reviewed in Refs. <a href="#B78">78</A>, <a href="#B159">159</A>, <a href="#B217">217</A>, <a href="#B337">337</A>).<SUP> </SUP></P>
	
    
	
	<P>The COOH terminal is about seven times longer for the D<SUB>1</SUB>-like receptors than for the D<SUB>2</SUB>-like receptors, is rich in serine<SUP> </SUP>and threonine residues, and contains a cysteine residue that is<SUP> </SUP>conserved in all G protein-coupled receptors and that has been<SUP> </SUP>shown to be palmitoylated in the <IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BASELINE ALT="beta ">-adrenergic receptors and in<SUP> </SUP>rhodopsin probably to anchor the cytoplasmic tail to the membrane<SUP> </SUP>(<a href="#B338">338</A>, <a href="#B347">347</A>). In the D<SUB>1</SUB>-like receptors, this cysteine residue is<SUP> </SUP>located near the beginning of the COOH terminus, whereas in the<SUP> </SUP>D<SUB>2</SUB>-like receptors, the COOH terminus ends with this cysteine residue<SUP> </SUP>(Fig. <a href="#F1">1</a>). Likewise, as in all G protein-coupled receptors, DA<SUP> </SUP>receptors possess two cysteine residues in extracellular loops<SUP> </SUP>2&nbsp;and 3&nbsp;(reviewed in Refs. <a href="#B78">78</A>, <a href="#B159">159</A>, <a href="#B217">217</A>, <a href="#B337">337</A>), which have been<SUP> </SUP>suggested to form an intramolecular disulfide bridge to stabilize<SUP> </SUP>the receptor structure (<a href="#B111">111</A>, <a href="#B142">142</A>). The D<SUB>2</SUB>-like receptors have<SUP> </SUP>a long third intracellular loop, a feature which is common to<SUP> </SUP>receptors interacting with G<SUB>i</SUB> proteins to inhibit AC, whereas<SUP> </SUP>the D<SUB>1</SUB>-like receptors are characterized by a short third loop<SUP> </SUP>as in many receptors coupled to G<SUB>s</SUB> protein (reviewed in Refs.<SUP> </SUP><a href="#B78">78</A>, <a href="#B159">159</A>, <a href="#B337">337</A>).</P>
	
    
	
	<P>The D<SUB>1</SUB> and D<SUB>5</SUB> receptor third intracellular loop and the COOH terminus are similar in size but divergent in their sequence.<SUP> </SUP>In contrast, the small cytoplasmic loops 1&nbsp;and 2&nbsp;are highly conserved<SUP> </SUP>so that any difference in the biology of these receptors can be<SUP> </SUP>probably related to the third cytoplasmic loop and the COOH-terminal<SUP> </SUP>tail (reviewed in Refs. <a href="#B78">78</A>, <a href="#B159">159</A>, <a href="#B337">337</A>). The external loop between<SUP> </SUP>TM4 and TM5 is considerably different in the two receptor subtypes,<SUP> </SUP>being shorter (27&nbsp;amino acids) in the D<SUB>1</SUB> receptor than in the<SUP> </SUP>D<SUB>5</SUB> receptor (41&nbsp;amino acids). The amino acid sequence of this<SUP> </SUP>loop, in addition, is divergent in the D<SUB>5</SUB> and in its rat counterpart<SUP> </SUP>D<SUB>1b</SUB> (<a href="#B431">431</A>, <a href="#B441">441</A>).</P>
	
    
	
	<P>Site-directed mutagenesis for catecholamine receptors (<a href="#B233">233</A>, <a href="#B426">426</A>, <a href="#B427">427</A>) and protein modeling with the <IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BASELINE ALT="beta "><SUB>2</SUB>-, <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "><SUB>2</SUB>-, and D<SUB>2</SUB> receptors<SUP> </SUP>(<a href="#B189">189</A>, <a href="#B190">190</A>, <a href="#B443">443</A>) suggested that the agonist binding likely occurs<SUP> </SUP>within the hydrophobic TM domains (Fig. <a href="#F1">1</a>). Highly conserved residues<SUP> </SUP>are present in the core of the protein and define a narrow binding<SUP> </SUP>pocket that most probably corresponds to the agonist binding site<SUP> </SUP>(<a href="#B190">190</A>). In particular, an aspartate residue in TM3 is most probably<SUP> </SUP>involved in binding the amine group of the catecholamine side<SUP> </SUP>chain (<a href="#B190">190</A>, <a href="#B427">427</A>). Two serine residues in TM5 have been shown to<SUP> </SUP>be hydrogen bond donors to bind the hydroxyl groups of the catechol<SUP> </SUP>moiety for the <IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BASELINE ALT="beta "><SUB>2</SUB>- (<a href="#B426">426</A>), <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "><SUB>2</SUB>- (<a href="#B458">458</A>), D<SUB>2</SUB> (<a href="#B85">85</A>, <a href="#B282">282</A>), and D<SUB>1</SUB> (<a href="#B442">442</A>)<SUP> </SUP>receptors. A phenylalanine in TM6 is highly conserved in all receptors<SUP> </SUP>interacting with catecholamine neurotransmitters and can make<SUP> </SUP>a stabilizing orthogonal interaction with the aromatic moiety<SUP> </SUP>of the ligand. A highly conserved aspartate residue in TM2 has<SUP> </SUP>been shown to play a crucial role in <IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BASELINE ALT="beta "><SUB>2</SUB>-adrenergic (<a href="#B77">77</A>, <a href="#B190">190</A>, <a href="#B427">427</A>),<SUP> </SUP><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "><SUB>2</SUB>-adrenergic (<a href="#B458">458</A>), and D<SUB>1</SUB> (<a href="#B442">442</A>) and D<SUB>2</SUB> dopaminergic (<a href="#B328">328</A>)<SUP> </SUP>receptor activation and to affect agonist binding (<a href="#B190">190</A>, <a href="#B414">414</A>, <a href="#B442">442</A>).<SUP> </SUP>It has been suggested that the interaction between this aspartate<SUP> </SUP>and the agonist is allosteric and can be modulated by Na<SUP>+</SUP> or H<SUP>+</SUP> (<a href="#B189">189</A>, <a href="#B196">196</A>, <a href="#B328">328</A>). A number of cytoplasmic residues, such as the<SUP> </SUP>DRY sequence in the second intracellular loop or the alanine residue<SUP> </SUP>in the third intracellular loop of the <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha ">-adrenoceptor, also play<SUP> </SUP>a role in receptor activation (<a href="#B233">233</A>, <a href="#B427">427</A>).<SUP> </SUP></P>
	
    

    
    <A NAME="SEC5">
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;V. RECEPTOR VARIANTS</FONT></TH>
</TR>
</TABLE>
<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Top</A><BR>






<A HREF="#SEC4"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Previous</A><BR>



<A HREF="#SEC6"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Next</A><BR>


<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">References</A>

</FONT></TH>
</TR></TABLE>

    
	
	<A NAME="SEC5_1">
<P ALIGN=LEFT><B>A. D<SUB>2</SUB> Receptor</B>
</P>

	
	    
	    <P>The D<SUB>2</SUB> receptor exists as two alternatively spliced isoforms differing in the insertion of a stretch of 29&nbsp;amino acids in<SUP> </SUP>the third intracellular loop (D<SUB>2S</SUB> and D<SUB>2L</SUB>) (<a href="#B91">91</A>, <a href="#B162">162</A>, <a href="#B315">315</A>). Because<SUP> </SUP>this loop seems to play a central role in receptor coupling, the<SUP> </SUP>existence of a splicing mechanism at this level could imply functional<SUP> </SUP>diversity. However, in spite of the efforts of several groups,<SUP> </SUP>no obvious differences have emerged so far between the two D<SUB>2</SUB><SUP> </SUP>receptor isoforms. Both variants share the same distribution pattern,<SUP> </SUP>with the shorter form less abundantly transcribed (<a href="#B91">91</A>, <a href="#B162">162</A>, <a href="#B315">315</A>, <a href="#B328">328</A>).<SUP> </SUP>Both isoforms revealed the same pharmacological profile, even<SUP> </SUP>if a marginal difference in the affinity of some substituted benzamides<SUP> </SUP>has been reported (<a href="#B66">66</A>, <a href="#B278">278</A>). When expressed in host cell lines,<SUP> </SUP>both isoforms inhibited AC (<a href="#B91">91</A>, <a href="#B162">162</A>, <a href="#B315">315</A>). However, the D<SUB>2S</SUB> receptor<SUP> </SUP>isoform displayed higher affinity than the D<SUB>2L</SUB> in this effect<SUP> </SUP>(<a href="#B91">91</A>, <a href="#B317">317</A>). Both isoforms mediate a phosphatidylinositol-linked<SUP> </SUP>mobilization of intracellular calcium in mouse Ltk<SUP><IMG SRC="/math/12pt/normal/scr/minus.gif" ALIGN=BASELINE ALT="-"></SUP> fibroblasts. Protein kinase C (PKC), however, differentially<SUP> </SUP>modulates D<SUB>2S</SUB>- and D<SUB>2L</SUB>-activated transmembrane signaling in this<SUP> </SUP>system with a selective inhibitory effect on the D<SUB>2S</SUB>-mediated<SUP> </SUP>response (<a href="#B265">265</A>). Attempts to identify the preferred G protein<SUP> </SUP><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha ">-subunit for D<SUB>2S</SUB> and D<SUB>2L</SUB> have led to conflicting results. One<SUP> </SUP>group suggested, in fact, that the 29-amino acid insertion in<SUP> </SUP>the D<SUB>2L</SUB> receptor directs its interaction with G<SUB>i-2</SUB><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "> (<a href="#B175">175</A>, <a href="#B318">318</A>),<SUP> </SUP>whereas another report showed that in transfected cell lines the<SUP> </SUP>D<SUB>2S</SUB> isoform signals preferentially through G<SUB>i-2</SUB><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "> and the D<SUB>2L</SUB> through<SUP> </SUP>G<SUB>i-3</SUB><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "> (<a href="#B405">405</A>). The two receptor variants, in addition, appear to<SUP> </SUP>differ in their mode of regulation (<a href="#B240">240</A>, <a href="#B283">283</A>, <a href="#B479">479</A>).<SUP> </SUP></P>
	    
	
	
    
	
	<A NAME="SEC5_2">
<P ALIGN=LEFT><B>B. D<SUB>3</SUB> Receptor</B>
</P>

	
	    
	    <P>Splice variants of the D<SUB>3</SUB> receptor have also been identified. One transcript carries a 113-bp deletion in TM3 and a frame<SUP> </SUP>shift in the coding sequences generating a stop codon shortly<SUP> </SUP>after the deletion and encodes a 100-amino acid-long truncated<SUP> </SUP>form of the receptor (<a href="#B418">418</A>). A second variant derives from a deletion<SUP> </SUP>of 54&nbsp;bp between TM5 and TM6 of the D<SUB>3</SUB> receptor. Although this<SUP> </SUP>structure may be compatible with the occurrence of seven transmembrane<SUP> </SUP>domains, cell lines transfected with this cDNA failed to show<SUP> </SUP>any binding (<a href="#B161">161</A>). Two alternatively spliced forms of the D<SUB>3</SUB><SUP> </SUP>receptors have been identified in the mouse (<a href="#B137">137</A>), but not in<SUP> </SUP>other species (<a href="#B161">161</A>). These differ by a stretch of 21&nbsp;amino acids<SUP> </SUP>in the third intracellular loop and are generated by a splicing<SUP> </SUP>mechanism that uses an internal acceptor site inside an exon,<SUP> </SUP>rather than a separate exon like the D<SUB>2</SUB> receptor. Both isoforms<SUP> </SUP>bind dopaminergic ligands with a D<SUB>3</SUB> pharmacological profile and<SUP> </SUP>have the same distribution pattern with the longer form predominant<SUP> </SUP>(<a href="#B137">137</A>).</P>
	    
	
	
    
	
	<A NAME="SEC5_3">
<P ALIGN=LEFT><B>C. D<SUB>4</SUB> Receptor</B>
</P>

	
	    
	    <P>Analysis of the deduced amino acid sequence of the D<SUB>4</SUB> receptor reveals that it is the most distantly related of the D<SUB>2</SUB>-like<SUP> </SUP>receptors. In human polymorphic variants, the D<SUB>4</SUB> receptor exists<SUP> </SUP>with different insertions in the third intracellular loop. This<SUP> </SUP>loop contains repeat sequences of 16&nbsp;amino acids with the number<SUP> </SUP>of repeats differing in the different forms of the receptor. The<SUP> </SUP>four-repeat form (D<SUB>4.4</SUB>) is the predominant in the human population<SUP> </SUP>(60%). The D<SUB>4.7</SUB> variant is present in 14% of the population and<SUP> </SUP>the D<SUB>4.2</SUB> in 10% (<a href="#B401">401</A>, <a href="#B451">451</A>). Receptor forms with up to 10&nbsp;repeats<SUP> </SUP>have also been identified but are much less frequent (<a href="#B401">401</A>). The<SUP> </SUP>functional significance of these variants has not been elucidated.<SUP> </SUP>They display a slightly different affinity for the neuroleptic<SUP> </SUP>clozapine, but none of them has been related to an increased incidence<SUP> </SUP>of schizophrenia (<a href="#B401">401</A>, <a href="#B451">451</A>).</P>
	    
	
	
    

    
    <A NAME="SEC6">
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;VI. PHARMACOLOGICAL PROPERTIES
OF DOPAMINE RECEPTORS</FONT></TH>
</TR>
</TABLE>
<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Top</A><BR>







<A HREF="#SEC5"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Previous</A><BR>



<A HREF="#SEC7"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Next</A><BR>


<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">References</A>

</FONT></TH>
</TR></TABLE>

    
	
	<P>Although the pharmacological profiles of D<SUB>1</SUB>-like and D<SUB>2</SUB>-like receptors are substantially different, the main pharmacological<SUP> </SUP>differences described so far within each receptor subfamily are<SUP> </SUP>only represented by a variable shift in the affinity of certain<SUP> </SUP>agonists and antagonists (Table <a href="#T2">2</a>).

<P><CENTER>
<TABLE BORDER WIDTH="95%" CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1><TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF>&nbsp;<BR><STRONG>View this table:</STRONG>
<BR><NOBR><A HREF="/cgi/content/full/78/1/189/T2">[in this window]</A></NOBR>
<NOBR><A HREF="/cgi/content-nw/full/78/1/189/T2"
	onClick="startTarget('T2', 500, 400); this.href='/cgi/content-nw/full/78/1/189/T2'"
	onMouseOver="window.status='View figure in a separate window';
	        return true"
TARGET='T2'>[in a new window]</A><BR>&nbsp;</NOBR>
</TD>
<TD ALIGN=LEFT VALIGN=TOP>
<A NAME="T2"><!-- TABLE 2 --></A>
<font size=-1>TABLE</font> 2. &nbsp;

    <I> Pharmacological profile of dopamine receptors</I>
</P>

</CENTER>
</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>
<P>
</P>
	
    
	
	<P>So far, it has not been possible to pharmacologically differentiate D<SUB>1</SUB> and D<SUB>5</SUB> receptors. The sensitivities of these two receptor<SUP> </SUP>subtypes to antagonists are similar. Nevertheless, these compounds<SUP> </SUP>generally show a slightly higher affinity for the D<SUB>1</SUB> than for<SUP> </SUP>the D<SUB>5</SUB> ,&nbsp;with (+)-butaclamol as the most discriminating (Table<SUP> </SUP><a href="#T2">2</a>) (<a href="#B401">401</A>, <a href="#B441">441</A>). The affinity of agonists at D<SUB>1</SUB> and D<SUB>5</SUB> receptors<SUP> </SUP>is almost identical. The most consistent difference is represented<SUP> </SUP>by DA itself, which has ~10 times higher affinity for the D<SUB>5</SUB> than<SUP> </SUP>the D<SUB>1</SUB> (Table <a href="#T2">2</a>) (<a href="#B431">431</A>, <a href="#B441">441</A>). Cell lines expressing the D<SUB>5</SUB>/D<SUB>1b</SUB><SUP> </SUP>receptor show a higher basal AC activity than those expressing<SUP> </SUP>the D<SUB>1</SUB> (<a href="#B440">440</A>). This property, together with the observations that<SUP> </SUP>DA has a higher affinity for the D<SUB>5</SUB> than for the D<SUB>1</SUB> receptor and<SUP> </SUP>that some antagonists display negative efficacy at the D<SUB>5</SUB> ,&nbsp;but<SUP> </SUP>not at the D<SUB>1</SUB> ,&nbsp;make the D<SUB>5</SUB> receptor similar to various mutated<SUP> </SUP>G protein-coupled receptors that exhibit constitutive activity<SUP> </SUP>(<a href="#B250">250</A>, <a href="#B386">386</A>). Functionally, whether the D<SUB>5</SUB> receptor represents a<SUP> </SUP>naturally occurring constitutively active counterpart of the D<SUB>1</SUB><SUP> </SUP>receptor remains to be clarified.<SUP> </SUP></P>
	
    
	
	<P>Analysis of the pharmacological profiles of D<SUB>2</SUB>-like receptors shows that there are no compounds that discriminate between<SUP> </SUP>the short and the long variants of the D<SUB>2</SUB> receptor. A marginal<SUP> </SUP>difference in the affinities of sulpiride and raclopride for the<SUP> </SUP>two isoforms has been described (<a href="#B66">66</A>, <a href="#B278">278</A>). With respect to the<SUP> </SUP>D<SUB>3</SUB> and D<SUB>4</SUB> receptors, it has been shown that although they bind<SUP> </SUP>hallmark D<SUB>2</SUB>-selective ligands with high affinity, nevertheless<SUP> </SUP>both of these receptors have distinguishing pharmacological characteristics<SUP> </SUP>(Table <a href="#T2">2</a>).</P>
	
    
	
	<P>The pharmacological profile of the D<SUB>3</SUB> receptor reveals that some agonists and antagonists can distinguish it from the D<SUB>2</SUB> .<SUP> </SUP>Dopamine itself has 20&nbsp;times higher affinity at the D<SUB>3</SUB> than at<SUP> </SUP>the D<SUB>2</SUB> receptor (<a href="#B420">420</A>), and this has been related in part to their<SUP> </SUP>sequence differences in the third intracellular loop (<a href="#B378">378</A>). Among<SUP> </SUP>agonists, although apomorphine and bromocriptine display similar<SUP> </SUP>affinities for both receptors, TL-99, pergolide, quinpirole, and<SUP> </SUP>7-hydroxy-dipropylaminotetralin (7-OH-DPAT) bind with higher affinity<SUP> </SUP>at the D<SUB>3</SUB> than at the D<SUB>2</SUB> .&nbsp;Quinpirole and 7-OH-DPAT are the most<SUP> </SUP>discriminating compounds, with affinities 100&nbsp;and 10&nbsp;times higher<SUP> </SUP>than at the D<SUB>2</SUB> ,&nbsp;respectively (Table <a href="#T2">2</a>) (<a href="#B420">420</A>). Most neuroleptics<SUP> </SUP>display nanomolar affinity at both receptors. However, haloperidol<SUP> </SUP>and spiperone show 10-&nbsp;to 20-fold higher affinity at the D<SUB>2</SUB> than<SUP> </SUP>at the D<SUB>3</SUB> ,&nbsp;whereas (<IMG SRC="/math/12pt/normal/minus.gif" ALIGN=BASELINE ALT="-">)-sulpiride, clozapine, and raclopride do<SUP> </SUP>not substantially discriminate between the two receptor subtypes<SUP> </SUP>(<a href="#B420">420</A>). The antagonists UH-232 and AJ-76 have been shown to have<SUP> </SUP>three to four times higher affinity at the D<SUB>3</SUB> than at the D<SUB>2</SUB> (<a href="#B420">420</A>).<SUP> </SUP>Antagonists with some selectivity for the D<SUB>3</SUB> receptor (10-30 times<SUP> </SUP>difference) were recently developed, such as nafadotride (reviewed<SUP> </SUP>in Ref. <a href="#B421">421</A>), S-14297 (<a href="#B371">371</A>, <a href="#B421">421</A>), and U-99194A (<a href="#B460">460</A>).<SUP> </SUP></P>
	
    
	
	<P>The pharmacological profile of the D<SUB>4</SUB> receptor closely resembles those of D<SUB>2</SUB> and D<SUB>3</SUB> receptors, but specific differences have<SUP> </SUP>emerged (<a href="#B450">450</A>). The most important feature distinguishing the<SUP> </SUP>D<SUB>4</SUB> from D<SUB>2</SUB> and D<SUB>3</SUB> receptors is its higher affinity for clozapine<SUP> </SUP>(<a href="#B450">450</A>). Raclopride, remoxipride, and chlorpromazine, on the other<SUP> </SUP>hand, exhibit 10-20 times lower affinity at the D<SUB>4</SUB> than at the<SUP> </SUP>D<SUB>2</SUB> and D<SUB>3</SUB> (Table <a href="#T2">2</a>) (<a href="#B401">401</A>, <a href="#B450">450</A>). The D<SUB>4</SUB> receptors have been indirectly<SUP> </SUP>measured in brain tissues using [<SUP>3</SUP>H]nemonapride, which readily labels all three receptor subtypes,<SUP> </SUP>and [<SUP>3</SUP>H]raclopride, which labels D<SUB>2</SUB> and D<SUB>3</SUB> but to a much lesser extent<SUP> </SUP>D<SUB>4</SUB> receptors. The difference in binding densities of these two<SUP> </SUP>ligands has been proposed to reflect specific D<SUB>4</SUB> receptor binding<SUP> </SUP>(<a href="#B400">400</A>).</P>
	
    

    
    <A NAME="SEC7">
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;VII. SIGNAL TRANSDUCTION OF
DOPAMINE RECEPTORS</FONT></TH>
</TR>
</TABLE>
<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Top</A><BR>








<A HREF="#SEC6"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Previous</A><BR>



<A HREF="#SEC8"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Next</A><BR>


<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">References</A>

</FONT></TH>
</TR></TABLE>

    
	
	<P>The coupling of DA receptors to second messenger pathways has been a subject of intense interest ever since their existence<SUP> </SUP>was recognized. Originally, studies of this subject were carried<SUP> </SUP>out in preparations from brain or in some cases using purified<SUP> </SUP>reconstituted receptors. However, since DA receptor cloning, their<SUP> </SUP>coupling properties have been studied predominantly in cell lines<SUP> </SUP>transfected with each receptor cDNA. This gave the advantage of<SUP> </SUP>working with a pure population of receptor, whereas most brain<SUP> </SUP>regions express multiple DA receptor subtypes. However, heterologous<SUP> </SUP>expression systems have the disadvantage of mostly being fibroblast<SUP> </SUP>in nature, whereas the DA receptors are endogenously expressed<SUP> </SUP>primarily in neuronal cells. This raises the possibility of the<SUP> </SUP>receptors being expressed in an environment that may contain different<SUP> </SUP>complements of G proteins, effectors, and other molecules than<SUP> </SUP>they are in vivo. As a result, the use of different heterologous<SUP> </SUP>expression systems has often led to apparently conflicting results.<SUP> </SUP></P>
	
    
	
	<A NAME="SEC7_2">
<P ALIGN=LEFT><B>A. Adenylyl Cyclase</B>
</P>

	
	    
	    <P>As early as the 1970s, it was recognized that DA receptors could influence the activity of AC (reviewed in Ref. <a href="#B226">226</A>). The<SUP> </SUP>existence of a D<SUB>1</SUB> receptor-stimulated AC was recognized in most<SUP> </SUP>dopaminergic brain regions, such as striatum, nucleus accumbens,<SUP> </SUP>and olfactory tubercle (<a href="#B299">299</A>). After the cloning of the D<SUB>1</SUB> receptor<SUP> </SUP>in 1990,&nbsp;it was possible to examine its signaling properties in<SUP> </SUP>transfected cell lines. In a variety of cell culture lines, it<SUP> </SUP>was shown that the D<SUB>1</SUB> receptor robustly stimulated cAMP accumulation<SUP> </SUP>(<a href="#B95">95</A>, <a href="#B314">314</A>, <a href="#B480">480</A>). Upon the cloning of the second D<SUB>1</SUB>-like receptor,<SUP> </SUP>the D<SUB>5</SUB> was also found to be coupled to stimulation of AC, as was<SUP> </SUP>predicted from its structural similarity to the D<SUB>1</SUB> receptor (<a href="#B169">169</A>, <a href="#B431">431</A>, <a href="#B441">441</A>, <a href="#B464">464</A>).<SUP> </SUP>Interestingly, the D<SUB>5</SUB> receptor appears to exhibit an increased<SUP> </SUP>agonist-independent activity when compared with the D<SUB>1</SUB> receptor<SUP> </SUP>in 293&nbsp;cells (<a href="#B440">440</A>) and raises the questions of whether this is<SUP> </SUP>a naturally occurring constitutively active receptor and whether<SUP> </SUP>this feature is of relevance to its physiological role. Recent<SUP> </SUP>cloning of two more nonmammalian D<SUB>1</SUB>-like receptor subtypes has<SUP> </SUP>indicated that these subtypes also stimulate cAMP accumulation<SUP> </SUP>in COS-7 cells (<a href="#B101">101</A>, <a href="#B430">430</A>). Thus activation of AC seems to be a<SUP> </SUP>general property of all D<SUB>1</SUB>-like receptors.<SUP> </SUP></P>
	    
	
	    
	    <P>It is generally assumed that the activation of AC by D<SUB>1</SUB>-like receptors is mediated by the G<SUB>s</SUB><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "> subunit of G proteins. However,<SUP> </SUP>it has also been shown that G<SUB>olf</SUB><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha ">, which also stimulates AC, is<SUP> </SUP>expressed in caudate, nucleus accumbens, and olfactory tubercle<SUP> </SUP>and is more abundant in these tissues than G<SUB>s</SUB><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "> (<a href="#B188">188</A>). This suggests<SUP> </SUP>that the D<SUB>1</SUB> receptor in particular, which is highly expressed<SUP> </SUP>in these brain areas, may couple to AC by previously unappreciated<SUP> </SUP>mechanisms. Recent studies suggested that D<SUB>1</SUB>-like receptors can<SUP> </SUP>also couple to G proteins different from G<SUB>s</SUB><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha ">. In particular, striatal<SUP> </SUP>D<SUB>1</SUB> receptors appear to be associated with G<SUB>i</SUB><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "> proteins when reconstituted<SUP> </SUP>in phospholipid vesicles (<a href="#B413">413</A>). In transfected GH<SUB>4</SUB>C<SUB>1</SUB> cells, D<SUB>1</SUB><SUP> </SUP>receptors interact with an inhibitory G<SUB>i</SUB><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha ">/G<SUB>o</SUB><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "> protein that has<SUP> </SUP>not been better identified (<a href="#B229">229</A>). In addition, immunoprecipitation<SUP> </SUP>with antibodies specific for different G protein subtypes revealed<SUP> </SUP>that the D<SUB>1</SUB> receptor coprecipitates with both G<SUB>o</SUB><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "> (<a href="#B230">230</A>) and G<SUB>q</SUB><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "><SUP> </SUP>(<a href="#B459">459</A>), the latter coupling D<SUB>1</SUB> receptors to phosphoinositide metabolism<SUP> </SUP>(<a href="#B459">459</A>, <a href="#B477">477</A>).</P>
	    
	
	    
	    <P>That the D<SUB>2</SUB> receptor can inhibit AC was shown in the early 1980s in the pituitary (<a href="#B99">99</A>, <a href="#B121">121</A>, <a href="#B289">289</A>, <a href="#B345">345</A>) and in the CNS (<a href="#B344">344</A>).<SUP> </SUP>As expected, the cloning of the D<SUB>2</SUB> receptor confirmed these observations<SUP> </SUP>(reviewed in Ref. <a href="#B159">159</A>).</P>
	    
	
	    
	    <P>Although not immediately apparent, the D<SUB>3</SUB> receptor has been shown to be coupled to inhibition of AC. Initially, it was reported<SUP> </SUP>that this receptor did not inhibit AC in cell lines and did not<SUP> </SUP>couple to G proteins as shown by the lack of a guanine nucleotide<SUP> </SUP>shift of agonist binding curves (<a href="#B420">420</A>). Similarly, subsequent<SUP> </SUP>observations also indicated that the D<SUB>3</SUB> receptor did not inhibit<SUP> </SUP>cAMP accumulation in various cell lines (<a href="#B144">144</A>, <a href="#B274">274</A>, <a href="#B438">438</A>). However,<SUP> </SUP>more recently it has been shown that the D<SUB>3</SUB> receptor does weakly<SUP> </SUP>inhibit AC in some cell lines (<a href="#B75">75</A>, <a href="#B287">287</A>, <a href="#B360">360</A>, <a href="#B377">377</A>).<SUP> </SUP></P>
	    
	
	    
	    <P>On the other hand, that the D<SUB>4</SUB> receptor can inhibit cAMP accumulation was reported in retina (<a href="#B80">80</A>) and a variety of cell<SUP> </SUP>culture lines (<a href="#B74">74</A>, <a href="#B287">287</A>, <a href="#B290">290</A>, <a href="#B438">438</A>). Thus inhibition of AC seems<SUP> </SUP>to be a general property of the D<SUB>2</SUB>-like receptors.<SUP> </SUP></P>
	    
	
	
    
	
	<A NAME="SEC7_3">
<P ALIGN=LEFT><B>B. Calcium Channels</B>
</P>

	
	    
	    <P>The D<SUB>1</SUB>-like receptors appear to modulate intracellular calcium levels by a variety of mechanisms. One mechanism is via the<SUP> </SUP>stimulation of phosphatidylinositol (PI) hydrolysis by phospholipase<SUP> </SUP>C (PLC), resulting in the production of inositol 1,4,5-trisphosphate,<SUP> </SUP>which mobilizes intracellular calcium stores. There have been<SUP> </SUP>conflicting reports as to whether D<SUB>1</SUB>-like receptors are capable<SUP> </SUP>of stimulating PI hydrolysis. Upon the cloning of each of the<SUP> </SUP>D<SUB>1</SUB>-like receptors, it was reported that these receptors could<SUP> </SUP>not stimulate PI turnover in COS-7 cells (<a href="#B95">95</A>, <a href="#B101">101</A>, <a href="#B430">430</A>, <a href="#B441">441</A>). In<SUP> </SUP>addition, Pedersen et al. (<a href="#B351">351</A>) reported that neither D<SUB>1</SUB> nor<SUP> </SUP>D<SUB>5</SUB> receptors affected intracellular calcium concentration in Chinese<SUP> </SUP>hamster ovary (CHO) or baby hamster kidney cells. In contrast,<SUP> </SUP>it has been shown that D<SUB>1</SUB>-like receptor agonists cause increases<SUP> </SUP>in PI metabolism in various brain regions (<a href="#B444">444</A>, <a href="#B445">445</A>). However,<SUP> </SUP>it should be noted that greater than 100&nbsp;&#181;M agonist is required<SUP> </SUP>to see this effect, calling into question the physiological relevance<SUP> </SUP>of this response. Other results have suggested indirectly that<SUP> </SUP>D<SUB>1</SUB>-like receptors activate PKC via a PLC-mediated mechanism. The<SUP> </SUP>D<SUB>1</SUB> agonists cause neurite retraction of catfish horizontal cells<SUP> </SUP>in culture, and this effect is mimicked by activators of PKC such<SUP> </SUP>as phorbol esters or diacylglycerol (<a href="#B379">379</A>). In addition, the D<SUB>1</SUB><SUP> </SUP>receptor stimulates PI hydrolysis in Ltk<SUP><IMG SRC="/math/12pt/normal/scr/minus.gif" ALIGN=BASELINE ALT="-"></SUP> cells (<a href="#B266">266</A>). In both of these cases, a significant effect was<SUP> </SUP>observed at 1&nbsp;&#181;M DA, suggesting that coupling to PLC may be a<SUP> </SUP>real mechanism of D<SUB>1</SUB>-like receptor signaling, at least in some<SUP> </SUP>cases.</P>
	    
	
	    
	    <P>On the other hand, the D<SUB>1</SUB> receptor appears to stimulate release of intracellular calcium stores via a mechanism other than<SUP> </SUP>stimulation of PI turnover. D<SUB>1</SUB> receptor-induced increase in intracellular<SUP> </SUP>calcium levels in 293&nbsp;cells (<a href="#B140">140</A>, <a href="#B263">263</A>) is mimicked, in fact, by<SUP> </SUP>other means of increasing cAMP levels (<a href="#B263">263</A>), and thus is probably<SUP> </SUP>the result of activation of protein kinase A (PKA).<SUP> </SUP></P>
	    
	
	    
	    <P>Finally, the D<SUB>1</SUB> receptor appears to affect the activity of calcium channels. In both rat striatal neurons and D<SUB>1</SUB> receptor-transfected<SUP> </SUP>GH<SUB>4</SUB>C<SUB>1</SUB> cells, D<SUB>1</SUB> agonists increase calcium currents by L-type calcium<SUP> </SUP>channels. In both cases, the effect is mimicked by cAMP analogs<SUP> </SUP>(<a href="#B266">266</A>, <a href="#B432">432</A>) and blocked by PKA inhibitors (<a href="#B432">432</A>), suggesting that<SUP> </SUP>it may be the result of phosphorylation of calcium channels by<SUP> </SUP>PKA. In addition, in rat striatal neurons, D<SUB>1</SUB> agonists reduce<SUP> </SUP>calcium currents carried by N- and P-type calcium channels. This<SUP> </SUP>activity of the D<SUB>1</SUB> receptor was also mimicked by cAMP analogs<SUP> </SUP>and blocked by PKA inhibitors as well as the phosphatase inhibitor<SUP> </SUP>okadaic acid (<a href="#B432">432</A>). The proposed model is that D<SUB>1</SUB> receptors reduce<SUP> </SUP>these currents by PKA stimulation of a phosphatase which, in turn,<SUP> </SUP>dephosphorylates the channels leading to their inactivation. Thus<SUP> </SUP>the regulation of calcium by D<SUB>1</SUB>-like receptors appears to be quite<SUP> </SUP>complex and occurs through a variety of mechanisms.<SUP> </SUP></P>
	    
	
	    
	    <P>D<SUB>2</SUB>-like receptors also mediate changes in intracellular calcium levels. In some transfected cell systems, the D<SUB>2</SUB> receptor<SUP> </SUP>produces an increase in intracellular calcium via stimulation<SUP> </SUP>of PI hydrolysis. This has been observed in Ltk<SUP><IMG SRC="/math/12pt/normal/scr/minus.gif" ALIGN=BASELINE ALT="-"></SUP> cells (<a href="#B448">448</A>) and in CCL1.3 cells (<a href="#B438">438</A>). However, in many other<SUP> </SUP>cell lines, the D<SUB>2</SUB> receptor has been shown not to couple to this<SUP> </SUP>second messenger. In addition, D<SUB>2</SUB> receptors in the pituitary have<SUP> </SUP>been shown to inhibit PI metabolism (<a href="#B52">52</A>, <a href="#B122">122</A>, <a href="#B416">416</A>). Neither D<SUB>3</SUB><SUP> </SUP>nor D<SUB>4</SUB> receptors increase PI hydrolysis in any cell line tested.<SUP> </SUP>D<SUB>2</SUB> receptors have also been shown to cause release of intracellular<SUP> </SUP>calcium stores in NG108-15 cells, although the mechanism for this<SUP> </SUP>release has not been examined (<a href="#B64">64</A>).<SUP> </SUP></P>
	    
	
	    
	    <P>D<SUB>2</SUB>-like receptors can also cause a decrease in intracellular calcium levels by inhibition of inward calcium currents. This<SUP> </SUP>is the case for the D<SUB>2</SUB> receptor in GH<SUB>4</SUB>C<SUB>1</SUB> cells (<a href="#B396">396</A>, <a href="#B448">448</A>), pituitary<SUP> </SUP>lactotrophs (<a href="#B268">268</A>), melanotrophs (<a href="#B468">468</A>), and differentiated NG108-15<SUP> </SUP>cells (<a href="#B397">397</A>). D<SUB>3</SUB> receptors also inhibit calcium currents in differentiated<SUP> </SUP>NG108-15 cells (<a href="#B395">395</A>), whereas D<SUB>4</SUB> receptors have this effect in<SUP> </SUP>GH<SUB>4</SUB>C<SUB>1</SUB> cells (<a href="#B396">396</A>). Two mechanisms may be responsible for this<SUP> </SUP>effect: D<SUB>2</SUB>-like receptor-induced activation of potassium currents<SUP> </SUP>leading to alterations in membrane potential (reviewed in Ref.<SUP> </SUP><a href="#B447">447</A>) and activation of G proteins that directly inhibit some<SUP> </SUP>calcium channels. In both pituitary lactotrophs and GH<SUB>4</SUB>C<SUB>1</SUB> cells,<SUP> </SUP>inactivation of G<SUB>o</SUB><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "> subunits by antisense oligonucleotides abolishes<SUP> </SUP>inhibition of calcium currents by D<SUB>2</SUB> receptors (<a href="#B15">15</A>, <a href="#B267">267</A>). In<SUP> </SUP>contrast, in pituitary cells, alterations in potassium currents<SUP> </SUP>by the D<SUB>2</SUB> receptor appear to be mediated via G<SUB>i-3</SUB><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "> subunits (<a href="#B15">15</A>, <a href="#B268">268</A>),<SUP> </SUP>suggesting that the D<SUB>2</SUB> modulation of calcium currents is independent<SUP> </SUP>of changes in potassium conductance. Thus, similar to the D<SUB>1</SUB>-like<SUP> </SUP>receptors, the D<SUB>2</SUB> receptor seems to alter intracellular calcium<SUP> </SUP>levels through multiple mechanisms, whereas to date, the D<SUB>3</SUB> and<SUP> </SUP>D<SUB>4</SUB> receptors have only been shown to inhibit calcium currents.<SUP> </SUP></P>
	    
	
	
    
	
	<A NAME="SEC7_4">
<P ALIGN=LEFT><B>C. Potassium Channels</B>
</P>

	
	    
	    <P>Dopamine receptors have been shown to influence the activity of potassium channels. This has not been well documented in the<SUP> </SUP>case of the D<SUB>1</SUB>-like receptors. D<SUB>1</SUB>-like agonists were shown to<SUP> </SUP>increase potassium efflux from chick retinal cells via a cAMP-independent<SUP> </SUP>mechanism (<a href="#B243">243</A>). In contrast, a D<SUB>1</SUB>-like agonist inhibited a potassium<SUP> </SUP>current in rat striatal neurons (<a href="#B232">232</A>).<SUP> </SUP></P>
	    
	
	    
	    <P>The role of D<SUB>2</SUB>-like receptors in modulating potassium currents has been more extensively studied. In many preparations, it<SUP> </SUP>has been shown that D<SUB>2</SUB>-like receptors increase outward potassium<SUP> </SUP>currents, leading to cell hyperpolarization. Such effects have<SUP> </SUP>been observed in rat striatal and mesencephalic neurons as well<SUP> </SUP>as in anterior pituitary (<a href="#B65">65</A>, <a href="#B119">119</A>, <a href="#B172">172</A>, <a href="#B232">232</A>, <a href="#B264">264</A>, <a href="#B467">467</A>). This activation<SUP> </SUP>of potassium currents appears to be modulated by G protein mechanisms.<SUP> </SUP>The effect of DA on potassium currents in melanotrophs is in fact<SUP> </SUP>abolished by pertussis toxin (PTX) treatment (<a href="#B264">264</A>, <a href="#B467">467</A>). In addition,<SUP> </SUP>treatment of cells with G protein antibodies or antisense oligonucleotides<SUP> </SUP>blocks the D<SUB>2</SUB> receptor stimulation of potassium currents. In pituitary,<SUP> </SUP>activation of potassium currents appears to be mediated by G<SUB>i-3</SUB><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "><SUP> </SUP>(<a href="#B15">15</A>, <a href="#B268">268</A>), whereas in rat mesencephalon cultures, by G<SUB>o</SUB><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "> (<a href="#B264">264</A>).<SUP> </SUP>Such discrepancies may be the result of varying G protein subunit<SUP> </SUP>expression between different cells, or may reflect the modulation<SUP> </SUP>of different potassium conductances by D<SUB>2</SUB> receptors.<SUP> </SUP></P>
	    
	
	    
	    <P>The functional significance of cell hyperpolarization appears to be the inhibition of DA release by autoreceptors in the brain<SUP> </SUP>and of prolactin secretion in the pituitary. Blockade of potassium<SUP> </SUP>channels with 4-aminopyridine (4-AP) or tetraethylammonium (TEA)<SUP> </SUP>abolished the inhibition of evoked DA release by D<SUB>2</SUB>-like agonists<SUP> </SUP>in striatal slices or synaptosomes (<a href="#B39">39</A>, <a href="#B63">63</A>). Furthermore, in<SUP> </SUP>transfected MN9D cells, D<SUB>2</SUB> or D<SUB>3</SUB> receptor-mediated inhibition<SUP> </SUP>of DA release was also blocked by 4-AP and TEA (<a href="#B439">439</A>).<SUP> </SUP></P>
	    
	
	
    
	
	<A NAME="SEC7_5">
<P ALIGN=LEFT><B>D. Arachidonic Acid</B>
</P>

	
	    
	    <P>In 1991,&nbsp;several groups showed that in CHO cells, the D<SUB>2</SUB> receptor potentiates the release of arachidonic acid (AA) evoked<SUP> </SUP>by calcium (<a href="#B125">125</A>, <a href="#B227">227</A>, <a href="#B356">356</A>). These results were confirmed later<SUP> </SUP>by Freedman et al. (<a href="#B144">144</A>) and MacKenzie et al. (<a href="#B274">274</A>). In addition,<SUP> </SUP>in primary striatal neuron cultures, D<SUB>2</SUB>-like agonists also cause<SUP> </SUP>potentiation of calcium-evoked AA release (<a href="#B392">392</A>). The D<SUB>3</SUB> receptor<SUP> </SUP>does not appear to have this effect in cultured cell lines, but<SUP> </SUP>the D<SUB>4</SUB> receptor does potentiate AA release in CHO cells (<a href="#B74">74</A>).<SUP> </SUP>This pathway is sensitive to PTX (<a href="#B74">74</A>, <a href="#B356">356</A>), suggesting that G<SUB>i</SUB><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "><SUP> </SUP>subunits are involved. The mechanism by which D<SUB>2</SUB>-like receptors<SUP> </SUP>potentiate AA release is not clear. In some reports, this effect<SUP> </SUP>is not related to changes in cAMP levels that might be mediated<SUP> </SUP>by the D<SUB>2</SUB> or D<SUB>4</SUB> receptors (<a href="#B74">74</A>, <a href="#B225">225</A>). Although Piomelli et al.<SUP> </SUP>(<a href="#B356">356</A>) observed an enhancement of the D<SUB>2</SUB> receptor potentiation<SUP> </SUP>of AA release in the presence of a cAMP analog, PKC seems more<SUP> </SUP>likely to play a role in this signaling system. Downregulation<SUP> </SUP>of PKC by 24-h treatment of cells with phorbol 12-myristate 13-acetate<SUP> </SUP>blocks the D<SUB>2</SUB> and D<SUB>4</SUB> effect (<a href="#B74">74</A>, <a href="#B225">225</A>) as does treatment with<SUP> </SUP>the PKC inhibitor staurosporine (<a href="#B125">125</A>). In addition, activation<SUP> </SUP>of PKC increases the maximal AA release in the presence of D<SUB>2</SUB><SUP> </SUP>agonists and calcium ionophore and increases the potency of agonist<SUP> </SUP>to elicit this response (<a href="#B109">109</A>). This evidence suggests that potentiation<SUP> </SUP>of AA release is mediated by alterations in PKC activity.<SUP> </SUP></P>
	    
	
	    
	    <P>There is little evidence that D<SUB>1</SUB>-like receptors affect AA release. Piomelli et al. (<a href="#B356">356</A>) reported that in CHO cells, the<SUP> </SUP>D<SUB>1</SUB> receptor did not affect calcium-evoked AA release. However,<SUP> </SUP>when D<SUB>1</SUB> and D<SUB>2</SUB> receptors were expressed simultaneously in CHO<SUP> </SUP>cells, a combination of D<SUB>1</SUB> and D<SUB>2</SUB> agonists caused a greater potentiation<SUP> </SUP>of AA release than D<SUB>2</SUB> agonists alone. In contrast, in primary<SUP> </SUP>cultures of striatal neurons, D<SUB>1</SUB>-like agonists caused an inhibition<SUP> </SUP>of calcium-evoked AA release (<a href="#B392">392</A>), an effect that was mimicked<SUP> </SUP>by forskolin, suggesting the involvement of PKA in this response.<SUP> </SUP></P>
	    
	
	
    
	
	<A NAME="SEC7_6">
<P ALIGN=LEFT><B>E. Na<SUP>+</SUP>/H<SUP>+</SUP> Exchange</B>
</P>

	
	    
	    <P>Dopamine receptors also appear to affect the activity of amiloride-sensitive Na<SUP>+</SUP>/H<SUP>+</SUP> exchangers, which are responsible for regulation of intracellular<SUP> </SUP>pH and cell volume. This exchanger is also the major player in<SUP> </SUP>sodium absorption in many epithelia (<a href="#B478">478</A>). The activity of the<SUP> </SUP>Na<SUP>+</SUP>/H<SUP>+</SUP> exchanger is regulated by multiple mechanisms, including phosphorylation-dependent<SUP> </SUP>and -independent events and direct regulation by the G<SUB>i-3</SUB><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "> subunit<SUP> </SUP>(<a href="#B104">104</A>, <a href="#B478">478</A>). In preparations of renal brush-border membrane vesicles,<SUP> </SUP>D<SUB>1</SUB> receptor agonists cause an inhibition of the activity of the<SUP> </SUP>Na<SUP>+</SUP>/H<SUP>+</SUP> exchanger by both cAMP-dependent and cAMP-independent mechanisms<SUP> </SUP>(<a href="#B123">123</A>, <a href="#B125">125</A>).</P>
	    
	
	    
	    <P>In contrast, the D<SUB>2</SUB> receptor activates a Na<SUP>+</SUP>/H<SUP>+</SUP> exchanger in many cells. This has been observed in renal brush-border membrane<SUP> </SUP>vesicles (<a href="#B123">123</A>) in transfected C6 glioma and Ltk<SUP><IMG SRC="/math/12pt/normal/scr/minus.gif" ALIGN=BASELINE ALT="-"></SUP> cells (<a href="#B329">329</A>) and in primary cultures of anterior pituitary cells<SUP> </SUP>(<a href="#B147">147</A>). In these systems, the observed increase in extracellular<SUP> </SUP>acidification was not blocked by PTX, suggesting that a mechanism<SUP> </SUP>other than G<SUB>i</SUB><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "> was involved. However, in CHO cells, D<SUB>2</SUB> ,&nbsp;D<SUB>3</SUB> ,<SUP> </SUP>and D<SUB>4</SUB> receptors all increase extracellular acidification rates<SUP> </SUP>in a PTX-sensitive manner (<a href="#B74">74</A>). These conflicting reports are<SUP> </SUP>presumably the result of the existence of multiple subtypes of<SUP> </SUP>amiloride-sensitive Na<SUP>+</SUP>/H<SUP>+</SUP> exchangers as well as multiple mechanisms for their regulation.<SUP> </SUP></P>
	    
	
	
    
	
	<A NAME="SEC7_7">
<P ALIGN=LEFT><B>F. Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase</B>
</P>

	
	    
	    <P>The Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase, which pumps sodium out of cells and potassium in, is essential for maintaining the electrochemical gradient<SUP> </SUP>that is responsible for the excitability of nerve and muscle cells<SUP> </SUP>and drives the transport of fluid and solutes across epithelial<SUP> </SUP>membranes. It has been known that DA receptors influence the activity<SUP> </SUP>of this ion pump. In this manner, DA regulates fluid absorption<SUP> </SUP>in the kidney and neuronal excitability in the brain. Most work<SUP> </SUP>has suggested that DA effects on the Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase are mediated through the D<SUB>1</SUB> receptor. However, some reports<SUP> </SUP>also suggested that activation of both D<SUB>1</SUB> and D<SUB>2</SUB> receptors may<SUP> </SUP>be required. In a preparation of dissociated striatal neurons,<SUP> </SUP>Bertorello et al. (<a href="#B34">34</A>) found that inhibition of the Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase required the presence of DA or a combination of D<SUB>1</SUB> and<SUP> </SUP>D<SUB>2</SUB> agonists. However, other studies have suggested that D<SUB>1</SUB> receptors<SUP> </SUP>alone are sufficient to evoke an inhibition of the Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase. In the chick retina, DA inhibits Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase activity, and this has been suggested to be mediated by<SUP> </SUP>D<SUB>1</SUB> receptors (<a href="#B243">243</A>). In addition, in renal proximal tubule preparations<SUP> </SUP>and the Madin-Darby canine kidney cell culture model of cortical<SUP> </SUP>collecting tubule, D<SUB>1</SUB>-like agonists cause an inhibition of the<SUP> </SUP>Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase, whereas D<SUB>2</SUB>-like agonists have no effect (<a href="#B70">70</A>, <a href="#B407">407</A>). In<SUP> </SUP>the kidney, the effects of DA receptor activation on Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase activity appear to be the result of phosphorylation cascades<SUP> </SUP>involving both PKA and PKC. However, in Ltk<SUP><IMG SRC="/math/12pt/normal/scr/minus.gif" ALIGN=BASELINE ALT="-"></SUP> fibroblast cells transfected with the D<SUB>1</SUB> receptor, D<SUB>1</SUB>-like agonists<SUP> </SUP>inhibit Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase activity in a PKA-dependent manner (<a href="#B195">195</A>). Therefore,<SUP> </SUP>although in general it appears that D<SUB>1</SUB> receptors are responsible<SUP> </SUP>for regulation of the Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase, the mechanism may vary according to the tissue examined.<SUP> </SUP></P>
	    
	
	
    
	
	<A NAME="SEC7_8">
<P ALIGN=LEFT><B>G. Additional Signal Transduction Pathways Involved in Mitogenesis</B>
</P>

	
	    
	    <P>Recent evidence has suggested that in some cases D<SUB>2</SUB>-like receptors are involved in mitogenesis and cell differentiation. The<SUP> </SUP>D<SUB>3</SUB> receptor stimulates [<SUP>3</SUP>H]thymidine incorporation in NG108-15 cells (<a href="#B355">355</A>), and both D<SUB>2</SUB><SUP> </SUP>and D<SUB>3</SUB> receptors have this effect in CHO cells (<a href="#B75">75</A>, <a href="#B244">244</A>, <a href="#B434">434</A>).<SUP> </SUP>This effect is blocked by PTX and appears to be independent of<SUP> </SUP>alterations in cAMP levels. Lajiness et al. (<a href="#B244">244</A>) found that<SUP> </SUP>the D<SUB>2</SUB> mitogenic effect was accompanied by an increase in tyrosine<SUP> </SUP>phosphorylation levels and was blocked by the tyrosine kinase<SUP> </SUP>inhibitor genistein, suggesting that this receptor may cause the<SUP> </SUP>activation of the mitogen-activated protein kinase pathway.<SUP> </SUP></P>
	    
	
	    
	    <P>In contrast to the above results, the D<SUB>2</SUB> receptor has also been shown to inhibit cell growth in some cell lines. GH<SUB>4</SUB>C<SUB>1</SUB> cells<SUP> </SUP>transfected with the D<SUB>2</SUB> receptor respond to agonists with a decrease<SUP> </SUP>in [<SUP>3</SUP>H]thymidine uptake. Florio et al. (<a href="#B138">138</A>) found that this effect<SUP> </SUP>was abolished by PTX, was accompanied by an increase in phosphotyrosine<SUP> </SUP>phosphatase (PTP) activity, and was blocked by the PTP inhibitor<SUP> </SUP>vanadate. In contrast, another study found that in GH<SUB>4</SUB>C<SUB>1</SUB> ,&nbsp;the<SUP> </SUP>D<SUB>2</SUB> receptor-mediated inhibition of [<SUP>3</SUP>H]thymidine uptake was not blocked by PTX but was blocked by downregulation<SUP> </SUP>of PKC and by PKC inhibitors (<a href="#B406">406</A>). Thus, although the mechanism<SUP> </SUP>of inhibition of mitogenesis by D<SUB>2</SUB> receptors in GH<SUB>4</SUB>C<SUB>1</SUB> cells is<SUP> </SUP>not clear, it may result from PKC-mediated activation of a phosphatase.<SUP> </SUP>The effects of D<SUB>2</SUB> receptor activation on cell growth appear to<SUP> </SUP>highly depend on the cell type examined.<SUP> </SUP></P>
	    
	
	    
	    <P>Finally, the D<SUB>2</SUB>-like receptors may promote some aspects of cell differentiation. When D<SUB>2</SUB> ,&nbsp;D<SUB>3</SUB> ,&nbsp;or D<SUB>4</SUB> receptors were expressed<SUP> </SUP>in the mesencephalic cell line MN9D, agonists caused increases<SUP> </SUP>in neurite number and length as well as total neuritic extent<SUP> </SUP>(<a href="#B435">435</A>). However, in a study using primary cultures of rat mesencephalon<SUP> </SUP>neurons, a D<SUB>2</SUB>-like receptor agonist did not affect survival or<SUP> </SUP>differentiation of these cells (<a href="#B449">449</A>). The role of D<SUB>2</SUB>-like receptors<SUP> </SUP>in neuronal differentiation thus remains to be clarified.<SUP> </SUP></P>
	    
	
	    
	    <P>In conclusion, much effort has gone into studying the signal transduction of the DA receptors during the last 20&nbsp;years. Many<SUP> </SUP>second messengers for these receptors have been identified, including<SUP> </SUP>cAMP, calcium, potassium, and AA. In addition, these receptors<SUP> </SUP>modulate other "effectors" by more indirect means, including Na<SUP>+</SUP>/H<SUP>+</SUP> exchangers, the Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase, and cell growth and differentiation pathways (Fig. <a href="#F2">2</a>).<SUP> </SUP>However, in many cases, there is conflicting evidence in the literature<SUP> </SUP>for the modulation of various messengers, or the mechanism by<SUP> </SUP>which an effector is modulated by the DA receptors. Many of these<SUP> </SUP>discrepancies probably arise from the use of different tissues<SUP> </SUP>or cell culture lines. It is now known that many of the components<SUP> </SUP>of signal transduction pathways have multiple isoforms, including<SUP> </SUP>receptors, G proteins, and effectors, and that these have differing<SUP> </SUP>patterns of expression and regulatory properties. Defining which<SUP> </SUP>of these specific signal transduction events is involved in the<SUP> </SUP>various physiological actions of DA may require the development<SUP> </SUP>of specific pharmacological agents or genetic animals models.<SUP> </SUP>

    
	
<A NAME="F2"><!-- FIG 2 --></A>

<P><CENTER><TABLE WIDTH=95% CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1>
<TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF>

	
    <A HREF="/cgi/content/full/78/1/189/F2">
    <IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=200 HEIGHT=139 SRC="/content/vol78/issue1/images/small/jnp.ja09f2.gif"></A><BR>
<STRONG>View larger version</STRONG> (37K):
<BR><NOBR><A HREF="/cgi/content/full/78/1/189/F2">[in this window]</A>
<BR><A HREF="/cgi/content-nw/full/78/1/189/F2"
    onClick="startTarget('F2', 590, 505); this.href='/cgi/content-nw/full/78/1/189/F2'"
    onMouseOver="window.status='View figure in a separate window'; return true"
    TARGET="F2">[in a new window]</A><BR>&nbsp;
    </NOBR>

	

</TD><TD ALIGN=LEFT VALIGN=top><font size=-1>FIG.</font> 2. &nbsp;
Signal transduction of dopamine receptors. AC, adenylate cyclase; PLC, phospholipase C.

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>
<P>
<!-- /FIG 2 -->

    

</P>
	    
	
	
    

    
    <A NAME="SEC8">
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;VIII. DOPAMINE RECEPTORS IN THE BRAIN</FONT></TH>
</TR>
</TABLE>
<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Top</A><BR>









<A HREF="#SEC7"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Previous</A><BR>



<A HREF="#SEC9"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Next</A><BR>


<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">References</A>

</FONT></TH>
</TR></TABLE>

    
	
	<A NAME="SEC8_1">
<P ALIGN=LEFT><B>A. Distribution of Dopamine Receptors</B>
</P>

	
	    
	    <P>Dopaminergic neurons in the substantia nigra pars compacta, the ventral tegmental area, and the hypothalamus give origin to<SUP> </SUP>three main pathways, the nigrostriatal, the mesolimbocortical,<SUP> </SUP>and the tuberoinfundibular. Because of the lack of ligands specific<SUP> </SUP>for each receptor subtype, in situ hybridization has been extensively<SUP> </SUP>used to study the distribution of DA receptor mRNAs in the brain.<SUP> </SUP></P>
	    
	
	    
	    <P>The D<SUB>1</SUB> receptor is the most widespread DA receptor and is expressed at higher levels than any other DA receptor (<a href="#B95">95</A>, <a href="#B145">145</A>, <a href="#B463">463</A>).<SUP> </SUP>D<SUB>1</SUB> mRNA has been found in the striatum, the nucleus accumbens,<SUP> </SUP>and the olfactory tubercle. In addition, D<SUB>1</SUB> receptors have been<SUP> </SUP>detected in the limbic system, hypothalamus, and thalamus. On<SUP> </SUP>the other hand, in other areas where the D<SUB>1</SUB> receptor protein is<SUP> </SUP>highly expressed such as the entopeducular nucleus and the substantia<SUP> </SUP>nigra pars reticulata (<a href="#B153">153</A>, <a href="#B255">255</A>), no mRNA has been detected (<a href="#B95">95</A>, <a href="#B145">145</A>, <a href="#B463">463</A>).<SUP> </SUP>This suggests that in these areas the D<SUB>1</SUB> receptor is mainly present<SUP> </SUP>in projections (<a href="#B95">95</A>, <a href="#B145">145</A>, <a href="#B463">463</A>). As a matter of fact, D<SUB>1</SUB> receptors<SUP> </SUP>in the entopeduncular nucleus and in the substantia nigra pars<SUP> </SUP>reticulata are preferentially localized on striatal GABAergic<SUP> </SUP>neurons coexpressing substance P (<a href="#B153">153</A>, <a href="#B255">255</A>).<SUP> </SUP></P>
	    
	
	    
	    <P>The D<SUB>5</SUB> receptor is poorly expressed in rat brain when compared with the D<SUB>1</SUB> receptor. A distribution restricted to the hippocampus,<SUP> </SUP>the lateral mamillary nucleus, and the parafascicular nucleus<SUP> </SUP>of the thalamus, where the D<SUB>1</SUB> receptor is not significantly expressed,<SUP> </SUP>was originally reported (<a href="#B293">293</A>, <a href="#B441">441</A>), with little or no message<SUP> </SUP>detected in the dorsal striatum, nucleus accumbens, and olfactory<SUP> </SUP>tubercle. Upon further examination, D<SUB>5</SUB> receptor mRNA has been<SUP> </SUP>found in several rostral forebrain regions including cerebral<SUP> </SUP>cortex, lateral thalamus, diagonal band area, striatum, and, to<SUP> </SUP>a lesser extent, substantia nigra, medial thalamus, and hippocampus<SUP> </SUP>(<a href="#B76">76</A>, <a href="#B203">203</A>, <a href="#B366">366</A>).</P>
	    
	
	    
	    <P>The development of specific antibodies against DA receptor subtypes recently made it possible to define their cellular and<SUP> </SUP>subcellular localization in different regions of primate brain.<SUP> </SUP>Both D<SUB>1</SUB> and D<SUB>5</SUB> receptors are coexpressed in pyramidal neurons<SUP> </SUP>of prefrontal, premotor, cingulate and entorhinal cortex, the<SUP> </SUP>hippocampus, and the dentate gyrus (<a href="#B27">27</A>, <a href="#B28">28</A>, <a href="#B197">197</A>, <a href="#B417">417</A>). Electron<SUP> </SUP>microscopy analysis demonstrated that in the prefrontal cortex<SUP> </SUP>and the hippocampus, D<SUB>1</SUB> and D<SUB>5</SUB> receptors have both pre- and postsynaptic<SUP> </SUP>localization, with the postsynaptic one more frequently observed.<SUP> </SUP>Ultrastructural analysis suggested that within individual pyramidal<SUP> </SUP>neurons, D<SUB>1</SUB> and D<SUB>5</SUB> receptors have a different localization with<SUP> </SUP>the D<SUB>1</SUB> concentrated in dentritic spines and the D<SUB>5</SUB> in dendritic<SUP> </SUP>shafts (<a href="#B28">28</A>, <a href="#B417">417</A>). In the olfactor bulb D<SUB>1</SUB> receptors are restricted<SUP> </SUP>to the internal granular and plexiform layers and in the amygdala<SUP> </SUP>in the intercalated and basolateral nuclei (<a href="#B260">260</A>). In the caudate<SUP> </SUP>nucleus, D<SUB>1</SUB> and D<SUB>5</SUB> receptors are mostly localized within medium-sized<SUP> </SUP>GABAergic neurons (<a href="#B28">28</A>, <a href="#B197">197</A>, <a href="#B417">417</A>). D<SUB>5</SUB> but not D<SUB>1</SUB> receptors are<SUP> </SUP>present also in large cholinergic interneurons (<a href="#B28">28</A>). Ultrastructural<SUP> </SUP>analysis suggested that D<SUB>1</SUB> receptors are present on spines postsynaptic<SUP> </SUP>to asymmetrical synapses, that both D<SUB>1</SUB> and D<SUB>5</SUB> receptors are at<SUP> </SUP>postsynaptic densities of small synapses characteristics of DA<SUP> </SUP>terminals, and that presynaptic D<SUB>1</SUB> and D<SUB>5</SUB> receptors are on axons<SUP> </SUP>forming asymmetrical synapses (<a href="#B28">28</A>, <a href="#B187">187</A>, <a href="#B260">260</A>, <a href="#B417">417</A>). D<SUB>1</SUB> receptors<SUP> </SUP>have been localized in the entopeduncular nucleus and in the pars<SUP> </SUP>reticulata of the substantia nigra, where D<SUB>5</SUB> receptors are undetectable<SUP> </SUP>(<a href="#B28">28</A>, <a href="#B187">187</A>, <a href="#B260">260</A>). This observation suggests that if D<SUB>1</SUB> and D<SUB>5</SUB> receptors<SUP> </SUP>are colocalized in medium-sized spiny neurons of caudate, only<SUP> </SUP>the D<SUB>1</SUB> receptor is transported to striatonigral terminals. These<SUP> </SUP>differences in the cellular and subcellular localization thus<SUP> </SUP>suggest that although D<SUB>1</SUB> and D<SUB>5</SUB> receptors exhibit similar pharmacology,<SUP> </SUP>they are not functionally redundant.<SUP> </SUP></P>
	    
	
	    
	    <P>The D<SUB>2</SUB> receptor has been found mainly in the striatum, in the olfactory tubercle, in the core of nucleus accumbens (<a href="#B38">38</A>;<SUP> </SUP>reviewed in Ref. <a href="#B217">217</A>), where it is expressed by GABAergic neurons<SUP> </SUP>coexpressing enkephalins (<a href="#B253">253</A>, <a href="#B256">256</A>), and in the septal pole of<SUP> </SUP>the shell of the nucleus accumbens where it is expressed by neurotensin-containing<SUP> </SUP>neurons (<a href="#B105">105</A>). D<SUB>2</SUB> receptor mRNA is also present in the prefrontal,<SUP> </SUP>cingulate, temporal, and enthorinal cortex, in the septal region,<SUP> </SUP>in the amygdala, and in the granule cells of the hippocampal formation<SUP> </SUP>(<a href="#B38">38</A>; reviewed in Ref. <a href="#B217">217</A>). It is also found in the hypothalamus,<SUP> </SUP>in the substantia nigra pars compacta, and in the ventral tegmental<SUP> </SUP>area, where it is expressed by dopaminergic neurons (<a href="#B38">38</A>, <a href="#B292">292</A>, <a href="#B463">463</A>).<SUP> </SUP>Immunohistochemical analysis with specific antibodies revealed<SUP> </SUP>that D<SUB>2</SUB> receptors are present in medium spiny neurons of the striatum<SUP> </SUP>where they are more concentrated in spiny dendrites and spine<SUP> </SUP>heads than in the somata. Colocalization with D<SUB>1</SUB> receptors is<SUP> </SUP>rare. D<SUB>2</SUB> immunoreactive terminals are frequently detectable, forming<SUP> </SUP>symmetrical, rather than asymmetrical, synapses (<a href="#B187">187</A>, <a href="#B260">260</A>). The<SUP> </SUP>D<SUB>2</SUB> receptors are present in perikarya and dendrites within the<SUP> </SUP>substantia nigra pars compacta and are much more concentrated<SUP> </SUP>in the external segment of the globus pallidus than in other striatal<SUP> </SUP>projections (<a href="#B260">260</A>). D<SUB>2</SUB> receptor immunoreactivity has been detected<SUP> </SUP>in the glomerular and internal plexiform layers of the olfactory<SUP> </SUP>nerve and in the central nucleus of the amygdala (<a href="#B260">260</A>).<SUP> </SUP></P>
	    
	
	    
	    <P>The D<SUB>3</SUB> receptor has a specific distribution to limbic areas (<a href="#B245">245</A>, <a href="#B246">246</A>) such as the ventromedial shell of the nucleus accumbens<SUP> </SUP>(<a href="#B38">38</A>) where it is expressed by substance P and neurotensin neurons<SUP> </SUP>projecting to the ventral pallidum (<a href="#B105">105</A>, <a href="#B106">106</A>), the olfactory tubercle,<SUP> </SUP>and the islands of Calleja (<a href="#B38">38</A>, <a href="#B258">258</A>). In contrast, it is poorly<SUP> </SUP>expressed in the dorsal striatum (<a href="#B38">38</A>, <a href="#B258">258</A>, <a href="#B420">420</A>). The D<SUB>3</SUB> mRNA was<SUP> </SUP>also found in the substantia nigra pars compacta, in the ventral<SUP> </SUP>tegmental area, where it is expressed in a minority of dopaminergic<SUP> </SUP>neurons when compared with the D<SUB>2</SUB> receptors and in the cerebellum<SUP> </SUP>(<a href="#B105">105</A>, <a href="#B106">106</A>). In the islands of Calleja, both D<SUB>3</SUB> receptor binding<SUP> </SUP>and mRNA are present in granule cells (<a href="#B106">106</A>, <a href="#B258">258</A>), which are known<SUP> </SUP>to make sparse contacts with dopaminergic axons. Purkinje cells<SUP> </SUP>in lobules 9&nbsp;and 10&nbsp;of the archicerebellum express D<SUB>3</SUB> mRNA, whereas<SUP> </SUP>binding sites were detectable only in the molecular layer (<a href="#B106">106</A>, <a href="#B258">258</A>).<SUP> </SUP>No dopaminergic projections are present in this area, suggesting<SUP> </SUP>that the D<SUB>3</SUB> receptor may respond to DA diffusing extrasynaptically<SUP> </SUP>(<a href="#B106">106</A>). The D<SUB>3</SUB> receptor was also found at low expression levels<SUP> </SUP>in the hippocampus, in the septal area, and in various cortical<SUP> </SUP>layers and subregions of the medial-temporal lobe (<a href="#B38">38</A>).<SUP> </SUP></P>
	    
	
	    
	    <P>Low levels of the D<SUB>4</SUB> receptor mRNA have been found in the basal ganglia. In contrast, this receptor appears to be highly expressed<SUP> </SUP>in the frontal cortex, amygdala, hippocampus, hypothalamus, and<SUP> </SUP>mesencephalon (<a href="#B343">343</A>, <a href="#B450">450</A>). Significant levels of D<SUB>4</SUB> mRNA were also<SUP> </SUP>found in the retina (<a href="#B80">80</A>). Recently, a specific antibody directed<SUP> </SUP>against the D<SUB>4</SUB> receptor has been developed. Immunohistochemical<SUP> </SUP>and electron microscopy analysis revealed that in both the cerebral<SUP> </SUP>cortex and hippocampus, D<SUB>4</SUB> receptors are present in pyramidal<SUP> </SUP>and nonpyramidal neurons that have been identified as GABAergic<SUP> </SUP>interneurons (<a href="#B319">319</A>). In the cerebral cortex and hippocampus, D<SUB>4</SUB><SUP> </SUP>receptors thus modulate the GABAergic transmission. D<SUB>4</SUB> receptors<SUP> </SUP>have been also found in GABAergic neurons of both segments of<SUP> </SUP>globus pallidus and of the substantia nigra pars reticulata and<SUP> </SUP>in the reticular nucleus of the thalamus (<a href="#B319">319</A>).<SUP> </SUP></P>
	    
	
	
    
	
	<A NAME="SEC8_2">
<P ALIGN=LEFT><B>B. Function of Brain Dopamine Receptors</B>
</P>

	
	    
	    <P>The behavioral effects of DA have been extensively reviewed (<a href="#B92">92</A>, <a href="#B217">217</A>, <a href="#B235">235</A>, <a href="#B469">469</A>). Here we briefly summarize some of the functional<SUP> </SUP>effects of DA with particular attention to some behaviors where<SUP> </SUP>the role of the different DA receptor subtypes has been investigated.<SUP> </SUP></P>
	    
	
	    
	    <P>The effects of DA on motor activity have been extensively investigated (reviewed in Refs. <a href="#B79">79</A>, <a href="#B217">217</A>, <a href="#B456">456</A>, <a href="#B457">457</A>). The degree of<SUP> </SUP>forward locomotion is primarily controlled by the ventral striatum<SUP> </SUP>through activation of D<SUB>1</SUB> ,&nbsp;D<SUB>2</SUB> ,&nbsp;and D<SUB>3</SUB> receptors. Activation of<SUP> </SUP>D<SUB>2</SUB> autoreceptors, which results in decreased DA release, has been<SUP> </SUP>shown to decrease locomotor activity (reviewed in Ref. <a href="#B217">217</A>),<SUP> </SUP>whereas activation of postsynaptic D<SUB>2</SUB> receptors slightly increases<SUP> </SUP>locomotion. Activation of D<SUB>1</SUB> receptors has little or no effect<SUP> </SUP>on locomotor activity (<a href="#B155">155</A>; reviewed in Ref. <a href="#B217">217</A>). However,<SUP> </SUP>it is now clear that there is synergistic interaction between<SUP> </SUP>D<SUB>1</SUB> and D<SUB>2</SUB> receptors in determining forward locomotion so that<SUP> </SUP>concomitant stimulation of D<SUB>1</SUB> receptors is essential for D<SUB>2</SUB> agonists<SUP> </SUP>to produce maximal locomotor stimulation (<a href="#B41">41</A>, <a href="#B116">116</A>; reviewed in<SUP> </SUP>Refs. <a href="#B79">79</A>, <a href="#B217">217</A>, <a href="#B456">456</A>, <a href="#B457">457</A>). As discussed in section <font size=-1>VIII </font><I>D</I>, these<SUP> </SUP>pharmacological observations have been explicitly confirmed by<SUP> </SUP>targeted inactivation of the D<SUB>1</SUB> receptor gene in the mouse (<a href="#B471">471</A>, <a href="#B472">472</A>).<SUP> </SUP></P>
	    
	
	    
	    <P>The D<SUB>3</SUB> receptor, which has been shown to be mainly postsynaptically located in the nucleus accumbens (<a href="#B106">106</A>), seems to play<SUP> </SUP>an inhibitory role on locomotion. D<SUB>3</SUB>-preferring agonists inhibit,<SUP> </SUP>in fact, locomotor activity (<a href="#B93">93</A>; reviewed in Ref. <a href="#B421">421</A>), whereas<SUP> </SUP>D<SUB>3</SUB>-preferring antagonists evoke motor activation (reviewed in<SUP> </SUP>Refs. <a href="#B421">421</A>, <a href="#B461">461</A>). The opposing effects of D<SUB>2</SUB> and D<SUB>3</SUB> receptors on<SUP> </SUP>locomotor activity may find a neurochemical correlate in their<SUP> </SUP>opposite effects on neurotensin gene expression in the nucleus<SUP> </SUP>accumbens (<a href="#B105">105</A>).</P>
	    
	
	    
	    <P>Mesolimbocortical DA is implicated in reward and reinforcement mechanisms as shown by the observation that administration<SUP> </SUP>of psychostimulants and drugs of abuse elicits an increase of<SUP> </SUP>DA release in the mesolimbic areas, whereas withdrawal of these<SUP> </SUP>drugs results in a reduction of dopaminergic transmission. A vast<SUP> </SUP>amount of literature has been written in this area (<a href="#B108">108</A>, <a href="#B252">252</A>, <a href="#B365">365</A>, <a href="#B404">404</A>, <a href="#B469">469</A>).<SUP> </SUP>Various experimental models have been developed such as intracranial<SUP> </SUP>self-stimulation and drug self-administration. In the intracranial<SUP> </SUP>self-stimulation paradigm, rats work to obtain electrical stimulation<SUP> </SUP>that has rewarding properties and results in DA release in the<SUP> </SUP>prefrontal cortex and nucleus accumbens (reviewed in Ref. <a href="#B217">217</A>).<SUP> </SUP>Pharmacological studies clearly show that both D<SUB>1</SUB> and D<SUB>2</SUB> receptors<SUP> </SUP>are involved in this behavior, with agonists at both receptors<SUP> </SUP>stimulating and antagonists inhibiting the behavior (<a href="#B141">141</A>, <a href="#B234">234</A>).<SUP> </SUP></P>
	    
	
	    
	    <P>In the case of drug self-administration, it has been shown that both D<SUB>1</SUB> and D<SUB>2</SUB> receptors are involved in the reinforcing properties<SUP> </SUP>of different drugs of abuse, with D<SUB>2</SUB> receptors mediating the stimulant<SUP> </SUP>drug reinforcement and D<SUB>1</SUB> receptors playing a permissive role<SUP> </SUP>(<a href="#B25">25</A>, <a href="#B277">277</A>, <a href="#B354">354</A>, <a href="#B403">403</A>). Stimulation of D<SUB>1</SUB> receptors by endogenous<SUP> </SUP>DA is thus required for the expression of D<SUB>2</SUB> receptor-mediated<SUP> </SUP>behaviors and gene regulation. A recent study suggested that although<SUP> </SUP>D<SUB>1</SUB>-like and D<SUB>2</SUB>-like receptor agonists are themselves reinforcing<SUP> </SUP>and can both substitute for cocaine in drug discrimination tests,<SUP> </SUP>they nevertheless may mediate qualitatively different aspects<SUP> </SUP>of the reinforcing stimulus produced by cocaine. In particular,<SUP> </SUP>activation of D<SUB>2</SUB>-like receptors has been shown to mediate the<SUP> </SUP>incentive to seek further cocaine reinforcement in an animal model<SUP> </SUP>of cocaine-seeking behavior. In contrast, D<SUB>1</SUB>-like receptors appear<SUP> </SUP>to mediate a reduction in the drive to seek further cocaine reinforcement<SUP> </SUP>(<a href="#B403">403</A>). Agonists of D<SUB>1</SUB>-like receptors may thus be evaluated as<SUP> </SUP>a possible therapy of cocaine addiction. Recently, it has been<SUP> </SUP>shown that D<SUB>3</SUB> receptor stimulation inhibits cocaine self-administration<SUP> </SUP>in the rat in a way indicating an enhancement of cocaine reinforcement<SUP> </SUP>(<a href="#B51">51</A>, <a href="#B349">349</A>).</P>
	    
	
	    
	    <P>Although some inconsistencies are present in the literature, there is a general agreement that mesolimbocortical DA plays<SUP> </SUP>a role in learning and memory. In the monkey, DA neurons in the<SUP> </SUP>A10 area have been reported to be involved with transient changes<SUP> </SUP>of impulsive activity in basic attention and motivational processes<SUP> </SUP>underlying learning and cognitive behavior (<a href="#B394">394</A>). Pharmacological<SUP> </SUP>studies have shown that both D<SUB>1</SUB> and D<SUB>2</SUB> receptors mediate the effects<SUP> </SUP>of DA on learning and memory. Activation of both D<SUB>1</SUB> and D<SUB>2</SUB> receptors<SUP> </SUP>in the hippocampus improves acquisition and retention of different<SUP> </SUP>working memory tasks in the rat (<a href="#B261">261</A>, <a href="#B348">348</A>, <a href="#B465">465</A>, <a href="#B466">466</A>). In the monkey,<SUP> </SUP>activation of both D<SUB>1</SUB> and D<SUB>2</SUB> receptors in the prefrontal cortex<SUP> </SUP>has been reported to improve performance in a working memory task<SUP> </SUP>(<a href="#B12">12</A>, <a href="#B390">390</A>, <a href="#B391">391</A>). Because of the lack of true agonists and antagonists<SUP> </SUP>discriminating among D<SUB>1</SUB>-like and D<SUB>2</SUB>-like receptors, the role of<SUP> </SUP>DA receptor subtypes in learning and memory has not been investigated.<SUP> </SUP>However, it is worth noting that although the D<SUB>1</SUB> receptor is poorly<SUP> </SUP>expressed in the hippocampal formation, the D<SUB>5</SUB> receptor is highly<SUP> </SUP>expressed in this area so that the D<SUB>5</SUB> ,&nbsp;more than the D<SUB>1</SUB> receptor,<SUP> </SUP>is likely to mediate the effects of D<SUB>1</SUB> agonists on learning and<SUP> </SUP>memory. Similarly, D<SUB>3</SUB> and D<SUB>4</SUB> receptors are expressed in the hippocampus,<SUP> </SUP>and D<SUB>3</SUB> receptors are present in the septal area, suggesting a<SUP> </SUP>possible contribution of these receptor subtypes to the behavioral<SUP> </SUP>effects of D<SUB>2</SUB> agonists. In contrast, because of their distribution<SUP> </SUP>at the cortical level, a central role of D<SUB>1</SUB> and D<SUB>2</SUB> receptors can<SUP> </SUP>be proposed in the prefrontal cortex-mediated behaviors.<SUP> </SUP></P>
	    
	
	    
	    <P>The role of D<SUB>3</SUB> and D<SUB>4</SUB> receptors in the physiology of dopaminergic system is still mostly unknown. They are specifically expressed<SUP> </SUP>in limbic and cortical regions involved in the control of cognition<SUP> </SUP>and emotion and, to a lesser extent in the dorsal striatum, and<SUP> </SUP>this makes them attractive and promising targets for new generations<SUP> </SUP>of antipsychotic drugs with low incidence of extrapyramidal side<SUP> </SUP>effects.</P>
	    
	
	
    
	
	<A NAME="SEC8_3">
<P ALIGN=LEFT><B>C. Dopamine Receptors and Regulation
of Gene Expression</B>
</P>

	
	    
	    <P>The study of receptor and peptide levels in the striatum after perturbation of DA transmission has been useful in better understanding<SUP> </SUP>the organization and regulation of the dopaminergic system. The<SUP> </SUP>paradigms used in these approaches have included consequences<SUP> </SUP>of blockade of DA receptors (as occurring after neuroleptic treatment),<SUP> </SUP>interruption of dopaminergic transmission (as occurring in Parkinson's<SUP> </SUP>disease), or after the hyperactivation of the DA system (observed<SUP> </SUP>after abuse of psychostimulants such as cocaine and amphetamine).<SUP> </SUP>Activation of DA receptors results in fact in modulation of both<SUP> </SUP>peptide and immediate early gene expression. On the other hand,<SUP> </SUP>expression of the genes encoding DA receptors is subject to modulation<SUP> </SUP>by DA itself and other signals.<SUP> </SUP></P>
	    
	
	    
	    <A NAME="SEC8_3_2">
<P ALIGN=LEFT><B><I>1. Immediate early genes</I></B></font>
</P>

	    
		
		Fos is the protein product of the immediate-early gene c-<I>fos</I> and is considered to be a marker of some neuronal activities.<SUP> </SUP>Fos appears to be required for long-lasting modifications of gene<SUP> </SUP>expression in response to acute stimuli and has been shown to<SUP> </SUP>be one of the final targets in the signaling cascade of DA receptors<SUP> </SUP>(<a href="#B374">374</A>). Basal c-<I>fos</I> expression in the striatum is very low. However,<SUP> </SUP>administration of caffeine (<a href="#B322">322</A>), haloperidol (<a href="#B330">330</A>, <a href="#B372">372</A>), raclopride<SUP> </SUP>(<a href="#B102">102</A>), cocaine, and amphetamine (<a href="#B171">171</A>, <a href="#B193">193</A>, <a href="#B213">213</A>, <a href="#B330">330</A>) remarkably<SUP> </SUP>stimulates c-<I>fos</I> expression in the ventral and dorsal striatum<SUP> </SUP>with regional and cellular specificity depending on the drug used.<SUP> </SUP>Therefore, it has been proposed that Fos and Fos-related antigens<SUP> </SUP>may be used to map specific pathways involved in the response<SUP> </SUP>to modifications of the neuronal environment. Retrograde tracing<SUP> </SUP>studies suggested that cocaine and amphetamine preferentially<SUP> </SUP>increase Fos-like immunoreactivity in striatonigral neurons, whereas<SUP> </SUP>the stimulatory effects of neuroleptics are limited to striatopallidal<SUP> </SUP>neurons (<a href="#B67">67</A>, <a href="#B375">375</A>). Both in the core and shell regions of nucleus<SUP> </SUP>accumbens, D<SUB>1</SUB> agonists increase <I>fos</I> expression in projections<SUP> </SUP>to the midbrain and the ventral pallidum. On the other hand, blockade<SUP> </SUP>of D<SUB>2</SUB> receptors results in a preferential increase of <I>fos</I> expression<SUP> </SUP>in the projections to the ventral pallidum (<a href="#B373">373</A>).<SUP> </SUP></P>
		
		
		
		Concomitant stimulation of D<SUB>1</SUB> and D<SUB>2</SUB> receptors appears to produce a synergistic effect on c-<I>fos</I> expression (<a href="#B242">242</A>). Separate<SUP> </SUP>administration of selective D<SUB>1</SUB> or D<SUB>2</SUB> agonists induces an increase<SUP> </SUP>of Fos immunoreactivity in few neurons, whereas combined administration<SUP> </SUP>of D<SUB>1</SUB> and D<SUB>2</SUB> agonists produced patches of intensely stained immunoreactive<SUP> </SUP>nuclei in the striatum (<a href="#B350">350</A>). In line with this, administration<SUP> </SUP>of SKF-38393 to DA-depleted rats increased the striatal expression<SUP> </SUP>of c-<I>fos</I>, whereas quinpirole did not significantly modify it (<a href="#B227">227</A>).<SUP> </SUP>Combined administration of SKF-38393 and quinpirole, however,<SUP> </SUP>produced a higher extent of c-<I>fos</I> expression than SKF-38393 alone<SUP> </SUP>(<a href="#B227">227</A>). Moreover, amphetamine and cocaine, which increase DA overflow,<SUP> </SUP>appear to be more effective in inducing c-<I>fos</I> expression than<SUP> </SUP>receptor-selective direct agonists.<SUP> </SUP></P>
		
		
		
		These findings are in line with behavioral and electrophysiological evidence suggesting the existence of D<SUB>1</SUB> and D<SUB>2</SUB> synergism<SUP> </SUP>in the striatum (<a href="#B79">79</A>, <a href="#B116">116</A>, <a href="#B242">242</A>, <a href="#B375">375</A>, <a href="#B455">455</A>). However, the anatomic<SUP> </SUP>basis of this synergism is still a matter of debate.<SUP> </SUP></P>
		
		
	    
	
	    
	    <A NAME="SEC8_3_3">
<P ALIGN=LEFT><B><I>2. Neuropeptides</I></B></font>
</P>

	    
		
		Anatomic, pharmacological, and molecular studies have given some insights in the mechanisms underlying D<SUB>1</SUB>/D<SUB>2</SUB> synergism. Striatal<SUP> </SUP>efferent neurons are known to be under the influence of DA. As<SUP> </SUP>shown in Figure <a href="#F3">3</a>, two major types of neurons have been defined<SUP> </SUP>that are distinguished by their primary sites of axonal projections<SUP> </SUP>and neuropeptide synthesis (for a review, see Ref. <a href="#B152">152</A>). One<SUP> </SUP>population projects to the entopeduncular nucleus and the substantia<SUP> </SUP>nigra pars reticulata (striatonigral) and expresses the neuropeptides<SUP> </SUP>substance P (SP) and dynorphin (Dyn) (<a href="#B152">152</A>, <a href="#B255">255</A>). The other projects<SUP> </SUP>to the external segment of the globus pallidus (striatopallidal)<SUP> </SUP>and contains enkephalin (<a href="#B152">152</A>, <a href="#B256">256</A>). The striatonigral neurons<SUP> </SUP>preferentially express D<SUB>1</SUB> receptors that mediate the stimulatory<SUP> </SUP>effects of DA on SP and Dyn expression (<a href="#B153">153</A>, <a href="#B255">255</A>), whereas the<SUP> </SUP>striatopallidal neurons mainly express D<SUB>2</SUB> receptors, inhibiting<SUP> </SUP>the expression of preproenkephalin A (PPA) (Fig. <a href="#F3">3</a>) (<a href="#B153">153</A>, <a href="#B256">256</A>).<SUP> </SUP>A similar receptor organization was found in the nucleus accumbens<SUP> </SUP>with D<SUB>1</SUB> receptors mostly expressed in SP neurons (<a href="#B253">253</A>), D<SUB>2</SUB> in<SUP> </SUP>enkephalin and neurotensin neurons (<a href="#B253">253</A>), and D<SUB>3</SUB> receptors in<SUP> </SUP>SP and neurotensin neurons (<a href="#B105">105</A>, <a href="#B106">106</A>).


    
	
<A NAME="F3"><!-- FIG 3 --></A>

<P><CENTER><TABLE WIDTH=95% CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1>
<TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF>

	
    <A HREF="/cgi/content/full/78/1/189/F3">
    <IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=200 HEIGHT=187 SRC="/content/vol78/issue1/images/small/jnp.ja09f3.gif"></A><BR>
<STRONG>View larger version</STRONG> (40K):
<BR><NOBR><A HREF="/cgi/content/full/78/1/189/F3">[in this window]</A>
<BR><A HREF="/cgi/content-nw/full/78/1/189/F3"
    onClick="startTarget('F3', 590, 611); this.href='/cgi/content-nw/full/78/1/189/F3'"
    onMouseOver="window.status='View figure in a separate window'; return true"
    TARGET="F3">[in a new window]</A><BR>&nbsp;
    </NOBR>

	

</TD><TD ALIGN=LEFT VALIGN=top><font size=-1>FIG.</font> 3. &nbsp;
Organization of striatal dopaminergic synapses. D<SUB>1</SUB> receptors are preferentially expressed by <IMG SRC="/math/12pt/normal/gamma.gif" ALIGN=BASELINE ALT="gamma ">-aminobutyric acid (GABA)ergic neurons coexpressing substance P (SP) and dynorphin (Dyn) and projecting to entopeduncular nucleus and substantia nigra, whereas D<SUB>2</SUB> receptors are segregated on GABAergic neurons containing enkephalin and projecting to globus pallidus. D<SUB>2</SUB>-like autoreceptors are present on dopaminergic terminals. PPA, preproenkephalin A; DAT, dopamine transporter; VAT, vesicular transporter; TH, tyrosine hydroxylase.

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>
<P>
<!-- /FIG 3 -->

    

</P>
		
		
		
		In the ventral shell of the nucleus accumbens, D<SUB>3</SUB> receptors tonically activate neurotensin gene expression (<a href="#B105">105</A>), whereas<SUP> </SUP>D<SUB>2</SUB> receptors in the septal pole of the nucleus accumbens inhibit<SUP> </SUP>neurotensin gene expression (<a href="#B105">105</A>).<SUP> </SUP></P>
		
		
		
		Although some controversy arose concerning colocalization or segregation of D<SUB>1</SUB> and D<SUB>2</SUB> receptors in the different neuronal<SUP> </SUP>populations, there is now a general agreement that D<SUB>1</SUB> and D<SUB>2</SUB> receptors<SUP> </SUP>are segregated in SP and enkephalin neurons, respectively, with<SUP> </SUP>a small percentage of neurons coexpressing both receptor genes.<SUP> </SUP>This was clearly demonstrated in in situ hybridization studies<SUP> </SUP>showing that striatal D<SUB>1</SUB> receptors are coexpressed with SP and<SUP> </SUP>D<SUB>2</SUB> receptor with PPA (<a href="#B90">90</A>, <a href="#B153">153</A>, <a href="#B253">253</A>, <a href="#B255">255</A>, <a href="#B256">256</A>).<SUP> </SUP></P>
		
		
		
		On the other hand, other studies suggested that D<SUB>1</SUB> and D<SUB>2</SUB> receptors are mostly colocalized in the same neurons (<a href="#B11">11</A>, <a href="#B257">257</A>, <a href="#B433">433</A>).<SUP> </SUP>However, immunohistochemistry studies with D<SUB>1</SUB> and D<SUB>2</SUB> antibodies<SUP> </SUP>recently confirmed that D<SUB>1</SUB> and D<SUB>2</SUB> receptor are indeed segregated<SUP> </SUP>in distinct neurons of the dorsal striatum (<a href="#B187">187</A>).<SUP> </SUP></P>
		
		
		
		In line with these observations, pharmacological studies have shown that DA agonists and antagonists as well as disruption<SUP> </SUP>of dopaminergic transmission by either 6-hydroxydopamine (6-OHDA)<SUP> </SUP>or reserpine modulate striatal peptide gene expression in a way<SUP> </SUP>that confirms the concept of receptor segregation. Chronic administration<SUP> </SUP>of haloperidol and sulpiride increases the mRNA level of PPA,<SUP> </SUP>which is under the inhibitory control of D<SUB>2</SUB> receptors (<a href="#B29">29</A>, <a href="#B45">45</A>, <a href="#B216">216</A>, <a href="#B333">333</A>),<SUP> </SUP>whereas SP and Dyn are not modified by these treatments. Dopamine<SUP> </SUP>receptor stimulation, on the other hand, resulted in increases<SUP> </SUP>of both SP and Dyn levels (<a href="#B178">178</A>, <a href="#B179">179</A>). Disruption of dopaminergic<SUP> </SUP>transmission by 6-OHDA treatment resulted in an increase of striatal<SUP> </SUP>PPA mRNA, an effect which was reversible upon chronic treatment<SUP> </SUP>with quinpirole but not with the D<SUB>1</SUB> agonist SKF-38393 (<a href="#B153">153</A>).<SUP> </SUP>In the same model, SP mRNA was decreased, and this effect was<SUP> </SUP>reversed by SKF-38393 but not by quinpirole (<a href="#B153">153</A>). A decrease<SUP> </SUP>in SP and Dyn precursor mRNAs was also observed after DA depletion<SUP> </SUP>by reserpine treatment (<a href="#B42">42</A>, <a href="#B49">49</A>, <a href="#B214">214</A>, <a href="#B215">215</A>). On the other hand,<SUP> </SUP>in mutant mice having a constitutively hyperactive dopaminergic<SUP> </SUP>transmission, due to targeted inactivation of the DA transporter<SUP> </SUP>gene, the mRNA levels of Dyn precursor are greatly increased and<SUP> </SUP>those of PPA significantly decreased (<a href="#B160">160</A>).<SUP> </SUP></P>
		
		
		
		At present, the data thus seem to converge to support the concept that, for the most part, D<SUB>1</SUB> and D<SUB>2</SUB> receptors are segregated<SUP> </SUP>with only a small population of neurons, showing coexpression<SUP> </SUP>of D<SUB>1</SUB>/D<SUB>2</SUB> .&nbsp;Taken together, these observations imply that the D<SUB>1</SUB>/D<SUB>2</SUB><SUP> </SUP>synergistic effects observed at molecular, electrophysiological,<SUP> </SUP>and behavioral levels may occur by interneuronal interactions.<SUP> </SUP>A D<SUB>2</SUB>-mediated suppression of striatopallidal neurons might in<SUP> </SUP>fact relieve a tonic inhibitory influence of enkephalin or GABA<SUP> </SUP>on striatonigral neurons, thus increasing D<SUB>1</SUB>-mediated responses<SUP> </SUP>(<a href="#B227">227</A>). On the other hand, in vitro studies suggested D<SUB>1</SUB>/D<SUB>2</SUB> synergism<SUP> </SUP>to take place at the single-cell level (<a href="#B34">34</A>, <a href="#B356">356</A>, <a href="#B433">433</A>). On this<SUP> </SUP>basis, the possibility should be considered that D<SUB>1</SUB> and D<SUB>2</SUB> synergism<SUP> </SUP>may occur by the coexpression of D<SUB>1</SUB>-like and D<SUB>2</SUB>-like receptors<SUP> </SUP>in the same neurons (<a href="#B60">60</A>). In this case, the same neurons would<SUP> </SUP>express D<SUB>1</SUB>/D<SUB>3</SUB>/D<SUB>4</SUB> or D<SUB>2</SUB>/D<SUB>5</SUB> receptors. Supporting this hypothesis,<SUP> </SUP>a recent report by Bergson et al. (<a href="#B28">28</A>) documents that in the<SUP> </SUP>primate brain the D<SUB>5</SUB> receptor is expressed by large spiny neurons<SUP> </SUP>in the striatum, known to be cholinergic interneurons expressing<SUP> </SUP>the D<SUB>2</SUB> receptor. Similarly, D<SUB>1</SUB> and D<SUB>3</SUB> receptors were found to<SUP> </SUP>be colocalized in the granule cells of the islands of Calleja,<SUP> </SUP>in some medium spiny neurons in the nucleus accumbens, and in<SUP> </SUP>the ventral striatum, suggesting that, in this last region, D<SUB>1</SUB>/D<SUB>2</SUB>-like<SUP> </SUP>synergism may occur at a single neuronal level in a significant<SUP> </SUP>proportion of SP/dynorphin neurons (<a href="#B90">90</A>, <a href="#B106">106</A>, <a href="#B254">254</A>).<SUP> </SUP></P>
		
		
	    
	
	    
	    <A NAME="SEC8_3_4">
<P ALIGN=LEFT><B><I>3. Dopamine receptor gene expression</I></B></font>
</P>

	    
		
		An indication of the importance of DA receptors in the regulation of gene expression is the modulation of the expression of<SUP> </SUP>the genes encoding the DA receptors themselves. Chronic treatment<SUP> </SUP>with neuroleptic drugs such as haloperidol and sulpiride increases<SUP> </SUP>the mRNA level of D<SUB>2</SUB> ,&nbsp;but not D<SUB>1</SUB> ,&nbsp;receptors in the striatum<SUP> </SUP>(<a href="#B29">29</A>, <a href="#B45">45</A>, <a href="#B216">216</A>, <a href="#B333">333</A>). Disruption of nigrostriatal dopaminergic neurons<SUP> </SUP>by 6-OHDA results in an increase in D<SUB>2</SUB> mRNA and a decrease in<SUP> </SUP>D<SUB>1</SUB> mRNA expression, both effects being reversed by treatment with<SUP> </SUP>quinpirole or SKF-38393, respectively (<a href="#B42">42</A>, <a href="#B153">153</A>). The 6-OHDA-induced<SUP> </SUP>increases in the mRNA and protein levels of the D<SUB>2</SUB> receptors are<SUP> </SUP>maintained for weeks (<a href="#B153">153</A>), suggesting that an increased rate<SUP> </SUP>of receptor synthesis is required to sustain an increased number<SUP> </SUP>of receptors even in the absence of the natural agonist. On the<SUP> </SUP>other hand, mutant mice lacking the DA transporter and thus having<SUP> </SUP>a constitutively hyperactive dopaminergic transmission clearly<SUP> </SUP>have a remarkable downregulation of both D<SUB>1</SUB> and D<SUB>2</SUB> mRNAs in the<SUP> </SUP>striatum (<a href="#B160">160</A>).</P>
		
		
		
		D<SUB>3</SUB> receptors have been shown to be regulated opposite from the D<SUB>2</SUB> receptors. Denervation leads to D<SUB>3</SUB> receptor downregulation.<SUP> </SUP>This paradoxical effect seems to be unrelated to deprivation of<SUP> </SUP>either DA or one of its cotransmitters and has been proposed to<SUP> </SUP>be dependent on a yet unidentified putative messenger released<SUP> </SUP>from dopaminergic neurons (<a href="#B259">259</A>).<SUP> </SUP></P>
		
		
		
		Factors other than DA or dopaminergic drugs have also been shown to modulate DA receptor gene expression. Treatment of Y79<SUP> </SUP>human retinoblastoma cells with dibutyryl cAMP results in the<SUP> </SUP>expression of D<SUB>2</SUB> receptors (<a href="#B313">313</A>), and exposure of the GH<SUB>3</SUB> cell<SUP> </SUP>line to epidermal growth factor (EGF) results in a remarkable<SUP> </SUP>increase in the levels of both D<SUB>2S</SUB> and D<SUB>2L</SUB> mRNAs (<a href="#B302">302</A>). In addition,<SUP> </SUP>EGF as well as basic fibroblast growth factor and neurotrophins<SUP> </SUP>have been shown to exert a differentiative and trophic effect<SUP> </SUP>on central dopaminergic neurons (<a href="#B22">22</A>, <a href="#B61">61</A>, <a href="#B62">62</A>, <a href="#B136">136</A>, <a href="#B428">428</A>). These<SUP> </SUP>observations suggest that specific factors originating from surrounding<SUP> </SUP>cells such as glial cells or from afferent neurons or by the dopaminergic<SUP> </SUP>neurons themselves may regulate DA receptor gene expression during<SUP> </SUP>development and adaptation to abnormal stimuli or pharmacological<SUP> </SUP>treatments.</P>
		
		
	    
	
	
    
	
	<A NAME="SEC8_4">
<P ALIGN=LEFT><B>D. Development of Transgenic Animals in the Study of Dopamine Receptor Physiology</B>
</P>

	
	    
	    <P>Although there has been a general consensus regarding the general role and function of D<SUB>1</SUB> and D<SUB>2</SUB> DA receptors in the basal<SUP> </SUP>ganglia, there are still many questions that remain unanswered.<SUP> </SUP>The specific participation of each of these receptors in behavioral<SUP> </SUP>paradigms and regulation of gene expression is still a matter<SUP> </SUP>of debate, as discussed in section <font size=-1>VIII </font><I>B</I>.<SUP> </SUP></P>
	    
	
	    
	    <P>Gene targeting using homologous recombination to inactivate a chosen gene has been used for D<SUB>1</SUB> and D<SUB>2</SUB> DA receptors (<a href="#B18">18</A>, <a href="#B114">114</A>, <a href="#B471">471</A>, <a href="#B472">472</A>).<SUP> </SUP></P>
	    
	
	    
	    <P>Disruption of the D<SUB>1</SUB> receptor gene has been independently reported by two groups (<a href="#B114">114</A>, <a href="#B472">472</A>). One group showed locomotor hyperactivity<SUP> </SUP>in mutant mice compared with wild type, an effect likely due to<SUP> </SUP>compensatory mechanisms activated by the lack of D<SUB>1</SUB> receptors<SUP> </SUP>(<a href="#B472">472</A>), whereas the other group did not detect any significant<SUP> </SUP>change in the locomotor activity of mutant mice (<a href="#B114">114</A>). D<SUB>1</SUB> mutant<SUP> </SUP>mice showed no increase in their locomotor activity in response<SUP> </SUP>to cocaine, thus explicitly confirming that in the absence of<SUP> </SUP>D<SUB>1</SUB> receptors psychomotor stimulation mediated by D<SUB>2</SUB> receptors<SUP> </SUP>cannot occur (<a href="#B471">471</A>). The finding that high doses of cocaine inhibit<SUP> </SUP>locomotor activity in mutant mice (<a href="#B471">471</A>) could suggest that removal<SUP> </SUP>of D<SUB>1</SUB> receptor may have enhanced D<SUB>3</SUB> receptor-mediated locomotor<SUP> </SUP>suppression. On the other hand, a role of the serotoninergic system<SUP> </SUP>in this response to cocaine has not been excluded (<a href="#B158">158</A>, <a href="#B471">471</A>).<SUP> </SUP>The study of gene expression modifications in mice lacking the<SUP> </SUP>D<SUB>1</SUB> receptor showed that, correlating with the distribution of<SUP> </SUP>DA receptors at neuronal level, SP mRNA was decreased in mutant<SUP> </SUP>mice, whereas PPA mRNA levels were unchanged (<a href="#B114">114</A>). These molecular<SUP> </SUP>changes demonstrate that these mice exhibit selective functional<SUP> </SUP>changes in striatal neurons with a direct output pathway to the<SUP> </SUP>substantia nigra.</P>
	    
	
	    
	    <P>Inactivation of the D<SUB>2</SUB> gene produced almost the opposite phenotype in the mutant mice. Animals lacking D<SUB>2</SUB> receptors are akinetic<SUP> </SUP>and bradykinetic, with significantly reduced spontaneous movement<SUP> </SUP>(<a href="#B18">18</A>). This mouse phenotype resembles that obtained with D<SUB>2</SUB> antagonist<SUP> </SUP>administration and is reminiscent of the extrapyramidal symptoms<SUP> </SUP>of Parkinson's disease. At the molecular level, PPA mRNA, which<SUP> </SUP>is under the inhibitory control of DA via the D<SUB>2</SUB> receptors, is<SUP> </SUP>increased by 40% in the mutant mice (<a href="#B18">18</A>).<SUP> </SUP></P>
	    
	
	    
	    <P>On the basis of these results, inactivation of the other members of the DA receptor family could provide valuable information<SUP> </SUP>about their physiological functions. The drawback of this approach,<SUP> </SUP>however, is that inactivation of specific receptor genes in the<SUP> </SUP>mouse germ line produces animal phenotypes where possible developmental<SUP> </SUP>alterations and compensatory changes are superimposed on the true<SUP> </SUP>effects of receptor removal, so that behavioral alterations in<SUP> </SUP>the mutant mice should be interpreted with some caution. Development<SUP> </SUP>of spatially and temporally targeted inactivation of specific<SUP> </SUP>receptor genes could be helpful to overcome this problem and to<SUP> </SUP>produce a clearer picture of the function of DA receptors in adult<SUP> </SUP>animals as opposed to their role in development.<SUP> </SUP></P>
	    
	
	
    
	
	<A NAME="SEC8_5">
<P ALIGN=LEFT><B>E. Clinical and Pharmacological Implications
of Multiple Dopamine Receptors</B>
</P>

	
	    
	    <P>The hypothesis that the dopaminergic system is overactive in schizophrenia is based on the observation that neuroleptics,<SUP> </SUP>which are used in the management of the major symptoms of this<SUP> </SUP>disorder, selectively block DA receptors (<a href="#B223">223</A>, <a href="#B286">286</A>, <a href="#B368">368</A>, <a href="#B415">415</A>). The<SUP> </SUP>DA hypothesis was further strengthened by the fact that amphetamine<SUP> </SUP>induces psychotic states resembling those observed in the positive<SUP> </SUP>symptoms of schizophrenia (euphoria, auditory hallucinations,<SUP> </SUP>and akathisia or the inability to remain inactive).<SUP> </SUP></P>
	    
	
	    
	    <P>Treatment with neuroleptics has the major drawback that most of patients under medication suffer from extreme movement disorders<SUP> </SUP>known as extrapyramidal syndrome. The symptoms include muscular<SUP> </SUP>rigidity and akinesia that are sometimes difficult to distinguish<SUP> </SUP>from the negative symptoms of schizophrenia. Moreover, prolonged<SUP> </SUP>treatment invariably leads to irreversible tardive dyskinesia.<SUP> </SUP>It is believed that the antipsychotic effects of neuroleptics<SUP> </SUP>are due to their action on the dopaminergic receptors in the mesolimbic<SUP> </SUP>system, whereas the extrapyramidal side effects are thought to<SUP> </SUP>result from blockade of D<SUB>2</SUB> receptors in the striatum (reviewed<SUP> </SUP>in Refs. <a href="#B103">103</A>, <a href="#B297">297</A>, <a href="#B415">415</A>). From this perspective, the discovery of<SUP> </SUP>multiple DA receptors with differential expression in the brain<SUP> </SUP>and with different affinities for antipsychotic drugs is of great<SUP> </SUP>interest.</P>
	    
	
	    
	    <P>The high overall sequence homology between DA receptors of the same subfamily has made it extremely laborious to develop specific<SUP> </SUP>ligands that do not interact with related receptors. Of particular<SUP> </SUP>interest is the high affinity of "atypical" neuroleptics, such<SUP> </SUP>as sulpiride and its derivatives and clozapine, for D<SUB>3</SUB> and D<SUB>4</SUB><SUP> </SUP>receptors, respectively (<a href="#B154">154</A>, <a href="#B399">399</A>, <a href="#B420">420</A>). The low level of expression<SUP> </SUP>of the D<SUB>3</SUB> and D<SUB>4</SUB> receptors in the striatum and their relatively<SUP> </SUP>high expression in limbic and cortical areas led to the suggestion<SUP> </SUP>that the antipsychotic actions of neuroleptics may be mainly mediated<SUP> </SUP>through D<SUB>3</SUB> and D<SUB>4</SUB> receptors, whereas the side effects may be mediated<SUP> </SUP>through D<SUB>2</SUB> receptors. This hypothesis is further strengthened<SUP> </SUP>by the observation that administration of clozapine is associated<SUP> </SUP>with a very low incidence of extrapyramidal side effects. However,<SUP> </SUP>clozapine at therapeutic doses also blocks many other types of<SUP> </SUP>receptors, in addition to the D<SUB>4</SUB> receptor, so that it is difficult<SUP> </SUP>to draw conclusions on the mechanism of action of its antipsychotic<SUP> </SUP>effects (<a href="#B296">296</A>, <a href="#B401">401</A>). There were recent claims that D<SUB>4</SUB> receptors,<SUP> </SUP>measured by indirect binding, may be increased in the brain of<SUP> </SUP>schizophrenic patients (<a href="#B402">402</A>, <a href="#B400">400</A>). Additional work will be required<SUP> </SUP>to confirm these findings, since many of these observations came<SUP> </SUP>from indirect measurements with partially selective ligands. The<SUP> </SUP>development of specific antipsychotics targeting a single DA receptor<SUP> </SUP>subtype should shed more light on the role of each of the DA receptors<SUP> </SUP>in schizophrenia.</P>
	    
	
	    
	    <A NAME="SEC8_5_4">
<P ALIGN=LEFT><B><I>1. Genetic linkage of dopamine receptors
to pathophysiologies</I></B></font>
</P>

	    
		
		The cloning and characterization of the human genes for the five DA receptors have initiated studies of their genetic relationship<SUP> </SUP>with neuropsychiatric disorders associated with the DA system.<SUP> </SUP>These include bipolar disorder (<a href="#B96">96</A>, <a href="#B228">228</A>, <a href="#B411">411</A>), schizophrenia (<a href="#B83">83</A>, <a href="#B324">324</A>, <a href="#B367">367</A>, <a href="#B429">429</A>),<SUP> </SUP>manic depression (<a href="#B220">220</A>), Parkinson's disease (<a href="#B325">325</A>), and Tourette's<SUP> </SUP>syndrome (<a href="#B151">151</A>). For all of these conditions, there is strong<SUP> </SUP>evidence against linkage of any of the five DA receptors. For<SUP> </SUP>example, chromosome 11&nbsp;has long been suspected to harbor a gene<SUP> </SUP>causing predisposition to bipolar disorder. It has been extensively<SUP> </SUP>studied for genetic linkage with genes coding for tyrosine hydroxylase,<SUP> </SUP>tyrosinase, and D<SUB>2</SUB> and D<SUB>4</SUB> DA receptors, all of which can be found<SUP> </SUP>on human chromosome 11&nbsp;(<a href="#B96">96</A>, <a href="#B228">228</A>, <a href="#B411">411</A>). All studies conducted to<SUP> </SUP>date exclude any possible association between these markers and<SUP> </SUP>the pathogenesis of bipolar disorder at least in the pedigrees<SUP> </SUP>examined.</P>
		
		
		
		Because the implication of the dopaminergic system in the etiology of schizophrenia is strong, the alleles coding for five<SUP> </SUP>DA receptors have been investigated and all systematically excluded<SUP> </SUP>in many pedigrees including Japanese, Swedish, Italian, Irish<SUP> </SUP>Californian, and Amish (<a href="#B83">83</A>, <a href="#B324">324</A>, <a href="#B367">367</A>, <a href="#B429">429</A>). Crocq et al. (<a href="#B86">86</A>),<SUP> </SUP>however, detected a small but significant increase in the risk<SUP> </SUP>of schizophrenia in two French and British populations associated<SUP> </SUP>with homozygosity at D<SUB>3</SUB> .&nbsp;These findings, however, need to be<SUP> </SUP>confirmed. None of the various alleles of the D<SUB>4</SUB> receptor seems<SUP> </SUP>to be associated with an increased risk of schizophrenia (<a href="#B273">273</A>, <a href="#B312">312</A>, <a href="#B325">325</A>).<SUP> </SUP></P>
		
		
		
		The situation is not clear regarding appetite and addictive behaviors such as alcoholism. Indeed, early reports did indicate<SUP> </SUP>that the A1 allele of the <I>Taq</I> I restriction fragment length polymorphism<SUP> </SUP>containing the D<SUB>2</SUB> DA receptor gene may confer susceptibility to<SUP> </SUP>alcoholism. This claim has proved to be controversial, with three<SUP> </SUP>reports confirming the original findings and two others excluding<SUP> </SUP>the existence of a possible linkage (reviewed in Refs. <a href="#B82">82</A>, <a href="#B167">167</A>).<SUP> </SUP>The possibility that a remote regulatory element controlling the<SUP> </SUP>expression of a candidate gene could be involved in the disorder<SUP> </SUP>investigated should also be taken into consideration.<SUP> </SUP></P>
		
		
	    
	
	
    

    
    <A NAME="SEC9">
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;IX. DOPAMINE RECEPTORS IN THE PITUITARY</FONT></TH>
</TR>
</TABLE>
<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Top</A><BR>










<A HREF="#SEC8"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Previous</A><BR>



<A HREF="#SEC10"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Next</A><BR>


<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">References</A>

</FONT></TH>
</TR></TABLE>

    
	
	<P>In the late 1970s, with the use of the radioligand binding assay, it was first directly shown that D<SUB>2</SUB> receptors are present<SUP> </SUP>in the anterior and intermediate lobes of the pituitary gland<SUP> </SUP>(reviewed in Refs. <a href="#B26">26</A>, <a href="#B59">59</A>, <a href="#B320">320</A>) where they mediate the tonic<SUP> </SUP>inhibitory control of hypothalamic DA on prolactin (Prl) (<a href="#B26">26</A>, <a href="#B121">121</A>, <a href="#B298">298</A>)<SUP> </SUP>and <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha ">-melanocyte-stimulating hormone (<a href="#B84">84</A>, <a href="#B425">425</A>) secretion.<SUP> </SUP></P>
	
    
	
	<P>The genes encoding the D<SUB>2</SUB> receptor have been later found in the pituitary (<a href="#B47">47</A>, <a href="#B91">91</A>, <a href="#B162">162</A>, <a href="#B292">292</A>, <a href="#B315">315</A>). In particular, D<SUB>2S</SUB> and D<SUB>2L</SUB><SUP> </SUP>receptor isoforms are expressed in both melanotroph (47,&nbsp;91; 292)<SUP> </SUP>and lactotroph cells, where the longer form is predominant (<a href="#B91">91</A>, <a href="#B162">162</A>, <a href="#B292">292</A>, <a href="#B315">315</A>).<SUP> </SUP>Interestingly, subpopulations of lactotrophs have been identified<SUP> </SUP>that express different D<SUB>2L</SUB>/D<SUB>2S</SUB> mRNA ratios. Gonadal steroids have<SUP> </SUP>been shown to influence this ratio in vitro, providing a possible<SUP> </SUP>basis for variation in the density of pituitary D<SUB>2</SUB> receptors during<SUP> </SUP>the estrous cycle (<a href="#B240">240</A>).</P>
	
    
	
	<P>The D<SUB>4</SUB> receptor and in particular its D<SUB>4.4</SUB> variant is also expressed in the anterior pituitary (<a href="#B451">451</A>). Its role in the physiology<SUP> </SUP>of the gland, however, has not been examined yet.<SUP> </SUP></P>
	
    
	
	<P>Multiple transduction mechanisms are activated by D<SUB>2</SUB> receptors in the pituitary. In addition to inhibition of AC (<a href="#B121">121</A>, <a href="#B289">289</A>, <a href="#B298">298</A>, <a href="#B344">344</A>),<SUP> </SUP>pituitary D<SUB>2</SUB> receptors inhibit PI metabolism (<a href="#B52">52</A>, <a href="#B122">122</A>, <a href="#B416">416</A>), activate<SUP> </SUP>voltage-activated potassium channels (<I>I</I><SUB>A</SUB> and <I>I</I><SUB>K</SUB> currents) (<a href="#B65">65</A>, <a href="#B212">212</A>, <a href="#B269">269</A>, <a href="#B270">270</A>),<SUP> </SUP>and decrease voltage-activated L-type and T-type calcium currents<SUP> </SUP>(<a href="#B269">269</A>, <a href="#B270">270</A>, <a href="#B447">447</A>). All these effects are mediated by G proteins,<SUP> </SUP>with G<SUB>o</SUB><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "> mostly involved in the inhibition of calcium currents<SUP> </SUP>and G<SUB>i-3</SUB><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "> in the activation of voltage-dependent potassium channels<SUP> </SUP>(<a href="#B268">268</A>, <a href="#B302">302</A>).</P>
	
    
	
	<P>In addition, the recent findings that the expression of the POU/Pit1 transcription factor, which activates growth hormone<SUP> </SUP>(GH) and Prl gene expression (<a href="#B210">210</A>, <a href="#B454">454</A>), is inhibited by activation<SUP> </SUP>of D<SUB>2</SUB> receptors in transfected cell lines (<a href="#B120">120</A>, <a href="#B262">262</A>) suggest the<SUP> </SUP>existence of a dopaminergic control on Prl gene expression.<SUP> </SUP></P>
	
    
	
	<P>The presence of D<SUB>2</SUB> receptors inhibiting Prl secretion in the anterior pituitary leads to a major therapeutic application in<SUP> </SUP>the treatment of hyperprolactinemia either due to functional hypothalamus-pituitary<SUP> </SUP>defects or to the presence of Prl-secreting tumors. D<SUB>2</SUB> receptor<SUP> </SUP>agonists, such as bromocriptine, are in fact the most effective<SUP> </SUP>pharmacological tool to normalize plasma Prl levels in these patients<SUP> </SUP>(reviewed in Ref. <a href="#B89">89</A>).</P>
	
    
	
	<P>These observations stimulated the study of D<SUB>2</SUB> receptor pharmacology, biochemistry, and functional properties as well as the<SUP> </SUP>mechanisms regulating its expression in the pituitary. Primary<SUP> </SUP>cultures from the anterior pituitary, however, have the limitation<SUP> </SUP>of being nonhomogeneous cell systems. The GH<SUB>3</SUB> cell line, derived<SUP> </SUP>from a rat anterior pituitary tumor, is the most widely used model<SUP> </SUP>to study the regulation of Prl secretion. The recent findings<SUP> </SUP>that different neurotrophic factors, such as EGF (<a href="#B149">149</A>, <a href="#B302">302</A>, <a href="#B306">306</A>)<SUP> </SUP>and nerve growth factor (NGF) (<a href="#B305">305</A>), can induce the expression<SUP> </SUP>of D<SUB>2</SUB> receptors in this cell line made it an excellent model to<SUP> </SUP>study D<SUB>2</SUB> receptor regulation. These observations also suggest<SUP> </SUP>that neurotrophic factors may be operative in the anterior pituitary<SUP> </SUP>to regulate the expression of D<SUB>2</SUB> receptors during development<SUP> </SUP>(<a href="#B135">135</A>, <a href="#B303">303</A>, <a href="#B359">359</A>) or in particular pathophysiological conditions.<SUP> </SUP></P>
	
    
	
	<P>The clinical relevance of these findings concerns the therapy of those Prl-secreting tumors that do not respond to the conventional<SUP> </SUP>pharmacological treatment with bromocriptine and require neurosurgical<SUP> </SUP>intervention (<a href="#B89">89</A>). The major biochemical defect contributing<SUP> </SUP>to DA agonist resistance in those prolactinomas is, in fact, decreased<SUP> </SUP>density (<a href="#B352">352</A>) or absence (<a href="#B304">304</A>) of D<SUB>2</SUB> receptors. The observation<SUP> </SUP>that short-term exposure of resistant prolactinomas to NGF, both<SUP> </SUP>in vitro and in vivo, results in the expression of D<SUB>2</SUB> receptors<SUP> </SUP>(<a href="#B304">304</A>) may open the way to a new therapy for these patients. Nerve<SUP> </SUP>growth factor treatment, by inducing the expression of D<SUB>2</SUB> receptors<SUP> </SUP>in the tumor, restores the molecular target for subsequent therapy<SUP> </SUP>with bromocriptine. Therefore, sequential therapy with NGF and<SUP> </SUP>bromocriptine appears to be a potential alternative to neurosurgical<SUP> </SUP>intervention for patients with DA-resistant prolactinomas (<a href="#B310">310</A>).<SUP> </SUP></P>
	
    

    
    <A NAME="SEC10">
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;X. PERIPHERAL DOPAMINE RECEPTORS</FONT></TH>
</TR>
</TABLE>
<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Top</A><BR>











<A HREF="#SEC9"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Previous</A><BR>



<A HREF="#SEC11"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Next</A><BR>


<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">References</A>

</FONT></TH>
</TR></TABLE>

    
	
	<P>Dopamine receptors in the cardiovascular system were originally characterized by physiological evaluation of changes in blood<SUP> </SUP>flow in response to the administration of catecholaminergic agonists<SUP> </SUP>and antagonists. Two distinct patterns of responsiveness were<SUP> </SUP>observed, and these were classified as DA<SUB>1</SUB> and DA<SUB>2</SUB> (reviewed in<SUP> </SUP>Ref. <a href="#B166">166</A>) in a scheme that paralleled the D<SUB>1</SUB>/D<SUB>2</SUB> classification<SUP> </SUP>of Kebabian and Calne (<a href="#B226">226</A>).</P>
	
    
	
	<P>The cloning and molecular characterization of DA receptors later indicated that the same molecular species are present in<SUP> </SUP>the CNS and in some peripheral tissues. The existence of different<SUP> </SUP>D<SUB>1</SUB>-like and D<SUB>2</SUB>-like receptors in the cardiovascular system, however,<SUP> </SUP>has not been systematically investigated. It has been shown that<SUP> </SUP>all the cloned DA receptors are present in the kidney (<a href="#B148">148</A>, <a href="#B285">285</A>, <a href="#B326">326</A>, <a href="#B420">420</A>, <a href="#B473">473</A>)<SUP> </SUP>and that D<SUB>4</SUB> receptors are present in the heart (<a href="#B343">343</A>). However,<SUP> </SUP>little is known to date about the molecular nature of DA receptors<SUP> </SUP>in blood vessels, in postganglionic sympathetic nerve terminals,<SUP> </SUP>and in the adrenal cortex, so their function and classification<SUP> </SUP>in these regions are largely based on pharmacological data. The<SUP> </SUP>distribution and function of peripheral DA receptors are summarized<SUP> </SUP>in Table <a href="#T3">3</a>.

<P><CENTER>
<TABLE BORDER WIDTH="95%" CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1><TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF>&nbsp;<BR><STRONG>View this table:</STRONG>
<BR><NOBR><A HREF="/cgi/content/full/78/1/189/T3">[in this window]</A></NOBR>
<NOBR><A HREF="/cgi/content-nw/full/78/1/189/T3"
	onClick="startTarget('T3', 500, 400); this.href='/cgi/content-nw/full/78/1/189/T3'"
	onMouseOver="window.status='View figure in a separate window';
	        return true"
TARGET='T3'>[in a new window]</A><BR>&nbsp;</NOBR>
</TD>
<TD ALIGN=LEFT VALIGN=TOP>
<A NAME="T3"><!-- TABLE 3 --></A>
<font size=-1>TABLE</font> 3. &nbsp;

    <I> Distribution and function of peripheral dopamine receptors</I>
</P>

</CENTER>
</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>
<P>
</P>
	
    
	
	<A NAME="SEC10_3">
<P ALIGN=LEFT><B>A. Dopamine Receptors in Blood Vessels</B>
</P>

	
	    
	    <P>Initial screening for D<SUB>1</SUB> and D<SUB>2</SUB> activities was conducted in the anesthetized dog with simultaneous recordings of cardiac contractility,<SUP> </SUP>heart rate, arterial blood pressure, and renal and femoral blood<SUP> </SUP>flows (reviewed in Ref. <a href="#B166">166</A>). The results of these studies led<SUP> </SUP>to the current paradigm that postjunctional D<SUB>1</SUB> receptors producing<SUP> </SUP>direct vasodilatation are present in the renal artery and that<SUP> </SUP>prejunctional D<SUB>2</SUB> receptors on postganglionic sympathetic nerve<SUP> </SUP>terminals inhibit norepinephrine release to indirectly induce<SUP> </SUP>vasodilatation in the femoral artery and decrease of cardiac contractility<SUP> </SUP>(<a href="#B166">166</A>).</P>
	    
	
	    
	    <P>Subsequent studies using either radioligand binding combined with autoradiography or measurement of AC activity confirmed<SUP> </SUP>and extended the results of physiological studies. D<SUB>1</SUB> receptors<SUP> </SUP>associated with stimulation of AC have been identified in the<SUP> </SUP>renal, mesenteric, and splenic arteries (<a href="#B307">307</A>) and were shown<SUP> </SUP>to be concentrated in the medial layer and to be insensitive to<SUP> </SUP>chemical sympathectomy (<a href="#B5">5</A>), thus confirming their preferential<SUP> </SUP>postjunctional localization.</P>
	    
	
	    
	    <P>D<SUB>2</SUB> receptors were shown to be localized in the adventitial as well as the adventitial-medial border and intimal layer of renal,<SUP> </SUP>mesenteric, and splenic arteries (<a href="#B4">4</A>) and to be associated with<SUP> </SUP>inhibition of AC (<a href="#B307">307</A>). Chemical sympathectomy remarkably reduced<SUP> </SUP>the density of D<SUB>2</SUB> receptors in the adventitial and adventitial-medial<SUP> </SUP>layers, but not in the intimal layer (<a href="#B4">4</A>), thus suggesting that<SUP> </SUP>both prejunctional and postjunctional D<SUB>2</SUB> receptors are present<SUP> </SUP>in arterial vessels. In addition, chemical sympathectomy did not<SUP> </SUP>modify the extent of inhibition of AC by D<SUB>2</SUB> agonists, suggesting<SUP> </SUP>that postjunctional D<SUB>2</SUB> receptors are associated with inhibition<SUP> </SUP>of cAMP formation, whereas prejunctional D<SUB>2</SUB> receptors are not<SUP> </SUP>(<a href="#B307">307</A>). The role of postjunctional D<SUB>2</SUB> receptors in arterial physiology<SUP> </SUP>has yet to be revealed.</P>
	    
	
	    
	    <P>The pharmacological profiles of D<SUB>1</SUB> and D<SUB>2</SUB> receptors in blood vessels are very similar to those of D<SUB>1</SUB> and D<SUB>2</SUB> receptors in the<SUP> </SUP>CNS. It should be noted, however, that the compounds shown to<SUP> </SUP>partially discriminate among different DA receptor subtypes have<SUP> </SUP>not been tested on these tissues and that the existence of the<SUP> </SUP>mRNAs for D<SUB>1</SUB>-like and D<SUB>2</SUB>-like receptors in the vasculature has<SUP> </SUP>not been investigated to date. Thus, although the definition of<SUP> </SUP>DA receptors in the arteries as D<SUB>1</SUB> and D<SUB>2</SUB> is generally accepted,<SUP> </SUP>further studies are necessary to definitely ascertain their molecular<SUP> </SUP>identity.</P>
	    
	
	
    
	
	<A NAME="SEC10_4">
<P ALIGN=LEFT><B>B. Dopamine Receptors Controlling the Renin-Angiotensin-Aldosterone System</B>
</P>

	
	    
	    <A NAME="SEC10_4_1">
<P ALIGN=LEFT><B><I>1. Effects of dopamine on renin secretion</I></B></font>
</P>

	    
		
		The physiological role of a direct dopaminergic mechanism in the regulation of renin secretion is still a matter of controversy.<SUP> </SUP>The wide range of activity of DA in the cardiovascular system<SUP> </SUP>makes the results of in vivo studies difficult to interpret. The<SUP> </SUP>effects of DA on blood pressure, cardiac output, and regional<SUP> </SUP>blood flow distribution may in fact indirectly influence renin<SUP> </SUP>secretion.</P>
		
		
		
		In vivo studies in conscious and anesthetized dogs have shown that intrarenal infusions of DA either increases renin secretion,<SUP> </SUP>an effect associated with renal vasodilatation, or does not affect<SUP> </SUP>plasma renin activity (PRA) (reviewed in Ref. <a href="#B309">309</A>). In most studies<SUP> </SUP>in humans, no consistent effects of intravenous infusion of DA<SUP> </SUP>on renin secretion were observed (<a href="#B54">54</A>, <a href="#B53">53</A>, <a href="#B115">115</A>, <a href="#B334">334</A>, <a href="#B423">423</A>). Fragmentary<SUP> </SUP>observations reported that infusion of low doses of DA or administration<SUP> </SUP>of gludopa decreased PRA, whereas high, pressor doses of DA increased<SUP> </SUP>PRA in healthy subjects (reviewed in Ref. <a href="#B309">309</A>). Administration<SUP> </SUP>of either bromocriptine to normal subjects in sodium balance (<a href="#B56">56</A>)<SUP> </SUP>or dihydroergotoxine to hypertensive patients kept on both normal<SUP> </SUP>and low sodium intake (<a href="#B271">271</A>) does not modify PRA. On the other<SUP> </SUP>hand, it has been shown that D<SUB>1</SUB> agonists can stimulate renin secretion<SUP> </SUP>from renal cortical slices (<a href="#B9">9</A>, <a href="#B241">241</A>) and that D<SUB>1</SUB> receptors are<SUP> </SUP>present on renin-containing vesicles within the juxtaglomerular<SUP> </SUP>apparatus (<a href="#B336">336</A>). Thus the major effect of DA on renin secretion<SUP> </SUP>is stimulatory and is mediated by D<SUB>1</SUB> receptors.<SUP> </SUP></P>
		
		
	    
	
	    
	    <A NAME="SEC10_4_2">
<P ALIGN=LEFT><B><I>2. Dopaminergic mechanisms controlling
aldosterone production</I></B></font>
</P>

	    
		
		The first evidence for a role of DA in the control of aldosterone secretion came from in vivo studies in both humans and experimental<SUP> </SUP>animals.</P>
		
		
		
		Administration of the D<SUB>2</SUB> antagonist metoclopramide to both rats and humans was shown to increase plasma aldosterone levels<SUP> </SUP>without modifying any of the known stimulators of the hormone<SUP> </SUP>release, an effect that was blocked by intravenous infusion of<SUP> </SUP>DA (<a href="#B56">56</A>, <a href="#B334">334</A>, <a href="#B422">422</A>). Administration of DA and of DA agonists such<SUP> </SUP>as bromocriptine, however, did not modify basal plasma aldosterone<SUP> </SUP>levels (<a href="#B37">37</A>, <a href="#B53">53</A>, <a href="#B56">56</A>, <a href="#B57">57</A>, <a href="#B470">470</A>). These observations thus suggested<SUP> </SUP>that aldosterone production is under maximum tonic dopaminergic<SUP> </SUP>inhibition.</P>
		
		
		
		Subsequent studies confirmed this hypothesis and pointed to the sodium balance state as being crucial for the effects of exogenous<SUP> </SUP>DA on aldosterone secretion. During sodium depletion, DA excretion<SUP> </SUP>is decreased, circulating aldosterone is increased, and plasma<SUP> </SUP>aldosterone responsiveness to angiotensin II is increased (<a href="#B57">57</A>, <a href="#B191">191</A>).<SUP> </SUP>Reciprocal findings were reported in the sodium-replete state<SUP> </SUP>(<a href="#B2">2</A>). According to these concepts, it has been shown that the<SUP> </SUP>increase in plasma aldosterone levels induced by angiotensin II<SUP> </SUP>infusion and by upright posture was remarkably inhibited by both<SUP> </SUP>DA and D<SUB>2</SUB> agonists in normal subjects in metabolic balance at<SUP> </SUP>low sodium intake, but not in sodium-repleted subjects (<a href="#B58">58</A>, <a href="#B115">115</A>, <a href="#B276">276</A>).<SUP> </SUP>Similarly, the D<SUB>2</SUB> agonist dihydroergotoxine remarkably reduced<SUP> </SUP>plasma aldosterone levels in hypertensive patients kept on a low-sodium<SUP> </SUP>diet (<a href="#B271">271</A>). The effects of DA on aldosterone secretion have been<SUP> </SUP>demonstrated to be mediated by D<SUB>2</SUB> receptors located on adrenal<SUP> </SUP>glomerulosa cells.</P>
		
		
	    
	
	    
	    <A NAME="SEC10_4_3">
<P ALIGN=LEFT><B><I>3. Dopamine receptors in the adrenal cortex</I></B></font>
</P>

	    
		
		In vitro binding studies indicated that saturable and stereospecific binding sites labeled by [<SUP>3</SUP>H]spiperone, <SUP>3</SUP>H-labeled 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene<SUP> </SUP>(ADTN), and (<IMG SRC="/math/12pt/normal/minus.gif" ALIGN=BASELINE ALT="-">)-[<SUP>3</SUP>H]sulpiride are present in bovine and rat adrenal cortex. The<SUP> </SUP>pharmacological characterization of the binding sites made it<SUP> </SUP>possible to classify DA receptors in the adrenal cortex as D<SUB>1</SUB><SUP> </SUP>and D<SUB>2</SUB> (reviewed in Ref. <a href="#B309">309</A>). Autoradiographic analysis of [<SUP>3</SUP>H]spiperone binding revealed that the majority of adrenocortical<SUP> </SUP>D<SUB>2</SUB> receptors are concentrated in the zona glomerulosa and, to<SUP> </SUP>a lesser extent, in the zona reticularis. The same pattern of<SUP> </SUP>D<SUB>2</SUB> receptor distribution has been found in the human adrenal cortex<SUP> </SUP>(<a href="#B3">3</A>). No information is available to date concerning the presence<SUP> </SUP>of the other D<SUB>2</SUB>-like and D<SUB>1</SUB>-like receptors in the adrenal cortex.<SUP> </SUP></P>
		
		
		
		Analysis of the transduction pathways activated by DA receptors in glomerulosa cells revealed that D<SUB>1</SUB> receptors are associated<SUP> </SUP>with stimulation of AC (<a href="#B308">308</A>). D<SUB>2</SUB> receptors have been shown to<SUP> </SUP>inhibit both cAMP formation (<a href="#B308">308</A>) and T-type voltage-dependent<SUP> </SUP>calcium channels in this tissue (<a href="#B146">146</A>, <a href="#B346">346</A>).<SUP> </SUP></P>
		
		
		
		In vitro studies with isolated adrenal glomerulosa cells demonstrated that activation of D<SUB>2</SUB> receptors resulted in a remarkable<SUP> </SUP>inhibition of angiotensin II-induced aldosterone secretion but<SUP> </SUP>did not modify the hormone release under basal conditions or after<SUP> </SUP>stimulation by adrenocorticotropic hormone (<a href="#B311">311</A>). Consistent<SUP> </SUP>with this, it has also been shown that activation of D<SUB>2</SUB> receptors<SUP> </SUP>inhibits cAMP formation and Ca<SUP>2+</SUP> influx, both induced by angiotensin II (<a href="#B146">146</A>, <a href="#B309">309</A>). These data<SUP> </SUP>thus indicated that the effects of DA on aldosterone secretion<SUP> </SUP>are mediated by D<SUB>2</SUB> receptors in adrenal glomerulosa cells and<SUP> </SUP>pointed to a selective, functional interaction between DA and<SUP> </SUP>angiotensin II in the regulation of the production of aldosterone.<SUP> </SUP></P>
		
		
		
		One issue that is still open concerns the origin of DA in this system. In particular, whether D<SUB>2</SUB> receptors in glomerulosa<SUP> </SUP>cells are the target of circulating DA or whether a dopaminergic<SUP> </SUP>innervation is present in the adrenal cortex is still matter of<SUP> </SUP>investigation. No evidence for the presence of dopaminergic terminals<SUP> </SUP>in the adrenal cortex has been reported so far. However, it has<SUP> </SUP>been shown that noradrenergic varicosities surrounding the zona<SUP> </SUP>glomerulosa are able to accumulate DA from the circulation and<SUP> </SUP>to release it in response to neural activity or to convert it<SUP> </SUP>into norepinephrine (<a href="#B358">358</A>, <a href="#B453">453</A>), thus providing the possibility<SUP> </SUP>of a fine tuning of local circulation and glomerulosa cell activity.<SUP> </SUP></P>
		
		
	    
	
	
    
	
	<A NAME="SEC10_5">
<P ALIGN=LEFT><B>C. Dopamine Receptors Controlling
Catecholamine Release</B>
</P>

	
	    
	    <P>The presence of DA-containing cells in sympathetic ganglia, i.e., small intensely fluorescent (SIF) cells, has been known<SUP> </SUP>for a long time. In vivo studies on anesthetized dogs and in vitro<SUP> </SUP>studies on arterial preparations pointed to the existence of D<SUB>2</SUB><SUP> </SUP>receptors on sympathetic nerve endings inhibiting norepinephrine<SUP> </SUP>release (<a href="#B4">4</A>, <a href="#B166">166</A>, <a href="#B307">307</A>). Subsequent studies identified D<SUB>2</SUB> receptors<SUP> </SUP>and D<SUB>2</SUB> receptor mRNA in adrenal medulla and in isolated chromaffin<SUP> </SUP>cell preparations (<a href="#B272">272</A>, <a href="#B361">361</A>). Functional studies in the anesthetized<SUP> </SUP>dog reported that activation of adrenomedullary D<SUB>2</SUB> receptors by<SUP> </SUP>quinpirole inhibited epinephrine release induced by splanchnic<SUP> </SUP>nerve stimulation, whereas blockade of these receptors by domperidone<SUP> </SUP>potentiated the adrenal response to nerve stimulation (<a href="#B139">139</A>).<SUP> </SUP>Similarly, stimulation of D<SUB>2</SUB> receptors reduced epinephrine and<SUP> </SUP>norepinephrine content in rat adrenal gland (<a href="#B316">316</A>). These effects<SUP> </SUP>have been suggested to be mediated through inhibition of slowly<SUP> </SUP>inactivating, voltage-gated calcium channels by D<SUB>2</SUB> receptors (<a href="#B35">35</A>, <a href="#B36">36</A>).<SUP> </SUP></P>
	    
	
	    
	    <P>In line with these data are the results of studies in humans showing that blockade of D<SUB>2</SUB> receptors by domperidone induces<SUP> </SUP>a greater norepinephrine and epinephrine release in response to<SUP> </SUP>physical exercise (<a href="#B281">281</A>) and to glucagon (<a href="#B280">280</A>). Similarly, activation<SUP> </SUP>of D<SUB>2</SUB> receptors by bromocriptine produced a significant decrease<SUP> </SUP>in plasma norepinephrine both in the supine and in the upright<SUP> </SUP>posture (<a href="#B280">280</A>).</P>
	    
	
	    
	    <P>Studies with radiolabeled ligands did not reveal the presence of D<SUB>1</SUB> receptors in the adrenal medulla. However, the development<SUP> </SUP>of fluorescent ligands for DA receptors made it possible to prove<SUP> </SUP>the previously unappreciated existence of D<SUB>1</SUB> receptors in adrenal<SUP> </SUP>chromaffin cells by fluorescence microscopy (<a href="#B14">14</A>). Stimulation<SUP> </SUP>of these receptors activates the facilitation 27-pS dihydropyridine-sensitive<SUP> </SUP>calcium channels in the absence of predepolarizations or repetitive<SUP> </SUP>activity (<a href="#B14">14</A>). Facilitation calcium channels in unstimulated<SUP> </SUP>bovine chromaffin cells are normally quiescent and are activated<SUP> </SUP>by large predepolarizations or by repetitive depolarizations,<SUP> </SUP>such as increased nerve splanchnic activity. This activation resulting<SUP> </SUP>in a twofold increase in calcium current suggests a physiological<SUP> </SUP>role for these channels in stimulating rapid catecholamine secretion<SUP> </SUP>in response to danger or stress (<a href="#B14">14</A>). The recruitment of these<SUP> </SUP>channels by D<SUB>1</SUB> receptor stimulation may thus be the basis of a<SUP> </SUP>positive-feedback loop mechanism for catecholamine secretion mediated<SUP> </SUP>by DA (<a href="#B14">14</A>).</P>
	    
	
	    
	    <P>In conclusion, DA seems to have a dual effect on catecholamine release, a tonic inhibitory activity mediated by D<SUB>2</SUB> receptors<SUP> </SUP>on sympathetic nerve endings and on chromaffin cells, and a stimulatory<SUP> </SUP>action mediated by D<SUB>1</SUB> receptors on chromaffin cells that can be<SUP> </SUP>activated in response to stressful situations.<SUP> </SUP></P>
	    
	
	
    
	
	<A NAME="SEC10_6">
<P ALIGN=LEFT><B>D. Dopamine Receptors in the Kidney</B>
</P>

	
	    
	    <P>Dopamine has been shown to act at specific dopaminergic receptors in the renal vasculature and renal parenchyma to produce<SUP> </SUP>changes in renal function (reviewed in Ref. <a href="#B166">166</A>). Although regulation<SUP> </SUP>of calcium (<a href="#B284">284</A>) and phosphate (<a href="#B88">88</A>, <a href="#B97">97</A>, <a href="#B163">163</A>, <a href="#B211">211</A>, <a href="#B224">224</A>) excretion<SUP> </SUP>by DA have also been described, the bulk of recent investigations<SUP> </SUP>have focused on the regulation of sodium homeostasis, and the<SUP> </SUP>effects of renal dopaminergic regulation of sodium handling have<SUP> </SUP>been found to be most pronounced under conditions of mild sodium<SUP> </SUP>excess (<a href="#B46">46</A>, <a href="#B72">72</A>, <a href="#B177">177</A>, <a href="#B363">363</A>).</P>
	    
	
	    
	    <P>Intravascular administration of DA causes increases in renal blood flow and in sodium and water excretion in human subjects<SUP> </SUP>(<a href="#B2">2</A>, <a href="#B87">87</A>, <a href="#B164">164</A>, <a href="#B288">288</A>) and experimental animals (<a href="#B19">19</A>, <a href="#B291">291</A>, <a href="#B353">353</A>). At<SUP> </SUP>low doses, which do not affect systemic hemodynamics, DA produces<SUP> </SUP>renal vasodilation, diuresis, and natriuresis (<a href="#B50">50</A>, <a href="#B300">300</A>), and<SUP> </SUP>these effects have led to the clinical use of low-dose DA infusion<SUP> </SUP>in certain pathological conditions (<a href="#B165">165</A>, <a href="#B251">251</A>, <a href="#B364">364</A>). Either high<SUP> </SUP>dietary salt intake or volume expansion with normal saline causes<SUP> </SUP>a rise in urinary excretion of DA with a concomitant natriuresis<SUP> </SUP>and diuresis (<a href="#B183">183</A>, <a href="#B335">335</A>) that can be blocked by administration<SUP> </SUP>of dopaminergic antagonists (<a href="#B143">143</A>, <a href="#B237">237</A>).<SUP> </SUP></P>
	    
	
	    
	    <P>Within the kidney, DA is formed in renal nerves and in the epithelial cells of certain nephron regions. Dopaminergic nerve<SUP> </SUP>endings have been detected in proximity to the vascular pole/juxtaglomerular<SUP> </SUP>apparatus of renal cortical glomeruli (<a href="#B23">23</A>, <a href="#B110">110</A>), and neural input<SUP> </SUP>appears to be important for regulation of the renal hemodynamic<SUP> </SUP>responses to volume expansion with saline (<a href="#B185">185</A>). Dopamine formed<SUP> </SUP>within the renal tubular epithelium also acts as an intrarenal<SUP> </SUP>paracrine or autocrine hormone to regulate the reabsorption of<SUP> </SUP>sodium ions within the nephron (<a href="#B24">24</A>, <a href="#B130">130</A>, <a href="#B198">198</A>, <a href="#B222">222</A>, <a href="#B247">247</A>, <a href="#B249">249</A>). Furthermore,<SUP> </SUP>D<SUB>1</SUB> dopaminergic agonists stimulate the secretion of renin (<a href="#B9">9</A>, <a href="#B241">241</A>),<SUP> </SUP>and interactions of dopaminergic signal transduction with signaling<SUP> </SUP>by other renal hormones such as angiotensin II (<a href="#B71">71</A>), atrial<SUP> </SUP>natriuretic peptide (<a href="#B182">182</A>, <a href="#B462">462</A>), and antidiuretic hormone (<a href="#B321">321</A>)<SUP> </SUP>have been described.</P>
	    
	
	    
	    <P>Interestingly, some patients with hypertension and animal models of essential hypertension exhibit abnormal dopaminergic responses<SUP> </SUP>to saline loading or inefficient dopaminergic signal transduction<SUP> </SUP>through renal DA receptors. It is possible that molecular characterization<SUP> </SUP>of the DA receptor subtypes and mechanisms of dopaminergic signal<SUP> </SUP>transduction within the kidney will lead to the identification<SUP> </SUP>of potential targets for new antihypertensive agents.<SUP> </SUP></P>
	    
	
	    
	    <A NAME="SEC10_6_5">
<P ALIGN=LEFT><B><I>1. Pharmacology and signal transduction of renal dopamine receptors</I></B></font>
</P>

	    
		
		<font size=-1>A) D</font><SUB>1</SUB>-<font size=-1>LIKE RECEPTORS.</font> Studies of D<SUB>1</SUB>-like receptor binding on membranes prepared from homogenates of renal cortex (<a href="#B131">131</A>, <a href="#B200">200</A>, <a href="#B323">323</A>, <a href="#B412">412</A>),<SUP> </SUP>purified renal proximal tubules (<a href="#B127">127</A>), kidney-derived established<SUP> </SUP>cell lines (<a href="#B20">20</A>), and primary cultures (<a href="#B44">44</A>) have shown that<SUP> </SUP>the pharmacological profiles of renal DA receptors are very similar<SUP> </SUP>to those of central DA receptors (<a href="#B44">44</A>). Dissociation constants<SUP> </SUP>for D<SUB>1</SUB>-selective ligands are higher in homogenates of renal tissue<SUP> </SUP>than in membrane preparations from the brain (<a href="#B412">412</A>). However,<SUP> </SUP>the dissociation constants for binding of D<SUB>1</SUB>-selective ligands<SUP> </SUP>to the opossum kidney (OK) cell D<SUB>1</SUB> receptor are higher when the<SUP> </SUP>receptor is expressed endogenously in OK cell membranes than when<SUP> </SUP>the receptor is transfected into COS cells, although comparison<SUP> </SUP>reveals a linear relationship between the two data sets (<a href="#B20">20</A>, <a href="#B326">326</A>).<SUP> </SUP>This suggests that some factor independent of the primary sequence<SUP> </SUP>of the protein might be responsible for the lower affinities of<SUP> </SUP>drugs for renal receptors.</P>
		
		
		
		Adenylate cyclase is stimulated by DA or dopaminergic agonists in renal preparations (<a href="#B124">124</A>, <a href="#B410">410</A>) with an order of agonist potency<SUP> </SUP>that resembles the DA-stimulated AC in striatal membranes, although<SUP> </SUP>the efficacy of all agonists appears to be reduced two- to fivefold<SUP> </SUP>in renal membranes in comparison with brain preparations (<a href="#B130">130</A>).<SUP> </SUP>Dopamine and D<SUB>1</SUB>-specific agonists also stimulate PI hydrolysis<SUP> </SUP>in proximal tubules by a cAMP-independent mechanism (<a href="#B124">124</A>, <a href="#B126">126</A>).<SUP> </SUP>Both the human and goldfish D<SUB>1</SUB> receptors have been found to increase<SUP> </SUP>intracellular calcium when expressed in HEK 293&nbsp;cells by a cAMP-dependent<SUP> </SUP>mechanism (<a href="#B263">263</A>).</P>
		
		
		
		<font size=-1>B) D</font><SUB>2</SUB>-<font size=-1>LIKE RECEPTORS</font>. Radioligand binding identified high-affinity and low-affinity haloperidol binding sites in homogenates<SUP> </SUP>of renal cortex and high-affinity spiroperidol sites in purified<SUP> </SUP>proximal tubule cells. The high-affinity site shows a pharmacological<SUP> </SUP>profile very similar to central D<SUB>2</SUB> receptors (<a href="#B21">21</A>, <a href="#B127">127</A>, <a href="#B323">323</A>). Radioligand<SUP> </SUP>autoradiography of rat renal slices with [<SUP>3</SUP>H]spiperone has been used to characterize a D<SUB>2</SUB>-like receptor that<SUP> </SUP>has been termed the D<SUB>2K</SUB> (<a href="#B207">207</A>). The pharmacological profile of<SUP> </SUP>this receptor appears unique to the kidney; however, there are<SUP> </SUP>insufficient data for a satisfactory comparison with the cloned<SUP> </SUP>D<SUB>3</SUB> and D<SUB>4</SUB> receptors (<a href="#B401">401</A>).</P>
		
		
		
		Dopamine inhibits AC in isolated glomeruli (<a href="#B129">129</A>) and rat renal cortical membranes (<a href="#B369">369</A>). In inner medullary collecting duct<SUP> </SUP>cells, the putative D<SUB>2K</SUB> receptor has been linked to the production<SUP> </SUP>of prostaglandin (PG) E<SUB>2</SUB> by phospholipase A<SUB>2</SUB> and to the mobilization<SUP> </SUP>of intracellular calcium via a PTX-sensitive G protein (<a href="#B204">204</A>, <a href="#B206">206</A>).<SUP> </SUP></P>
		
		
	    
	
	    
	    <A NAME="SEC10_6_6">
<P ALIGN=LEFT><B><I>2. Dopaminergic sites of action within the kidney</I></B></font>
</P>

	    
		
		<font size=-1>A) GLOMERULUS.</font> At the vascular pole of the glomerulus, DA has been shown to exert a dose-dependent relaxation of both efferent<SUP> </SUP>and afferent glomerular arterioles (<a href="#B117">117</A>) that is mimicked by<SUP> </SUP>D<SUB>1</SUB> agonists fenoldopam or SKF-87516 and blocked by a D<SUB>1</SUB> antagonist<SUP> </SUP>(<a href="#B118">118</A>). In the rat, DA released from intrarenal nerve endings<SUP> </SUP>plays a role in the increased glomerular filtration rate that<SUP> </SUP>is part of the dopaminergic response to volume expansion with<SUP> </SUP>saline or increased dietary intake of salt (<a href="#B16">16</A>). Although the<SUP> </SUP>importance of dopaminergic neurotransmission is controversial<SUP> </SUP>(<a href="#B40">40</A>, <a href="#B107">107</A>), DA has been shown to regulate the release of norepinephrine<SUP> </SUP>through D<SUB>2</SUB> receptors located on nerve endings (<a href="#B381">381</A>). Dopamine<SUP> </SUP>receptors within the vascular elements adjacent to the renal glomeruli,<SUP> </SUP>or D<SUB>1</SUB>-like receptors in mesangial cells, may be at least in part<SUP> </SUP>responsible for DA-induced changes in glomerular filtration rate.<SUP> </SUP></P>
		
		
		
		D<SUB>1</SUB>-like receptors have been identified within the juxtaglomerular apparatus by the ability of fenoldopam to stimulate the<SUP> </SUP>secretion of renin from renal cortical tissue slices (<a href="#B9">9</A>, <a href="#B241">241</A>).<SUP> </SUP>Electron microscopic immunocytochemical experiments have recently<SUP> </SUP>demonstrated the presence of D<SUB>1</SUB> receptors on renin-containing<SUP> </SUP>granules within the juxtaglomerular apparatus (<a href="#B336">336</A>).<SUP> </SUP></P>
		
		
		
		Experiments with isolated glomeruli demonstrated a weak inhibition of adenylyl cyclase at high concentrations of DA, which<SUP> </SUP>may indicate the presence of D<SUB>2</SUB>-like receptors (<a href="#B129">129</A>), although<SUP> </SUP>autoradiography using the D<SUB>2</SUB>-selective radioligand [<SUP>3</SUP>H]spiroperidol failed to detect any specific binding within the<SUP> </SUP>glomeruli (<a href="#B369">369</A>). Binding experiments with D<SUB>1</SUB>-selective radioligands<SUP> </SUP>are inconclusive, since some groups (<a href="#B199">199</A>, <a href="#B437">437</A>), but not others<SUP> </SUP>(<a href="#B131">131</A>, <a href="#B205">205</A>), report the presence of specific binding within the<SUP> </SUP>glomeruli. Immunohistochemistry also failed to detect the presence<SUP> </SUP>of the D<SUB>1</SUB> receptors in rat glomeruli (<a href="#B336">336</A>). On the other hand,<SUP> </SUP>primary cultures of rat glomerular mesangial cells express a D<SUB>1</SUB>-like<SUP> </SUP>receptor that has been well characterized pharmacologically (<a href="#B43">43</A>, <a href="#B44">44</A>).<SUP> </SUP></P>
		
		
		
		<font size=-1>B) PROXIMAL TUBULE.</font> The proximal tubule is the site of reabsorption for two-thirds of the water and sodium present in the<SUP> </SUP>glomerular filtrate as well as for virtually all important metabolic<SUP> </SUP>products (e.g., amino acids and glucose) (<a href="#B279">279</A>, <a href="#B382">382</A>). Membranes<SUP> </SUP>prepared from isolated proximal tubules contain both D<SUB>1</SUB>-like and<SUP> </SUP>D<SUB>2</SUB>-like receptors (<a href="#B127">127</A>). Thus the proximal tubule is likely to<SUP> </SUP>play an important role in the natriuretic and diuretic responses<SUP> </SUP>to renal DA.</P>
		
		
		
		The proximal tubule also is the major site of DA synthesis within the kidney due to a high concentration of <font size=-1>L</font>-aromatic amino<SUP> </SUP>acid decarboxylase at the apical pole of the tubular epithelium<SUP> </SUP>(<a href="#B33">33</A>). The vast majority of urinary DA is derived from <font size=-1>L</font>-dopa<SUP> </SUP>that is decarboxylated at this epithelial site (<a href="#B481">481</A>). The regulation<SUP> </SUP>of intrarenal DA synthesis is still not well understood; however,<SUP> </SUP>plasma sodium concentration is thought to act at several levels<SUP> </SUP>to increase the effective concentration of DA (reviewed in Ref.<SUP> </SUP><a href="#B419">419</A>). First, the uptake of <font size=-1>L</font>-dopa is sodium dependent; thus higher<SUP> </SUP>sodium concentrations yield a higher rate of substrate delivery<SUP> </SUP>(<a href="#B419">419</A>). Additionally, an increase in sodium concentration inhibits<SUP> </SUP>the oxidation/inactivation of DA by monoamine oxidases in tissues<SUP> </SUP>slices (<a href="#B419">419</A>). In the intact animal, however, a simple increase<SUP> </SUP>in the concentration of sodium within the renal tubules is not<SUP> </SUP>sufficient to trigger the dopaminergic response associated with<SUP> </SUP>increased dietary salt intake or volume expansion with isotonic<SUP> </SUP>saline (<a href="#B184">184</A>).</P>
		
		
		
		Tubular DA acts to inhibit the reabsorption of sodium within the proximal tubule and possibly at more distal sites along the<SUP> </SUP>nephron (<a href="#B202">202</A>, <a href="#B382">382</A>). Dopamine inhibits the apical Na<SUP>+</SUP>/H<SUP>+</SUP> antiporter in proximal tubule cells (<a href="#B156">156</A>) via activation of<SUP> </SUP>D<SUB>1</SUB>-like receptors (<a href="#B218">218</A>) by both cAMP-dependent (<a href="#B125">125</A>) and cAMP-independent<SUP> </SUP>(<a href="#B123">123</A>) mechanisms. This protein is responsible for the vast majority<SUP> </SUP>of sodium uptake from the glomerular filtrate. Additionally, the<SUP> </SUP>reuptake of sodium is dependent on the maintenance of a gradient<SUP> </SUP>in sodium concentration across the cellular membrane that is produced<SUP> </SUP>by the action of Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase located on the basolateral membrane of the epithelial<SUP> </SUP>cell. Dopamine has been found to inhibit the action of Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase (<a href="#B17">17</A>) by a mechanism that requires activation of both<SUP> </SUP>D<SUB>1</SUB>-like and D<SUB>2</SUB>-like receptors. Selective agonists, in fact, have<SUP> </SUP>no effect, whereas combined treatment with D<SUB>1</SUB> and D<SUB>2</SUB> agonists<SUP> </SUP>mimic the effects of DA (<a href="#B31">31</A>, <a href="#B388">388</A>, <a href="#B437">437</A>), suggesting the existence<SUP> </SUP>of D<SUB>1</SUB>/D<SUB>2</SUB> synergism at this level. The mechanism by which DA acts<SUP> </SUP>to inhibit Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase is still not well understood. In experiments using isolated<SUP> </SUP>proximal tubules, DA inhibition of Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase was shown to be dependent on activation of PKC (<a href="#B36">36</A>, <a href="#B388">388</A>).<SUP> </SUP>In vitro studies demonstrate that phosphorylation of the catalytic<SUP> </SUP>subunit of Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase with either PKA or PKC is sufficient to inhibit pump activity<SUP> </SUP>(<a href="#B32">32</A>, <a href="#B195">195</A>). However, within the proximal tubule, PKA does not<SUP> </SUP>appear to be responsible for Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase inhibition (<a href="#B388">388</A>). Furthermore, the straightforward mechanism<SUP> </SUP>of a direct interaction of Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase with PKC leading to an inhibition of the pump does not<SUP> </SUP>readily account for the requirement of both D<SUB>1</SUB>-like and D<SUB>2</SUB>-like<SUP> </SUP>receptor activation (<a href="#B70">70</A>). The inhibition of Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase by DA has been shown to be sensitive to mepacrine, an<SUP> </SUP>inhibitor of phospholipase A<SUB>2</SUB> (<a href="#B388">388</A>). Although further investigations<SUP> </SUP>are warranted, the fact that activation of D<SUB>1</SUB> and D<SUB>2</SUB> subtype DA<SUP> </SUP>receptors coexpressed in CHO cells leads to a synergistic enhancement<SUP> </SUP>of AA release (<a href="#B356">356</A>) supplies further evidence for a role of arachidonate<SUP> </SUP>pathways in dopaminergic inhibition of Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase.</P>
		
		
		
		Dopamine in the proximal tubule inhibits sodium-coupled transport of phosphate (<a href="#B211">211</A>). This effect has also been demonstrated<SUP> </SUP>in OK cells (<a href="#B163">163</A>), an established cell line model of the proximal<SUP> </SUP>tubule epithelium that expresses only the D<SUB>1</SUB> receptor (<a href="#B326">326</A>).<SUP> </SUP>This result suggests that activation of this subtype is sufficient<SUP> </SUP>for phosphate transport inhibition.<SUP> </SUP></P>
		
		
		
		<font size=-1>C) DISTAL TUBULE SEGMENTS.</font> Studies of sodium reabsorption during DA infusion have demonstrated that DA-induced natriuresis<SUP> </SUP>is due to increased delivery of sodium from the proximal tubule,<SUP> </SUP>which is inadequately compensated for by the distal nephron segments<SUP> </SUP>(<a href="#B342">342</A>). Because the distal nephron is, in general, theoretically<SUP> </SUP>capable of compensation for increases in sodium delivery, the<SUP> </SUP>poor compensation observed during DA infusion may arise from the<SUP> </SUP>action of DA at sites along the distal nephron. In line with this<SUP> </SUP>assumption, specific DA binding sites have been detected in all<SUP> </SUP>cortical and outer medullary nephron segments with the highest<SUP> </SUP>density present in the proximal tubule (<a href="#B186">186</A>, <a href="#B437">437</A>). The presence<SUP> </SUP>of D<SUB>1</SUB>-like receptors in the medullary thick ascending limb of<SUP> </SUP>the loop of Henle had been strengthened by the presence of DA-sensitive<SUP> </SUP>Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase and by the expression of DA- and cAMP-regulated phosphoprotein<SUP> </SUP>(DARPP-32) (<a href="#B294">294</A>). In the outer renal medulla, the presence of<SUP> </SUP>D<SUB>1</SUB>-like receptors has been supported by the presence of a DA-sensitive<SUP> </SUP>AC (<a href="#B6">6</A>). D<SUB>1</SUB>-like receptors in the thick ascending limb inhibit<SUP> </SUP>Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase by a cAMP-dependent mechanism that appears to involve<SUP> </SUP>DARPP-32 (<a href="#B294">294</A>), and thus different from the mechanism of inhibition<SUP> </SUP>in the proximal tubule. Additionally, D<SUB>1</SUB>-like receptor binding<SUP> </SUP>and AC stimulation are present in the cortical collecting duct<SUP> </SUP>(CCD) (<a href="#B339">339</A>, <a href="#B436">436</A>). In the CCD, DA-stimulated increases in intracellular<SUP> </SUP>cAMP inhibit Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase by a mechanism that involves phospholipase A<SUB>2</SUB> (<a href="#B387">387</A>).<SUP> </SUP>The dopaminergic blockade of the action of vasopressin (<a href="#B236">236</A>, <a href="#B321">321</A>)<SUP> </SUP>is also thought to occur in the distal nephron. The mechanism<SUP> </SUP>of this effect is unclear, but no inhibition of the vasopressin-stimulated<SUP> </SUP>AC was observed in microdissected CCD after treatment with fenoldopam<SUP> </SUP>(<a href="#B339">339</A>). The antagonism of vasopressin signaling observed physiologically<SUP> </SUP>is hypothesized to involve D<SUB>2</SUB>-like receptors (<a href="#B339">339</A>). The intramedullary<SUP> </SUP>collecting duct has been demonstrated to express the so-called<SUP> </SUP>D<SUB>2K</SUB> receptor (<a href="#B204">204</A>, <a href="#B206">206</A>, <a href="#B207">207</A>). The specific role of this receptor<SUP> </SUP>in the dopaminergic control of renal function remains unclear,<SUP> </SUP>although PGE<SUB>2</SUB> is an inhibitor of sodium transport (<a href="#B181">181</A>) and of<SUP> </SUP>Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase (<a href="#B81">81</A>, <a href="#B389">389</A>), and DA-sensitive release of PGE<SUB>2</SUB> has been<SUP> </SUP>demonstrated to increase during salt loading (<a href="#B475">475</A>).<SUP> </SUP></P>
		
		
	    
	
	    
	    <A NAME="SEC10_6_7">
<P ALIGN=LEFT><B><I>3. Identification of cloned dopamine receptor subtypes within the kidney</I></B></font>
</P>

	    
		
		<font size=-1>A) D</font><SUB>1</SUB>-<font size=-1>LIKE RECEPTORS</font>. The mRNA for both D<SUB>1</SUB> and D<SUB>5</SUB> receptors has been detected by ribonuclease protection in mammalian kidney<SUP> </SUP>(<a href="#B326">326</A>, <a href="#B473">473</A>), and the D<SUB>1</SUB> has also been detected by PCR and in situ<SUP> </SUP>hybridization in the rat kidney (<a href="#B295">295</A>, <a href="#B473">473</A>). The D<SUB>1</SUB> subtype is<SUP> </SUP>also endogenously expressed in both the OK cell and LLC-PK<SUB>1</SUB> cell<SUP> </SUP>lines (<a href="#B20">20</A>, <a href="#B173">173</A>, <a href="#B174">174</A>, <a href="#B326">326</A>). Immunohistochemistry with D<SUB>1</SUB>-specific<SUP> </SUP>antibodies has localized this receptor within the renal artery,<SUP> </SUP>intrarenal vasculature, juxtaglomerular apparatus, proximal tubule,<SUP> </SUP>and CCD (<a href="#B336">336</A>). No D<SUB>1</SUB> immunoreactivity was observed in the glomeruli.<SUP> </SUP>Within the proximal tubule epithelium, D<SUB>1</SUB> immunoreactivity was<SUP> </SUP>observed in both basolateral and apical membranes (<a href="#B336">336</A>).<SUP> </SUP></P>
		
		
		
		<font size=-1>B) D</font><SUB>2</SUB>-<font size=-1>LIKE RECEPTORS</font>. Expression of mRNA from all of the cloned D<SUB>2</SUB>-like receptor genes has been detected in mammalian kidney<SUP> </SUP>by PCR, including the D<SUB>2L</SUB> in rat (<a href="#B148">148</A>), the D<SUB>3</SUB> in rat (<a href="#B420">420</A>),<SUP> </SUP>and the D<SUB>4</SUB> in human kidney (<a href="#B285">285</A>). Autoradiography with [<SUP>3</SUP>H]spiroperidol demonstrated D<SUB>2</SUB>-like binding in cortical tubules<SUP> </SUP>from both proximal and distal nephron segments, medullary collecting<SUP> </SUP>tubules, and intrarenal arteries (<a href="#B4">4</A>, <a href="#B370">370</A>). However, no further<SUP> </SUP>information is presently available concerning the intrarenal localizations<SUP> </SUP>and putative functions of these receptor subtypes.<SUP> </SUP></P>
		
		
		
		<font size=-1>C) UNCLONED RECEPTOR SUBTYPES.</font> Several arguments have been proposed for the existence of additional uncloned DA receptors<SUP> </SUP>in the kidney. One is that the question of whether the cloned<SUP> </SUP>D<SUB>1</SUB>-like receptors are able to couple to PI hydrolysis remains<SUP> </SUP>unanswered. Renal D<SUB>1</SUB>-like receptors have been shown to be associated<SUP> </SUP>to PI turnover. The report of D<SUB>1</SUB> receptors-coupled PI turnover<SUP> </SUP>in the striatum (<a href="#B275">275</A>), however, is controversial (<a href="#B380">380</A>). On the<SUP> </SUP>other hand, coupling of D<SUB>1</SUB> receptors to PI hydrolysis has been<SUP> </SUP>reported (<a href="#B263">263</A>). Another argument is that the low levels of D<SUB>1</SUB>-like<SUP> </SUP>receptor mRNAs detected in the kidney do not account for the relatively<SUP> </SUP>high levels of D<SUB>1</SUB> ligand binding in renal tissue (<a href="#B336">336</A>). Finally,<SUP> </SUP>some experiments have revealed biphasic binding curves with D<SUB>1</SUB>-selective<SUP> </SUP>ligands (most notably with SCH-23390) in renal cortical membranes<SUP> </SUP>(<a href="#B131">131</A>, <a href="#B200">200</A>, <a href="#B205">205</A>) or kidney-derived cell lines (<a href="#B20">20</A>), and the lower<SUP> </SUP>affinity site has been suggested to potentially represent an unidentified<SUP> </SUP>subtype (<a href="#B20">20</A>, <a href="#B198">198</A>). This lower affinity site has been demonstrated,<SUP> </SUP>however, to lack stereoselectivity and most likely represents<SUP> </SUP>binding to a nonreceptor site (<a href="#B192">192</A>). With respect to potential<SUP> </SUP>novel D<SUB>2</SUB>-like subtypes, a fair argument can be made that the D<SUB>2K</SUB><SUP> </SUP>binding site described in inner medullary collecting duct is pharmacologically<SUP> </SUP>different from the cloned D<SUB>2</SUB> receptor (<a href="#B204">204</A>, <a href="#B206">206</A>, <a href="#B207">207</A>). However,<SUP> </SUP>insufficient data are available to allow a satisfactory comparison<SUP> </SUP>of the D<SUB>2K</SUB> binding site with the pharmacological properties of<SUP> </SUP>the cloned D<SUB>3</SUB> and D<SUB>4</SUB> DA receptor subtypes (<a href="#B401">401</A>). Because the<SUP> </SUP>current understanding of the localizations and functions of the<SUP> </SUP>cloned DA receptor subtypes within the kidney remains fragmentary,<SUP> </SUP>the suggestion of the existence of novel receptor subtypes in<SUP> </SUP>renal tissue remains highly speculative.<SUP> </SUP></P>
		
		
	    
	
	
    

    
    <A NAME="SEC11">
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;XI. DOPAMINERGIC SIGNAL TRANSDUCTION AND HYPERTENSION</FONT></TH>
</TR>
</TABLE>
<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Top</A><BR>












<A HREF="#SEC10"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Previous</A><BR>



<A HREF="#SEC12"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Next</A><BR>


<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">References</A>

</FONT></TH>
</TR></TABLE>

    
	
	<A NAME="SEC11_1">
<P ALIGN=LEFT><B>A. Human Hypertension</B>
</P>

	
	    
	    <P>Several lines of evidence suggest that defects in the renal dopaminergic system may underlie some forms of essential (idiopathic)<SUP> </SUP>hypertension. Several groups of patients with high blood pressure<SUP> </SUP>have been found to have either high (<a href="#B238">238</A>, <a href="#B383">383</A>) or low (<a href="#B10">10</A>, <a href="#B208">208</A>, <a href="#B209">209</A>)<SUP> </SUP>levels of urinary DA excretion, suggesting a heterogeneity of<SUP> </SUP>underlying defects (<a href="#B238">238</A>). Although normal subjects demonstrate<SUP> </SUP>a rise in urinary DA excretion after salt loading (<a href="#B335">335</A>), some<SUP> </SUP>hypertensive patients display a paradoxical fall in urinary DA<SUP> </SUP>excretion (<a href="#B180">180</A>). Furthermore, some hypertensive patients have<SUP> </SUP>been shown to respond with an exaggerated level of natriuresis<SUP> </SUP>and diuresis to the administration of DA (<a href="#B8">8</A>), fenoldopam (<a href="#B55">55</A>),<SUP> </SUP>or a dopaminergic prodrug (gludopa, Ref. <a href="#B248">248</A>). Comparison of<SUP> </SUP>normotensive subjects with or without a family history of hypertension<SUP> </SUP>revealed abnormal levels of DA excretion before the development<SUP> </SUP>of high blood pressure, suggesting that the dopaminergic abnormalities<SUP> </SUP>are not a secondary effect (<a href="#B208">208</A>, <a href="#B384">384</A>, <a href="#B409">409</A>).<SUP> </SUP></P>
	    
	
	
    
	
	<A NAME="SEC11_2">
<P ALIGN=LEFT><B>B. Animal Models of Hypertension</B>
</P>

	
	    
	    <P>Two rat models of genetic hypertension, the Dahl salt-sensitive strain and the spontaneously hypertensive rat (SHR) Okamoto-Aoki<SUP> </SUP>strain, display abnormalities in renal DA production or signal<SUP> </SUP>transduction (<a href="#B133">133</A>, <a href="#B221">221</A>, <a href="#B239">239</A>). After introduction of a high-salt<SUP> </SUP>diet, DA production decreased in the Dahl strain (<a href="#B100">100</A>, <a href="#B239">239</A>, <a href="#B474">474</A>)<SUP> </SUP>reminiscent of the response of low renin essential hypertension<SUP> </SUP>patients (<a href="#B239">239</A>). The Dahl strain also shows an impaired natriuretic<SUP> </SUP>and diuretic response to volume expansion with isotonic saline<SUP> </SUP>(<a href="#B385">385</A>). Examination of isolated proximal tubules from these animals<SUP> </SUP>revealed a decreased ability of dopaminergic agonists to stimulate<SUP> </SUP>production of cAMP (<a href="#B340">340</A>) and a loss of the dopaminergic regulation<SUP> </SUP>of Na<SUP>+</SUP>-K<SUP>+</SUP>ATPase (<a href="#B331">331</A>, <a href="#B332">332</A>).</P>
	    
	
	    
	    <P>In contrast, 4-wk-old SHR have higher urinary DA levels than control rats (<a href="#B475">475</A>), and maintenance on a high-salt diet increased<SUP> </SUP>DA production in a manner similar to the response of some groups<SUP> </SUP>of essential hypertension patients (<a href="#B238">238</A>, <a href="#B239">239</A>, <a href="#B408">408</A>). This strain<SUP> </SUP>also possesses a blunted natriuretic response to administration<SUP> </SUP>of D<SUB>1</SUB> agonists (<a href="#B134">134</A>) despite a similar DA D<SUB>1</SUB>-like receptor density<SUP> </SUP>to Wistar-Kyoto rats (WKY), the normotensive counterpart of SHR<SUP> </SUP>(<a href="#B231">231</A>, <a href="#B414">414</A>). Comparison of the receptor density of both D<SUB>1</SUB>-like<SUP> </SUP>and D<SUB>2</SUB>-like receptors in the proximal tubules of both the SHR<SUP> </SUP>and WKY strains revealed no interstrain differences up to the<SUP> </SUP>age of 75&nbsp;wk (<a href="#B48">48</A>). However, stimulation of AC by D<SUB>1</SUB> agonists<SUP> </SUP>is defective in isolated proximal tubules, although stimulation<SUP> </SUP>of AC by parathyroid hormone or forskolin is intact (<a href="#B231">231</A>). This<SUP> </SUP>defect in signal transduction is specific to this nephron segment,<SUP> </SUP>since AC was stimulated normally by the D<SUB>1</SUB> receptor in cortical<SUP> </SUP>collecting duct (<a href="#B341">341</A>) and striatum (<a href="#B123">123</A>). Activation of PLC<SUP> </SUP>by D<SUB>1</SUB> agonists is also defective (<a href="#B73">73</A>). Competition binding of<SUP> </SUP>D<SUB>1</SUB> agonists for the DA receptor in the proximal tubule reveals<SUP> </SUP>only a low-affinity site that is insensitive to nonhydrolyzable<SUP> </SUP>GTP analogs, and this abnormality of the ligand binding site persists<SUP> </SUP>after solubilization of the receptor (<a href="#B414">414</A>). In comparison with<SUP> </SUP>tissue from WKY, there is a relative inability of dopaminergic<SUP> </SUP>agonists but not antagonists to protect the binding site from<SUP> </SUP>photoaffinity labeling (<a href="#B446">446</A>). The loss of high-affinity agonist<SUP> </SUP>binding suggests a defect in G protein coupling that is reinforced<SUP> </SUP>by the observation that coadministration of G protein activators<SUP> </SUP>(e.g., NaF) and fenoldopam yields a synergistic inhibition of<SUP> </SUP>angiotensin II-induced vasoconstriction (<a href="#B68">68</A>).<SUP> </SUP></P>
	    
	
	    
	    <P>Isolated proximal tubules from SHR show a decrease in dopaminergic inhibition of Na<SUP>+</SUP>/H<SUP>+</SUP> antiporter activity (<a href="#B157">157</A>, <a href="#B194">194</A>). Although Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase activity is increased in the proximal tubule of the SHR<SUP> </SUP>strain through the age of 5&nbsp;wk (<a href="#B150">150</A>, <a href="#B176">176</A>), dopaminergic inhibition<SUP> </SUP>of Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase is also impaired (<a href="#B69">69</A>). Investigation of the effect of<SUP> </SUP>cholera and PTXs on DA inhibition of Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase in SHR demonstrated that this effect could be partially<SUP> </SUP>recovered after treatment of proximal tubule preparation with<SUP> </SUP>PTX (<a href="#B176">176</A>). Interestingly, the regulation of sodium-coupled phosphate<SUP> </SUP>transport appears to function normally in these animals (<a href="#B98">98</A>).<SUP> </SUP>Amplification of a region of the D<SUB>1</SUB> gene by PCR from the genomic<SUP> </SUP>DNA of SHR revealed no mutations within the third intracellular<SUP> </SUP>loop, a region which is important for G protein coupling, although<SUP> </SUP>other receptor regions were not examined (<a href="#B473">473</A>). Defects may also<SUP> </SUP>be present in downstream components of the dopaminergic signal<SUP> </SUP>transduction pathway, since the Na<SUP>+</SUP>/H<SUP>+</SUP> exchange activity within the proximal tubule was inhibited by<SUP> </SUP>exogenously added 8-chlorophenylthio-cAMP in 3-&nbsp;to 4-wk old rats,<SUP> </SUP>but this inhibition was lost in adults (<a href="#B194">194</A>).<SUP> </SUP></P>
	    
	
	    
	    <P>Although it is not at all clear that the underlying defects in these animal models correspond to those underlying human pathology,<SUP> </SUP>it would seem clear that the study of DA receptors and dopaminergic<SUP> </SUP>signal transduction in the kidney holds the promise of providing<SUP> </SUP>a better understanding of the pathophysiology of human hypertension<SUP> </SUP>and will perhaps also lead to the identification of new molecular<SUP> </SUP>targets for therapeutic intervention and new pharmacological agents.<SUP> </SUP></P>
	    
	
	    
	    <P>In conclusion, the distribution and function of receptors for DA within the cardiovascular system is such that DA agonists,<SUP> </SUP>by acting at different levels, may induce changes that synergistically<SUP> </SUP>operate to reduce blood pressure, thus making them the potential<SUP> </SUP>target for a new class of antihypertensive drugs. In particular,<SUP> </SUP>the dilatation of splanchnic vascular beds, the reduction of circulating<SUP> </SUP>catecholamines, the inhibition of norepinephrine release at synaptic<SUP> </SUP>terminals, the inhibition of stimulated aldosterone secretion,<SUP> </SUP>and the increase of sodium excretion are involved in the hypotensive<SUP> </SUP>effects of DA.</P>
	    
	
	    
	    <P>Similarly, the property of DA of reducing afterload through D<SUB>1</SUB> receptor-mediated vasodilatation, of increasing renal blood<SUP> </SUP>flow and improving renal function, and of decreasing aldosterone<SUP> </SUP>secretion and norepinephrine release together with its positive<SUP> </SUP>inotropic effect provide beneficial hemodynamic effects that have<SUP> </SUP>potential applications in the treatment of congestive heart failure<SUP> </SUP>(<a href="#B165">165</A>).</P>
	    
	
	
    

    
    <A NAME="SEC12">
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;XII. CONCLUDING REMARKS</FONT></TH>
</TR>
</TABLE>
<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Top</A><BR>













<A HREF="#SEC11"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Previous</A><BR>



<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">Next</A><BR>


<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">References</A>

</FONT></TH>
</TR></TABLE>

    
	
	<P>The development of the recombinant DNA technologies made it possible to identify new DA receptor subtypes and provided valuable<SUP> </SUP>information about the structure of the receptor proteins. The<SUP> </SUP>use of site-directed mutagenesis and receptor chimeras allowed<SUP> </SUP>us to find the determinants of ligand binding and of coupling<SUP> </SUP>to specific G proteins. The use of PCR and in situ hybridization<SUP> </SUP>with the cloned DA receptor probes made it possible to define<SUP> </SUP>the localization of DA receptor subtypes even in brain areas where<SUP> </SUP>they were undetectable with more classical methods. The progress<SUP> </SUP>made in the study of signal transduction has played a critical<SUP> </SUP>role in providing a molecular basis to understand how activation<SUP> </SUP>of DA receptors translates in changes in neuronal and peripheral<SUP> </SUP>cell function. On the other hand, two major issues are still open:<SUP> </SUP><I>1</I>) pharmacological agents selective for each receptor subtype<SUP> </SUP>are not yet available, and <I>2</I>) the physiological function of the<SUP> </SUP>newly cloned DA receptor subtypes is still mostly unknown. Thus,<SUP> </SUP>if the structural and transductional properties of each DA receptor<SUP> </SUP>subtype have now been largely elucidated, defining their physiological<SUP> </SUP>functions and finding selective potential therapeutic agents remain<SUP> </SUP>the challenges of the next years.<SUP> </SUP></P>
	
    
	
	<P>There are indications that the diversity in DA receptors will not be limited to the five subtypes already characterized. Biochemical,<SUP> </SUP>pharmacological, and molecular studies suggested the existence<SUP> </SUP>of further heterogeneity within D<SUB>2</SUB> receptors in the pituitary.<SUP> </SUP>Although the majority of DA agonists can activate with the same<SUP> </SUP>efficiency both inhibition of AC and opening of potassium channels<SUP> </SUP>in pituitary lactotrophs (<a href="#B65">65</A>, <a href="#B212">212</A>, <a href="#B269">269</A>, <a href="#B270">270</A>, <a href="#B298">298</A>), the benzazepine<SUP> </SUP>derivative BHT-920 does not inhibit cAMP formation, while activating<SUP> </SUP>potassium channels (<a href="#B357">357</A>). This observation may suggest that two<SUP> </SUP>distinct D<SUB>2</SUB>-like receptor subtypes may exist with different affinities<SUP> </SUP>for BHT-920 and be individually coupled to one or the other signaling<SUP> </SUP>pathway. Consistent with this idea are the results of binding<SUP> </SUP>studies in the anterior pituitary and in the striatum, unraveling<SUP> </SUP>the existence of an extra D<SUB>2</SUB> site with low affinity for spiperone<SUP> </SUP>(<a href="#B398">398</A>) and in GH<SUB>3</SUB> cells that express a D<SUB>2</SUB>-like receptor with an<SUP> </SUP>unusual low affinity for haloperidol in response to NGF (<a href="#B305">305</A>).<SUP> </SUP>Similarly, studies with the kidney pointed to the existence of<SUP> </SUP>a unique renal D<SUB>2</SUB>-like receptor (D<SUB>2K</SUB>) and suggested the existence<SUP> </SUP>of heterogeneity within D<SUB>1</SUB>-like receptors as well.<SUP> </SUP></P>
	
    
	
	<P>Behavioral studies also suggested the existence of D<SUB>1</SUB>-like receptors that either display unique affinities for some D<SUB>1</SUB>-selective<SUP> </SUP>compounds or are not defined as AC coupled (<a href="#B13">13</A>, <a href="#B94">94</A>, <a href="#B113">113</A>, <a href="#B301">301</A>).<SUP> </SUP>In addition, evidence showing differential order of potencies<SUP> </SUP>and efficacies for a series of benzazepine compounds in stimulating<SUP> </SUP>phosphoinositide hydrolysis and in activating AC in brain tissues<SUP> </SUP>suggests that the D<SUB>1</SUB> receptor that is linked to PLC differs from<SUP> </SUP>that coupled to AC (<a href="#B445">445</A>). In line with this, it has been shown<SUP> </SUP>that when rat striatal mRNA is fractionated and then expressed<SUP> </SUP>in <I>Xenopus</I> oocytes, the mRNA fraction that demonstrates a PLC-coupled<SUP> </SUP>DA receptor is prominently different in size from AC-coupled D<SUB>1</SUB><SUP> </SUP>receptor mRNA (<a href="#B275">275</A>). The recent cloning and characterization<SUP> </SUP>of a novel D<SUB>1</SUB>-like receptor subtype, named D<SUB>1C</SUB> ,&nbsp;from <I>Xenopus<SUP> </SUP>laevis</I> (<a href="#B430">430</A>) and of another unique subtype, named D<SUB>1D</SUB> ,&nbsp;from<SUP> </SUP><I>Gallus domesticus</I> (<a href="#B101">101</A>) may hint to the existence of a further<SUP> </SUP>heterogeneity within mammalian D<SUB>1</SUB>-like receptors.<SUP> </SUP></P>
	
    
	
	<P>In spite of this evidence, however, cloning by homology has not identified any new DA receptor in mammals since 1991.&nbsp;However,<SUP> </SUP>the possibility should not be excluded that, as is the case for<SUP> </SUP>other neurotransmitters, DA receptors structurally divergent from<SUP> </SUP>the ones that have been already cloned still remain to be identified<SUP> </SUP>and characterized.</P>
	
    

</TXT>



<!-- Stray figures and tables -->


<!-- Acknowledgements -->

<!-- Abbreviations -->

<!-- Appendices -->


<!-- Footnotes -->




<A NAME="foo"><!-- comment for mosaic --></A>

<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;FOOTNOTES</FONT></TH>
</TR>
</TABLE>







<P>

&nbsp;&nbsp;
C. Missale was on sabbatical leave from the Division of Pharmacology, Department of Biomedical Sciences and Biotechnology,<SUP> </SUP>University of Brescia, Faculty of Medicine, Brescia, Italy.<SUP> </SUP>

<BR><P>
&nbsp;&nbsp;
M. Jaber was a recipient of an EMBO long-term fellowship, and S.&nbsp;R. Nash was supported by a fellowship from the Japan Society<SUP> </SUP>for the Promotion of Science.

<BR>




<P>&nbsp;&nbsp;
</P>


<!-- Bibliography -->

<A NAME="References"><!-- comment for mosaic --></A>



<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;REFERENCES</FONT></TH>
</TR>
</TABLE>
<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>
<A HREF="#top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Top</A><BR>














<A HREF="#SEC12"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">Previous</A><BR>




</FONT></TH>
</TR></TABLE>

<a name="B1"><!-- comment for mosaic --></a>
<P>1. &nbsp; 

ALBERT, P<font size=-1>. </font>R<font size=-1>.</font>,
K<font size=-1>. </font>A<font size=-1>.</font> NEVE,
J<font size=-1>. </font>R<font size=-1>.</font> BUNZOW,
 <font size=-1>AND</font> O<font size=-1>.</font> CIVELLI.



Coupling of a cloned rat dopamine D<SUB>2</SUB> receptor to inhibition of adenylyl cyclase and prolactin secretion.
<I>J. Biol. Chem.</I>
265: 2098-2104, 1990<!-- HIGHWIRE ID="78:1:189:1" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=265/4/2098" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B2"><!-- comment for mosaic --></a>
<P>2. &nbsp; 

ALEXANDER, R<font size=-1>. </font>W<font size=-1>.</font>,
J<font size=-1>. </font>R<font size=-1>.</font> GILL,
 <font size=-1>AND</font> H<font size=-1>.</font> YAMABE.



Effects of dietary sodium and acute saline infusion on the interrelationship between dopamine excretion and adrenergic activity in man.
<I>J. Clin. Invest.</I>
54: 194-200, 1974<!-- HIGHWIRE ID="78:1:189:2" --><A HREF="/cgi/external_ref?access_num=4600048&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B3"><!-- comment for mosaic --></a>
<P>3. &nbsp; 

AMENTA, F<font size=-1>.</font>,
L<font size=-1>.</font> CHIANDUSSI,
M<font size=-1>.</font> MANCINI,
A<font size=-1>.</font> RICCI,
M<font size=-1>.</font> SCHENA,
 <font size=-1>AND</font> F<font size=-1>.</font> VEGLIO.



Pharmacological characterization and autoradiographic localization of dopamine receptors in the human adrenal cortex.
<I>Eur. J.&nbsp;Endocrinol.</I>
131: 91-96, 1994<!-- HIGHWIRE ID="78:1:189:3" --><A HREF="/cgi/external_ref?access_num=8038912&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B4"><!-- comment for mosaic --></a>
<P>4. &nbsp; 

AMENTA, F<font size=-1>.</font>,
W<font size=-1>. </font>L<font size=-1>.</font> COLLIER,
 <font size=-1>AND</font> A<font size=-1>.</font> RICCI.



Autoradiographic localization of vascular dopamine receptors.
<I>Am. J.&nbsp;Hypertens.</I>
3, <I>Suppl.</I>: 34S-36S, 1990<!-- HIGHWIRE ID="78:1:189:4" --><A HREF="/cgi/external_ref?access_num=2200435&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B5"><!-- comment for mosaic --></a>
<P>5. &nbsp; 

AMENTA, F<font size=-1>.</font>,
 <font size=-1>AND</font> A<font size=-1>.</font> RICCI.



Autoradiographic localization of dopamine DA<SUB>1</SUB> receptors in the rat renal vasculature using [<SUP>3</SUP>H]SCH 23390&nbsp;as a ligand.
<I>J. Auton. Pharmacol.</I>
10: 373-383, 1990<!-- HIGHWIRE ID="78:1:189:5" --><A HREF="/cgi/external_ref?access_num=2151196&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B6"><!-- comment for mosaic --></a>
<P>6. &nbsp; 

AMENTA, F<font size=-1>.</font>,
A<font size=-1>.</font> RICCI,
 <font size=-1>AND</font> J<font size=-1>. </font>A<font size=-1>.</font> VEGA.



Pharmacological characterization of rat renal medulla dopamine-sensitive cyclic adenosine monophosphate generating system.
<I>J. Pharmacol. Exp. Ther.</I>
253: 246-249, 1990<!-- HIGHWIRE ID="78:1:189:6" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jpet&resid=253/1/246" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B7"><!-- comment for mosaic --></a>
<P>7. &nbsp; 

ANDERSEN, P<font size=-1>. </font>H<font size=-1>.</font>,
J<font size=-1>. </font>A<font size=-1>.</font> GINGRICH,
M<font size=-1>. </font>D<font size=-1>.</font> BATES,
A<font size=-1>.</font> DEARRY,
P<font size=-1>.</font> FALARDEAU,
S<font size=-1>. </font>E<font size=-1>.</font> SENOGLES,
 <font size=-1>AND</font> M<font size=-1>. </font>G<font size=-1>.</font> CARON.



Dopamine receptor subtypes: beyond the D<SUB>1</SUB>/D<SUB>2</SUB> classification.
<I>Trends Pharmacol. Sci.</I>
11: 231-236, 1990<!-- HIGHWIRE ID="78:1:189:7" --><A HREF="/cgi/external_ref?access_num=2200181&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B8"><!-- comment for mosaic --></a>
<P>8. &nbsp; 

ANDREJAK, M<font size=-1>.</font>,
 <font size=-1>AND</font> L<font size=-1>.</font> HARY.



Enhanced renal responsiveness in patients with hypertension.
<I>Clin. Pharmacol. Ther.</I>
40: 610-614, 1986<!-- HIGHWIRE ID="78:1:189:8" --><A HREF="/cgi/external_ref?access_num=3780122&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B9"><!-- comment for mosaic --></a>
<P>9. &nbsp; 

ANTONIPILLAI, I<font size=-1>.</font>,
M<font size=-1>. </font>I<font size=-1>.</font> BROERS,
 <font size=-1>AND</font> D<font size=-1>.</font> LANG.



Evidence that specific dopamine-1 receptor activation is involved in dopamine-induced renin release.
<I>Hypertension</I>
13: 463-468, 1989<!-- HIGHWIRE ID="78:1:189:9" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=hypertensionaha&resid=13/5/463" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B10"><!-- comment for mosaic --></a>
<P>10. &nbsp; 

AOKI, K<font size=-1>.</font>,
K<font size=-1>.</font> KIKUCHI,
I<font size=-1>.</font> YAMAJI,
M<font size=-1>.</font> NISHIMURA,
C<font size=-1>.</font> HONMA,
H<font size=-1>.</font> KOBAYAKAWA,
M<font size=-1>.</font> YAMAMOTO,
C<font size=-1>.</font> KUDOH,
M<font size=-1>.</font> SHIMAZAKI,
T<font size=-1>.</font> SAKAMOTO,
A<font size=-1>.</font> WADA,
 <font size=-1>AND</font> O<font size=-1>.</font> IIMURA.



Attenuated renal production of dopamine in patients with low renin essential hypertension.
<I>Clin. Exp. Hypertens.</I>
11, <I>Suppl</I>. 1: 403-409, 1989<!-- HIGHWIRE ID="78:1:189:10" --><!-- /HIGHWIRE -->.</P>
<a name="B11"><!-- comment for mosaic --></a>
<P>11. &nbsp; 

ARIANO, M<font size=-1>. </font>A<font size=-1>.</font>,
C<font size=-1>. </font>J<font size=-1>.</font> STROMSKI,
E<font size=-1>. </font>M<font size=-1>.</font> SMYK<font size=-1>-</font>RANDAL,
 <font size=-1>AND</font> D<font size=-1>. </font>R<font size=-1>.</font> SIBLEY.



D<SUB>2</SUB> dopamine receptor localization on striatonigral neurons.
<I>Neurosci. Lett.</I>
144: 215-220, 1992<!-- HIGHWIRE ID="78:1:189:11" --><A HREF="/cgi/external_ref?access_num=1436705&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B12"><!-- comment for mosaic --></a>
<P>12. &nbsp; 

ARNSTEN, A<font size=-1>. </font>F<font size=-1>.</font>,
J<font size=-1>. </font>X<font size=-1>.</font> CAI,
J<font size=-1>. </font>C<font size=-1>.</font> STEERE,
 <font size=-1>AND</font> P<font size=-1>. </font>S<font size=-1>.</font> GOLDMAN<font size=-1>-</font>RAKIC.



Dopamine D<SUB>2</SUB> receptor mechanisms contribute to age-related cognitive decline: the effects of quinpirole on memory and motor performance in monkeys.
<I>J. Neurosci.</I>
15: 3429-3439, 1995<!-- HIGHWIRE ID="78:1:189:12" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jneuro&resid=15/5/3429" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B13"><!-- comment for mosaic --></a>
<P>13. &nbsp; 

ARNT, J<font size=-1>.</font>,
J<font size=-1>.</font> HYTTEL,
 <font size=-1>AND</font> C<font size=-1>.</font> SANCHEZ.



Partial and full dopamine D<SUB>1</SUB> receptor agonists in mice and rats: relation between behavioral effects and stimulation of adenylate cyclase activity in vitro.
<I>Eur. J.&nbsp;Pharmacol.</I>
213: 259-267, 1992<!-- HIGHWIRE ID="78:1:189:13" --><A HREF="/cgi/external_ref?access_num=1355737&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B14"><!-- comment for mosaic --></a>
<P>14. &nbsp; 

ARTALEJO, C<font size=-1>. </font>R<font size=-1>.</font>,
M<font size=-1>. </font>A<font size=-1>.</font> ARIANO,
R<font size=-1>. </font>L<font size=-1>.</font> PERLMAN,
 <font size=-1>AND</font> A<font size=-1>. </font>P<font size=-1>.</font> FOX.



Activation of facilitation calcium channels in chromaffin cells by D<SUB>1</SUB> dopamine receptors through a cAMP/protein kinase A-dependent mechanism.
<I>Nature</I>
348: 239-242, 1990<!-- HIGHWIRE ID="78:1:189:14" --><A HREF="/cgi/external_ref?access_num=2172839&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B15"><!-- comment for mosaic --></a>
<P>15. &nbsp; 

BAERTSCHI, A<font size=-1>. </font>J<font size=-1>.</font>,
Y<font size=-1>.</font> AUDIGIER,
P<font size=-1>.-</font>M<font size=-1>.</font> LLEDO,
J<font size=-1>.-</font>M<font size=-1>.</font> ISRAEL,
J<font size=-1>.</font> BOCKAERT,
 <font size=-1>AND</font> J<font size=-1>.-</font>D<font size=-1>.</font> VINCENT.



Dialysis of lactotropes with antisense oligonucleotides assigns guanine nucleotide binding protein subtypes to their channel effectors.
<I>Mol. Endocrinol.</I>
6: 2257-2265, 1992<!-- HIGHWIRE ID="78:1:189:15" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=mend&resid=6/12/2257" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B16"><!-- comment for mosaic --></a>
<P>16. &nbsp; 

BAINES, A<font size=-1>. </font>D<font size=-1>.</font>,
 <font size=-1>AND</font> R<font size=-1>.</font> DRANGOVA.



Neural not tubular dopamine increases glomerular filtration rate in perfused rat kidneys.
<I>Am. J.&nbsp;Physiol.</I>
250(<I>Renal Fluid Electrolyte Physiol.</I> 19): F674-F679, 1986<!-- HIGHWIRE ID="78:1:189:16" --><A HREF="/cgi/external_ref?access_num=2421588&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B17"><!-- comment for mosaic --></a>
<P>17. &nbsp; 

BAINES, A<font size=-1>. </font>D<font size=-1>.</font>,
P<font size=-1>.</font> HO,
 <font size=-1>AND</font> R<font size=-1>.</font> DRANGOVA.



Proximal tubular dopamine production regulates basolateral Na<SUP>+</SUP>,K<SUP>+</SUP>-ATPase.
<I>Am. J.&nbsp;Physiol.</I>
262(<I>Renal Fluid Electrolyte Physiol.</I> 31): F566-F571, 1992<!-- HIGHWIRE ID="78:1:189:17" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=262/4/F566" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B18"><!-- comment for mosaic --></a>
<P>18. &nbsp; 

BALK, J<font size=-1>.-</font>H<font size=-1>.</font>,
R<font size=-1>.</font> PICETTI,
A<font size=-1>.</font> SALARDI,
G<font size=-1>.</font> THIRIET,
A<font size=-1>.</font> DIETRICH,
A<font size=-1>.</font> DEPAULLS,
M<font size=-1>.</font> LE MEUR,
 <font size=-1>AND</font> E<font size=-1>.</font> BORRELLI.



Parkinsonian-like locomotor impairment in mice lacking dopamine D<SUB>2</SUB> receptors.
<I>Nature</I>
377: 424-428, 1995<!-- HIGHWIRE ID="78:1:189:18" --><A HREF="/cgi/external_ref?access_num=7566118&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B19"><!-- comment for mosaic --></a>
<P>19. &nbsp; 

BALL, S<font size=-1>. </font>G<font size=-1>.</font>,
 <font size=-1>AND</font> M<font size=-1>. </font>R<font size=-1>.</font> LEE.



Increased urinary dopamine in salt loaded rats.
<I>Clin. Sci. Mol. Med.</I>
52: 20p-21p, 1977<!-- HIGHWIRE ID="78:1:189:19" --><!-- /HIGHWIRE -->.</P>
<a name="B20"><!-- comment for mosaic --></a>
<P>20. &nbsp; 

BATES, M<font size=-1>. </font>D<font size=-1>.</font>,
M<font size=-1>. </font>G<font size=-1>.</font> CARON,
 <font size=-1>AND</font> J<font size=-1>. </font>R<font size=-1>.</font> RAYMOND.



Desensitization of DA<SUB>1</SUB> dopamine receptors coupled to adenylyl cyclase in opossum kidney cells.
<I>Am. J.&nbsp;Physiol.</I>
260(<I>Renal Fluid Electrolyte Physiol.</I> 29): F937-F945, 1991<!-- HIGHWIRE ID="78:1:189:20" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=260/6/F937" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B21"><!-- comment for mosaic --></a>
<P>21. &nbsp; 

BECK, F<font size=-1>. </font>W<font size=-1>.</font><font size=-1>&nbsp;</font>J<font size=-1>.</font>,
 <font size=-1>AND</font> J<font size=-1>. </font>R<font size=-1>.</font> SOWERS.



Identification of dopamine receptors in rat kidney cortical tubules using [<SUP>3</SUP>H]-spiroperidol binding (Abstract).
<I>Clin. Res.</I>
32: 18A, 1984<!-- HIGHWIRE ID="78:1:189:21" --><!-- /HIGHWIRE -->.</P>
<a name="B22"><!-- comment for mosaic --></a>
<P>22. &nbsp; 

BECK, K<font size=-1>. </font>D<font size=-1>.</font>,
B<font size=-1>.</font> KNUSEL,
 <font size=-1>AND</font> F<font size=-1>.</font> HEFTI.



The nature of the trophic action of brain-derived neurotrophic factor, des(<a href="#B1">1</A>-<a href="#B3">3</A>)-insulin-like growth factor-1, and basic fibroblast growth factor on mesencephalic dopaminergic neurons developing in culture.
<I>Neuroscience</I>
52: 855-866, 1993<!-- HIGHWIRE ID="78:1:189:22" --><A HREF="/cgi/external_ref?access_num=8095710&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B23"><!-- comment for mosaic --></a>
<P>23. &nbsp; 

BELL, C<font size=-1>.</font>,
W<font size=-1>. </font>J<font size=-1>.</font> LANG,
 <font size=-1>AND</font> F<font size=-1>.</font> LASKAR.



Dopamine containing vasomotor nerves in the dog kidney.
<I>J. Neurochem.</I>
31: 77-83, 1978<!-- HIGHWIRE ID="78:1:189:23" --><A HREF="/cgi/external_ref?access_num=671042&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B24"><!-- comment for mosaic --></a>
<P>24. &nbsp; 

BELLO<font size=-1>-</font>REUSS, E<font size=-1>.</font>,
Y<font size=-1>.</font> HIGASHI,
 <font size=-1>AND</font> Y<font size=-1>.</font> KANEDA.



Dopamine decreases fluid reabsorption in straight portions of rabbit proximal tubule.
<I>Am. J.&nbsp;Physiol.</I>
242(<I>Renal Fluid Electrolyte Physiol.</I> 11): F634-F640, 1982<!-- HIGHWIRE ID="78:1:189:24" --><A HREF="/cgi/external_ref?access_num=7091317&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B25"><!-- comment for mosaic --></a>
<P>25. &nbsp; 

BENINGER, R<font size=-1>. </font>J<font size=-1>.</font>,
D<font size=-1>. </font>C<font size=-1>.</font> HOFFMAN,
 <font size=-1>AND</font> E<font size=-1>. </font>J<font size=-1>.</font> MAZURSKI.



Receptor subtype-specific dopaminergic agents and conditioned behavior.
<I>Neurosci. Biobehav. Rev.</I>
13: 113-122, 1989<!-- HIGHWIRE ID="78:1:189:25" --><A HREF="/cgi/external_ref?access_num=2573022&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B26"><!-- comment for mosaic --></a>
<P>26. &nbsp; 

BEN<font size=-1>-</font>JONATHAN, N<font size=-1>.</font>.



Dopamine: a prolactin-inhibiting hormone.
<I>Endocr. Rev.</I>
6: 564-589, 1985<!-- HIGHWIRE ID="78:1:189:26" --><A HREF="/cgi/external_ref?access_num=2866952&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B27"><!-- comment for mosaic --></a>
<P>27. &nbsp; 

BERGSON, C<font size=-1>.</font>,
L<font size=-1>.</font> MRZLJAK,
M<font size=-1>. </font>S<font size=-1>.</font> LIDOW,
P<font size=-1>. </font>S<font size=-1>.</font> GOLDMAN<font size=-1>-</font>RAKIC,
 <font size=-1>AND</font> R<font size=-1>.</font> LEVENSON.



Characterization of subtype-specific antibodies to the human D<SUB>5</SUB> dopamine receptor: studies in primate brain and transfected mammalian cells.
<I>Proc. Natl. Acad. Sci. USA</I>
92: 3468-3472, 1995<!-- HIGHWIRE ID="78:1:189:27" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=92/8/3468" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B28"><!-- comment for mosaic --></a>
<P>28. &nbsp; 

BERGSON, C<font size=-1>.</font>,
L<font size=-1>.</font> MRZLJAK,
J<font size=-1>. </font>F<font size=-1>.</font> SMILEY,
M<font size=-1>.</font> PAPPY,
R<font size=-1>.</font> LEVENSON,
 <font size=-1>AND</font> P<font size=-1>. </font>S<font size=-1>.</font> GOLDMAN<font size=-1>-</font>RAKIC.



Regional, cellular, and subcellular variations in the distribution of D<SUB>1</SUB> and D<SUB>5</SUB> dopamine receptors in primate brain.
<I>J. Neurosci.</I>
15: 7821-7836, 1995<!-- HIGHWIRE ID="78:1:189:28" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jneuro&resid=15/12/7821" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B29"><!-- comment for mosaic --></a>
<P>29. &nbsp; BERNARD V., C.&nbsp;LE MOINE, <font size=-1>AND</font> B.&nbsp;BLOCH. Striatal neurons express increased level of dopamine D<SUB>2</SUB> receptor mRNA in response to haloperidol treatment: a quantitative in situ hybridization study. <I>Neuroscience</I> 45: 117-126, 1991.<!-- HIGHWIRE ID="78:1:189:29" --><!-- /HIGHWIRE --></P>
<a name="B30"><!-- comment for mosaic --></a>
<P>30. &nbsp; 

BERTORELLO, A<font size=-1>.</font>,
 <font size=-1>AND</font> A<font size=-1>.</font> APERIA.



Na<SUP>+</SUP>,K<SUP>+</SUP>-ATPase is an effector protein for protein kinase C in renal proximal tubule cells.
<I>Am. J.&nbsp;Physiol.</I>
256(<I>Renal Fluid Electrolyte Physiol.</I> 25): F370-F373, 1989<!-- HIGHWIRE ID="78:1:189:30" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=256/2/F370" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B31"><!-- comment for mosaic --></a>
<P>31. &nbsp; 

BERTORELLO, A<font size=-1>.</font>,
 <font size=-1>AND</font> A<font size=-1>.</font> APERIA.



Inhibition of proximal tubule Na<SUP>+</SUP>,K<SUP>+</SUP>-ATPase activity requires simultaneous activation of DA<SUB>1</SUB> and DA<SUB>2</SUB> receptors.
<I>Am. J.&nbsp;Physiol.</I>
259(<I>Renal Fluid Electrolyte Physiol.</I> 28): F924-F928, 1990<!-- HIGHWIRE ID="78:1:189:31" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=259/6/F924" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B32"><!-- comment for mosaic --></a>
<P>32. &nbsp; 

BERTORELLO, A<font size=-1>. </font>M<font size=-1>.</font>,
A<font size=-1>.</font> APERIA,
S<font size=-1>. </font>I<font size=-1>.</font> WALAS,
A<font size=-1>. </font>C<font size=-1>.</font> NAIRN,
 <font size=-1>AND</font> P<font size=-1>.</font> GREENGARD.



Phosphorylation of the catalytic subunit of Na<SUP>+</SUP>,K<SUP>+</SUP>-ATPase inhibits the activity of the enzyme.
<I>Proc. Natl. Acad. Sci. USA</I>
88: 11359-11362, 1991<!-- HIGHWIRE ID="78:1:189:32" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=88/24/11359" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B33"><!-- comment for mosaic --></a>
<P>33. &nbsp; 

BERTORELLO, A<font size=-1>.</font>,
T<font size=-1>.</font> H<font size=-1>&Uuml;</font>KFELT,
M<font size=-1>.</font> GOLDSTEIN,
 <font size=-1>AND</font> A<font size=-1>.</font> APERIA.



Proximal tubule Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase activity is inhibited during high salt diet: evidence for dopamine-mediated effect.
<I>Am. J.&nbsp;Physiol.</I>
254(<I>Renal Fluid Electrolyte Physiol.</I> 23): F795-F801, 1988<!-- HIGHWIRE ID="78:1:189:33" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=254/6/F795" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B34"><!-- comment for mosaic --></a>
<P>34. &nbsp; 

BERTORELLO, A<font size=-1>. </font>M<font size=-1>.</font>,
J<font size=-1>. </font>F<font size=-1>.</font> HOPFIELD,
A<font size=-1>.</font> APERIA,
 <font size=-1>AND</font> P<font size=-1>.</font> GREENGARD.



Inhibition by dopamine of (Na<SUP>+</SUP>,K<SUP>+</SUP>)ATPase activity in neostriatal neurons through D<SUB>1</SUB> and D<SUB>2</SUB> dopamine receptor synergism.
<I>Nature</I>
347: 386-388, 1990<!-- HIGHWIRE ID="78:1:189:34" --><A HREF="/cgi/external_ref?access_num=1977083&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B35"><!-- comment for mosaic --></a>
<P>35. &nbsp; 

BIGORNIA, L<font size=-1>.</font>,
C<font size=-1>. </font>N<font size=-1>.</font> ALLEN,
C<font size=-1>. </font>R<font size=-1>.</font> JAN,
R<font size=-1>. </font>A<font size=-1>.</font> LYON,
M<font size=-1>.</font> TITELER,
 <font size=-1>AND</font> A<font size=-1>. </font>S<font size=-1>.</font> SCHNEIDER.



D<SUB>2</SUB> dopamine receptors modulate calcium channel currents and catecholamine secretion in bovine adrenal chromaffin cells.
<I>J. Pharmacol. Exp. Ther.</I>
252: 586-592, 1990<!-- HIGHWIRE ID="78:1:189:35" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jpet&resid=252/2/586" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B36"><!-- comment for mosaic --></a>
<P>36. &nbsp; 

BIGORNIA, L<font size=-1>.</font>,
M<font size=-1>.</font> SUOZZO,
K<font size=-1>. </font>A<font size=-1>.</font> RYAN,
D<font size=-1>.</font> NAPP,
 <font size=-1>AND</font> A<font size=-1>. </font>S<font size=-1>.</font> SCHNEIDER.



Dopamine receptors on adrenal chromaffin cells modulate calcium uptake and catecholamine release.
<I>J. Neurochem.</I>
51: 999-1006, 1988<!-- HIGHWIRE ID="78:1:189:36" --><A HREF="/cgi/external_ref?access_num=2458437&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B37"><!-- comment for mosaic --></a>
<P>37. &nbsp; 

BIRKHAUSER, M<font size=-1>.</font>,
A<font size=-1>.</font> RIONDEL,
 <font size=-1>AND</font> M<font size=-1>. </font>B<font size=-1>.</font> VALLOTTON.



Bromocriptine-induced modulation of the plasma aldosterone response to acute stimulation.
<I>Acta Endocrinol.</I>
91: 294-302, 1979<!-- HIGHWIRE ID="78:1:189:37" --><A HREF="/cgi/external_ref?access_num=223355&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B38"><!-- comment for mosaic --></a>
<P>38. &nbsp; 

BOUTHENET, M<font size=-1>. </font>L<font size=-1>.</font>,
E<font size=-1>.</font> SOUIL,
M<font size=-1>. </font>P<font size=-1>.</font> MARTRES,
P<font size=-1>.</font> SOKOLOFF,
B<font size=-1>.</font> GIROS,
 <font size=-1>AND</font> J<font size=-1>. </font>C<font size=-1>.</font> SCHWARTZ.



Localization of dopamine D<SUB>3</SUB> receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D<SUB>2</SUB> receptor mRNA.
<I>Brain Res.</I>
564: 203-219, 1991<!-- HIGHWIRE ID="78:1:189:38" --><A HREF="/cgi/external_ref?access_num=1839781&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B39"><!-- comment for mosaic --></a>
<P>39. &nbsp; 

BOWYER, J<font size=-1>. </font>F<font size=-1>.</font>,
 <font size=-1>AND</font> N<font size=-1>.</font> WEINER.



K<SUP>+</SUP> channel and adenylate cyclase involvement in regulation of Ca<SUP>2+</SUP>-evoked release of [<SUP>3</SUP>H]dopamine from synaptosomes.
<I>J. Pharmacol. Exp. Ther.</I>
248: 514-520, 1989<!-- HIGHWIRE ID="78:1:189:39" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jpet&resid=248/2/514" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B40"><!-- comment for mosaic --></a>
<P>40. &nbsp; 

BRADLEY, T<font size=-1>.</font>,
E<font size=-1>. </font>D<font size=-1>.</font> FREDERICKSON,
 <font size=-1>AND</font> L<font size=-1>. </font>I<font size=-1>.</font> GOLDBERG.



Effect of DA<SUB>1</SUB> receptor blockade with SCH 23390&nbsp;on the renal response to electrical stimulation of the renal nerves.
<I>Proc. Soc. Exp. Biol. Med.</I>
181: 492-497, 1986<!-- HIGHWIRE ID="78:1:189:40" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=psebm&resid=181/4/492" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B41"><!-- comment for mosaic --></a>
<P>41. &nbsp; 

BREESE, G<font size=-1>. </font>R<font size=-1>.</font>,
G<font size=-1>. </font>E<font size=-1>.</font> DUNCAN,
T<font size=-1>. </font>C<font size=-1>.</font> NAPIER,
S<font size=-1>. </font>C<font size=-1>.</font> BONDY,
L<font size=-1>. </font>C<font size=-1>.</font> IORIO,
 <font size=-1>AND</font> R<font size=-1>. </font>A<font size=-1>.</font> MULLER.



6-Hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D<SUB>1</SUB> and D<SUB>2</SUB> dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
<I>J. Pharmacol. Exp. Ther.</I>
240: 167-176, 1987<!-- HIGHWIRE ID="78:1:189:41" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jpet&resid=240/1/167" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B42"><!-- comment for mosaic --></a>
<P>42. &nbsp; 

BRENE, S<font size=-1>.</font>,
N<font size=-1>.</font> LINDEFORS,
M<font size=-1>.</font> HERRERA<font size=-1>-</font>MARSCHITZ,
 <font size=-1>AND</font> H<font size=-1>.</font> PERSSON.



Expression of dopamine D<SUB>2</SUB> receptor and choline acetyltransferase mRNA in the dopamine deafferented rat caudate-putamen.
<I>Exp. Brain Res.</I>
83: 96-104, 1990<!-- HIGHWIRE ID="78:1:189:42" --><A HREF="/cgi/external_ref?access_num=2150048&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B43"><!-- comment for mosaic --></a>
<P>43. &nbsp; 

BRYSON, S<font size=-1>. </font>E<font size=-1>.</font>,
A<font size=-1>. </font>J<font size=-1>.</font> BALMFORTH,
 <font size=-1>AND</font> S<font size=-1>. </font>G<font size=-1>.</font> BALL.



Pharmacological characterization of the dopamine receptor expressed by rat glomerular mesangial cells in culture.
<I>Eur. J.&nbsp;Pharmacol.</I>
183: 746-747, 1990<!-- HIGHWIRE ID="78:1:189:43" --><!-- /HIGHWIRE -->.</P>
<a name="B44"><!-- comment for mosaic --></a>
<P>44. &nbsp; 

BRYSON, S<font size=-1>. </font>E<font size=-1>.</font>,
G<font size=-1>. </font>M<font size=-1>.</font> DREW,
A<font size=-1>. </font>S<font size=-1>.</font> HALL,
S<font size=-1>. </font>G<font size=-1>.</font> BALL,
 <font size=-1>AND</font> A<font size=-1>. </font>J<font size=-1>.</font> BALMFORTH.



Characterization of the dopamine receptor expressed by rat glomerular mesangial cells in culture.
<I>Eur. J.&nbsp;Pharmacol.</I>
225: 1-5, 1992<!-- HIGHWIRE ID="78:1:189:44" --><A HREF="/cgi/external_ref?access_num=1347268&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B45"><!-- comment for mosaic --></a>
<P>45. &nbsp; 

BUCKLAND, P<font size=-1>. </font>R<font size=-1>.</font>,
M<font size=-1>. </font>C<font size=-1>.</font> O<font size=-1>'</font>DONOVAN,
 <font size=-1>AND</font> P<font size=-1>.</font> M<font size=-1>C</font>GUFFIN.



Changes in dopamine D<SUB>1</SUB>, D<SUB>2</SUB> and D<SUB>3</SUB> receptor mRNA levels in the rat brain following antipsychotic treatment.
<I>Psychopharmacology</I>
106: 479-483, 1992<!-- HIGHWIRE ID="78:1:189:45" --><A HREF="/cgi/external_ref?access_num=1349752&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B46"><!-- comment for mosaic --></a>
<P>46. &nbsp; 

BUGHI, S<font size=-1>.</font>,
E<font size=-1>.</font> JOST<font size=-1>-</font>VU,
I<font size=-1>.</font> ANTONIPILLAI,
J<font size=-1>.</font> NADLER,
 <font size=-1>AND</font> R<font size=-1>.</font> HORTON.



Effect of dopamine<SUB>2</SUB> blockade on renal function under varied sodium intake.
<I>J. Clin. Endocrinol. Metab.</I>
78: 1079-1084, 1994<!-- HIGHWIRE ID="78:1:189:46" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jcem&resid=78/5/1079" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B47"><!-- comment for mosaic --></a>
<P>47. &nbsp; 

BUNZOW, J<font size=-1>. </font>R<font size=-1>.</font>,
H<font size=-1>. </font>H<font size=-1>.</font><font size=-1>&nbsp;</font>M<font size=-1>.</font> VAN TOL,
D<font size=-1>. </font>K<font size=-1>.</font> GRANDY,
P<font size=-1>.</font> ALBERT,
A<font size=-1>.</font> SALON,
M<font size=-1>. </font>D<font size=-1>.</font> CHRISTIE,
C<font size=-1>. </font>A<font size=-1>.</font> MACHIDA,
K<font size=-1>. </font>A<font size=-1>.</font> NEVE,
 <font size=-1>AND</font> O<font size=-1>.</font> CIVELLI.



Cloning and expression of a rat D<SUB>2</SUB> dopamine receptor cDNA.
<I>Nature</I>
336: 783-787, 1988<!-- HIGHWIRE ID="78:1:189:47" --><A HREF="/cgi/external_ref?access_num=2974511&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B48"><!-- comment for mosaic --></a>
<P>48. &nbsp; 

CACHERO, S<font size=-1>.</font>,
J<font size=-1>. </font>B<font size=-1>.</font> VAN<font size=-1>-</font>LIEW,
 <font size=-1>AND</font> L<font size=-1>. </font>G<font size=-1>.</font> FELD.



Long-term renal handling of sodium and calcium in spontaneously hypertensive rats.
<I>Renal Physiol. Biochem.</I>
15: 83-88, 1992.<!-- HIGHWIRE ID="78:1:189:48" --><A HREF="/cgi/external_ref?access_num=1375767&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --></P>
<a name="B49"><!-- comment for mosaic --></a>
<P>49. &nbsp; 

CADET, J<font size=-1>. </font>L<font size=-1>.</font>,
S<font size=-1>. </font>M<font size=-1>.</font> ZHU,
 <font size=-1>AND</font> J<font size=-1>. </font>A<font size=-1>.</font> ANGULO.



Quantitative in situ hybridization evidence for differential regulation of proenkephalin and dopamine D<SUB>2</SUB> receptor mRNA levels in the rat striatum: effects of unilateral intrastriatal injections of 6-hydroxydopamine.
<I>Mol. Brain Res.</I>
12: 59-67, 1992.<!-- HIGHWIRE ID="78:1:189:49" --><A HREF="/cgi/external_ref?access_num=1312206&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --></P>
<a name="B50"><!-- comment for mosaic --></a>
<P>50. &nbsp; 

CADNAPAPHORNCHAI, P<font size=-1>.</font>,
S<font size=-1>. </font>M<font size=-1>.</font> TAHER,
 <font size=-1>AND</font> K<font size=-1>. </font>D<font size=-1>.</font> M<font size=-1>C</font>DONALD.



Mechanism of dopamine diuresis in the dog.
<I>Am. J.&nbsp;Physiol.</I>
232(<I>Renal Fluid Electrolyte Physiol.</I> 1): F524-F528, 1977<!-- HIGHWIRE ID="78:1:189:50" --><A HREF="/cgi/external_ref?access_num=879287&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B51"><!-- comment for mosaic --></a>
<P>51. &nbsp; 

CAINE, S<font size=-1>. </font>B<font size=-1>.</font>,
 <font size=-1>AND</font> G<font size=-1>. </font>F<font size=-1>.</font> KOOB.



Modulation of cocaine self-administration in the rat through D<SUB>3</SUB> dopamine receptors.
<I>Science</I>
260: 1814-1816, 1993<!-- HIGHWIRE ID="78:1:189:51" --><A HREF="/cgi/external_ref?access_num=8099761&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B52"><!-- comment for mosaic --></a>
<P>52. &nbsp; 

CANONICO, P<font size=-1>. </font>L<font size=-1>.</font>,
C<font size=-1>. </font>A<font size=-1>.</font> VALDENEGRO,
 <font size=-1>AND</font> R<font size=-1>. </font>M<font size=-1>.</font> MACLEOD.



The inhibition of phosphatidylinositol turnover: a possible post receptor mechanism for the prolactin secretion-inhibiting effect of dopamine.
<I>Endocrinology</I>
113: 7-14, 1983<!-- HIGHWIRE ID="78:1:189:52" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=endo&resid=113/1/7" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B53"><!-- comment for mosaic --></a>
<P>53. &nbsp; 

CAREY, R<font size=-1>. </font>M<font size=-1>.</font>.



Acute dopaminergic inhibition of aldosterone secretion is independent of angiotensin II and adrenocorticotropin.
<I>J. Clin. Endocrinol. Metab.</I>
54: 463-469, 1982<!-- HIGHWIRE ID="78:1:189:53" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jcem&resid=54/2/463" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B54"><!-- comment for mosaic --></a>
<P>54. &nbsp; 

CAREY, R<font size=-1>. </font>M<font size=-1>.</font>,
 <font size=-1>AND</font> C<font size=-1>. </font>R<font size=-1>.</font> DRAKE.



Dopamine selectively inhibits aldosterone responses to angiotensin II in humans.
<I>Hypertension</I>
8: 399-406, 1986<!-- HIGHWIRE ID="78:1:189:54" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=hypertensionaha&resid=8/5/399" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B55"><!-- comment for mosaic --></a>
<P>55. &nbsp; 

CAREY, R<font size=-1>. </font>M<font size=-1>.</font>,
R<font size=-1>. </font>M<font size=-1>.</font> STOTE,
J<font size=-1>. </font>W<font size=-1>.</font> DUBB,
L<font size=-1>. </font>H<font size=-1>.</font> TOWNSEND,
C<font size=-1>.</font> ROSE,
 <font size=-1>AND</font> D<font size=-1>. </font>L<font size=-1>.</font> KAISER.



Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension.
<I>J. Clin. Invest.</I>
74: 2198-2207, 1984<!-- HIGHWIRE ID="78:1:189:55" --><A HREF="/cgi/external_ref?access_num=6150942&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B56"><!-- comment for mosaic --></a>
<P>56. &nbsp; 

CAREY, R<font size=-1>. </font>M<font size=-1>.</font>,
M<font size=-1>. </font>O<font size=-1>.</font> THORNER,
 <font size=-1>AND</font> E<font size=-1>. </font>M<font size=-1>.</font> ORTT.



Effects of metoclopramide and bromocriptine on the renin-angiotensin-aldosterone system in man: dopaminergic control of aldosterone.
<I>J. Clin. Invest.</I>
63: 727-735, 1979<!-- HIGHWIRE ID="78:1:189:56" --><A HREF="/cgi/external_ref?access_num=438333&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B57"><!-- comment for mosaic --></a>
<P>57. &nbsp; 

CAREY, R<font size=-1>. </font>M<font size=-1>.</font>,
M<font size=-1>. </font>O<font size=-1>.</font> THORNER,
 <font size=-1>AND</font> E<font size=-1>. </font>M<font size=-1>.</font> ORTT.



Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man: dissociation of responses to dopamine and bromocriptine.
<I>J. Clin. Invest.</I>
66: 10-18, 1980<!-- HIGHWIRE ID="78:1:189:57" --><A HREF="/cgi/external_ref?access_num=7400305&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B58"><!-- comment for mosaic --></a>
<P>58. &nbsp; 

CAREY, R<font size=-1>. </font>M<font size=-1>.</font>,
G<font size=-1>. </font>R<font size=-1>.</font> VAN LOON,
A<font size=-1>. </font>D<font size=-1>.</font> BAINES,
 <font size=-1>AND</font> E<font size=-1>. </font>M<font size=-1>.</font> ORTT.



Decreased plasma and urinary dopamine during dietary sodium depletion in man.
<I>J. Clin. Endocrinol. Metab.</I>
52: 903-907, 1981<!-- HIGHWIRE ID="78:1:189:58" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jcem&resid=52/5/903" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B59"><!-- comment for mosaic --></a>
<P>59. &nbsp; 

CARON, M<font size=-1>. </font>G<font size=-1>.</font>,
M<font size=-1>.</font> BEAULIEU,
V<font size=-1>.</font> RAYMOND,
B<font size=-1>.</font> GAGNE,
J<font size=-1>.</font> DROUIN,
R<font size=-1>. </font>J<font size=-1>.</font> LEFKOWITZ,
 <font size=-1>AND</font> F<font size=-1>.</font> LABRIE.



Dopaminergic receptors in the anterior pituitary gland.
<I>J. Biol. Chem.</I>
253: 2244-2253, 1978<!-- HIGHWIRE ID="78:1:189:59" --><A HREF="/cgi/external_ref?access_num=416027&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B60"><!-- comment for mosaic --></a>
<P>60. &nbsp; 

CARTER<font size=-1>-</font>RUSSEL, H<font size=-1>. </font>R<font size=-1>.</font>,
W<font size=-1>.-</font>J<font size=-1>.</font> SONG,
 <font size=-1>AND</font> D<font size=-1>. </font>J<font size=-1>.</font> SURMEIER.



Coordinated expression of dopamine receptors (D<SUB>1</SUB>-D<SUB>5</SUB>) in single neostriatal neurons.
<I>Soc. Neurosci. Abstr.</I>
559: 11, 1995<!-- HIGHWIRE ID="78:1:189:60" --><!-- /HIGHWIRE -->.</P>
<a name="B61"><!-- comment for mosaic --></a>
<P>61. &nbsp; 

CASPER, D<font size=-1>.</font>,
 <font size=-1>AND</font> M<font size=-1>.</font> BLUM.



Epidermal growth factor and basic fibroblast growth factor protect dopaminergic neurons from glutamate toxicity in culture.
<I>J. Neurochem.</I>
65: 1016-1026, 1995<!-- HIGHWIRE ID="78:1:189:61" --><A HREF="/cgi/external_ref?access_num=7643081&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B62"><!-- comment for mosaic --></a>
<P>62. &nbsp; 

CASPER, D<font size=-1>.</font>,
G<font size=-1>. </font>J<font size=-1>.</font> ROBOZ,
 <font size=-1>AND</font> M<font size=-1>.</font> BLUM.



Epidermal growth factor and basic fibroblast growth factor have independent actions on mesencephalic dopamine neurons in culture.
<I>J. Neurochem.</I>
62: 2166-2177, 1994<!-- HIGHWIRE ID="78:1:189:62" --><A HREF="/cgi/external_ref?access_num=8189225&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B63"><!-- comment for mosaic --></a>
<P>63. &nbsp; 

CASS, W<font size=-1>. </font>A<font size=-1>.</font>,
 <font size=-1>AND</font> N<font size=-1>. </font>R<font size=-1>.</font> ZAHNISER.



Potassium channel blockers inhibit D<SUB>2</SUB> dopamine, but not A<SUB>1</SUB> adenosine, receptor-mediated inhibition of striatal dopamine release.
<I>J. Neurochem.</I>
57: 147-152, 1991<!-- HIGHWIRE ID="78:1:189:63" --><A HREF="/cgi/external_ref?access_num=1828829&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B64"><!-- comment for mosaic --></a>
<P>64. &nbsp; 

CASTELLANO, M<font size=-1>. </font>A<font size=-1>.</font>,
L<font size=-1>.-</font>X<font size=-1>.</font> LIU,
F<font size=-1>. </font>J<font size=-1>.</font> MONSMA,
D<font size=-1>. </font>R<font size=-1>.</font> SIBLEY,
G<font size=-1>.</font> KAPATOS,
 <font size=-1>AND</font> L<font size=-1>. </font>A<font size=-1>.</font> CHIODO.



Transfected D<SUB>2</SUB> short dopamine receptors inhibit voltage-dependent potassium current in neuroblastoma&nbsp;&#215;&nbsp;glioma hybrid (NG108-15) cells.
<I>Mol. Pharmacol.</I>
44: 649-656, 1993<!-- HIGHWIRE ID="78:1:189:64" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=44/3/649" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B65"><!-- comment for mosaic --></a>
<P>65. &nbsp; 

CASTELLETTI, L<font size=-1>.</font>,
M<font size=-1>.</font> MEMO,
C<font size=-1>.</font> MISSALE,
P<font size=-1>. </font>F<font size=-1>.</font> SPANO,
 <font size=-1>AND</font> A<font size=-1>.</font> VALERIO.



Potassium channels involved in the transduction mechanism of dopamine D<SUB>2</SUB> receptors in rat lactotrophs.
<I>J. Physiol. (Lond.)</I>
410: 251-265, 1989<!-- HIGHWIRE ID="78:1:189:65" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jphysiol&resid=410/1/251" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B66"><!-- comment for mosaic --></a>
<P>66. &nbsp; 

CASTRO, S<font size=-1>. </font>W<font size=-1>.</font>,
 <font size=-1>AND</font> P<font size=-1>.</font> STRANGE.



Differences in ligand binding properties of the short and long versions of the dopamine D<SUB>2</SUB> receptor.
<I>J. Neurochem.</I>
60: 372-375, 1993<!-- HIGHWIRE ID="78:1:189:66" --><A HREF="/cgi/external_ref?access_num=8417160&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B67"><!-- comment for mosaic --></a>
<P>67. &nbsp; 

CENI, M<font size=-1>. </font>A<font size=-1>.</font>,
K<font size=-1>.</font> CAMPBELL,
K<font size=-1>.</font> WICTORIN,
 <font size=-1>AND</font> A<font size=-1>.</font> BJORKLUND.



Striatal c-<I>fos</I> induction by cocaine or apomorphine occurs preferentially in output neurons projecting to the substantia nigra in the rat.
<I>Eur. J.&nbsp;Neurosci.</I>
4: 376-380, 1992<!-- HIGHWIRE ID="78:1:189:67" --><A HREF="/cgi/external_ref?access_num=12106364&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B68"><!-- comment for mosaic --></a>
<P>68. &nbsp; 

CHATZIANTONIOU, C<font size=-1>.</font>,
X<font size=-1>.</font> RUAN,
 <font size=-1>AND</font> W<font size=-1>. </font>J<font size=-1>.</font> ARENDSHORST.



Defective G protein activation of the cAMP pathway in rat kidney during genetic hypertension.
<I>Proc. Natl. Acad. Sci. USA</I>
92: 2924-2928, 1995<!-- HIGHWIRE ID="78:1:189:68" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=92/7/2924" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B69"><!-- comment for mosaic --></a>
<P>69. &nbsp; 

CHEN, C<font size=-1>.</font>,
R<font size=-1>. </font>E<font size=-1>.</font> BEACH,
 <font size=-1>AND</font> M<font size=-1>. </font>F<font size=-1>.</font> LOKHANDWALA.



Dopamine fails to inhibit renal tubular sodium pump in hypertensive rats.
<I>Hypertension</I>
21: 364-372, 1993<!-- HIGHWIRE ID="78:1:189:69" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=hypertensionaha&resid=21/3/364" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B70"><!-- comment for mosaic --></a>
<P>70. &nbsp; 

CHEN, C<font size=-1>.</font>,
 <font size=-1>AND</font> M<font size=-1>. </font>F<font size=-1>.</font> LOKHANDWALA.



Inhibition of Na<SUP>+</SUP>,K<SUP>+</SUP>-ATPase in rat renal proximal tubules by dopamine involved DA-1 receptor activation.
<I>Naunyn-Schmiedebergs Arch. Pharmacol.</I>
347: 289-295, 1993<!-- HIGHWIRE ID="78:1:189:70" --><A HREF="/cgi/external_ref?access_num=8097567&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B71"><!-- comment for mosaic --></a>
<P>71. &nbsp; 

CHEN, C<font size=-1>. </font>J<font size=-1>.</font>,
S<font size=-1>.</font> APPARSUNDARAM,
 <font size=-1>AND</font> M<font size=-1>. </font>F<font size=-1>.</font> LOKHANDWALA.



Intrarenally produced angiotensin II opposes the natriuretic action of the dopamine-1 receptor agonist fenoldopam in rats.
<I>J. Pharmacol. Exp. Ther.</I>
256: 486-491, 1991<!-- HIGHWIRE ID="78:1:189:71" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jpet&resid=256/2/486" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B72"><!-- comment for mosaic --></a>
<P>72. &nbsp; 

CHEN, C<font size=-1>. </font>J<font size=-1>.</font>,
 <font size=-1>AND</font> M<font size=-1>. </font>F<font size=-1>.</font> LOCKHANDWALA.



Role of endogenous dopamine in the natriuretic response to various degrees of iso-osmotic volume expansion in rats.
<I>Clin. Exp. Hypertens.</I>
13: 1117-1126, 1991<!-- HIGHWIRE ID="78:1:189:72" --><!-- /HIGHWIRE -->.</P>
<a name="B73"><!-- comment for mosaic --></a>
<P>73. &nbsp; 

CHEN, C<font size=-1>. </font>J<font size=-1>.</font>,
S<font size=-1>. </font>J<font size=-1>.</font> VYAS,
J<font size=-1>.</font> EICHBERG,
 <font size=-1>AND</font> M<font size=-1>. </font>F<font size=-1>.</font> LOCKHANDWALA.



Diminished phospholipase C activation by dopamine in spontaneously hypertensive rats.
<I>Hypertension</I>
19: 102-108, 1992<!-- HIGHWIRE ID="78:1:189:73" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=hypertensionaha&resid=19/1/102" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B74"><!-- comment for mosaic --></a>
<P>74. &nbsp; 

CHIO, C<font size=-1>. </font>L<font size=-1>.</font>,
R<font size=-1>. </font>F<font size=-1>.</font> DRONG,
D<font size=-1>. </font>T<font size=-1>.</font> RILEY,
G<font size=-1>. </font>S<font size=-1>.</font> GILL,
J<font size=-1>. </font>L<font size=-1>.</font> SLIGHTOM,
 <font size=-1>AND</font> R<font size=-1>. </font>M<font size=-1>.</font> HUFF.



D<SUB>4</SUB> dopamine receptor-mediated signaling events determined in transfected Chinese hamster ovary cells.
<I>J. Biol. Chem.</I>
269: 11813-11819, 1994<!-- HIGHWIRE ID="78:1:189:74" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=269/16/11813" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B75"><!-- comment for mosaic --></a>
<P>75. &nbsp; 

CHIO, C<font size=-1>. </font>L<font size=-1>.</font>,
M<font size=-1>. </font>E<font size=-1>.</font> LAJINESS,
 <font size=-1>AND</font> R<font size=-1>. </font>M<font size=-1>.</font> HUFF.



Activation of heterologously expressed D<SUB>3</SUB> dopamine receptors: comparison with D<SUB>2</SUB> dopamine receptors.
<I>Mol. Pharmacol.</I>
45: 51-60, 1994<!-- HIGHWIRE ID="78:1:189:75" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=45/1/51" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B76"><!-- comment for mosaic --></a>
<P>76. &nbsp; 

CHOI, W<font size=-1>. </font>S<font size=-1>.</font>,
C<font size=-1>.</font> MACHIDA,
 <font size=-1>AND</font> O<font size=-1>. </font>K<font size=-1>.</font> RONNEKLEIV.



Distribution of dopamine D<SUB>1</SUB> ,&nbsp;D<SUB>2</SUB> and D<SUB>5</SUB> mRNAs in the monkey brain: ribonuclease protection assay analysis.
<I>Mol. Brain Res.</I>
31: 86-94, 1995.<!-- HIGHWIRE ID="78:1:189:76" --><A HREF="/cgi/external_ref?access_num=7476036&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --></P>
<a name="B77"><!-- comment for mosaic --></a>
<P>77. &nbsp; 

CHUNG, F<font size=-1>. </font>Z<font size=-1>.</font>,
C<font size=-1>. </font>D<font size=-1>.</font> WANG,
P<font size=-1>. </font>C<font size=-1>.</font> POTTER,
J<font size=-1>. </font>C<font size=-1>.</font> VENTER,
 <font size=-1>AND</font> C<font size=-1>. </font>M<font size=-1>.</font> FRASER.



Site-directed mutagenesis and continuous expression of human <IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BASELINE ALT="beta ">&nbsp;adrenergic receptors: identification of a conserved aspartate residue involved in agonist binding and receptor activation.
<I>J. Biol. Chem.</I>
263: 4052-4055, 1988<!-- HIGHWIRE ID="78:1:189:77" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=263/9/4052" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B78"><!-- comment for mosaic --></a>
<P>78. &nbsp; 

CIVELLI, O<font size=-1>.</font>,
J<font size=-1>. </font>R<font size=-1>.</font> BUNZOW,
 <font size=-1>AND</font> D<font size=-1>. </font>K<font size=-1>.</font> GRANDY.



Molecular diversity of the dopamine receptors.
<I>Annu. Rev. Pharmacol. Toxicol.</I>
32: 281-307, 1993<!-- HIGHWIRE ID="78:1:189:78" --><!-- /HIGHWIRE -->.</P>
<a name="B79"><!-- comment for mosaic --></a>
<P>79. &nbsp; 

CLARK, D<font size=-1>.</font>,
 <font size=-1>AND</font> F<font size=-1>. </font>J<font size=-1>.</font> WHITE.



D<SUB>1</SUB> dopamine receptor <IMG SRC="/math/12pt/normal/mdash.gif" ALIGN=BASELINE ALT="---">&nbsp;the search for a function.
<I>Synapse</I>
1: 347-388, 1987<!-- HIGHWIRE ID="78:1:189:79" --><A HREF="/cgi/external_ref?access_num=2971273&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B80"><!-- comment for mosaic --></a>
<P>80. &nbsp; 

COHEN, A<font size=-1>. </font>I<font size=-1>.</font>,
R<font size=-1>. </font>D<font size=-1>.</font> TODD,
S<font size=-1>.</font> HARMON,
 <font size=-1>AND</font> K<font size=-1>. </font>L<font size=-1>.</font> O<font size=-1>'</font>MALLEY.



Photoreceptors of mouse retinas possess D<SUB>4</SUB> receptors coupled to adenylate cyclase.
<I>Proc. Natl. Acad. Sci. USA</I>
89: 12093-12097, 1992<!-- HIGHWIRE ID="78:1:189:80" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=89/24/12093" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B81"><!-- comment for mosaic --></a>
<P>81. &nbsp; 

COHEN<font size=-1>-</font>LURIA, R<font size=-1>.</font>,
G<font size=-1>.</font> RIMON,
 <font size=-1>AND</font> A<font size=-1>.</font> MORAN.



PGE<SUB>2</SUB> inhibits Na-K-ATPase activity and oubain binding in MDCK cells.
<I>Am. J.&nbsp;Physiol.</I>
264(<I>Renal Fluid Electrolyte Physiol.</I> 33): F61-F65, 1993<!-- HIGHWIRE ID="78:1:189:81" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=264/1/F61" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B82"><!-- comment for mosaic --></a>
<P>82. &nbsp; 

COOK, C<font size=-1>. </font>C<font size=-1>.</font>,
 <font size=-1>AND</font> H<font size=-1>. </font>M<font size=-1>.</font> GURLING.



The D<SUB>2</SUB> dopamine receptor gene and alcoholism: a genetic effect in the liability for alcoholism.
<I>J. R.&nbsp;Soc. Med.</I>
87: 400-402, 1994<!-- HIGHWIRE ID="78:1:189:82" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jrsm&resid=87/7/400" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B83"><!-- comment for mosaic --></a>
<P>83. &nbsp; 

COON, H<font size=-1>.</font>,
W<font size=-1>.</font> BYERLEY,
J<font size=-1>.</font> HOLIK,
M<font size=-1>.</font> HOFF,
M<font size=-1>.</font> MYLES<font size=-1>-</font>WORSLEY,
L<font size=-1>.</font> LANNFELT,
P<font size=-1>.</font> SOKOLOFF,
J<font size=-1>. </font>C<font size=-1>.</font> SCHWARTZ,
M<font size=-1>.</font> WALDO,
 <font size=-1>AND</font> R<font size=-1>.</font> FREEDMAN.



Linkage analysis of schizophrenia with five dopamine receptor genes in nine pedigrees.
<I>Am. J.&nbsp;Hum. Genet.</I>
52: 327-334, 1993<!-- HIGHWIRE ID="78:1:189:83" --><A HREF="/cgi/external_ref?access_num=8094267&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B84"><!-- comment for mosaic --></a>
<P>84. &nbsp; 

COTE, T<font size=-1>. </font>E<font size=-1>.</font>,
R<font size=-1>. </font>L<font size=-1>.</font> ESKAY,
E<font size=-1>. </font>A<font size=-1>.</font> FREY,
C<font size=-1>. </font>W<font size=-1>.</font> GREWE,
M<font size=-1>.</font> MUNEMURA,
J<font size=-1>. </font>C<font size=-1>.</font> STOOF,
K<font size=-1>.</font> TSURUTA,
 <font size=-1>AND</font> J<font size=-1>. </font>W<font size=-1>.</font> KEBABIAN.



Biochemical and physiological studies of the <IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BASELINE ALT="beta ">&nbsp;adrenoceptor and the D<SUB>2</SUB> dopamine receptor in the intermediate lobe of the rat pituitary gland: a review.
<I>Neuroendocrinology</I>
35: 217-224, 1982<!-- HIGHWIRE ID="78:1:189:84" --><A HREF="/cgi/external_ref?access_num=6290925&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B85"><!-- comment for mosaic --></a>
<P>85. &nbsp; 

COX, B<font size=-1>. </font>A<font size=-1>.</font>,
R<font size=-1>. </font>A<font size=-1>.</font> HENNINGSEN,
A<font size=-1>.</font> SPANOYANNIS,
R<font size=-1>. </font>L<font size=-1>.</font> NEVE,
 <font size=-1>AND</font> K<font size=-1>. </font>A<font size=-1>.</font> NEVE.



Contributions of conserved serine residues to the interactions of ligands with dopamine D<SUB>2</SUB> receptors.
<I>J. Neurochem.</I>
59: 627-635, 1992<!-- HIGHWIRE ID="78:1:189:85" --><A HREF="/cgi/external_ref?access_num=1321233&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B86"><!-- comment for mosaic --></a>
<P>86. &nbsp; 

CROCQ, M<font size=-1>. </font>A<font size=-1>.</font>,
R<font size=-1>.</font> MANT,
P<font size=-1>.</font> ASHERSON,
J<font size=-1>.</font> WILLIAMS,
Y<font size=-1>.</font> HODE,
A<font size=-1>.</font> MAYEROVA,
D<font size=-1>.</font> COLLIER,
L<font size=-1>.</font> LANNFELT,
P<font size=-1>.</font> SOKOLOFF,
 <font size=-1>AND</font> J<font size=-1>. </font>C<font size=-1>.</font> SCHWARTZ.



Association between schizophrenia and homozygosity at the dopamine D<SUB>3</SUB> receptor gene.
<I>J. Med. Genet.</I>
29: 858-860, 1992<!-- HIGHWIRE ID="78:1:189:86" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jmedgenet&resid=29/12/858" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B87"><!-- comment for mosaic --></a>
<P>87. &nbsp; 

CUCHE, J<font size=-1>. </font>L<font size=-1>.</font>,
O<font size=-1>.</font> KUCHEL,
A<font size=-1>.</font> BARBEAU,
R<font size=-1>.</font> BOUCHER,
 <font size=-1>AND</font> J<font size=-1>.</font> GENEST.



Relationship between the adrenergic nervous system and renin during adaptation to upright posture: a possible role for 3,4-dihydroxyphenethylamine (dopamine).
<I>Clin. Sci. (Lond.)</I>
43: 381-391, 1972<!-- HIGHWIRE ID="78:1:189:87" --><!-- /HIGHWIRE -->.</P>
<a name="B88"><!-- comment for mosaic --></a>
<P>88. &nbsp; 

CUCHE, J<font size=-1>. </font>L<font size=-1>.</font>,
G<font size=-1>. </font>R<font size=-1>.</font> MARCHAND,
R<font size=-1>. </font>F<font size=-1>.</font> GREGER,
F<font size=-1>. </font>C<font size=-1>.</font> LANG,
 <font size=-1>AND</font> F<font size=-1>. </font>G<font size=-1>.</font> KNOX.



Phosphaturic effect of dopamine in dogs. Possible role of intrarenally produced dopamine in phosphate regulation.
<I>J. Clin. Invest.</I>
58: 71-76, 1976<!-- HIGHWIRE ID="78:1:189:88" --><A HREF="/cgi/external_ref?access_num=932210&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B89"><!-- comment for mosaic --></a>
<P>89. &nbsp; 

CUNNAH, D<font size=-1>.</font>,
 <font size=-1>AND</font> M<font size=-1>.</font> BESSER.



Management of prolactinomas.
<I>Clin. Endocrinol.</I>
34: 231-235, 1991<!-- HIGHWIRE ID="78:1:189:89" --><A HREF="/cgi/external_ref?access_num=2036731&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B90"><!-- comment for mosaic --></a>
<P>90. &nbsp; 

CURRAN, E<font size=-1>. </font>J<font size=-1>.</font>,
 <font size=-1>AND</font> S<font size=-1>. </font>J<font size=-1>.</font> WATSON.



J<font size=-1>R</font>. Dopamine receptor mRNA expression patterns by opioid peptide cells in the nucleus accumbens of the rat: a double in situ hybridization study.
<I>J. Comp. Neurol.</I>
361: 57-76, 1995<!-- HIGHWIRE ID="78:1:189:90" --><A HREF="/cgi/external_ref?access_num=8550882&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B91"><!-- comment for mosaic --></a>
<P>91. &nbsp; 

DAL TOSO, R<font size=-1>.</font>,
B<font size=-1>.</font> SOMMER,
M<font size=-1>.</font> EWART,
A<font size=-1>.</font> HERB,
D<font size=-1>. </font>B<font size=-1>.</font> PRITCHETT,
A<font size=-1>.</font> BACH,
B<font size=-1>. </font>D<font size=-1>.</font> SHIVERS,
 <font size=-1>AND</font> P<font size=-1>. </font>H<font size=-1>.</font> SEEBURG.



The dopamine receptor: two molecular forms generated by alternative splicing.
<I>EMBO J.</I>
8: 4025-4034, 1989<!-- HIGHWIRE ID="78:1:189:91" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=emboj&resid=8/13/4025" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B92"><!-- comment for mosaic --></a>
<P>92. &nbsp; 

DALY, S<font size=-1>. </font>A<font size=-1>.</font>,
 <font size=-1>AND</font> J<font size=-1>. </font>L<font size=-1>.</font> WADDINGTON.



New classes of selective D<SUB>1</SUB> dopamine receptor antagonist provide further evidence for two directions of D<SUB>1</SUB>:D<SUB>2</SUB> interaction.
<I>Neurochem. Int.</I>
20, <I>Suppl</I>. 1: 135S-139S, 1992<!-- HIGHWIRE ID="78:1:189:92" --><A HREF="/cgi/external_ref?access_num=1365412&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B93"><!-- comment for mosaic --></a>
<P>93. &nbsp; 

DALY, S<font size=-1>. </font>A<font size=-1>.</font>,
 <font size=-1>AND</font> J<font size=-1>. </font>L<font size=-1>.</font> WADDINGTON.



Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other "D-2-like" agonists.
<I>Neuropharmacology</I>
32: 509-510, 1993<!-- HIGHWIRE ID="78:1:189:93" --><A HREF="/cgi/external_ref?access_num=8321432&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B94"><!-- comment for mosaic --></a>
<P>94. &nbsp; 

DALY, S<font size=-1>. </font>A<font size=-1>.</font>,
 <font size=-1>AND</font> J<font size=-1>. </font>L<font size=-1>.</font> WADDINGTON.



Behavioral evidences for "D<SUB>1</SUB>-like" dopamine receptor subtypes in rat brain using the new isochroman agonis A 68930&nbsp;and isoquinoline antagonist BW 737C.
<I>Psychopharmacology</I>
113: 45-50, 1993<!-- HIGHWIRE ID="78:1:189:94" --><A HREF="/cgi/external_ref?access_num=7862827&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B95"><!-- comment for mosaic --></a>
<P>95. &nbsp; 

DEARRY, A<font size=-1>.</font>,
J<font size=-1>. </font>A<font size=-1>.</font> GINGRICH,
P<font size=-1>.</font> FALARDEAU,
R<font size=-1>. </font>T<font size=-1>.</font> FREMEAU,
M<font size=-1>. </font>D<font size=-1>.</font> BATES,
 <font size=-1>AND</font> M<font size=-1>. </font>G<font size=-1>.</font> CARON.



Molecular cloning and expression of the gene for a human D<SUB>1</SUB> dopamine receptor.
<I>Nature</I>
347: 72-76, 1990<!-- HIGHWIRE ID="78:1:189:95" --><A HREF="/cgi/external_ref?access_num=2144334&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B96"><!-- comment for mosaic --></a>
<P>96. &nbsp; 

DE BRUYN, A<font size=-1>.</font>,
K<font size=-1>.</font> MENDELBAUM,
L<font size=-1>. </font>A<font size=-1>.</font> SANDKUIJIL,
V<font size=-1>.</font> DELVENNE,
D<font size=-1>.</font> HIRSCH,
L<font size=-1>.</font> STANER,
J<font size=-1>.</font> MENDLEWICZ,
 <font size=-1>AND</font> C<font size=-1>.</font> VAN BROECKHOVEN.



Nonlinkage of bipolar illness to tyrosine hydroxylase, tyrosine, and D<SUB>2</SUB> and D<SUB>4</SUB> dopamine receptor genes on chromosome 11.
<I>Am. J.&nbsp;Psychiatry</I>
151: 102-106, 1994<!-- HIGHWIRE ID="78:1:189:96" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajp&resid=151/1/102" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B97"><!-- comment for mosaic --></a>
<P>97. &nbsp; 

DEBSKA<font size=-1>-</font>SLIZIEN, A<font size=-1>.</font>,
P<font size=-1>.</font> HO,
R<font size=-1>.</font> DRANGOVA,
 <font size=-1>AND</font> A<font size=-1>. </font>D<font size=-1>.</font> BAINES.



Endogenous dopamine regulates phosphate reabsorption but not NaK-ATPase in spontaneously hypertensive rat kidneys.
<I>J. Am. Soc. Nephrol.</I>
5: 1125-1132, 1994<!-- HIGHWIRE ID="78:1:189:97" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jnephrol&resid=5/4/1125" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B98"><!-- comment for mosaic --></a>
<P>98. &nbsp; 

DEBSKA<font size=-1>-</font>SLIZIEN, A<font size=-1>.</font>,
P<font size=-1>.</font> HO,
R<font size=-1>.</font> DRANGOVA,
 <font size=-1>AND</font> A<font size=-1>. </font>D<font size=-1>.</font> BAINES.



Endogenous renal dopamine production regulates phosphate excretion.
<I>Am. J.&nbsp;Physiol.</I>
266(<I>Renal Fluid Electrolyte Physiol.</I> 35): F858-F867, 1994<!-- HIGHWIRE ID="78:1:189:98" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=266/6/F858" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B99"><!-- comment for mosaic --></a>
<P>99. &nbsp; 

DE CAMILLI, P<font size=-1>.</font>,
D<font size=-1>.</font> MACCONI,
 <font size=-1>AND</font> A<font size=-1>.</font> SPADA.



Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas.
<I>Nature</I>
278: 252-254, 1979<!-- HIGHWIRE ID="78:1:189:99" --><A HREF="/cgi/external_ref?access_num=423973&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B100"><!-- comment for mosaic --></a>
<P>100. &nbsp; 

DE FEO, M<font size=-1>. </font>L<font size=-1>.</font>,
A<font size=-1>. </font>L<font size=-1>.</font> JADHAV,
 <font size=-1>AND</font> M<font size=-1>. </font>F<font size=-1>.</font> LOCKHANDWALA.



Dietary sodium intake and urinary dopamine and sodium excretion during the course of blood pressure development in Dahl salt-sensitive and salt-resistant rats.
<I>Clin. Exp. Hypertens. Part A Theory Pract.</I>
9: 2049-2060, 1987<!-- HIGHWIRE ID="78:1:189:100" --><!-- /HIGHWIRE -->.</P>
<a name="B101"><!-- comment for mosaic --></a>
<P>101. &nbsp; 

DEMCHYSHYN, L<font size=-1>. </font>L<font size=-1>.</font>,
K<font size=-1>. </font>S<font size=-1>.</font> SUGAMORI,
F<font size=-1>. </font>J<font size=-1>.</font><font size=-1>&nbsp;</font>S<font size=-1>.</font> LEE,
S<font size=-1>. </font>A<font size=-1>.</font> HAMADANIZADEH,
 <font size=-1>AND</font> H<font size=-1>. </font>B<font size=-1>.</font> NIZNIK.



The dopamine D<SUB>1D</SUB> receptor. Cloning and characterization of three pharmacologically distinct D<SUB>1</SUB>-like receptors from <I>Gallus domesticus</I>.
<I>J. Biol. Chem.</I>
270: 4005-4012, 1995<!-- HIGHWIRE ID="78:1:189:101" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=270/8/4005" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B102"><!-- comment for mosaic --></a>
<P>102. &nbsp; 

DEUTCH, A<font size=-1>. </font>Y<font size=-1>.</font>,
M<font size=-1>. </font>C<font size=-1>.</font> LEE,
 <font size=-1>AND</font> M<font size=-1>. </font>J<font size=-1>.</font> IADAROLA.



Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: the nucleus accumbens shell as a locus of antipsychotic action.
<I>Mol. Cell. Neurosci.</I>
3: 332-341, 1992<!-- HIGHWIRE ID="78:1:189:102" --><!-- /HIGHWIRE -->.</P>
<a name="B103"><!-- comment for mosaic --></a>
<P>103. &nbsp; 

DEUTCH, A<font size=-1>. </font>Y<font size=-1>.</font>,
B<font size=-1>.</font> MOGHADDAM,
R<font size=-1>. </font>B<font size=-1>.</font> INNIS,
J<font size=-1>. </font>H<font size=-1>.</font> KRYSTAL,
G<font size=-1>. </font>K<font size=-1>.</font> AGHAJANIAN,
B<font size=-1>. </font>S<font size=-1>.</font> BUNNEY,
 <font size=-1>AND</font> D<font size=-1>. </font>S<font size=-1>.</font> CHARNEY.



Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia.
<I>Schizophrenia Res.</I>
4: 121-156, 1991<!-- HIGHWIRE ID="78:1:189:103" --><A HREF="/cgi/external_ref?access_num=1674882&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B104"><!-- comment for mosaic --></a>
<P>104. &nbsp; 

DHANASEKARAN, N<font size=-1>.</font>,
 <font size=-1>AND</font> M<font size=-1>. </font>V<font size=-1>.</font><font size=-1>&nbsp;</font>V<font size=-1>.</font><font size=-1>&nbsp;</font>S<font size=-1>.</font> VARA.



PRASAD, S.&nbsp;J.&nbsp;WADSWORTH, J.&nbsp;M.&nbsp;DERMOTT, <font size=-1>AND</font> G.&nbsp;VAN ROSSUM. Protein kinase C-dependent and -independent activation of Na<SUP>+</SUP>/H<SUP>+</SUP> exchanger by G<IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "><SUB>12</SUB> class of G proteins.
<I>J. Biol. Chem.</I>
269: 11802-11806, 1994<!-- HIGHWIRE ID="78:1:189:104" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=269/16/11802" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B105"><!-- comment for mosaic --></a>
<P>105. &nbsp; 

DIAZ, J<font size=-1>.</font>,
D<font size=-1>.</font> LEVESQUE,
N<font size=-1>.</font> GRIFFON,
C<font size=-1>. </font>H<font size=-1>.</font> LAMMERS,
M<font size=-1>. </font>P<font size=-1>.</font> MARTRES,
P<font size=-1>.</font> SOKOLOFF,
 <font size=-1>AND</font> J<font size=-1>. </font>C<font size=-1>.</font> SCHWARTZ.



Opposing roles for dopamine D<SUB>2</SUB> and D<SUB>3</SUB> receptors on neurotensin mRNA expression in nucleus accumbens.
<I>Eur. J.&nbsp;Neurosci.</I>
6: 1384-1387, 1994<!-- HIGHWIRE ID="78:1:189:105" --><A HREF="/cgi/external_ref?access_num=7981879&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B106"><!-- comment for mosaic --></a>
<P>106. &nbsp; 

DIAZ, J<font size=-1>.</font>,
D<font size=-1>.</font> LEVESQUE,
C<font size=-1>. </font>H<font size=-1>.</font> LAMMERS,
N<font size=-1>.</font> GRIFFON,
M<font size=-1>. </font>P<font size=-1>.</font> MARTRES,
J<font size=-1>. </font>C<font size=-1>.</font> SCHWARTZ,
 <font size=-1>AND</font> P<font size=-1>.</font> SOKOLOFF.



Phenotypical characterization of neurons expressing the dopamine D<SUB>3</SUB> receptor in the rat brain.
<I>Neuroscience</I>
65: 731-745, 1995<!-- HIGHWIRE ID="78:1:189:106" --><A HREF="/cgi/external_ref?access_num=7609872&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B107"><!-- comment for mosaic --></a>
<P>107. &nbsp; D<font size=-1>I</font>BONA, G.&nbsp;F. Renal dopamine containing nerves. What is their functional significance? <I>Am. J.&nbsp;Hypertens.</I> 3,&nbsp;<I>Suppl.</I>: 64S-67S, 1990.<!-- HIGHWIRE ID="78:1:189:107" --><!-- /HIGHWIRE --></P>
<a name="B108"><!-- comment for mosaic --></a>
<P>108. &nbsp; 

DI CHIARA, G<font size=-1>.</font>.



The role of dopamine in drug abuse viewed from the perspective of its role in motivation.
<I>Drug Alcohol Depend.</I>
38: 95-137, 1995<!-- HIGHWIRE ID="78:1:189:108" --><A HREF="/cgi/external_ref?access_num=7671769&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B109"><!-- comment for mosaic --></a>
<P>109. &nbsp; 

DI MARZO, V<font size=-1>.</font>,
D<font size=-1>.</font> VIAL,
P<font size=-1>.</font> SOKOLOFF,
J<font size=-1>.-</font>C<font size=-1>.</font> SCHWARTZ,
 <font size=-1>AND</font> D<font size=-1>.</font> PIOMELLI.



Selection of alternative G<SUB>i</SUB>-mediated signaling pathways at the dopamine D<SUB>2</SUB> receptor by protein kinase C.
<I>J. Neurosci.</I>
13: 4846-4853, 1993<!-- HIGHWIRE ID="78:1:189:109" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jneuro&resid=13/11/4846" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B110"><!-- comment for mosaic --></a>
<P>110. &nbsp; 

DINERSTEIN, R<font size=-1>. </font>J<font size=-1>.</font>,
J<font size=-1>.</font> VANNICE,
R<font size=-1>. </font>C<font size=-1>.</font> HENDERSON,
L<font size=-1>. </font>J<font size=-1>.</font> ROTH,
L<font size=-1>. </font>I<font size=-1>.</font> GOLDBERG,
 <font size=-1>AND</font> P<font size=-1>. </font>C<font size=-1>.</font> HOFFMANN.



Histofluorescence techniques provide evidence for dopamine containing neuronal elements in canine kidney.
<I>Science</I>
205: 497-499, 1979<!-- HIGHWIRE ID="78:1:189:110" --><A HREF="/cgi/external_ref?access_num=451614&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B111"><!-- comment for mosaic --></a>
<P>111. &nbsp; 

DOHLMAN, H<font size=-1>. </font>G<font size=-1>.</font>,
M<font size=-1>. </font>G<font size=-1>.</font> CARON,
A<font size=-1>.</font> DEBLASI,
T<font size=-1>.</font> FRIELLE,
 <font size=-1>AND</font> R<font size=-1>. </font>J<font size=-1>.</font> LEFKOWITZ.



A role of extracellular disulfide bonded cysteines in the ligand binding function of the <IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BASELINE ALT="beta "><SUB>2</SUB> adrenergic receptor.
<I>Biochemistry</I>
29: 2335-2342, 1990<!-- HIGHWIRE ID="78:1:189:111" --><A HREF="/cgi/external_ref?access_num=2159799&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B112"><!-- comment for mosaic --></a>
<P>112. &nbsp; 

DOHLMAN, H<font size=-1>. </font>G<font size=-1>.</font>,
M<font size=-1>. </font>G<font size=-1>.</font> CARON,
 <font size=-1>AND</font> R<font size=-1>. </font>J<font size=-1>.</font> LEFKOWITZ.



A family of receptors coupled to guanine nucleotide regulatory proteins.
<I>Biochemistry</I>
26: 2657-2664, 1987<!-- HIGHWIRE ID="78:1:189:112" --><A HREF="/cgi/external_ref?access_num=3038163&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B113"><!-- comment for mosaic --></a>
<P>113. &nbsp; 

DOWNES, R<font size=-1>. </font>P<font size=-1>.</font>,
 <font size=-1>AND</font> J<font size=-1>. </font>L<font size=-1>.</font> WADDINGTON.



Grooming and vacuous chewing induced by SKF 83959,&nbsp;an agonist of dopamine D<SUB>1</SUB>-like receptors that inhibits dopamine-sensitive adenylyl cyclase.
<I>Eur. J.&nbsp;Pharmacol.</I>
234: 135-136, 1993<!-- HIGHWIRE ID="78:1:189:113" --><A HREF="/cgi/external_ref?access_num=8097163&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B114"><!-- comment for mosaic --></a>
<P>114. &nbsp; 

DRAGO, J<font size=-1>.</font>,
C<font size=-1>. </font>R<font size=-1>.</font> GERFEN,
J<font size=-1>. </font>E<font size=-1>.</font> LACHOWICZ,
H<font size=-1>.</font> STEINER,
T<font size=-1>. </font>R<font size=-1>.</font> HOLLON,
P<font size=-1>. </font>E<font size=-1>.</font> LOVE,
G<font size=-1>. </font>T<font size=-1>.</font> OOI,
A<font size=-1>.</font> GRINBERG,
E<font size=-1>. </font>J<font size=-1>.</font> LEE,
S<font size=-1>. </font>P<font size=-1>.</font> HUNAG,
P<font size=-1>. </font>F<font size=-1>.</font> BARTLETT,
P<font size=-1>. </font>A<font size=-1>.</font> JOSE,
D<font size=-1>. </font>R<font size=-1>.</font> SIBLEY,
 <font size=-1>AND</font> H<font size=-1>.</font> WESTPHAL.



Altered striatal function in a mutant mouse lacking D<SUB>1a</SUB> dopamine receptors.
<I>Proc. Natl. Acad. Sci. USA</I>
91: 12564-12568, 1994<!-- HIGHWIRE ID="78:1:189:114" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=91/26/12564" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B115"><!-- comment for mosaic --></a>
<P>115. &nbsp; 

DRAKE, C<font size=-1>. </font>R<font size=-1>.</font>,
N<font size=-1>. </font>V<font size=-1>.</font> RAGSDALE,
D<font size=-1>. </font>L<font size=-1>.</font> KAISER,
 <font size=-1>AND</font> R<font size=-1>. </font>M<font size=-1>.</font> CAREY.



Dopaminergic suppression of angiotensin II-induced aldosterone secretion in man: differential responses during sodium loading and depletion.
<I>Metabolism</I>
33: 696-702, 1984<!-- HIGHWIRE ID="78:1:189:115" --><A HREF="/cgi/external_ref?access_num=6379373&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B116"><!-- comment for mosaic --></a>
<P>116. &nbsp; 

DREHER, J<font size=-1>. </font>K<font size=-1>.</font>,
 <font size=-1>AND</font> D<font size=-1>. </font>M<font size=-1>.</font> JACKSON.



Role of D<SUB>1</SUB> and D<SUB>2</SUB> dopamine receptors in mediating locomotor activity elicited from the nucleus accumbens of rats.
<I>Brain Res.</I>
487: 267-277, 1988<!-- HIGHWIRE ID="78:1:189:116" --><!-- /HIGHWIRE -->.</P>
<a name="B117"><!-- comment for mosaic --></a>
<P>117. &nbsp; 

EDWARDS, R<font size=-1>. </font>M<font size=-1>.</font>.



Response of isolated renal arterioles to acetylcholine, dopamine, and bradykinin.
<I>Am. J.&nbsp;Physiol.</I>
248(<I>Renal Fluid Electrolyte Physiol.</I> 17): F183-F189, 1985<!-- HIGHWIRE ID="78:1:189:117" --><A HREF="/cgi/external_ref?access_num=3970208&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B118"><!-- comment for mosaic --></a>
<P>118. &nbsp; 

EDWARDS, R<font size=-1>. </font>M<font size=-1>.</font>.



Comparison of the effects of fenoldopam, SK &amp;&nbsp;F R-87516 and dopamine on renal arterioles in vitro.
<I>Eur. J.&nbsp;Pharmacol.</I>
126: 167-170, 1986<!-- HIGHWIRE ID="78:1:189:118" --><A HREF="/cgi/external_ref?access_num=2875883&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B119"><!-- comment for mosaic --></a>
<P>119. &nbsp; 

EINHORN, L<font size=-1>. </font>C<font size=-1>.</font>,
K<font size=-1>. </font>A<font size=-1>.</font> GREGERSON,
 <font size=-1>AND</font> G<font size=-1>. </font>S<font size=-1>.</font> OXFORD.



D<SUB>2</SUB> dopamine receptor activation of potassium channels in identified rat lactotrophs: whole-cell and single-channel recording.
<I>J. Neurosci.</I>
11: 3727-3737, 1991<!-- HIGHWIRE ID="78:1:189:119" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jneuro&resid=11/12/3727" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B120"><!-- comment for mosaic --></a>
<P>120. &nbsp; 

ELSHOLTZ, H<font size=-1>. </font>P<font size=-1>.</font>,
A<font size=-1>. </font>M<font size=-1>.</font> LEW,
P<font size=-1>. </font>R<font size=-1>.</font> ALBERT,
 <font size=-1>AND</font> V<font size=-1>. </font>C<font size=-1>.</font> SUNDMARK.



Inhibitory control of prolactin and Pit 1&nbsp;gene promoters by dopamine. Dual signaling pathways required for D<SUB>2</SUB> receptor regulated expression of the prolactin gene.
<I>J. Biol. Chem.</I>
266: 22919-22925, 1991<!-- HIGHWIRE ID="78:1:189:120" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=266/34/22919" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B121"><!-- comment for mosaic --></a>
<P>121. &nbsp; 

ENJALBERT, A<font size=-1>.</font>,
 <font size=-1>AND</font> J<font size=-1>.</font> BOCKAERT.



Pharmacological characterization of the D<SUB>2</SUB> dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary.
<I>Mol. Pharmacol.</I>
53: 576-584, 1983<!-- HIGHWIRE ID="78:1:189:121" --><!-- /HIGHWIRE -->.</P>
<a name="B122"><!-- comment for mosaic --></a>
<P>122. &nbsp; 

ENJALBERT, A<font size=-1>.</font>,
G<font size=-1>.</font> GUILLON,
B<font size=-1>.</font> MOUILLAC,
V<font size=-1>.</font> AUDINOT,
R<font size=-1>.</font> ROSOLONJANAHARY,
C<font size=-1>.</font> KORDON,
 <font size=-1>AND</font> J<font size=-1>.</font> BOCKAERT.



Dual mechanisms of inhibition by dopamine of basal and thyrotropin-releasing hormone-stimulated inositol phosphate production in anterior pituitary cells.
<I>J. Biol. Chem.</I>
265: 18816-18822, 1990<!-- HIGHWIRE ID="78:1:189:122" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=265/31/18816" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B123"><!-- comment for mosaic --></a>
<P>123. &nbsp; 

FELDER, C<font size=-1>. </font>C<font size=-1>.</font>,
F<font size=-1>. </font>A<font size=-1>.</font> ALBRECHT,
T<font size=-1>.</font> CAMPBELL,
G<font size=-1>. </font>M<font size=-1>.</font> EISNER,
 <font size=-1>AND</font> P<font size=-1>. </font>A<font size=-1>.</font> JOSE.



cAMP-independent, G protein-linked inhibition of Na<SUP>+</SUP>/H<SUP>+</SUP> exchange in renal brush border by D<SUB>1</SUB> agonists.
<I>Am. J.&nbsp;Physiol.</I>
264(<I>Renal Fluid Electrolyte Physiol.</I> 33): F1032-F1037, 1993<!-- HIGHWIRE ID="78:1:189:123" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=264/6/F1032" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B124"><!-- comment for mosaic --></a>
<P>124. &nbsp; 

FELDER, C<font size=-1>. </font>C<font size=-1>.</font>,
M<font size=-1>.</font> BLECHER,
 <font size=-1>AND</font> P<font size=-1>. </font>A<font size=-1>.</font> JOSE.



Dopamine-1-mediated stimulation of phospholipase C activity in rat renal cortical membranes.
<I>J. Biol. Chem.</I>
264: 8739-8745, 1989<!-- HIGHWIRE ID="78:1:189:124" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=264/15/8739" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B125"><!-- comment for mosaic --></a>
<P>125. &nbsp; 

FELDER, C<font size=-1>. </font>C<font size=-1>.</font>,
T<font size=-1>.</font> CAMPBELL,
F<font size=-1>. </font>A<font size=-1>.</font> ALBRECHT,
 <font size=-1>AND</font> P<font size=-1>. </font>A<font size=-1>.</font> JOSE.



Dopamine inhibits Na<SUP>+</SUP>/H<SUP>+</SUP> exchanger activity in renal BBMV by stimulation of adenylate cyclase.
<I>Am. J.&nbsp;Physiol.</I>
259(<I>Renal Fluid Electrolyte Physiol.</I> 28): F297-F303, 1990<!-- HIGHWIRE ID="78:1:189:125" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=259/2/F297" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B126"><!-- comment for mosaic --></a>
<P>126. &nbsp; 

FELDER, C<font size=-1>. </font>C<font size=-1>.</font>,
P<font size=-1>. </font>A<font size=-1>.</font> JOSE,
 <font size=-1>AND</font> J<font size=-1>.</font> AXELROD.



The dopamine-1 agonist, SKF 82526,&nbsp;stimulates phospholipase-C activity independent of adenylate cyclase.
<I>J. Pharmacol. Exp. Ther.</I>
248: 171-175, 1989<!-- HIGHWIRE ID="78:1:189:126" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jpet&resid=248/1/171" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B127"><!-- comment for mosaic --></a>
<P>127. &nbsp; 

FELDER, C<font size=-1>. </font>C<font size=-1>.</font>,
A<font size=-1>. </font>M<font size=-1>.</font> M<font size=-1>C</font>KELVEY,
M<font size=-1>. </font>S<font size=-1>.</font> GITLER,
G<font size=-1>. </font>M<font size=-1>.</font> EISNER,
 <font size=-1>AND</font> P<font size=-1>. </font>A<font size=-1>.</font> JOSE.



Dopamine receptor subtypes in renal brush border and basolateral membranes.
<I>Kidney Int.</I>
36: 183-193, 1989<!-- HIGHWIRE ID="78:1:189:127" --><A HREF="/cgi/external_ref?access_num=2528652&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B128"><!-- comment for mosaic --></a>
<P>128. &nbsp; 

FELDER, C<font size=-1>. </font>C<font size=-1>.</font>,
H<font size=-1>. </font>L<font size=-1>.</font> WILLIAMS,
 <font size=-1>AND</font> J<font size=-1>.</font> AXELROD.



A transduction pathway associated with receptors coupled to the inhibitory guanine nucleotide binding protein G<SUB>i</SUB> that amplifies ATP-mediated arachidonic acid release.
<I>Proc. Natl. Acad. Sci. USA</I>
88: 6477-6480, 1991<!-- HIGHWIRE ID="78:1:189:128" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=88/15/6477" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B129"><!-- comment for mosaic --></a>
<P>129. &nbsp; 

FELDER, R<font size=-1>. </font>A<font size=-1>.</font>,
M<font size=-1>.</font> BLECHER,
G<font size=-1>. </font>M<font size=-1>.</font> EISNER,
 <font size=-1>AND</font> P<font size=-1>. </font>A<font size=-1>.</font> JOSE.



Cortical tubular and glomerular dopamine receptors in the rat kidney.
<I>Am. J.&nbsp;Physiol.</I>
246(<I>Renal Fluid Electrolyte Physiol.</I> 15): F557-F568, 1984<!-- HIGHWIRE ID="78:1:189:129" --><A HREF="/cgi/external_ref?access_num=6720961&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B130"><!-- comment for mosaic --></a>
<P>130. &nbsp; 

FELDER, R<font size=-1>. </font>A<font size=-1>.</font>,
C<font size=-1>. </font>C<font size=-1>.</font> FELDER,
G<font size=-1>. </font>M<font size=-1>.</font> EISNER,
 <font size=-1>AND</font> P<font size=-1>. </font>A<font size=-1>.</font> JOSE.



The dopamine receptor in adult and maturing kidney.
<I>Am. J.&nbsp;Physiol.</I>
257(<I>Renal Fluid Electrolyte Physiol.</I> 26): F315-F327, 1989<!-- HIGHWIRE ID="78:1:189:130" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=257/3/F315" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B131"><!-- comment for mosaic --></a>
<P>131. &nbsp; 

FELDER, R<font size=-1>. </font>A<font size=-1>.</font>,
 <font size=-1>AND</font> P<font size=-1>. </font>A<font size=-1>.</font> JOSE.



Dopamine<SUB>1</SUB> receptors in rat kidneys identified with <SUP>125</SUP>I-SCH 23982.
<I>Am. J.&nbsp;Physiol.</I>
255(<I>Renal Fluid Electrolyte Physiol.</I> 24): F970-F976, 1988<!-- HIGHWIRE ID="78:1:189:131" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=255/5/F970" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B132"><!-- comment for mosaic --></a>
<P>132. &nbsp; 

FELDER, R<font size=-1>. </font>A<font size=-1>.</font>,
S<font size=-1>.</font> KINOSHITA,
K<font size=-1>.</font> OHBU,
M<font size=-1>. </font>M<font size=-1>.</font> MOURADIAN,
D<font size=-1>. </font>R<font size=-1>.</font> SIBLEY,
F<font size=-1>. </font>J<font size=-1>.</font> MONSMA,
T<font size=-1>.</font> MINOWA,
M<font size=-1>. </font>T<font size=-1>.</font> MINOWA,
L<font size=-1>. </font>M<font size=-1>.</font> CANESSA,
 <font size=-1>AND</font> P<font size=-1>. </font>A<font size=-1>.</font> JOSE.



Organ specificity of the dopamine<SUB>1</SUB> receptor/adenylyl cyclase coupling defect in spontaneously hypertensive rats.
<I>Am. J.&nbsp;Physiol.</I>
264(<I>Regulatory Integrative Comp. Physiol.</I> 33): R726-R732, 1993<!-- HIGHWIRE ID="78:1:189:132" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajpregu&resid=264/4/R726" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B133"><!-- comment for mosaic --></a>
<P>133. &nbsp; 

FELDER, R<font size=-1>. </font>A<font size=-1>.</font>,
S<font size=-1>.</font> KINOSHITA,
A<font size=-1>.</font> SIDHU,
K<font size=-1>.</font> OHBU,
 <font size=-1>AND</font> F<font size=-1>. </font>J<font size=-1>.</font> KASKEL.



A renal dopamine-1 receptor defect in two genetic models of hypertension.
<I>Am. J.&nbsp;Hypertens.</I>
3, <I>Suppl.</I>: 96S-99S, 1990<!-- HIGHWIRE ID="78:1:189:133" --><A HREF="/cgi/external_ref?access_num=1974447&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B134"><!-- comment for mosaic --></a>
<P>134. &nbsp; 

FELDER, R<font size=-1>. </font>A<font size=-1>.</font>,
M<font size=-1>. </font>G<font size=-1>.</font> SEIKALY,
P<font size=-1>.</font> CODY,
G<font size=-1>. </font>M<font size=-1>.</font> EISNER,
 <font size=-1>AND</font> P<font size=-1>. </font>A<font size=-1>.</font> JOSE.



Attenuated renal response to dopaminergic drugs in spontaneously hypertensive rats.
<I>Hypertension</I>
15: 560-569, 1990<!-- HIGHWIRE ID="78:1:189:134" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=hypertensionaha&resid=15/6/560" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B135"><!-- comment for mosaic --></a>
<P>135. &nbsp; 

FELIX, R<font size=-1>.</font>,
U<font size=-1>.</font> MEZA,
 <font size=-1>AND</font> G<font size=-1>.</font> COTA.



Induction of classical lactotropes by epidermal growth factor in rat pituitary cell cultures.
<I>Endocrinology</I>
136: 939-946, 1995<!-- HIGHWIRE ID="78:1:189:135" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=endo&resid=136/3/939" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B136"><!-- comment for mosaic --></a>
<P>136. &nbsp; 

FERRARI, G<font size=-1>.</font>,
G<font size=-1>.</font> TOFFANO,
 <font size=-1>AND</font> S<font size=-1>. </font>D<font size=-1>.</font> SKAPER.



Epidermal growth factor exerts neuronotrophic effects on dopaminergic and GABAergic CNS neurons: comparison with basic fibroblast growth factor.
<I>J. Neurosci. Res.</I>
30: 493-497, 1991<!-- HIGHWIRE ID="78:1:189:136" --><A HREF="/cgi/external_ref?access_num=1800771&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B137"><!-- comment for mosaic --></a>
<P>137. &nbsp; 

FISHBURN, C<font size=-1>. </font>S<font size=-1>.</font>,
D<font size=-1>.</font> BELLELI,
C<font size=-1>.</font> DAVID,
S<font size=-1>.</font> CARMON,
 <font size=-1>AND</font> S<font size=-1>.</font> FUCHS.



A novel short isoform of the D<SUB>3</SUB> dopamine receptor generated by alternative splicing in the third cytoplasmic loop.
<I>J. Biol. Chem.</I>
268: 5872-5878, 1993<!-- HIGHWIRE ID="78:1:189:137" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=268/8/5872" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B138"><!-- comment for mosaic --></a>
<P>138. &nbsp; 

FLORIO, T<font size=-1>.</font>,
M<font size=-1>.-</font>G<font size=-1>.</font> PAN,
B<font size=-1>.</font> NEWMAN,
R<font size=-1>. </font>E<font size=-1>.</font> HERSHBERGER,
O<font size=-1>.</font> CIVELLI,
 <font size=-1>AND</font> P<font size=-1>. </font>J<font size=-1>.</font><font size=-1>&nbsp;</font>S<font size=-1>.</font> STORK.



Dopaminergic inhibition of DNA synthesis in pituitary tumor cells is associated with phosphotyrosine phosphatase activity.
<I>J. Biol. Chem.</I>
267: 24169-24172, 1992<!-- HIGHWIRE ID="78:1:189:138" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=267/34/24169" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B139"><!-- comment for mosaic --></a>
<P>139. &nbsp; 

FOUCART, S<font size=-1>.</font>,
P<font size=-1>.</font> LACAILLE<font size=-1>-</font>BELANGER,
T<font size=-1>. </font>R<font size=-1>.</font> KIMURA,
 <font size=-1>AND</font> J<font size=-1>.</font> NADEAU.



DE CHAMPLAIN. Modulation of adrenal catecholamine release by DA<SUB>2</SUB> dopamine receptors in the anesthetized dog.
<I>Clin. Exp. Pharmacol. Physiol.</I>
15: 601-611, 1988<!-- HIGHWIRE ID="78:1:189:139" --><A HREF="/cgi/external_ref?access_num=2908435&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B140"><!-- comment for mosaic --></a>
<P>140. &nbsp; 

FRAIL, D<font size=-1>. </font>E<font size=-1>.</font>,
A<font size=-1>. </font>M<font size=-1>.</font> MANELLI,
D<font size=-1>. </font>G<font size=-1>.</font> WITTE,
C<font size=-1>. </font>W<font size=-1>.</font> LIN,
M<font size=-1>. </font>E<font size=-1>.</font> STEFFEY,
 <font size=-1>AND</font> R<font size=-1>. </font>G<font size=-1>.</font> MACKENZIE.



Cloning and characterization of a truncated dopamine D<SUB>1</SUB> receptor from goldfish retina: stimulation of cyclic AMP production and calcium mobilization.
<I>Mol. Pharmacol.</I>
44: 1113-1118, 1993<!-- HIGHWIRE ID="78:1:189:140" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=44/6/1113" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B141"><!-- comment for mosaic --></a>
<P>141. &nbsp; 

FRANKLIN, K<font size=-1>. </font>B<font size=-1>.</font><font size=-1>&nbsp;</font>J<font size=-1>.</font>,
 <font size=-1>AND</font> F<font size=-1>. </font>J<font size=-1>.</font> VACCARINO.



Differential effects of amphetamine isomers on SN self-stimulation: evidence for DA neuron subtypes.
<I>Pharmacol. Biochem. Behav.</I>
18: 747-751, 1983<!-- HIGHWIRE ID="78:1:189:141" --><A HREF="/cgi/external_ref?access_num=6856648&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B142"><!-- comment for mosaic --></a>
<P>142. &nbsp; 

FRASER, C<font size=-1>.</font>.



Site-directed mutagenesis of <IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BASELINE ALT="beta ">&nbsp;adrenergic receptors.
<I>J. Biol. Chem.</I>
264: 9266-9270, 1989<!-- HIGHWIRE ID="78:1:189:142" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=264/16/9266" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B143"><!-- comment for mosaic --></a>
<P>143. &nbsp; 

FREDERICKSON, E<font size=-1>. </font>D<font size=-1>.</font>,
T<font size=-1>.</font> BRADLEY,
 <font size=-1>AND</font> L<font size=-1>. </font>I<font size=-1>.</font> GOLDBERG.



Blockade of renal effects of dopamine in the dog by the DA<SUB>1</SUB> antagonist SCH 23390.
<I>Am. J.&nbsp;Physiol.</I>
249(<I>Renal Fluid Electrolyte Physiol.</I> 18): F236-F240, 1985<!-- HIGHWIRE ID="78:1:189:143" --><A HREF="/cgi/external_ref?access_num=3161340&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B144"><!-- comment for mosaic --></a>
<P>144. &nbsp; 

FREEDMAN, S<font size=-1>. </font>B<font size=-1>.</font>,
S<font size=-1>.</font> PATEL,
R<font size=-1>.</font> MARWOOD,
F<font size=-1>.</font> EMMS,
G<font size=-1>. </font>R<font size=-1>.</font> SEABROOK,
M<font size=-1>. </font>R<font size=-1>.</font> KNOWLES,
 <font size=-1>AND</font> G<font size=-1>.</font> M<font size=-1>C</font>ALLISTER.



Expression and pharmacological characterization of the human D<SUB>3</SUB> dopamine receptor.
<I>J. Pharmacol. Exp. Ther.</I>
268: 417-426, 1994<!-- HIGHWIRE ID="78:1:189:144" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jpet&resid=268/1/417" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B145"><!-- comment for mosaic --></a>
<P>145. &nbsp; 

FREMEAU, R<font size=-1>. </font>J<font size=-1>.</font>,
G<font size=-1>. </font>E<font size=-1>.</font> DUNCAN,
M<font size=-1>. </font>G<font size=-1>.</font> FORNARETTO,
A<font size=-1>.</font> DEARRY,
J<font size=-1>. </font>A<font size=-1>.</font> GINGRICH,
G<font size=-1>. </font>R<font size=-1>.</font> BREESE,
 <font size=-1>AND</font> M<font size=-1>. </font>G<font size=-1>.</font> CARON.



Localization of D<SUB>1</SUB> dopamine receptor mRNA in brain supports a role in cognitive, affective and neuroendocrine aspects of dopaminergic neurotransmission.
<I>Proc. Natl. Acad. Sci. USA</I>
91: 12564-12568, 1991<!-- HIGHWIRE ID="78:1:189:145" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=91/26/12564" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B146"><!-- comment for mosaic --></a>
<P>146. &nbsp; 

GALLO<font size=-1>-</font>PAYET, N<font size=-1>.</font>,
L<font size=-1>.</font> CHOUINARD,
M<font size=-1>. </font>N<font size=-1>.</font> BALESTRE,
 <font size=-1>AND</font> G<font size=-1>.</font> GUILLON.



Mechanisms involved in the interaction of dopamine with angiotensin II on aldosterone secretion in isolated and cultured rat adrenal glomerulosa cells.
<I>Mol. Cell. Endocrinol.</I>
81: 11-23, 1991<!-- HIGHWIRE ID="78:1:189:146" --><A HREF="/cgi/external_ref?access_num=1839152&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B147"><!-- comment for mosaic --></a>
<P>147. &nbsp; 

GANZ, M<font size=-1>. </font>B<font size=-1>.</font>,
J<font size=-1>. </font>A<font size=-1>.</font> PACHTER,
 <font size=-1>AND</font> D<font size=-1>. </font>L<font size=-1>.</font> BARBER.



Multiple receptors coupled to adenylate cyclase regulate Na-H exchange independent of cAMP.
<I>J. Biol. Chem.</I>
265: 8989-8992, 1990<!-- HIGHWIRE ID="78:1:189:147" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=265/16/8989" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B148"><!-- comment for mosaic --></a>
<P>148. &nbsp; 

GAO, D<font size=-1>. </font>Q<font size=-1>.</font>,
L<font size=-1>. </font>M<font size=-1>.</font> CANESSA,
M<font size=-1>. </font>M<font size=-1>.</font> MOURADIAN,
 <font size=-1>AND</font> P<font size=-1>. </font>A<font size=-1>.</font> JOSE.



Expression of the D<SUB>2</SUB> subfamily of dopamine receptor genes in kidney.
<I>Am. J.&nbsp;Physiol.</I>
266(<I>Renal Fluid Electrolyte Physiol.</I> 35): F646-F650, 1994<!-- HIGHWIRE ID="78:1:189:148" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=266/4/F646" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B149"><!-- comment for mosaic --></a>
<P>149. &nbsp; 

GARDETTE, R<font size=-1>.</font>,
R<font size=-1>.</font> ROSOLONJANAHARY,
C<font size=-1>.</font> KORDON,
 <font size=-1>AND</font> A<font size=-1>.</font> ENJALBERT.



Epidermal growth factor treatment induces D<SUB>2</SUB> dopamine receptors functionally coupled to delayed outward potassium current (Ik) in GH<SUB>4</SUB>C<SUB>1</SUB> clonal anterior pituitary cells.
<I>Neuroendocrinology</I>
59: 10-19, 1994<!-- HIGHWIRE ID="78:1:189:149" --><A HREF="/cgi/external_ref?access_num=8145892&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B150"><!-- comment for mosaic --></a>
<P>150. &nbsp; 

GARG, L<font size=-1>. </font>C<font size=-1>.</font>,
N<font size=-1>.</font> NARANG,
 <font size=-1>AND</font> S<font size=-1>.</font> M<font size=-1>C</font>CARDLE.



Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase in nephron segments of rats developing spontaneous hypertension.
<I>Am. J.&nbsp;Physiol.</I>
249(<I>Renal Fluid Electrolyte Physiol.</I> 18): F863-F869, 1985<!-- HIGHWIRE ID="78:1:189:150" --><A HREF="/cgi/external_ref?access_num=3000191&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B151"><!-- comment for mosaic --></a>
<P>151. &nbsp; 

GELERNTER, J<font size=-1>.</font>,
J<font size=-1>. </font>L<font size=-1>.</font> KENNEDY,
D<font size=-1>. </font>K<font size=-1>.</font> GRANDY,
Q<font size=-1>. </font>Y<font size=-1>.</font> ZHOU,
O<font size=-1>.</font> CIVELLI,
D<font size=-1>. </font>L<font size=-1>.</font> PAULS,
A<font size=-1>.</font> PAKSTIS,
R<font size=-1>.</font> KURLAN,
R<font size=-1>. </font>K<font size=-1>.</font> SUNAHARA,
 <font size=-1>AND</font> H<font size=-1>. </font>B<font size=-1>.</font> NIZNIK.



Exclusion of close linkage of Tourette's syndrome to D<SUB>1</SUB> dopamine receptor.
<I>Am. J.&nbsp;Psychiatry</I>
150: 449-453, 1993<!-- HIGHWIRE ID="78:1:189:151" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajp&resid=150/3/449" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B152"><!-- comment for mosaic --></a>
<P>152. &nbsp; 

GERFEN, C<font size=-1>. </font>R<font size=-1>.</font>.



The neostriatal mosaic: multiple levels of compartmental organization.
<I>Trends Neurosci.</I>
15: 133-138, 1992<!-- HIGHWIRE ID="78:1:189:152" --><A HREF="/cgi/external_ref?access_num=1374971&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B153"><!-- comment for mosaic --></a>
<P>153. &nbsp; 

GERFEN, C<font size=-1>. </font>R<font size=-1>.</font>,
T<font size=-1>. </font>M<font size=-1>.</font> ENGBER,
L<font size=-1>. </font>C<font size=-1>.</font> MAHAN,
Z<font size=-1>.</font> SUSEL,
T<font size=-1>. </font>N<font size=-1>.</font> CHASE,
 <font size=-1>AND</font> F<font size=-1>. </font>J<font size=-1>.</font> MOSMA.



J<font size=-1>R</font>., <font size=-1>AND</font> D.&nbsp;R.&nbsp;SIBLEY. D<SUB>1</SUB> and D<SUB>2</SUB> dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.
<I>Science</I>
250: 1429-1432, 1990<!-- HIGHWIRE ID="78:1:189:153" --><A HREF="/cgi/external_ref?access_num=2147780&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B154"><!-- comment for mosaic --></a>
<P>154. &nbsp; 

GERLACH, J<font size=-1>.</font>,
K<font size=-1>.</font> BEHNKEK,
J<font size=-1>.</font> HELTBERG,
E<font size=-1>.</font> MUNK<font size=-1>-</font>ANDERSON,
 <font size=-1>AND</font> H<font size=-1>.</font> NIELSEN.



Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations.
<I>Br. J.&nbsp;Psychiatry</I>
147: 283-288, 1985<!-- HIGHWIRE ID="78:1:189:154" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=bjprcpsych&resid=147/3/283" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B155"><!-- comment for mosaic --></a>
<P>155. &nbsp; 

GERSHANIK, O<font size=-1>.</font>,
R<font size=-1>. </font>E<font size=-1>.</font> HEIKKILA,
 <font size=-1>AND</font> R<font size=-1>. </font>C<font size=-1>.</font> DUVOISIN.



Behavioral correlations of dopamine receptor activation.
<I>Neurology</I>
33: 1489-1492, 1983<!-- HIGHWIRE ID="78:1:189:155" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=neurology&resid=33/11/1489" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B156"><!-- comment for mosaic --></a>
<P>156. &nbsp; 

GESEK, F<font size=-1>. </font>A<font size=-1>.</font>,
 <font size=-1>AND</font> A<font size=-1>. </font>C<font size=-1>.</font> SCHOOLWERTH.



Hormonal interactions with the proximal Na<SUP>+</SUP>/H<SUP>+</SUP> exchanger.
<I>Am. J.&nbsp;Physiol.</I>
258(<I>Renal Fluid Electrolyte Physiol.</I> 27): F514-F521, 1990<!-- HIGHWIRE ID="78:1:189:156" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=258/3/F514" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B157"><!-- comment for mosaic --></a>
<P>157. &nbsp; 

GESEK, F<font size=-1>. </font>A<font size=-1>.</font>,
 <font size=-1>AND</font> A<font size=-1>. </font>C<font size=-1>.</font> SCHOOLWERTH.



Hormone responses of proximal Na<SUP>+</SUP>-H<SUP>+</SUP> exchanger in spontaneously hypertensive rats.
<I>Am. J.&nbsp;Physiol.</I>
261(<I>Renal Fluid Electrolyte Physiol.</I> 30): F526-F536, 1991<!-- HIGHWIRE ID="78:1:189:157" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=261/3/F526" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B158"><!-- comment for mosaic --></a>
<P>158. &nbsp; 

GEYER, M<font size=-1>. </font>A<font size=-1>.</font>,
A<font size=-1>.</font> PUERTO,
D<font size=-1>. </font>B<font size=-1>.</font> MENKES,
D<font size=-1>. </font>S<font size=-1>.</font> SEGAL,
 <font size=-1>AND</font> A<font size=-1>. </font>J<font size=-1>.</font> MANDELL.



Behavioral studies following lesions of the mesolimbic and mesostriatal serotonergic pathways.
<I>Brain Res.</I>
106: 257-270, 1976<!-- HIGHWIRE ID="78:1:189:158" --><A HREF="/cgi/external_ref?access_num=1276871&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B159"><!-- comment for mosaic --></a>
<P>159. &nbsp; 

GINGRICH, J<font size=-1>. </font>A<font size=-1>.</font>,
 <font size=-1>AND</font> M<font size=-1>. </font>G<font size=-1>.</font> CARON.



Recent advances in the molecular biology of dopamine receptors.
<I>Annu. Rev. Neurosci.</I>
16: 299-321, 1993<!-- HIGHWIRE ID="78:1:189:159" --><A HREF="/cgi/external_ref?access_num=8460895&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B160"><!-- comment for mosaic --></a>
<P>160. &nbsp; 

GIROS, B<font size=-1>.</font>,
M<font size=-1>.</font> JABER,
S<font size=-1>. </font>R<font size=-1>.</font> JONES,
R<font size=-1>. </font>M<font size=-1>.</font> WIGHTMAN,
 <font size=-1>AND</font> M<font size=-1>. </font>G<font size=-1>.</font> CARON.



Disruption of the mouse dopamine transporter gene results in hyperdopaminergic phenotype and lack of response to cocaine and amphetamine.
<I>Nature</I>
379: 606-612, 1996<!-- HIGHWIRE ID="78:1:189:160" --><A HREF="/cgi/external_ref?access_num=8628395&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B161"><!-- comment for mosaic --></a>
<P>161. &nbsp; 

GIROS, B<font size=-1>.</font>,
M<font size=-1>. </font>P<font size=-1>.</font> MARTRES,
C<font size=-1>.</font> PILON,
P<font size=-1>.</font> SOKOLOFF,
 <font size=-1>AND</font> J<font size=-1>. </font>C<font size=-1>.</font> SCHWARTZ.



Shorter variants of the D<SUB>3</SUB> dopamine receptor produced through various patterns of alternative splicing.
<I>Biochem. Biophys. Res. Commun.</I>
176: 1584-1592, 1991<!-- HIGHWIRE ID="78:1:189:161" --><A HREF="/cgi/external_ref?access_num=2039532&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B162"><!-- comment for mosaic --></a>
<P>162. &nbsp; 

GIROS, B<font size=-1>.</font>,
P<font size=-1>.</font> SOKOLOFF,
M<font size=-1>. </font>P<font size=-1>.</font> MARTRES,
J<font size=-1>. </font>F<font size=-1>.</font> RIOU,
L<font size=-1>. </font>J<font size=-1>.</font> EMORINE,
 <font size=-1>AND</font> J<font size=-1>. </font>C<font size=-1>.</font> SCHWARTZ.



Alternative splicing directs the expression of two D<SUB>2</SUB> dopamine receptor isoforms.
<I>Nature</I>
342: 923-926, 1989<!-- HIGHWIRE ID="78:1:189:162" --><A HREF="/cgi/external_ref?access_num=2531847&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B163"><!-- comment for mosaic --></a>
<P>163. &nbsp; 

GLAHN, R<font size=-1>. </font>P<font size=-1>.</font>,
M<font size=-1>. </font>J<font size=-1>.</font> ONSGARD,
G<font size=-1>. </font>M<font size=-1>.</font> TYCE,
S<font size=-1>. </font>L<font size=-1>.</font> CHINNOW,
F<font size=-1>. </font>G<font size=-1>.</font> KNOX,
 <font size=-1>AND</font> T<font size=-1>. </font>P<font size=-1>.</font> DOUSA.



Autocrine/paracrine regulation of renal Na<SUP>+</SUP>-phosphate co-transport by dopamine.
<I>Am. J.&nbsp;Physiol.</I>
264(<I>Renal Fluid Electrolyte Physiol.</I> 33): F618-F622, 1993<!-- HIGHWIRE ID="78:1:189:163" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=264/4/F618" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B164"><!-- comment for mosaic --></a>
<P>164. &nbsp; 

GOLDBERG, L<font size=-1>. </font>I<font size=-1>.</font>,
R<font size=-1>. </font>H<font size=-1>.</font> M<font size=-1>C</font>DONALD,
 <font size=-1>AND</font> A<font size=-1>. </font>M<font size=-1>.</font> ZIMMERMAN.



Sodium diuresis produced by dopamine in patients with congestive heart failure.
<I>N. Engl. J.&nbsp;Med.</I>
269: 1060-1064, 1963<!-- HIGHWIRE ID="78:1:189:164" --><!-- /HIGHWIRE -->.</P>
<a name="B165"><!-- comment for mosaic --></a>
<P>165. &nbsp; 

GOLDBERG, L<font size=-1>. </font>I<font size=-1>.</font>,
 <font size=-1>AND</font> S<font size=-1>. </font>I<font size=-1>.</font> RAJFER.



Dopamine receptors: applications in clinical cardiology.
<I>Circulation</I>
72: 245-248, 1985<!-- HIGHWIRE ID="78:1:189:165" --><A HREF="/cgi/external_ref?access_num=2860983&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B166"><!-- comment for mosaic --></a>
<P>166. &nbsp; 

GOLDBERG, L<font size=-1>. </font>I<font size=-1>.</font>,
P<font size=-1>. </font>H<font size=-1>.</font> VOLKMAN,
 <font size=-1>AND</font> J<font size=-1>. </font>D<font size=-1>.</font> KOHLI.



A comparison of the vascular dopamine receptors with other dopamine receptors.
<I>Annu. Rev. Pharmacol. Toxicol.</I>
18: 57-79, 1978<!-- HIGHWIRE ID="78:1:189:166" --><A HREF="/cgi/external_ref?access_num=348069&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B167"><!-- comment for mosaic --></a>
<P>167. &nbsp; 

GOLDMAN, D<font size=-1>.</font>.



Recent developments in alcoholism: genetic transmission.
<I>Recent Dev. Alcohol</I>
11: 231-248, 1993<!-- HIGHWIRE ID="78:1:189:167" --><A HREF="/cgi/external_ref?access_num=8234925&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B168"><!-- comment for mosaic --></a>
<P>168. &nbsp; 

GRANDY, D<font size=-1>. </font>K<font size=-1>.</font>,
M<font size=-1>.</font> LITT,
J<font size=-1>. </font>R<font size=-1>.</font> ALLEN,
J<font size=-1>. </font>R<font size=-1>.</font> BUNZOW,
M<font size=-1>. </font>A<font size=-1>.</font> MARCHIONNI,
H<font size=-1>.</font> MAKAM,
L<font size=-1>.</font> REED,
R<font size=-1>. </font>E<font size=-1>.</font> MAGENIS,
 <font size=-1>AND</font> O<font size=-1>.</font> CIVELLI.



The human dopamine D<SUB>2</SUB> receptor gene is located on chromosome 11&nbsp;at q22-23 and identifies a Taq RFLP.
<I>Am. J.&nbsp;Hum. Genet.</I>
45: 778-785, 1989<!-- HIGHWIRE ID="78:1:189:168" --><A HREF="/cgi/external_ref?access_num=2573278&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B169"><!-- comment for mosaic --></a>
<P>169. &nbsp; 

GRANDY, D<font size=-1>. </font>K<font size=-1>.</font>,
M<font size=-1>. </font>A<font size=-1>.</font> MARCHIONNI,
H<font size=-1>.</font> MAKAM,
R<font size=-1>. </font>E<font size=-1>.</font> STOFKO,
M<font size=-1>.</font> ALFANO,
L<font size=-1>.</font> FROTHINGHAM,
J<font size=-1>. </font>B<font size=-1>.</font> FISCHER,
K<font size=-1>. </font>J<font size=-1>.</font> BURKE<font size=-1>-</font>HOWIE,
J<font size=-1>. </font>R<font size=-1>.</font> BUNZOW,
 <font size=-1>AND</font> A<font size=-1>. </font>C<font size=-1>.</font> SERVER.



Cloning of the cDNA and gene for a human D<SUB>2</SUB> dopamine receptor.
<I>Proc. Natl. Acad. Sci. USA</I>
86: 9762-9766, 1989<!-- HIGHWIRE ID="78:1:189:169" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=86/24/9762" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B170"><!-- comment for mosaic --></a>
<P>170. &nbsp; 

GRANDY, D<font size=-1>. </font>K<font size=-1>.</font>,
Y<font size=-1>.</font> ZHANG,
C<font size=-1>.</font> BOUVIER,
Q<font size=-1>.-</font>Y<font size=-1>.</font> ZHOU,
R<font size=-1>. </font>A<font size=-1>.</font> JOHNSON,
L<font size=-1>.</font> ALLEN,
K<font size=-1>.</font> BUCK,
J<font size=-1>. </font>R<font size=-1>.</font> BUNZOW,
J<font size=-1>.</font> SALON,
 <font size=-1>AND</font> O<font size=-1>.</font> CIVELLI.



Multiple human D<SUB>5</SUB> dopamine receptor genes: a functional receptor and two pseudogenes.
<I>Proc. Natl. Acad. Sci. USA</I>
88: 9175-9179, 1991<!-- HIGHWIRE ID="78:1:189:170" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=88/20/9175" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B171"><!-- comment for mosaic --></a>
<P>171. &nbsp; 

GRAYBIEL, A<font size=-1>. </font>M<font size=-1>.</font>,
R<font size=-1>.</font> MORATALLA,
 <font size=-1>AND</font> H<font size=-1>. </font>A<font size=-1>.</font> ROBERTSON.



Amphetamine and cocaine induce drug-specific activation of the c-<I>fos</I> gene in striosome-matrix compartments and limbic subdivisions of the striatum.
<I>Proc. Natl. Acad. Sci. USA</I>
87: 6912-6916, 1990<!-- HIGHWIRE ID="78:1:189:171" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=87/17/6912" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B172"><!-- comment for mosaic --></a>
<P>172. &nbsp; 

GREIF, G<font size=-1>. </font>J<font size=-1>.</font>,
Y<font size=-1>.-</font>J<font size=-1>.</font> LIN,
J<font size=-1>.-</font>C<font size=-1>.</font> LIU,
 <font size=-1>AND</font> J<font size=-1>. </font>E<font size=-1>.</font> FREEDMAN.



Dopamine-modulated potassium currents on rat striatal neurons: specific activation and cellular expression.
<I>J. Neurosci.</I>
15: 4533-4544, 1995<!-- HIGHWIRE ID="78:1:189:172" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jneuro&resid=15/6/4533" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B173"><!-- comment for mosaic --></a>
<P>173. &nbsp; 

GRENADER, A<font size=-1>.</font>,
 <font size=-1>AND</font> D<font size=-1>. </font>P<font size=-1>.</font> HEALY.



Locally formed dopamine stimulates cAMP accumulation in LLC-PK<SUB>1</SUB> cells via a DA<SUB>1</SUB> dopamine receptor.
<I>Am. J.&nbsp;Physiol.</I>
260(<I>Renal Fluid Electrolyte Physiol.</I> 29): F906-F912, 1991<!-- HIGHWIRE ID="78:1:189:173" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=260/6/F906" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B174"><!-- comment for mosaic --></a>
<P>174. &nbsp; 

GRENADER, A<font size=-1>. </font>C<font size=-1>.</font>,
D<font size=-1>. </font>A<font size=-1>.</font> O<font size=-1>'</font>ROURKE,
 <font size=-1>AND</font> D<font size=-1>. </font>P<font size=-1>.</font> HEALY.



Cloning of the porcine D<SUB>1a</SUB> dopamine receptor gene expressed in renal epithelial LLC-PK<SUB>1</SUB> cells.
<I>Am. J.&nbsp;Physiol.</I>
268(<I>Renal Fluid Electrolyte Physiol.</I> 37): F423-F434, 1995<!-- HIGHWIRE ID="78:1:189:174" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=268/3/F423" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B175"><!-- comment for mosaic --></a>
<P>175. &nbsp; 

GUIRAMAND, J<font size=-1>.</font>,
J<font size=-1>. </font>P<font size=-1>.</font> MONTMAYEUR,
J<font size=-1>.</font> CERALINE,
M<font size=-1>.</font> BHATIA,
 <font size=-1>AND</font> E<font size=-1>.</font> BORRELLI.



Alternative splicing of the dopamine D<SUB>2</SUB> receptor directs specificity of coupling to G proteins.
<I>J. Biol. Chem.</I>
270: 7354-7358, 1995<!-- HIGHWIRE ID="78:1:189:175" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=270/13/7354" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B176"><!-- comment for mosaic --></a>
<P>176. &nbsp; 

GURICH, R<font size=-1>. </font>W<font size=-1>.</font>,
 <font size=-1>AND</font> R<font size=-1>. </font>E<font size=-1>.</font> BEACH.



Abnormal regulation of renal proximal tubule Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase by G proteins in spontaneously hypertensive rats.
<I>Am. J.&nbsp;Physiol.</I>
267(<I>Renal Fluid Electrolyte Physiol.</I> 36): F1069-F1075, 1994<!-- HIGHWIRE ID="78:1:189:176" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=267/6/F1069" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B177"><!-- comment for mosaic --></a>
<P>177. &nbsp; 

HANSELL, P<font size=-1>.</font>,
 <font size=-1>AND</font> A<font size=-1>.</font> FASCHING.



The effect of dopamine receptor blockade on natriuresis is dependent on the degree of hypervolemia.
<I>Kidney Int.</I>
39: 253-258, 1991<!-- HIGHWIRE ID="78:1:189:177" --><A HREF="/cgi/external_ref?access_num=2002639&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B178"><!-- comment for mosaic --></a>
<P>178. &nbsp; 

HANSON, G<font size=-1>.</font>,
L<font size=-1>.</font> ALPHS,
S<font size=-1>.</font> PRADHAN,
 <font size=-1>AND</font> W<font size=-1>.</font> LOVENBERG.



Response of striatonigral substance P systems to a dopamine receptor agonist and antagonist.
<I>Neuropharmacology</I>
20: 541-548, 1981<!-- HIGHWIRE ID="78:1:189:178" --><A HREF="/cgi/external_ref?access_num=6165922&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B179"><!-- comment for mosaic --></a>
<P>179. &nbsp; 

HANSON, G<font size=-1>. </font>R<font size=-1>.</font>,
K<font size=-1>. </font>M<font size=-1>.</font> MERCHANT,
A<font size=-1>. </font>A<font size=-1>.</font> LETTER,
L<font size=-1>.</font> BUSH,
 <font size=-1>AND</font> J<font size=-1>. </font>W<font size=-1>.</font> GIBB.



Methamphetamine-induced changes in the striatal-nigral dynorphin system: role of D-1 and D-2 receptors.
<I>Eur. J.&nbsp;Pharmacol.</I>
144: 245-246, 1987<!-- HIGHWIRE ID="78:1:189:179" --><A HREF="/cgi/external_ref?access_num=2893739&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B180"><!-- comment for mosaic --></a>
<P>180. &nbsp; 

HARVEY, J<font size=-1>. </font>N<font size=-1>.</font>,
I<font size=-1>. </font>F<font size=-1>.</font> CASSON,
A<font size=-1>. </font>D<font size=-1>.</font> CLAYDEN,
G<font size=-1>. </font>F<font size=-1>.</font> COPE,
C<font size=-1>. </font>M<font size=-1>.</font> PERKINS,
 <font size=-1>AND</font> M<font size=-1>. </font>R<font size=-1>.</font> LEE.



A paradoxical fall in urine dopamine output when patients with essential hypertension are given added dietary salt.
<I>Clin. Sci.</I>
67: 83-88, 1984<!-- HIGHWIRE ID="78:1:189:180" --><A HREF="/cgi/external_ref?access_num=6375940&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B181"><!-- comment for mosaic --></a>
<P>181. &nbsp; 

HEBERT, R<font size=-1>. </font>L<font size=-1>.</font>,
H<font size=-1>. </font>R<font size=-1>.</font> JACOBSON,
 <font size=-1>AND</font> M<font size=-1>. </font>D<font size=-1>.</font> BREYER.



Prostaglandin E<SUB>2</SUB> inhibits sodium transport in rabbit cortical collecting duct by increasing intracellular calcium.
<I>J. Clin. Invest.</I>
87: 1992-1998, 1991<!-- HIGHWIRE ID="78:1:189:181" --><A HREF="/cgi/external_ref?access_num=1645747&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B182"><!-- comment for mosaic --></a>
<P>182. &nbsp; 

HEGDE, S<font size=-1>. </font>S<font size=-1>.</font>,
C<font size=-1>. </font>J<font size=-1>.</font> CHEN,
 <font size=-1>AND</font> M<font size=-1>. </font>F<font size=-1>.</font> LOKHANDWALA.



Involvement of endogenous dopamine and DA-1 receptors in the renal effects of atrial natriuretic factor in rats.
<I>Clin. Exp. Hypertens.</I>
13: 357-369, 1991<!-- HIGHWIRE ID="78:1:189:182" --><!-- /HIGHWIRE -->.</P>
<a name="B183"><!-- comment for mosaic --></a>
<P>183. &nbsp; 

HEGDE, S<font size=-1>. </font>S<font size=-1>.</font>,
A<font size=-1>. </font>L<font size=-1>.</font> JADHAV,
 <font size=-1>AND</font> M<font size=-1>. </font>F<font size=-1>.</font> LOCKHANDWALA.



Role of kidney dopamine in the natriuretic response to volume expansion in rats.
<I>Hypertension</I>
13: 828-834, 1989<!-- HIGHWIRE ID="78:1:189:183" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=hypertensionaha&resid=13/6/828" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B184"><!-- comment for mosaic --></a>
<P>184. &nbsp; 

HEGDE, S<font size=-1>. </font>S<font size=-1>.</font>,
 <font size=-1>AND</font> M<font size=-1>. </font>F<font size=-1>.</font> LOCKHANDWALA.



Renal dopamine and sodium excretion.
<I>Am. J.&nbsp;Hypertens.</I>
3, <I>Suppl.</I>: 78S-81S, 1990<!-- HIGHWIRE ID="78:1:189:184" --><A HREF="/cgi/external_ref?access_num=1974446&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B185"><!-- comment for mosaic --></a>
<P>185. &nbsp; 

HEGDE, S<font size=-1>. </font>S<font size=-1>.</font>,
 <font size=-1>AND</font> M<font size=-1>. </font>F<font size=-1>.</font> LOCKHANDWALA.



Stimulation of renal dopamine production during acute volume expansion requires the presence of intact vagi but not renal nerves.
<I>Clin. Exp. Hypertens.</I>
14: 1169-1188, 1992<!-- HIGHWIRE ID="78:1:189:185" --><!-- /HIGHWIRE -->.</P>
<a name="B186"><!-- comment for mosaic --></a>
<P>186. &nbsp; 

HEGDE, S<font size=-1>. </font>S<font size=-1>.</font>,
A<font size=-1>.</font> RICCI,
F<font size=-1>.</font> AMENTA,
 <font size=-1>AND</font> M<font size=-1>. </font>F<font size=-1>.</font> LOCKHANDWALA.



Evidence from functional and autoradiographic studies for the presence of tubular dopamine-1 receptors and their involvement in the renal effects of fenoldopam.
<I>J. Pharmacol. Exp. Ther.</I>
251: 1237-1245, 1989<!-- HIGHWIRE ID="78:1:189:186" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jpet&resid=251/3/1237" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B187"><!-- comment for mosaic --></a>
<P>187. &nbsp; 

HERSCH, S<font size=-1>. </font>M<font size=-1>.</font>,
B<font size=-1>. </font>J<font size=-1>.</font> CILIAX,
C<font size=-1>. </font>A<font size=-1>.</font> GUTEKUNST,
H<font size=-1>. </font>D<font size=-1>.</font> REES,
C<font size=-1>. </font>J<font size=-1>.</font> HEILMAN,
K<font size=-1>. </font>K<font size=-1>.</font> YUNG,
J<font size=-1>. </font>P<font size=-1>.</font> BOLAM,
E<font size=-1>.</font> INCE,
H<font size=-1>.</font> YI,
 <font size=-1>AND</font> A<font size=-1>. </font>I<font size=-1>.</font> LEVEY.



Electron microscopic analysis of D<SUB>1</SUB> and D<SUB>2</SUB> dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents.
<I>J. Neurosci.</I>
15: 5222-5237, 1995<!-- HIGHWIRE ID="78:1:189:187" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jneuro&resid=15/7/5222" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B188"><!-- comment for mosaic --></a>
<P>188. &nbsp; 

HERVE, D<font size=-1>.</font>,
M<font size=-1>.</font> LEVI<font size=-1>-</font>STRAUSS,
I<font size=-1>.</font> MAREY<font size=-1>-</font>SEMPER,
C<font size=-1>.</font> VERNEY,
J<font size=-1>.-</font>P<font size=-1>.</font> TASSIN,
J<font size=-1>.</font> GLOWINSKI,
 <font size=-1>AND</font> J<font size=-1>.-</font>A<font size=-1>.</font> GIRAULT.



G<SUB>olf</SUB> and G<SUB>s</SUB> in rat basal ganglia: possible involvement of G<SUB>olf</SUB> in the coupling of dopamine D<SUB>1</SUB> receptor with adenylyl cyclase.
<I>J. Neurosci.</I>
13: 2237-2248, 1993<!-- HIGHWIRE ID="78:1:189:188" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jneuro&resid=13/5/2237" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B189"><!-- comment for mosaic --></a>
<P>189. &nbsp; 

HIBERT, M<font size=-1>. </font>F<font size=-1>.</font>,
S<font size=-1>.</font> TRUMPP<font size=-1>-</font>KALLMEYER,
A<font size=-1>.</font> BRUINVELS,
 <font size=-1>AND</font> J<font size=-1>.</font> HOFLACK.



Three-dimensional models of neurotransmitter G-binding protein-coupled receptors.
<I>Mol. Pharmacol.</I>
40: 8-15, 1992<!-- HIGHWIRE ID="78:1:189:189" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=40/1/8" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B190"><!-- comment for mosaic --></a>
<P>190. &nbsp; 

HIBERT, M<font size=-1>. </font>F<font size=-1>.</font>,
S<font size=-1>.</font> TRUMPP<font size=-1>-</font>KALLMEYER,
J<font size=-1>.</font> HOFLACK,
 <font size=-1>AND</font> A<font size=-1>.</font> BRUINVELS.



This is not a G protein-coupled receptor.
<I>Trends Pharmacol. Sci.</I>
14: 7-12, 1993<!-- HIGHWIRE ID="78:1:189:190" --><A HREF="/cgi/external_ref?access_num=8095116&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B191"><!-- comment for mosaic --></a>
<P>191. &nbsp; 

HOLLENBERG, N<font size=-1>. </font>K<font size=-1>.</font>,
W<font size=-1>. </font>R<font size=-1>.</font> CHENITZ,
D<font size=-1>. </font>F<font size=-1>.</font> ADAMS,
 <font size=-1>AND</font> G<font size=-1>. </font>H<font size=-1>.</font> WILLIAMS.



Reciprocal influence of salt intake on adrenal glomerulosa and renal vascular responses to angiotensin II in normal man.
<I>J. Clin. Invest.</I>
54: 34-38, 1974<!-- HIGHWIRE ID="78:1:189:191" --><A HREF="/cgi/external_ref?access_num=4365595&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B192"><!-- comment for mosaic --></a>
<P>192. &nbsp; 

HOLLIS, C<font size=-1>. </font>M<font size=-1>.</font>,
J<font size=-1>. </font>D<font size=-1>.</font> TURNER,
 <font size=-1>AND</font> P<font size=-1>. </font>G<font size=-1>.</font> STRANGE.



Binding of [<SUP>3</SUP>H]SCH23390 to a non-dopaminergic site in bovine kidney.
<I>Biochem. Pharmacol.</I>
43: 1947-1955, 1992<!-- HIGHWIRE ID="78:1:189:192" --><A HREF="/cgi/external_ref?access_num=1375829&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B193"><!-- comment for mosaic --></a>
<P>193. &nbsp; 

HOPE, B<font size=-1>.</font>,
B<font size=-1>.</font> KOSOFSKY,
S<font size=-1>. </font>E<font size=-1>.</font> HYMAN,
 <font size=-1>AND</font> E<font size=-1>. </font>J<font size=-1>.</font> NESTLER.



Regulation of immediate-early genes expression and AP-1 binding in the rat nucleus accumbens by chronic cocaine.
<I>Proc. Natl. Acad. Sci. USA</I>
89: 5764-5768, 1992<!-- HIGHWIRE ID="78:1:189:193" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=89/13/5764" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B194"><!-- comment for mosaic --></a>
<P>194. &nbsp; 

HORIUCHI, A<font size=-1>.</font>,
F<font size=-1>. </font>E<font size=-1>.</font> ALBRECHT,
G<font size=-1>. </font>M<font size=-1>.</font> EISNER,
P<font size=-1>. </font>A<font size=-1>.</font> JOSE,
 <font size=-1>AND</font> R<font size=-1>. </font>A<font size=-1>.</font> FELDER.



Renal dopamine receptors and pre- and post-cAMP-mediated Na<SUP>+</SUP> transport defect in spontaneously hypertensive rats.
<I>Am. J.&nbsp;Physiol.</I>
263(<I>Renal Fluid Electrolyte Physiol.</I> 32): F1105-F1111, 1992<!-- HIGHWIRE ID="78:1:189:194" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=263/6/F1105" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B195"><!-- comment for mosaic --></a>
<P>195. &nbsp; 

HORIUCHI, A<font size=-1>.</font>,
K<font size=-1>.</font> TAKEYASU,
M<font size=-1>. </font>M<font size=-1>.</font> MOURADIAN,
P<font size=-1>. </font>A<font size=-1>.</font> JOSE,
 <font size=-1>AND</font> R<font size=-1>. </font>A<font size=-1>.</font> FELDER.



D<SUB>1A</SUB> dopamine receptor stimulation inhibits Na<SUP>+</SUP>/K<SUP>+</SUP>-ATPase activity through protein kinase A.
<I>Mol. Pharmacol.</I>
43: 281-285, 1993<!-- HIGHWIRE ID="78:1:189:195" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=43/2/281" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B196"><!-- comment for mosaic --></a>
<P>196. &nbsp; 

HORSTMAN, D<font size=-1>. </font>A<font size=-1>.</font>,
S<font size=-1>.</font> BRANDON,
A<font size=-1>.</font> WILSON,
C<font size=-1>.</font> GUYER,
E<font size=-1>.</font> CRAGOE,
 <font size=-1>AND</font> L<font size=-1>.</font> LIMBIRD.



An aspartate conserved among G-protein receptors confers allosteric regulation of <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "><SUB>2</SUB> adrenergic receptors by sodium.
<I>J. Biol. Chem.</I>
265: 21590-21595, 1990<!-- HIGHWIRE ID="78:1:189:196" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=265/35/21590" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B197"><!-- comment for mosaic --></a>
<P>197. &nbsp; 

HUANG, Q<font size=-1>.</font>,
D<font size=-1>.</font> ZHOU,
K<font size=-1>.</font> CHASE,
J<font size=-1>. </font>F<font size=-1>.</font> GUSELLA,
N<font size=-1>.</font> ARONIN,
 <font size=-1>AND</font> M<font size=-1>.</font> DIFIGLIA.



Immunohistochemical localization of the D<SUB>1</SUB> dopamine receptor in rat brain reveals its axonal transport, pre- and post-synaptic localization, and prevalence in the basal ganglia, limbic system and thalamic reticular nucleus.
<I>Proc. Natl. Acad Sci. USA</I>
89: 11988-11992, 1992<!-- HIGHWIRE ID="78:1:189:197" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=89/24/11988" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B198"><!-- comment for mosaic --></a>
<P>198. &nbsp; 

HUBBARD, P<font size=-1>. </font>C<font size=-1>.</font>,
 <font size=-1>AND</font> I<font size=-1>. </font>W<font size=-1>.</font> HENDERSON.



Renal dopamine and the tubular handling of sodium.
<I>J. Mol. Endocrinol.</I>
14: 139-155, 1995<!-- HIGHWIRE ID="78:1:189:198" --><A HREF="/cgi/external_ref?access_num=7619204&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B199"><!-- comment for mosaic --></a>
<P>199. &nbsp; 

HUGHES, A<font size=-1>.</font>,
M<font size=-1>.</font> SCHACHTER,
 <font size=-1>AND</font> P<font size=-1>.</font> SEVER.



Autoradiographic localization of dopamine D<SUB>1</SUB> receptors in human renal cortex.
<I>Biochem. Soc. Trans.</I>
17: 918-919, 1989<!-- HIGHWIRE ID="78:1:189:199" --><!-- /HIGHWIRE -->.</P>
<a name="B200"><!-- comment for mosaic --></a>
<P>200. &nbsp; 

HUGHES, A<font size=-1>.</font>,
 <font size=-1>AND</font> P<font size=-1>.</font> SEVER.



Specific binding of [<SUP>125</SUP>I]SCH 23982,&nbsp;a selective dopamine (D<SUB>1</SUB>) receptor ligand to plasma membranes derived from human kidney cortex.
<I>Biochem. Pharmacol.</I>
38: 781-785, 1989<!-- HIGHWIRE ID="78:1:189:200" --><A HREF="/cgi/external_ref?access_num=2522780&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B201"><!-- comment for mosaic --></a>
<P>201. &nbsp; 

HUGHES, A<font size=-1>. </font>D<font size=-1>.</font>,
S<font size=-1>. </font>A<font size=-1>.</font> THOM,
N<font size=-1>. </font>M<font size=-1>.</font> WOODALL,
D<font size=-1>.</font> REDMAN,
 <font size=-1>AND</font> P<font size=-1>. </font>S<font size=-1>.</font> SEVER.



Dopamine produces forearm vasodilatation following alpha-adrenoceptor blockade by an action on vascular dopamine (DA<SUB>1</SUB>) receptors in man.
<I>J. Hypertens.</I>
5: 337-340, 1987<!-- HIGHWIRE ID="78:1:189:201" --><A HREF="/cgi/external_ref?access_num=2886541&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B202"><!-- comment for mosaic --></a>
<P>202. &nbsp; 

HUGHES, J<font size=-1>. </font>M<font size=-1>.</font>,
T<font size=-1>. </font>R<font size=-1>.</font> BECK,
 <font size=-1>AND</font> C<font size=-1>. </font>E<font size=-1>.</font> ROSE.



J<font size=-1>R</font>., <font size=-1>AND</font> R.&nbsp;M.&nbsp;CAREY. Selective dopamine-1 receptor stimulation produces natriuresis by a direct tubular action.
<I>J. Hypertens.</I>
4, <I>Suppl</I>. 6: S106-S108, 1986<!-- HIGHWIRE ID="78:1:189:202" --><!-- /HIGHWIRE -->.</P>
<a name="B203"><!-- comment for mosaic --></a>
<P>203. &nbsp; 

HUNTLEY, G<font size=-1>. </font>W<font size=-1>.</font>,
J<font size=-1>. </font>W<font size=-1>.</font> MORRISON,
A<font size=-1>.</font> PRIKHOZHAN,
 <font size=-1>AND</font> S<font size=-1>. </font>C<font size=-1>.</font> SELFON.



Localization of multiple dopamine receptor subtype mRNAs in human and monkey motor cortex and striatum.
<I>Mol. Brain Res.</I>
15: 181-188, 1992.<!-- HIGHWIRE ID="78:1:189:203" --><A HREF="/cgi/external_ref?access_num=1331674&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --></P>
<a name="B204"><!-- comment for mosaic --></a>
<P>204. &nbsp; 

HUO, T<font size=-1>. </font>L<font size=-1>.</font>,
A<font size=-1>.</font> GRENADER,
P<font size=-1>.</font> BLANDINA,
 <font size=-1>AND</font> D<font size=-1>. </font>P<font size=-1>.</font> HEALY.



Prostaglandin E<SUB>2</SUB> production in rat IMCD cells. II. Possible role for locally formed dopamine.
<I>Am. J.&nbsp;Physiol.</I>
261(<I>Renal Fluid Electrolyte Physiol.</I> 30): F655-F662, 1991<!-- HIGHWIRE ID="78:1:189:204" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=261/4/F655" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B205"><!-- comment for mosaic --></a>
<P>205. &nbsp; 

HUO, T<font size=-1>.</font>,
 <font size=-1>AND</font> D<font size=-1>. </font>P<font size=-1>.</font> HEALY.



Autoradiographic localization of dopamine DA<SUB>1</SUB> receptors in rat kidney with [<SUP>3</SUP>H]SCH 23390.
<I>Am. J.&nbsp;Physiol.</I>
257(<I>Renal Fluid Electrolyte Physiol.</I> 26): F414-F423, 1989<!-- HIGHWIRE ID="78:1:189:205" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=257/3/F414" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B206"><!-- comment for mosaic --></a>
<P>206. &nbsp; 

HUO, T<font size=-1>. </font>L<font size=-1>.</font>,
 <font size=-1>AND</font> D<font size=-1>. </font>P<font size=-1>.</font> HEALY.



Prostaglandin E<SUB>2</SUB> production in rat IMCD cells. I.&nbsp;Stimulation by dopamine.
<I>Am. J.&nbsp;Physiol.</I>
261(<I>Renal Fluid Electrolyte Physiol.</I> 30): F647-F654, 1991<!-- HIGHWIRE ID="78:1:189:206" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=261/4/F647" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B207"><!-- comment for mosaic --></a>
<P>207. &nbsp; 

HUO, T<font size=-1>.</font>,
M<font size=-1>. </font>Q<font size=-1>.</font> YE,
 <font size=-1>AND</font> D<font size=-1>. </font>P<font size=-1>.</font> HEALY.



Characterization of a dopamine receptor (DA<SUB>2</SUB>K) in the kidney inner medulla.
<I>Proc. Natl. Acad. Sci. USA</I>
88: 3170-3174, 1991<!-- HIGHWIRE ID="78:1:189:207" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=88/8/3170" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B208"><!-- comment for mosaic --></a>
<P>208. &nbsp; 

IIMURA, O<font size=-1>.</font>,
 <font size=-1>AND</font> K<font size=-1>.</font> SHINAMOTO.



Suppressed dopaminergic activity and water sodium handling in the kidneys of the prehypertensive stage of hypertension.
<I>J. Auton. Pharmacol.</I>
10, <I>Suppl</I>. 1: S73-S77, 1990<!-- HIGHWIRE ID="78:1:189:208" --><A HREF="/cgi/external_ref?access_num=2098378&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B209"><!-- comment for mosaic --></a>
<P>209. &nbsp; 

IIMURA, O<font size=-1>.</font>,
K<font size=-1>.</font> SHINAMOTO,
N<font size=-1>.</font> URA,
M<font size=-1>.</font> NAKAGAWA,
T<font size=-1>.</font> NISHIMIYA,
T<font size=-1>.</font> ANDO,
Y<font size=-1>.</font> YAMAGUCHI,
A<font size=-1>.</font> MASUDA,
H<font size=-1>.</font> OGATA,
S<font size=-1>.</font> SAITO,
I<font size=-1>.</font> YAMAJI,
 <font size=-1>AND</font> S<font size=-1>.</font> FUKUYAMA.



The pathophysiological role of renal dopamine, kallikrein kinin, and prostaglandin systems in essential hypertension.
<I>Agents Actions Suppl.</I>
22: 247-256, 1987<!-- HIGHWIRE ID="78:1:189:209" --><A HREF="/cgi/external_ref?access_num=3324711&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B210"><!-- comment for mosaic --></a>
<P>210. &nbsp; 

INGRAHAM, H<font size=-1>. </font>A<font size=-1>.</font>,
V<font size=-1>. </font>R<font size=-1>.</font> ALBERT,
 <font size=-1>AND</font> R<font size=-1>.</font> CHEN.



A family of POU-domain and Pit-1 tissue-specific transcription factors in pituitary and neuroendocrine development.
<I>Annu. Rev. Physiol.</I>
52: 773-791, 1990<!-- HIGHWIRE ID="78:1:189:210" --><A HREF="/cgi/external_ref?access_num=2184776&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B211"><!-- comment for mosaic --></a>
<P>211. &nbsp; 

ISAAC, J<font size=-1>.</font>,
R<font size=-1>. </font>P<font size=-1>.</font> GLAHN,
M<font size=-1>. </font>M<font size=-1>.</font> APPEL,
M<font size=-1>.</font> ONSGARD,
T<font size=-1>. </font>P<font size=-1>.</font> DOUSA,
 <font size=-1>AND</font> F<font size=-1>. </font>G<font size=-1>.</font> KNOX.



Mechanism of dopamine inhibition of renal phosphate transport.
<I>J. Am. Soc. Nephrol.</I>
2: 1601-1607, 1992<!-- HIGHWIRE ID="78:1:189:211" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jnephrol&resid=2/11/1601" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B212"><!-- comment for mosaic --></a>
<P>212. &nbsp; 

ISRAEL, J<font size=-1>. </font>M<font size=-1>.</font>,
C<font size=-1>.</font> KIRK,
 <font size=-1>AND</font> J<font size=-1>. </font>D<font size=-1>.</font> VINCENT.



Electrophysiological responses to dopamine of rat hypophysial cells in lactotroph-enriched primary cultures.
<I>J. Physiol. (Lond.)</I>
390: 1-22, 1987<!-- HIGHWIRE ID="78:1:189:212" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jphysiol&resid=390/1/1" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B213"><!-- comment for mosaic --></a>
<P>213. &nbsp; 

JABER, M<font size=-1>.</font>,
M<font size=-1>.</font> CADORE,
B<font size=-1>.</font> DUMARTIN,
E<font size=-1>.</font> NORMAND,
L<font size=-1>.</font> STINUS,
 <font size=-1>AND</font> B<font size=-1>.</font> BLOCH.



Acute and chronic amphetamine treatments differently regulate neuropeptide mRNA levels and Fos immunoreactivity in rat striatal neurons.
<I>Neuroscience</I>
65: 1041-1050, 1995<!-- HIGHWIRE ID="78:1:189:213" --><A HREF="/cgi/external_ref?access_num=7617160&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B214"><!-- comment for mosaic --></a>
<P>214. &nbsp; 

JABER, M<font size=-1>.</font>,
M<font size=-1>. </font>C<font size=-1>.</font> FOURNIER,
 <font size=-1>AND</font> B<font size=-1>.</font> BLOCH.



Reserpine treatment stimulates enkephalin and D<SUB>2</SUB> dopamine receptor gene expression in the rat striatum.
<I>Mol. Brain Res.</I>
15: 189-194, 1992.<!-- HIGHWIRE ID="78:1:189:214" --><A HREF="/cgi/external_ref?access_num=1331675&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --></P>
<a name="B215"><!-- comment for mosaic --></a>
<P>215. &nbsp; 

JABER, M<font size=-1>.</font>,
E<font size=-1>.</font> NORMAND,
 <font size=-1>AND</font> B<font size=-1>.</font> BLOCH.



Effect of reserpine treatment on the preproenkephalin mRNA level in the rat striatum: an in situ hybridization study.
<I>Mol. Brain Res.</I>
32: 156-160, 1995.<!-- HIGHWIRE ID="78:1:189:215" --><A HREF="/cgi/external_ref?access_num=7494455&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --></P>
<a name="B216"><!-- comment for mosaic --></a>
<P>216. &nbsp; 

JABER, M<font size=-1>.</font>,
F<font size=-1>.</font> TISON,
M<font size=-1>. </font>C<font size=-1>.</font> FOURNIER,
 <font size=-1>AND</font> B<font size=-1>.</font> BLOCH.



Differential influence of haloperidol and sulpiride on dopamine receptors and peptide mRNA levels in the rat striatum and pituitary.
<I>Mol. Brain Res.</I>
23: 14-20, 1994.<!-- HIGHWIRE ID="78:1:189:216" --><A HREF="/cgi/external_ref?access_num=7518029&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --></P>
<a name="B217"><!-- comment for mosaic --></a>
<P>217. &nbsp; 

JACKSON, D<font size=-1>. </font>M<font size=-1>.</font>,
 <font size=-1>AND</font> A<font size=-1>.</font> WESTLIND<font size=-1>-</font>DANIELSSON.



Dopamine receptors: molecular biology, biochemistry and behavioral aspects.
<I>Pharmacol. Ther.</I>
64: 291-369, 1994<!-- HIGHWIRE ID="78:1:189:217" --><A HREF="/cgi/external_ref?access_num=7878079&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B218"><!-- comment for mosaic --></a>
<P>218. &nbsp; 

JADHAV, A<font size=-1>. </font>L<font size=-1>.</font>,
 <font size=-1>AND</font> Q<font size=-1>.</font> LIU.



DA<SUB>1</SUB> receptor mediated regulation of Na<SUP>+</SUP>-H<SUP>+</SUP> antiport activity in rat renal cortical brush border membrane vesicles.
<I>Clin. Exp. Hypertens.</I>
14: 653-666, 1992<!-- HIGHWIRE ID="78:1:189:218" --><!-- /HIGHWIRE -->.</P>
<a name="B219"><!-- comment for mosaic --></a>
<P>219. &nbsp; 

JADHAV, A<font size=-1>. </font>L<font size=-1>.</font>,
A<font size=-1>.</font> RICCI,
F<font size=-1>.</font> AMENTA,
 <font size=-1>AND</font> M<font size=-1>. </font>F<font size=-1>.</font> LOKHANDWALA.



Renal dopamine and changes in dopamine receptor ligand binding during high sodium intake.
<I>Clin. Exp. Hypertens.</I>
13: 1371-1381, 1991<!-- HIGHWIRE ID="78:1:189:219" --><!-- /HIGHWIRE -->.</P>
<a name="B220"><!-- comment for mosaic --></a>
<P>220. &nbsp; 

JENSEN, S<font size=-1>.</font>,
R<font size=-1>.</font> PLAETKE,
J<font size=-1>.</font> HOLIK,
M<font size=-1>.</font> HOFF,
P<font size=-1>.</font> O<font size=-1>'</font>CONNELL,
F<font size=-1>.</font> REIMHERR,
P<font size=-1>.</font> WENDER,
Q<font size=-1>. </font>Y<font size=-1>.</font> ZHOU,
O<font size=-1>.</font> CIVELLI,
 <font size=-1>AND</font> M<font size=-1>.</font> LITT.



Linkage analysis of the D<SUB>1</SUB> dopamine receptor gene and manic depression in six families Hum.
<I>Heredity</I>
42: 269-275, 1992<!-- HIGHWIRE ID="78:1:189:220" --><!-- /HIGHWIRE -->.</P>
<a name="B221"><!-- comment for mosaic --></a>
<P>221. &nbsp; 

JOSE, P<font size=-1>. </font>A<font size=-1>.</font>,
G<font size=-1>. </font>M<font size=-1>.</font> EISNER,
 <font size=-1>AND</font> R<font size=-1>. </font>A<font size=-1>.</font> FELDER.



Dopamine defect in hypertension.
<I>Pediatr. Nephrol.</I>
7: 859-864, 1993<!-- HIGHWIRE ID="78:1:189:221" --><A HREF="/cgi/external_ref?access_num=8130121&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B222"><!-- comment for mosaic --></a>
<P>222. &nbsp; 

JOSE, P<font size=-1>. </font>A<font size=-1>.</font>,
J<font size=-1>. </font>R<font size=-1>.</font> RAYMOND,
M<font size=-1>. </font>D<font size=-1>.</font> BATES,
A<font size=-1>.</font> APERIA,
R<font size=-1>. </font>A<font size=-1>.</font> FELDER,
 <font size=-1>AND</font> R<font size=-1>. </font>M<font size=-1>.</font> CAREY.



The renal dopamine receptors.
<I>J. Am. Soc. Nephrol.</I>
2: 1265-1278, 1992<!-- HIGHWIRE ID="78:1:189:222" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jnephrol&resid=2/8/1265" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B223"><!-- comment for mosaic --></a>
<P>223. &nbsp; 

KANE, J<font size=-1>. </font>M<font size=-1>.</font>,
 <font size=-1>AND</font> H<font size=-1>. </font>L<font size=-1>.</font> FREEMAN.



Towards more effective antipsychotic treatment.
<I>Br. J.&nbsp;Psychiatry</I>
165: 22-31, 1994<!-- HIGHWIRE ID="78:1:189:223" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=bjprcpsych&resid=165/1/22" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B224"><!-- comment for mosaic --></a>
<P>224. &nbsp; 

KANEDA, Y<font size=-1>.</font>,
 <font size=-1>AND</font> E<font size=-1>.</font> BELLO<font size=-1>-</font>REUSS.



Effect of dopamine on phosphate reabsorption in isolated perfused rabbit proximal tubules.
<I>Miner. Electrolyte Metab.</I>
9: 147-150, 1983<!-- HIGHWIRE ID="78:1:189:224" --><A HREF="/cgi/external_ref?access_num=6877190&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B225"><!-- comment for mosaic --></a>
<P>225. &nbsp; 

KANTERMAN, R<font size=-1>. </font>Y<font size=-1>.</font>,
L<font size=-1>. </font>C<font size=-1>.</font> MAHAN,
E<font size=-1>. </font>M<font size=-1>.</font> BRILEY,
F<font size=-1>. </font>J<font size=-1>.</font> MONSMA,
D<font size=-1>. </font>R<font size=-1>.</font> SIBLEY,
J<font size=-1>.</font> AXELROD,
 <font size=-1>AND</font> C<font size=-1>. </font>C<font size=-1>.</font> FELDER.



Transfected D<SUB>2</SUB> dopamine receptors mediate the potentiation of arachidonic acid release in Chinese hamster ovary cells.
<I>Mol. Pharmacol.</I>
39: 364-369, 1991<!-- HIGHWIRE ID="78:1:189:225" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=39/3/364" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B226"><!-- comment for mosaic --></a>
<P>226. &nbsp; 

KEBABIAN, J<font size=-1>. </font>W<font size=-1>.</font>,
 <font size=-1>AND</font> D<font size=-1>. </font>B<font size=-1>.</font> CALNE.



Multiple receptors for dopamine.
<I>Nature</I>
277: 93-96, 1979<!-- HIGHWIRE ID="78:1:189:226" --><A HREF="/cgi/external_ref?access_num=215920&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B227"><!-- comment for mosaic --></a>
<P>227. &nbsp; 

KEEFE, K<font size=-1>. </font>A<font size=-1>.</font>,
 <font size=-1>AND</font> C<font size=-1>. </font>R<font size=-1>.</font> GERFEN.



D<SUB>1</SUB>-D<SUB>2</SUB> dopamine receptor synergy in striatum: effects of intrastriatal infusions of dopamine agonists and antagonists on immediate early gene expression.
<I>Neuroscience</I>
66: 903-913, 1995<!-- HIGHWIRE ID="78:1:189:227" --><A HREF="/cgi/external_ref?access_num=7651617&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B228"><!-- comment for mosaic --></a>
<P>228. &nbsp; 

KELSOE, J<font size=-1>. </font>R<font size=-1>.</font>,
H<font size=-1>.</font> KRISTBJANARSON,
P<font size=-1>.</font> BERGESCH,
P<font size=-1>.</font> SHILLING,
S<font size=-1>.</font> HIRSCH,
A<font size=-1>.</font> MIROW,
A<font size=-1>.</font> MOISES,
H<font size=-1>. </font>W<font size=-1>.</font> MOISES,
T<font size=-1>.</font> HELGASON,
J<font size=-1>. </font>C<font size=-1>.</font> GILLINAND,
 <font size=-1>AND</font> J<font size=-1>. </font>A<font size=-1>.</font> EGELAND.



A genetic linkage study of bipolar disorder and 13&nbsp;markers on chromosome 11&nbsp;including the D<SUB>2</SUB> dopamine receptor.
<I>Neuropsychopharmacology</I>
9: 293-301, 1993<!-- HIGHWIRE ID="78:1:189:228" --><A HREF="/cgi/external_ref?access_num=7905737&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B229"><!-- comment for mosaic --></a>
<P>229. &nbsp; 

KIMURA, K<font size=-1>.</font>,
S<font size=-1>.</font> SELA,
C<font size=-1>.</font> BOUVIER,
D<font size=-1>. </font>K<font size=-1>.</font> GRAND,
 <font size=-1>AND</font> A<font size=-1>.</font> SIDHU.



Differential coupling of D<SUB>1</SUB> and D<SUB>5</SUB> dopamine receptors to guanine nucleotide binding proteins in transfected GH<SUB>4</SUB>C<SUB>1</SUB> rat somatornammotrophic cells.
<I>J. Neurochem.</I>
64: 2118-2124, 1995<!-- HIGHWIRE ID="78:1:189:229" --><A HREF="/cgi/external_ref?access_num=7722495&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B230"><!-- comment for mosaic --></a>
<P>230. &nbsp; 

KIMURA, K<font size=-1>.</font>,
B<font size=-1>. </font>H<font size=-1>.</font> WHITE,
 <font size=-1>AND</font> A<font size=-1>.</font> SIDHU.



Coupling of human D<SUB>1</SUB> dopamine receptors to different guanine nucleotide binding proteins. Evidence that D<SUB>1</SUB> dopamine receptors can couple to both G<SUB>s</SUB> and G<SUB>o</SUB> .
<I>J. Biol. Chem.</I>
270: 14672-14678, 1995<!-- HIGHWIRE ID="78:1:189:230" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=270/24/14672" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B231"><!-- comment for mosaic --></a>
<P>231. &nbsp; 

KINOSHITA, S<font size=-1>.</font>,
A<font size=-1>.</font> SIDHU,
 <font size=-1>AND</font> R<font size=-1>. </font>A<font size=-1>.</font> FELDER.



Defective dopamine-1 receptor adenylate cyclase coupling in the proximal convoluted tubule from the spontaneously hypertensive rat.
<I>J. Clin. Invest.</I>
84: 1849-1856, 1989<!-- HIGHWIRE ID="78:1:189:231" --><A HREF="/cgi/external_ref?access_num=2574187&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B232"><!-- comment for mosaic --></a>
<P>232. &nbsp; 

KITAI, S<font size=-1>. </font>T<font size=-1>.</font>,
 <font size=-1>AND</font> D<font size=-1>. </font>J<font size=-1>.</font> SURMEIER.



Cholinergic and dopaminergic modulation of potassium conductances in neostriatal neurons.
<I>Adv. Neurol.</I>
60: 40-52, 1993<!-- HIGHWIRE ID="78:1:189:232" --><A HREF="/cgi/external_ref?access_num=8380527&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B233"><!-- comment for mosaic --></a>
<P>233. &nbsp; 

KJELSBERG, M<font size=-1>. </font>A<font size=-1>.</font>,
S<font size=-1>.</font> COTECCHIA,
J<font size=-1>.</font> OSTROWSKI,
M<font size=-1>. </font>G<font size=-1>.</font> CARON,
 <font size=-1>AND</font> R<font size=-1>. </font>J<font size=-1>.</font> LEFKOWITZ.



Constitutive activation of the <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "><SUB>1B</SUB>-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region that constrains receptor activation.
<I>J. Biol. Chem.</I>
267: 1430-1433, 1992<!-- HIGHWIRE ID="78:1:189:233" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=267/3/1430" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B234"><!-- comment for mosaic --></a>
<P>234. &nbsp; 

KORNETSKY, C<font size=-1>.</font>,
 <font size=-1>AND</font> R<font size=-1>. </font>U<font size=-1>.</font> ESPOSITO.



Reward and detection thresholds for brain stimulation: dissociative effects of cocaine.
<I>Brain Res.</I>
209: 496-500, 1981<!-- HIGHWIRE ID="78:1:189:234" --><A HREF="/cgi/external_ref?access_num=6971689&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B235"><!-- comment for mosaic --></a>
<P>235. &nbsp; 

KOSHIKAWA, N<font size=-1>.</font>.



Role of the nucleus accumbens and the striatum in the production of turning behavior in intact rats.
<I>Rev. Neurosci.</I>
5: 331-346, 1994<!-- HIGHWIRE ID="78:1:189:235" --><A HREF="/cgi/external_ref?access_num=7697201&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B236"><!-- comment for mosaic --></a>
<P>236. &nbsp; 

KOYAMA, S<font size=-1>. </font>M<font size=-1>.</font>,
T<font size=-1>.</font> SASAKI,
K<font size=-1>.</font> SETOYAMA,
K<font size=-1>.</font> TAKAHASHI,
K<font size=-1>.</font> TOGASHI,
K<font size=-1>.</font> SUZUKI,
N<font size=-1>.</font> KAKKI,
 <font size=-1>AND</font> M<font size=-1>.</font> IMAI.



Dopaminergic modulation of the renal effect of arginine vasopressin in water-loaded rats.
<I>Jpn. J.&nbsp;Pharmacol.</I>
38: 25-30, 1985<!-- HIGHWIRE ID="78:1:189:236" --><A HREF="/cgi/external_ref?access_num=4021228&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B237"><!-- comment for mosaic --></a>
<P>237. &nbsp; 

KRISHNA, G<font size=-1>. </font>G<font size=-1>.</font>,
G<font size=-1>. </font>M<font size=-1>.</font> DANOVITCH,
F<font size=-1>. </font>W<font size=-1>.</font> BECK,
 <font size=-1>AND</font> J<font size=-1>. </font>R<font size=-1>.</font> SOWERS.



Dopaminergic mediation of the natriuretic response to volume expansion.
<I>J. Lab. Clin. Med.</I>
105: 214-218, 1985<!-- HIGHWIRE ID="78:1:189:237" --><A HREF="/cgi/external_ref?access_num=3973460&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B238"><!-- comment for mosaic --></a>
<P>238. &nbsp; 

KUCHEL, O<font size=-1>.</font>.



The heterogeneity of dopamine involvement in essential hypertension.
<I>Clin. Exp. Hypertens.</I>
11, <I>Suppl</I>. 1: 217-225, 1989<!-- HIGHWIRE ID="78:1:189:238" --><!-- /HIGHWIRE -->.</P>
<a name="B239"><!-- comment for mosaic --></a>
<P>239. &nbsp; 

KUCHEL, O<font size=-1>.</font>,
K<font size=-1>.</font> RACZ,
W<font size=-1>.</font> DEBINSKI,
P<font size=-1>.</font> FALARDEAU,
 <font size=-1>AND</font> N<font size=-1>. </font>T<font size=-1>.</font> BUU.



Contrasting dopaminergic patterns in two forms of genetic hypertension.
<I>Clin. Exp. Hypertens.</I>
11, <I>Suppl</I>. 1: 217-225, 1987<!-- HIGHWIRE ID="78:1:189:239" --><!-- /HIGHWIRE -->.</P>
<a name="B240"><!-- comment for mosaic --></a>
<P>240. &nbsp; 

KUKSTAS, L<font size=-1>. </font>A<font size=-1>.</font>,
C<font size=-1>.</font> DOMEC,
L<font size=-1>.</font> BASCLES,
J<font size=-1>.</font> BONNET,
D<font size=-1>.</font> VENIER,
J<font size=-1>. </font>M<font size=-1>.</font> ISRAEL,
 <font size=-1>AND</font> J<font size=-1>. </font>D<font size=-1>.</font> VINCENT.



Different expression of the two dopaminergic D<SUB>2</SUB> receptors, D<SUB>2415</SUB> and D<SUB>2444</SUB> ,&nbsp;in two types of lactotroph each characterized by their response to dopamine and modification of expression by sex steroids.
<I>Endocrinology</I>
129: 1101-1103, 1991<!-- HIGHWIRE ID="78:1:189:240" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=endo&resid=129/2/1101" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B241"><!-- comment for mosaic --></a>
<P>241. &nbsp; 

KURTZ, A<font size=-1>.</font>,
R<font size=-1>.</font> DELLA<font size=-1>-</font>BRUNA,
J<font size=-1>.</font> PRATZ,
 <font size=-1>AND</font> I<font size=-1>.</font> CAVERO.



Rat juxtaglomerular cells are endowed with DA-1 dopamine receptors mediating renin release.
<I>J. Cardiovasc. Pharmacol.</I>
12: 658-663, 1988<!-- HIGHWIRE ID="78:1:189:241" --><A HREF="/cgi/external_ref?access_num=2467083&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B242"><!-- comment for mosaic --></a>
<P>242. &nbsp; 

LAHOSTE, G<font size=-1>. </font>J<font size=-1>.</font>,
J<font size=-1>.</font> YU,
 <font size=-1>AND</font> J<font size=-1>. </font>F<font size=-1>.</font> MARSHALL.



Striatal Fos expression is indicative of dopamine D<SUB>1</SUB>/D<SUB>2</SUB> synergism and receptor supersensitivity.
<I>Proc. Natl. Acad. Sci. USA</I>
90: 7451-7455, 1993<!-- HIGHWIRE ID="78:1:189:242" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=90/16/7451" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B243"><!-- comment for mosaic --></a>
<P>243. &nbsp; 

LAITINEN, J<font size=-1>. </font>T<font size=-1>.</font>.



Dopamine stimulates K<SUP>+</SUP> efflux in the chick retina via D<SUB>1</SUB> receptors independently of adenylyl cyclase activation.
<I>J. Neurochem.</I>
61: 1461-1469, 1993<!-- HIGHWIRE ID="78:1:189:243" --><A HREF="/cgi/external_ref?access_num=8397294&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B244"><!-- comment for mosaic --></a>
<P>244. &nbsp; 

LAJINESS, M<font size=-1>. </font>E<font size=-1>.</font>,
C<font size=-1>. </font>L<font size=-1>.</font> CHIO,
 <font size=-1>AND</font> R<font size=-1>. </font>M<font size=-1>.</font> HUFF.



D<SUB>2</SUB> dopamine receptor stimulation of mitogenesis in transfected Chinese hamster ovary cells: relationship to dopamine stimulation of tyrosine phosphorylations.
<I>J. Pharmacol. Exp. Ther.</I>
267: 1573-1581, 1993<!-- HIGHWIRE ID="78:1:189:244" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jpet&resid=267/3/1573" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B245"><!-- comment for mosaic --></a>
<P>245. &nbsp; 

LANDWEHRMEYER, B<font size=-1>.</font>,
G<font size=-1>.</font> MENGOD,
 <font size=-1>AND</font> J<font size=-1>. </font>M<font size=-1>.</font> PALACIOS.



Dopamine D<SUB>3</SUB> receptor mRNA and binding sites in human brain.
<I>Mol. Brain Res.</I>
18: 187-192, 1993.<!-- HIGHWIRE ID="78:1:189:245" --><A HREF="/cgi/external_ref?access_num=8097550&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --></P>
<a name="B246"><!-- comment for mosaic --></a>
<P>246. &nbsp; 

LANDWEHRMEYER, B<font size=-1>.</font>,
G<font size=-1>.</font> MENGOD,
 <font size=-1>AND</font> J<font size=-1>. </font>M<font size=-1>.</font> PALACIOS.



Differential visualization of dopamine D<SUB>2</SUB> and D<SUB>3</SUB> receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography.
<I>Eur. J.&nbsp;Neurosci.</I>
5: 145-153, 1993<!-- HIGHWIRE ID="78:1:189:246" --><A HREF="/cgi/external_ref?access_num=8261096&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B247"><!-- comment for mosaic --></a>
<P>247. &nbsp; 

LEE, M<font size=-1>. </font>R<font size=-1>.</font>.



Dopamine and the kidney.
<I>Clin. Sci. (Lond.)</I>
62: 439-448, 1983<!-- HIGHWIRE ID="78:1:189:247" --><!-- /HIGHWIRE -->.</P>
<a name="B248"><!-- comment for mosaic --></a>
<P>248. &nbsp; 

LEE, M<font size=-1>. </font>R<font size=-1>.</font>.



Five years' experience with gamma-<font size=-1>L</font>-glutamyl <font size=-1>L</font>-dopa: a relatively renally specific dopaminergic prodrug in man.
<I>J. Auton. Pharmacol.</I>
10, <I>Suppl</I>. 1: S103-S108, 1990<!-- HIGHWIRE ID="78:1:189:248" --><A HREF="/cgi/external_ref?access_num=2129121&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B249"><!-- comment for mosaic --></a>
<P>249. &nbsp; 

LEE, M<font size=-1>. </font>R<font size=-1>.</font>.



Dopamine and the kidney: ten years on.
<I>Clin. Sci. (Lond.)</I>
84: 357-375, 1993<!-- HIGHWIRE ID="78:1:189:249" --><A HREF="/cgi/external_ref?access_num=8482041&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B250"><!-- comment for mosaic --></a>
<P>250. &nbsp; 

LEFKOWITZ, R<font size=-1>. </font>J<font size=-1>.</font>,
S<font size=-1>.</font> COTECCHIA,
P<font size=-1>.</font> SAMAMA,
 <font size=-1>AND</font> T<font size=-1>.</font> COSTA.



Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins.
<I>Trends Pharmacol. Sci.</I>
14: 303-307, 1993<!-- HIGHWIRE ID="78:1:189:250" --><A HREF="/cgi/external_ref?access_num=8249148&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B251"><!-- comment for mosaic --></a>
<P>251. &nbsp; 

LEIER, C<font size=-1>. </font>V<font size=-1>.</font>,
P<font size=-1>. </font>T<font size=-1>.</font> HEBAN,
P<font size=-1>.</font> HUSS,
C<font size=-1>. </font>A<font size=-1>.</font> BUSH,
 <font size=-1>AND</font> R<font size=-1>. </font>P<font size=-1>.</font> LEWIS.



Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure.
<I>Circulation</I>
58: 466-475, 1978<!-- HIGHWIRE ID="78:1:189:251" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=circulationaha&resid=58/3/466" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B252"><!-- comment for mosaic --></a>
<P>252. &nbsp; 

LE MOAL, M<font size=-1>.</font>,
 <font size=-1>AND</font> H<font size=-1>.</font> SIMON.



Mesolimbic dopaminergic network: functional and regulatory roles.
<I>Physiol. Rev.</I>
71: 155-234, 1991<!-- HIGHWIRE ID="78:1:189:252" --><A HREF="/cgi/ijlink?linkType=PDF&journalCode=physrev&resid=71/1/155" ><nobr>[<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B253"><!-- comment for mosaic --></a>
<P>253. &nbsp; 

LE MOINE, C<font size=-1>.</font>,
 <font size=-1>AND</font> B<font size=-1>.</font> BLOCH.



D<SUB>1</SUB> and D<SUB>2</SUB> dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D<SUB>1</SUB> and D<SUB>2</SUB> mRNAs in distinct neuronal populations of the dorsal and ventral striatum.
<I>J. Comp. Neurol.</I>
355: 418-426, 1995<!-- HIGHWIRE ID="78:1:189:253" --><A HREF="/cgi/external_ref?access_num=7636023&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B254"><!-- comment for mosaic --></a>
<P>254. &nbsp; 

LE MOINE, C<font size=-1>.</font>,
 <font size=-1>AND</font> B<font size=-1>.</font> BLOCH.



Expression of the D<SUB>3</SUB> dopamine receptor in peptidergic neurons of the nucleus accumbens: comparison with the D<SUB>1</SUB> and D<SUB>2</SUB> dopamine receptors.
<I>Neuroscience</I>
73: 131-143, 1996<!-- HIGHWIRE ID="78:1:189:254" --><A HREF="/cgi/external_ref?access_num=8783237&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B255"><!-- comment for mosaic --></a>
<P>255. &nbsp; 

LE MOINE, C<font size=-1>.</font>,
E<font size=-1>.</font> NORMAND,
 <font size=-1>AND</font> B<font size=-1>.</font> BLOCH.



Phenotypical characterization of the rat striatal neurons expressing the D<SUB>1</SUB> dopamine receptor gene.
<I>Proc. Natl. Acad. Sci. USA</I>
88: 4205-4209, 1991<!-- HIGHWIRE ID="78:1:189:255" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=88/10/4205" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B256"><!-- comment for mosaic --></a>
<P>256. &nbsp; 

LE MOINE, C<font size=-1>.</font>,
E<font size=-1>.</font> NORMAND,
A<font size=-1>. </font>F<font size=-1>.</font> GUITTENY,
B<font size=-1>.</font> FOUQUE,
R<font size=-1>.</font> TEOULE,
 <font size=-1>AND</font> B<font size=-1>.</font> BLOCH.



Dopamine receptor gene expression by enkephalin neurons in rat forebrain.
<I>Proc. Natl. Acad. Sci. USA</I>
87: 230-234, 1990<!-- HIGHWIRE ID="78:1:189:256" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=87/1/230" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B257"><!-- comment for mosaic --></a>
<P>257. &nbsp; 

LESTER, J<font size=-1>.</font>,
J<font size=-1>. </font>S<font size=-1>.</font> FINK,
N<font size=-1>.</font> ARONIN,
 <font size=-1>AND</font> M<font size=-1>.</font> DIFIGLIA.



Colocalization of D<SUB>1</SUB> and D<SUB>2</SUB> dopamine receptor messenger RNAs in striatal neurons.
<I>Brain Res.</I>
621: 106-110, 1993<!-- HIGHWIRE ID="78:1:189:257" --><A HREF="/cgi/external_ref?access_num=8221060&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B258"><!-- comment for mosaic --></a>
<P>258. &nbsp; 

LEVESQUE, D<font size=-1>.</font>,
J<font size=-1>.</font> DIAZ,
C<font size=-1>.</font> PILON,
M<font size=-1>. </font>P<font size=-1>.</font> MARTRES,
B<font size=-1>.</font> GIROS,
E<font size=-1>.</font> SOUIL,
D<font size=-1>.</font> SCHOTT,
J<font size=-1>. </font>L<font size=-1>.</font> MORGAT,
J<font size=-1>. </font>C<font size=-1>.</font> SCHWARTZ,
 <font size=-1>AND</font> P<font size=-1>.</font> SOKOLOFF.



Identification, characterization, and localization of the dopamine D<SUB>3</SUB> receptor in rat brain using 7-[<SUP>3</SUP>H]hydroxy-<I>N</I>,<I>N</I>-di-<I>n</I>-propyl-2-aminotetralin.
<I>Proc. Natl. Acad. Sci. USA</I>
89: 8155-8159, 1992<!-- HIGHWIRE ID="78:1:189:258" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=89/17/8155" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B259"><!-- comment for mosaic --></a>
<P>259. &nbsp; 

LEVESQUE, D<font size=-1>.</font>,
M<font size=-1>. </font>P<font size=-1>.</font> MARTRES,
J<font size=-1>.</font> DIAZ,
N<font size=-1>.</font> GRIFFON,
C<font size=-1>. </font>H<font size=-1>.</font> LAMMERS,
P<font size=-1>.</font> SOKOLOFF,
 <font size=-1>AND</font> J<font size=-1>. </font>C<font size=-1>.</font> SCHWARTZ.



A paradoxical regulation of the dopamine D<SUB>3</SUB> receptor expression suggests the involvement of an anterograde factor from dopamine neurons.
<I>Proc. Natl. Acad. Sci. USA</I>
92: 1719-1723, 1995<!-- HIGHWIRE ID="78:1:189:259" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=92/5/1719" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B260"><!-- comment for mosaic --></a>
<P>260. &nbsp; 

LEVEY, A<font size=-1>. </font>I<font size=-1>.</font>,
S<font size=-1>. </font>M<font size=-1>.</font> HERSCH,
D<font size=-1>. </font>B<font size=-1>.</font> RYE,
R<font size=-1>. </font>K<font size=-1>.</font> SUNAHARA,
H<font size=-1>. </font>B<font size=-1>.</font> NIZNIK,
C<font size=-1>. </font>A<font size=-1>.</font> KITT,
D<font size=-1>. </font>L<font size=-1>.</font> PRICE,
R<font size=-1>.</font> MAGGIO,
M<font size=-1>. </font>R<font size=-1>.</font> BRANN,
 <font size=-1>AND</font> B<font size=-1>. </font>J<font size=-1>.</font> CILIAX.



Localization of D<SUB>1</SUB> and spiperone (<a href="#B398">398</A>) and in GH<SUB>3</SUB> cells that express a D<SUB>2</SUB>-like receptor with an unusual low affinity for haloperidol in response to NGF (<a href="#B305">305</A>). D<SUB>2</SUB> dopamine receptors in brain with subtype-specific antibodies.
<I>Proc. Natl. Acad. Sci. USA</I>
90: 8861-8865, 1993<!-- HIGHWIRE ID="78:1:189:260" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=90/19/8861" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B261"><!-- comment for mosaic --></a>
<P>261. &nbsp; 

LEVIN, E<font size=-1>. </font>D<font size=-1>.</font>,
 <font size=-1>AND</font> J<font size=-1>. </font>E<font size=-1>.</font> ROSE.



Acute and chronic nicotinic interaction with dopamine systems and working memory performance.
<I>Ann. NY Acad. Sci.</I>
757: 245-252, 1995<!-- HIGHWIRE ID="78:1:189:261" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=anny&resid=757/1/245" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B262"><!-- comment for mosaic --></a>
<P>262. &nbsp; 

LEW, A<font size=-1>. </font>M<font size=-1>.</font>,
 <font size=-1>AND</font> H<font size=-1>. </font>P<font size=-1>.</font> ELSHOLTZ.



A dopamine-responsive domain in the N-terminal sequence of Pit-1.
<I>J. Biol. Chem.</I>
270: 7156-7160, 1995<!-- HIGHWIRE ID="78:1:189:262" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=270/13/7156" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B263"><!-- comment for mosaic --></a>
<P>263. &nbsp; 

LIN, C<font size=-1>. </font>W<font size=-1>.</font>,
T<font size=-1>. </font>R<font size=-1>.</font> MILLER,
D<font size=-1>. </font>G<font size=-1>.</font> WITTE,
B<font size=-1>. </font>R<font size=-1>.</font> BIANCHI,
M<font size=-1>.</font> STASHKO,
A<font size=-1>. </font>M<font size=-1>.</font> MANELLI,
 <font size=-1>AND</font> D<font size=-1>. </font>E<font size=-1>.</font> FRAIL.



Characterization of cloned human dopamine D<SUB>1</SUB> receptor-mediated calcium release in 293&nbsp;cells.
<I>Mol. Pharmacol.</I>
47: 131-139, 1995<!-- HIGHWIRE ID="78:1:189:263" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=47/1/131" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B264"><!-- comment for mosaic --></a>
<P>264. &nbsp; 

LIU, L<font size=-1>.</font>,
R<font size=-1>.-</font>Y<font size=-1>.</font> SHEN,
G<font size=-1>.</font> KAPATOS,
 <font size=-1>AND</font> L<font size=-1>. </font>A<font size=-1>.</font> CHIODO.



Dopamine neuron membrane physiology: characterization of the transient outward current (<I>I</I><SUB>A</SUB>) and demonstration of a common signal transduction pathway for <I>I</I><SUB>A</SUB> and <I>I</I><SUB>K</SUB> .
<I>Synapse</I>
17: 230-240, 1994<!-- HIGHWIRE ID="78:1:189:264" --><A HREF="/cgi/external_ref?access_num=7992198&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B265"><!-- comment for mosaic --></a>
<P>265. &nbsp; 

LIU, Y<font size=-1>. </font>F<font size=-1>.</font>,
O<font size=-1>.</font> CIVELLI,
D<font size=-1>. </font>K<font size=-1>.</font> GRANDY,
 <font size=-1>AND</font> P<font size=-1>. </font>R<font size=-1>.</font> ALBERT.



Differential sensitivity of the short and long human dopamine D<SUB>2</SUB> receptor subtypes to protein kinase C.
<I>J. Neurochem.</I>
59: 2311-2317, 1992<!-- HIGHWIRE ID="78:1:189:265" --><A HREF="/cgi/external_ref?access_num=1331329&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B266"><!-- comment for mosaic --></a>
<P>266. &nbsp; 

LIU, Y<font size=-1>. </font>F<font size=-1>.</font>,
O<font size=-1>.</font> CIVELLI,
Q<font size=-1>.-</font>Y<font size=-1>.</font> ZHOU,
 <font size=-1>AND</font> P<font size=-1>. </font>R<font size=-1>.</font> ALBERT.



Cholera toxin-sensitive 3',5'-cyclic adenosine monophosphate and calcium signals of the human dopamine-D<SUB>1</SUB> receptor: selective potentiation by protein kinase A.
<I>Mol. Endocrinol.</I>
6: 1815-1824, 1992<!-- HIGHWIRE ID="78:1:189:266" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=mend&resid=6/11/1815" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B267"><!-- comment for mosaic --></a>
<P>267. &nbsp; 

LIU, Y<font size=-1>. </font>F<font size=-1>.</font>,
K<font size=-1>. </font>H<font size=-1>.</font> JAKOBS,
M<font size=-1>. </font>M<font size=-1>.</font> RASENICK,
 <font size=-1>AND</font> P<font size=-1>. </font>R<font size=-1>.</font> ALBERT.



G protein specificity in receptor-effector coupling. Analysis of the roles of G<SUB>o</SUB> and G<SUB>i2</SUB> in GH<SUB>4</SUB>C<SUB>1</SUB> pituitary cells.
<I>J. Biol. Chem.</I>
269: 13880-13886, 1994<!-- HIGHWIRE ID="78:1:189:267" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=269/19/13880" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B268"><!-- comment for mosaic --></a>
<P>268. &nbsp; 

LLEDO, P<font size=-1>. </font>M<font size=-1>.</font>,
V<font size=-1>.</font> HOMBURGER,
J<font size=-1>.</font> BOCKAERT,
 <font size=-1>AND</font> J<font size=-1>. </font>D<font size=-1>.</font> VINCENT.



Differential G protein-mediated coupling of D-2 dopamine receptors to K<SUP>+</SUP> and Ca<SUP>2+</SUP> currents in rat anterior pituitary cells.
<I>Neuron</I>
8: 455-463, 1992<!-- HIGHWIRE ID="78:1:189:268" --><A HREF="/cgi/external_ref?access_num=1312848&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B269"><!-- comment for mosaic --></a>
<P>269. &nbsp; 

LLEDO, P<font size=-1>. </font>M<font size=-1>.</font>,
P<font size=-1>.</font> LEGENOHE,
J<font size=-1>. </font>M<font size=-1>.</font> ISRAEL,
 <font size=-1>AND</font> J<font size=-1>. </font>D<font size=-1>.</font> VINCENT.



Dopamine inhibits two characterized voltage-dependent calcium currents in identified rat lactotroph cells.
<I>Endocrinology</I>
127: 990-1001, 1990<!-- HIGHWIRE ID="78:1:189:269" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=endo&resid=127/3/990" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B270"><!-- comment for mosaic --></a>
<P>270. &nbsp; 

LLEDO, P<font size=-1>. </font>M<font size=-1>.</font>,
P<font size=-1>.</font> LEGENOHE,
J<font size=-1>.</font> ZHANG,
J<font size=-1>. </font>M<font size=-1>.</font> ISRAEL,
 <font size=-1>AND</font> J<font size=-1>. </font>D<font size=-1>.</font> VINCENT.



Effects of dopamine on voltage-dependent potassium currents in identified rat lactotroph cells.
<I>Neuroendocrinology</I>
52: 545-555, 1990<!-- HIGHWIRE ID="78:1:189:270" --><A HREF="/cgi/external_ref?access_num=2149427&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B271"><!-- comment for mosaic --></a>
<P>271. &nbsp; 

LOMBARDI, C<font size=-1>.</font>,
C<font size=-1>.</font> MISSALE,
R<font size=-1>.</font> DE COTIIS,
C<font size=-1>.</font> SPEDINI,
G<font size=-1>.</font> PIZZOCCOLO,
M<font size=-1>.</font> MEMO,
A<font size=-1>.</font> ALBERTINI,
 <font size=-1>AND</font> P<font size=-1>. </font>F<font size=-1>.</font> SPANO.



Inhibition of aldosterone response to sodium depletion in man by stimulation of dopamine DA<SUB>2</SUB> receptors.
<I>Eur. J.&nbsp;Clin. Pharmacol.</I>
35: 323-326, 1988<!-- HIGHWIRE ID="78:1:189:271" --><A HREF="/cgi/external_ref?access_num=2972550&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B272"><!-- comment for mosaic --></a>
<P>272. &nbsp; 

LYON, R<font size=-1>. </font>A<font size=-1>.</font>,
M<font size=-1>.</font> TITELER,
L<font size=-1>.</font> BIGORNIA,
 <font size=-1>AND</font> A<font size=-1>. </font>S<font size=-1>.</font> SCHNEIDER.



D<SUB>2</SUB> dopamine receptors on bovine chromaffin cell membranes: identification and characterization by [<SUP>3</SUP>H]<I>N</I>-methylspiperone binding.
<I>J. Neurochem.</I>
48: 631-635, 1987<!-- HIGHWIRE ID="78:1:189:272" --><A HREF="/cgi/external_ref?access_num=3794725&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B273"><!-- comment for mosaic --></a>
<P>273. &nbsp; 

MACCIARDI, F<font size=-1>.</font>,
A<font size=-1>.</font> PETRONIS,
H<font size=-1>. </font>H<font size=-1>.</font><font size=-1>&nbsp;</font>M<font size=-1>.</font> VAN TOL,
C<font size=-1>.</font> MARINO,
M<font size=-1>. </font>C<font size=-1>.</font> CAVALLINI,
E<font size=-1>.</font> SMERALDI,
 <font size=-1>AND</font> J<font size=-1>. </font>L<font size=-1>.</font> KENNEDY.



Analysis of the D<SUB>4</SUB> dopamine receptor gene variant in an Italian schizophrenia kindred.
<I>Arch. Gen. Psychiatry</I>
51: 288-293, 1994<!-- HIGHWIRE ID="78:1:189:273" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=archpsyc&resid=51/4/288" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B274"><!-- comment for mosaic --></a>
<P>274. &nbsp; 

MACKENZIE, R<font size=-1>. </font>G<font size=-1>.</font>,
D<font size=-1>.</font> VANLEEUWEN,
T<font size=-1>. </font>A<font size=-1>.</font> PUGSLEY,
Y<font size=-1>.-</font>H<font size=-1>.</font> SHIH,
S<font size=-1>.</font> DEMATTOS,
L<font size=-1>.</font> TANG,
R<font size=-1>. </font>D<font size=-1>.</font> TODD,
 <font size=-1>AND</font> K<font size=-1>. </font>L<font size=-1>.</font> O<font size=-1>'</font>MALLEY.



Characterization of the human dopamine D<SUB>3</SUB> receptor expressed in transfected cell lines.
<I>Eur. J.&nbsp;Pharmacol.</I>
266: 79-85, 1994<!-- HIGHWIRE ID="78:1:189:274" --><A HREF="/cgi/external_ref?access_num=7907989&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B275"><!-- comment for mosaic --></a>
<P>275. &nbsp; 

MAHAN, L<font size=-1>. </font>C<font size=-1>.</font>,
R<font size=-1>. </font>M<font size=-1>.</font> BURCH,
F<font size=-1>.</font> MONSMA,
 <font size=-1>AND</font> D<font size=-1>. </font>R<font size=-1>.</font> SIBLEY.



Expression of striatal D<SUB>1</SUB> dopamine receptors coupled to inositol phosphate production and Ca<SUP>2+</SUP> mobilization in <I>Xenopus</I> oocytes.
<I>Proc. Natl. Acad. Sci. USA</I>
87: 2196-2200, 1990<!-- HIGHWIRE ID="78:1:189:275" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=87/6/2196" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B276"><!-- comment for mosaic --></a>
<P>276. &nbsp; 

MALCHOFF, C<font size=-1>. </font>D<font size=-1>.</font>,
J<font size=-1>.</font> HUGHES,
S<font size=-1>.</font> SEN,
S<font size=-1>.</font> JACKSON,
 <font size=-1>AND</font> R<font size=-1>. </font>M<font size=-1>.</font> CAREY.



Dopamine inhibits the aldosterone response to upright posture.
<I>J. Clin. Endocrinol. Metab.</I>
63: 197-201, 1986<!-- HIGHWIRE ID="78:1:189:276" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jcem&resid=63/1/197" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B277"><!-- comment for mosaic --></a>
<P>277. &nbsp; 

MALDONADO, R<font size=-1>.</font>,
P<font size=-1>.</font> ROBLEDO,
A<font size=-1>. </font>J<font size=-1>.</font> CHOVER,
S<font size=-1>. </font>B<font size=-1>.</font> CAINE,
 <font size=-1>AND</font> G<font size=-1>. </font>F<font size=-1>.</font> KOOB.



D<SUB>1</SUB> dopamine receptors in the nucleus accumbens modulate cocaine self-administration in the rat.
<I>Pharmacol. Biochem. Behav.</I>
45: 239-242, 1993<!-- HIGHWIRE ID="78:1:189:277" --><A HREF="/cgi/external_ref?access_num=8516365&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B278"><!-- comment for mosaic --></a>
<P>278. &nbsp; 

MALMBERG, A<font size=-1>.</font>,
D<font size=-1>. </font>M<font size=-1>.</font> JACKSON,
A<font size=-1>.</font> ERIKSSON,
 <font size=-1>AND</font> N<font size=-1>.</font> MOHELL.



Unique binding characteristics of antipsychotic agents interacting with human dopamine D<SUB>2A</SUB> ,&nbsp;D<SUB>2B</SUB> ,&nbsp;and D<SUB>3</SUB> receptors.
<I>Mol. Pharmacol.</I>
43: 749-754, 1993<!-- HIGHWIRE ID="78:1:189:278" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=43/5/749" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B279"><!-- comment for mosaic --></a>
<P>279. &nbsp; 

MANDEL, L<font size=-1>. </font>J<font size=-1>.</font>.



Metabolic substrates, cellular energy production, and the regulation of proximal tubular transport.
<I>Annu. Rev. Physiol.</I>
47: 85-101, 1985<!-- HIGHWIRE ID="78:1:189:279" --><A HREF="/cgi/external_ref?access_num=3888090&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B280"><!-- comment for mosaic --></a>
<P>280. &nbsp; 

MANNELLI, M<font size=-1>.</font>,
G<font size=-1>.</font> DELITALA,
M<font size=-1>. </font>L<font size=-1>.</font> DE FEO,
M<font size=-1>.</font> MAGGI,
S<font size=-1>.</font> CUOMO,
M<font size=-1>.</font> PIAZZINI,
R<font size=-1>.</font> GUAZZELLI,
 <font size=-1>AND</font> M<font size=-1>.</font> SERIO.



Effects of different dopaminergic antagonists on bromocriptine-induced inhibition of norepinephrine release.
<I>J. Clin. Endocrinol. Metab.</I>
59: 74-78, 1984<!-- HIGHWIRE ID="78:1:189:280" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jcem&resid=59/1/74" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B281"><!-- comment for mosaic --></a>
<P>281. &nbsp; 

MANNELLI, M<font size=-1>.</font>,
C<font size=-1>.</font> PUPILLI,
G<font size=-1>.</font> FABBRI,
R<font size=-1>.</font> MUSANTE,
M<font size=-1>. </font>L<font size=-1>.</font> DE FEO,
F<font size=-1>.</font> FRANCHI,
 <font size=-1>AND</font> G<font size=-1>.</font> GIUSTI.



Endogenous dopamine and DA<SUB>2</SUB> receptors: a mechanism limiting excessive sympathetic-adrenal discharge in humans.
<I>J. Clin. Endocrinol. Metab.</I>
66: 626-631, 1988<!-- HIGHWIRE ID="78:1:189:281" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jcem&resid=66/3/626" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B282"><!-- comment for mosaic --></a>
<P>282. &nbsp; 

MANSOUR, A<font size=-1>.</font>,
F<font size=-1>.</font> MENG,
J<font size=-1>. </font>H<font size=-1>.</font> MEADOR<font size=-1>-</font>WOODRUFF,
L<font size=-1>. </font>P<font size=-1>.</font> TAYLOR,
O<font size=-1>.</font> CIVELLI,
 <font size=-1>AND</font> H<font size=-1>.</font> AKIL.



Site-directed mutagenesis of the human dopamine D<SUB>2</SUB> receptor.
<I>Eur. J.&nbsp;Pharmacol.</I>
227: 205-214, 1992<!-- HIGHWIRE ID="78:1:189:282" --><A HREF="/cgi/external_ref?access_num=1358663&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B283"><!-- comment for mosaic --></a>
<P>283. &nbsp; 

MARTRES, M<font size=-1>. </font>P<font size=-1>.</font>,
P<font size=-1>.</font> SOKOLOFF,
B<font size=-1>.</font> GIROS,
 <font size=-1>AND</font> J<font size=-1>. </font>C<font size=-1>.</font> SCHWARTZ.



Effects of dopaminergic transmission interruption on the D<SUB>2</SUB> receptor isoforms in various cerebral tissues.
<I>J. Neurochem.</I>
58: 673-679, 1992<!-- HIGHWIRE ID="78:1:189:283" --><A HREF="/cgi/external_ref?access_num=1309568&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B284"><!-- comment for mosaic --></a>
<P>284. &nbsp; 

MASSRY, S<font size=-1>. </font>G<font size=-1>.</font>,
R<font size=-1>. </font>M<font size=-1>.</font> FRIEDLER,
 <font size=-1>AND</font> J<font size=-1>. </font>W<font size=-1>.</font> COBURN.



Excretion of phosphate and calcium. Physiology of their renal handling and relation to clinical medicine.
<I>Arch. Int. Med.</I>
131: 828-859, 1973<!-- HIGHWIRE ID="78:1:189:284" --><A HREF="/cgi/external_ref?access_num=4706773&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B285"><!-- comment for mosaic --></a>
<P>285. &nbsp; 

MATSUMOTO, M<font size=-1>.</font>,
K<font size=-1>.</font> HIDAKA,
S<font size=-1>.</font> TADA,
Y<font size=-1>.</font> TASAKI,
 <font size=-1>AND</font> T<font size=-1>.</font> YAMAGUCHI.



Full-length cDNA cloning and distribution of human dopamine D<SUB>4</SUB> receptor.
<I>Mol. Brain Res.</I>
29: 157-162, 1995.<!-- HIGHWIRE ID="78:1:189:285" --><A HREF="/cgi/external_ref?access_num=7769992&link_type=MED" >[Medline]</A><!-- /HIGHWIRE --></P>
<a name="B286"><!-- comment for mosaic --></a>
<P>286. &nbsp; 

MATTHYSSE, S<font size=-1>.</font>.



Dopamine and the pharmacology of schizophrenia: the state of the evidence.
<I>J. Psychiatr. Res.</I>
11: 107-113, 1974<!-- HIGHWIRE ID="78:1:189:286" --><A HREF="/cgi/external_ref?access_num=4218872&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B287"><!-- comment for mosaic --></a>
<P>287. &nbsp; 

M<font size=-1>C</font>ALLISTER, G<font size=-1>.</font>,
M<font size=-1>. </font>R<font size=-1>.</font> KNOWLES,
S<font size=-1>. </font>M<font size=-1>.</font> WARD<font size=-1>-</font>BOOTH,
H<font size=-1>. </font>A<font size=-1>.</font> SINCLAIR,
S<font size=-1>.</font> PATEL,
R<font size=-1>.</font> MARWOOD,
F<font size=-1>.</font> EMMS,
A<font size=-1>.</font> SMITH,
G<font size=-1>. </font>R<font size=-1>.</font> SEABROOK,
 <font size=-1>AND</font> S<font size=-1>. </font>B<font size=-1>.</font> FREEDMAN.



Functional coupling of human D<SUB>2</SUB> ,&nbsp;D<SUB>3</SUB> ,&nbsp;and D<SUB>4</SUB> dopamine receptors in HEK293 cells.
<I>J. Receptor Signal Transduction Res.</I>
15: 267-281, 1995<!-- HIGHWIRE ID="78:1:189:287" --><A HREF="/cgi/external_ref?access_num=8903944&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B288"><!-- comment for mosaic --></a>
<P>288. &nbsp; 

M<font size=-1>C</font>DONALD, R<font size=-1>. </font>H<font size=-1>.</font>.



J<font size=-1>R</font>., L.&nbsp;I.&nbsp;GOLDBERG, J.&nbsp;L.&nbsp;M<font size=-1>C</font>NAY, <font size=-1>AND</font> E.&nbsp;P.&nbsp;TUTTLE. Effect of dopamine on man: augmentation of sodium excretion, glomerular filtration rate, and renal plasma flow.
<I>J. Clin. Invest.</I>
43: 1116-1124, 1964<!-- HIGHWIRE ID="78:1:189:288" --><!-- /HIGHWIRE -->.</P>
<a name="B289"><!-- comment for mosaic --></a>
<P>289. &nbsp; 

M<font size=-1>C</font>DONALD, W<font size=-1>. </font>M<font size=-1>.</font>,
D<font size=-1>. </font>R<font size=-1>.</font> SIBLEY,
B<font size=-1>. </font>F<font size=-1>.</font> KILPATRICK,
 <font size=-1>AND</font> M<font size=-1>. </font>G<font size=-1>.</font> CARON.



Dopaminergic inhibition of adenylate cyclase correlates with high affinity agonist binding to anterior pituitary D<SUB>2</SUB> dopamine receptors.
<I>Mol. Cell. Endocrinol.</I>
36: 201-209, 1984<!-- HIGHWIRE ID="78:1:189:289" --><A HREF="/cgi/external_ref?access_num=6540722&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B290"><!-- comment for mosaic --></a>
<P>290. &nbsp; 

M<font size=-1>C</font>HALE, M<font size=-1>.</font>,
M<font size=-1>. </font>C<font size=-1>.</font> COLDWELL,
N<font size=-1>.</font> HERRITY,
I<font size=-1>.</font> BOYFIELD,
F<font size=-1>. </font>M<font size=-1>.</font> WINN,
S<font size=-1>.</font> BALL,
T<font size=-1>.</font> COOK,
J<font size=-1>. </font>H<font size=-1>.</font> ROBINSON,
 <font size=-1>AND</font> I<font size=-1>. </font>S<font size=-1>.</font> GLOGER.



Expression and functional characterization of a synthetic version of the human D<SUB>4</SUB> dopamine receptor in a stable human cell line.
<I>FEBS Lett.</I>
345: 147-150, 1994<!-- HIGHWIRE ID="78:1:189:290" --><A HREF="/cgi/external_ref?access_num=8200447&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B291"><!-- comment for mosaic --></a>
<P>291. &nbsp; 

M<font size=-1>C</font>NAY, J<font size=-1>. </font>L<font size=-1>.</font>,
R<font size=-1>. </font>H<font size=-1>.</font> M<font size=-1>C</font>DONALD,
 <font size=-1>AND</font> L<font size=-1>. </font>I<font size=-1>.</font> GOLDBERG.



Direct renal vasodilation produced by dopamine in the dog.
<I>Circ. Res.</I>
16: 510-517, 1965<!-- HIGHWIRE ID="78:1:189:291" --><!-- /HIGHWIRE -->.</P>
<a name="B292"><!-- comment for mosaic --></a>
<P>292. &nbsp; 

MEADOR<font size=-1>-</font>WOODRUFF, J<font size=-1>. </font>H<font size=-1>.</font>,
A<font size=-1>.</font> MANSOUR,
J<font size=-1>. </font>R<font size=-1>.</font> BUNZOW,
H<font size=-1>. </font>H<font size=-1>.</font><font size=-1>&nbsp;</font>M<font size=-1>.</font> VAN TOL,
S<font size=-1>. </font>J<font size=-1>.</font> WATSON,
 <font size=-1>AND</font> O<font size=-1>.</font> CIVELLI.



Distribution of D<SUB>2</SUB> dopamine receptor mRNA in rat brain.
<I>Proc. Natl. Acad. Sci USA</I>
86: 7625-7628, 1989<!-- HIGHWIRE ID="78:1:189:292" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=86/19/7625" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B293"><!-- comment for mosaic --></a>
<P>293. &nbsp; 

MEADOR<font size=-1>-</font>WOODRUFF, J<font size=-1>. </font>H<font size=-1>.</font>,
A<font size=-1>.</font> MANSOUR,
D<font size=-1>. </font>K<font size=-1>.</font> GRANDY,
S<font size=-1>. </font>P<font size=-1>.</font> DAMASK,
O<font size=-1>.</font> CIVELLI,
 <font size=-1>AND</font> S<font size=-1>. </font>J<font size=-1>.</font> WATSON.



J<font size=-1>R</font>. Distribution of D<SUB>5</SUB> dopamine receptor mRNA in rat brain.
<I>Neurosci. Lett.</I>
145: 209-212, 1992<!-- HIGHWIRE ID="78:1:189:293" --><A HREF="/cgi/external_ref?access_num=1465219&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B294"><!-- comment for mosaic --></a>
<P>294. &nbsp; 

MEISTER, B<font size=-1>.</font>,
J<font size=-1>.</font> FRYCKSTEDT,
M<font size=-1>.</font> SCHALLING,
R<font size=-1>.</font> CORTES,
T<font size=-1>.</font> H<font size=-1>&Uuml;</font>KFELT,
A<font size=-1>.</font> APERIA,
 <font size=-1>AND</font> H<font size=-1>. </font>C<font size=-1>.</font> HEMMING.



J<font size=-1>R</font>., A.&nbsp;C.&nbsp;NAIRN, M.&nbsp;EHRLICH, <font size=-1>AND</font> P.&nbsp;GREENGARD. Dopamine- and cAMP-regulated phosphoprotein (DARPP-32) and dopamine DA<SUB>1</SUB> agonist-sensitive Na<SUP>+</SUP>,K<SUP>+</SUP>-ATPase in renal tubule cells.
<I>Proc. Natl. Acad. Sci. USA</I>
86: 8068-8072, 1989<!-- HIGHWIRE ID="78:1:189:294" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=86/20/8068" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B295"><!-- comment for mosaic --></a>
<P>295. &nbsp; 

MEISTER, B<font size=-1>.</font>,
H<font size=-1>.</font> HOLGER,
A<font size=-1>.</font> APERIA,
 <font size=-1>AND</font> T<font size=-1>.</font> H<font size=-1>&Uuml;</font>KFELT.



Dopamine D<SUB>1</SUB> receptor mRNA in rat kidney: localization by in situ hybridization.
<I>Acta Physiol. Scand.</I>
143: 447-449, 1991<!-- HIGHWIRE ID="78:1:189:295" --><A HREF="/cgi/external_ref?access_num=1840010&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B296"><!-- comment for mosaic --></a>
<P>296. &nbsp; 

MELTZER, H<font size=-1>. </font>Y<font size=-1>.</font>.



Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia.
<I>Psychopharmacology</I>
99, <I>Suppl.</I>: S18-S27, 1989<!-- HIGHWIRE ID="78:1:189:296" --><A HREF="/cgi/external_ref?access_num=2682729&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B297"><!-- comment for mosaic --></a>
<P>297. &nbsp; 

MELTZER, H<font size=-1>. </font>Y<font size=-1>.</font>.



The mechanism of action of novel antipsychotic drugs.
<I>Schizophr. Bull.</I>
17: 263-287, 1991<!-- HIGHWIRE ID="78:1:189:297" --><A HREF="/cgi/external_ref?access_num=1679253&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B298"><!-- comment for mosaic --></a>
<P>298. &nbsp; 

MEMO, M<font size=-1>.</font>,
L<font size=-1>.</font> CASTELLETTI,
C<font size=-1>.</font> MISSALE,
A<font size=-1>.</font> VALERIO,
M<font size=-1>. </font>O<font size=-1>.</font> CARRUBA,
 <font size=-1>AND</font> P<font size=-1>. </font>F<font size=-1>.</font> SPANO.



Dopaminergic inhibition of prolactin release and calcium influx induced by neurotensin in anterior pituitary is independent of cyclic AMP system.
<I>J. Neurochem.</I>
47: 1689-1695, 1986<!-- HIGHWIRE ID="78:1:189:298" --><A HREF="/cgi/external_ref?access_num=2430058&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B299"><!-- comment for mosaic --></a>
<P>299. &nbsp; 

MEMO, M<font size=-1>.</font>,
C<font size=-1>.</font> MISSALE,
M<font size=-1>. </font>O<font size=-1>.</font> CARRUBA,
 <font size=-1>AND</font> P<font size=-1>. </font>F<font size=-1>.</font> SPANO.



Pharmacology and biochemistry of dopamine receptors in the central nervous system and peripheral tissue.
<I>J. Neural Transm.</I>
22: 19-32, 1986<!-- HIGHWIRE ID="78:1:189:299" --><!-- /HIGHWIRE -->.</P>
<a name="B300"><!-- comment for mosaic --></a>
<P>300. &nbsp; 

MEYER, M<font size=-1>. </font>B<font size=-1>.</font>,
J<font size=-1>. </font>L<font size=-1>.</font> M<font size=-1>C</font>NAY,
 <font size=-1>AND</font> L<font size=-1>. </font>I<font size=-1>.</font> GOLDBERG.



Effects of dopamine on renal function and hemodynamics in the dog.
<I>J. Pharmacol. Exp. Ther.</I>
156: 186-192, 1967<!-- HIGHWIRE ID="78:1:189:300" --><A HREF="/cgi/external_ref?access_num=6023595&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B301"><!-- comment for mosaic --></a>
<P>301. &nbsp; 

MEYER, M<font size=-1>. </font>E<font size=-1>.</font>,
 <font size=-1>AND</font> J<font size=-1>. </font>M<font size=-1>.</font> SHULTS.



Dopamine D<SUB>1</SUB> receptor family agonists, SKF 38393,&nbsp;SKF 77434,&nbsp;and SKF 82958,&nbsp;differentially affect locomotor activities in rats.
<I>Pharmacol. Biochem. Behav.</I>
46: 269-274, 1993<!-- HIGHWIRE ID="78:1:189:301" --><A HREF="/cgi/external_ref?access_num=7903456&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B302"><!-- comment for mosaic --></a>
<P>302. &nbsp; 

MISSALE, C<font size=-1>.</font>,
F<font size=-1>.</font> BORONI,
L<font size=-1>.</font> CASTELLETTI,
R<font size=-1>.</font> DAL TOSO,
N<font size=-1>.</font> GABELLINI,
S<font size=-1>.</font> SIGALA,
 <font size=-1>AND</font> P<font size=-1>. </font>F<font size=-1>.</font> SPANO.



Lack of coupling of D<SUB>2</SUB> receptors to adenylate cyclase in GH<SUB>3</SUB> cells exposed to epidermal growth factor.
<I>J. Biol. Chem.</I>
266: 23392-23398, 1991<!-- HIGHWIRE ID="78:1:189:302" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=266/34/23392" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B303"><!-- comment for mosaic --></a>
<P>303. &nbsp; 

MISSALE, C<font size=-1>.</font>,
F<font size=-1>.</font> BORONI,
M<font size=-1>.</font> FRASSINE,
A<font size=-1>.</font> CARUSO,
 <font size=-1>AND</font> P<font size=-1>. </font>F<font size=-1>.</font> SPANO.



Nerve growth factor promotes the differentiation of pituitary mammotroph cells in vitro.
<I>Endocrinology</I>
136: 1205-1213, 1995<!-- HIGHWIRE ID="78:1:189:303" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=endo&resid=136/3/1205" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B304"><!-- comment for mosaic --></a>
<P>304. &nbsp; 

MISSALE, C<font size=-1>.</font>,
F<font size=-1>.</font> BORONI,
M<font size=-1>.</font> LOSA,
M<font size=-1>.</font> GIOVANELLI,
A<font size=-1>.</font> ZANELLATO,
R<font size=-1>.</font> DAL TOSO,
A<font size=-1>.</font> BALSARI,
 <font size=-1>AND</font> P<font size=-1>. </font>F<font size=-1>.</font> SPANO.



Nerve growth factor suppresses the transforming phenotype of human prolactinomas.
<I>Proc. Natl. Acad. Sci. USA</I>
90: 7961-7965, 1993<!-- HIGHWIRE ID="78:1:189:304" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=90/17/7961" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B305"><!-- comment for mosaic --></a>
<P>305. &nbsp; 

MISSALE, C<font size=-1>.</font>,
F<font size=-1>.</font> BORONI,
S<font size=-1>.</font> SIGALA,
A<font size=-1>.</font> ZANELLATO,
R<font size=-1>.</font> DAL TOSO,
A<font size=-1>.</font> BALSARI,
 <font size=-1>AND</font> P<font size=-1>. </font>F<font size=-1>.</font> SPANO.



Nerve growth factor directs differentiation of the bipotential cell line GH<SUB>3</SUB> into the mammotroph phenotype.
<I>Endocrinology</I>
135: 290-298, 1994<!-- HIGHWIRE ID="78:1:189:305" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=endo&resid=135/1/290" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B306"><!-- comment for mosaic --></a>
<P>306. &nbsp; 

MISSALE, C<font size=-1>.</font>,
L<font size=-1>.</font> CASTELLETTI,
F<font size=-1>.</font> BORONI,
M<font size=-1>.</font> MEMO,
 <font size=-1>AND</font> P<font size=-1>. </font>F<font size=-1>.</font> SPANO.



Epidermal growth factor induces the functional expression of dopamine receptors in the GH<SUB>3</SUB> cell line.
<I>Endocrinology</I>
127: 13-20, 1990<!-- HIGHWIRE ID="78:1:189:306" --><!-- /HIGHWIRE -->.</P>
<a name="B307"><!-- comment for mosaic --></a>
<P>307. &nbsp; 

MISSALE, C<font size=-1>.</font>,
L<font size=-1>.</font> CASTELLETTI,
M<font size=-1>.</font> MEMO,
M<font size=-1>. </font>O<font size=-1>.</font> CARRUBA,
 <font size=-1>AND</font> P<font size=-1>. </font>F<font size=-1>.</font> SPANO.



Identification of postsynaptic D<SUB>1</SUB> and D<SUB>2</SUB> dopamine receptors in the cardiovascular system.
<I>J. Cardiovasc. Pharmacol.</I>
11: 643-650, 1988<!-- HIGHWIRE ID="78:1:189:307" --><A HREF="/cgi/external_ref?access_num=2457758&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B308"><!-- comment for mosaic --></a>
<P>308. &nbsp; 

MISSALE, C<font size=-1>.</font>,
P<font size=-1>.</font> LIBERINI,
M<font size=-1>.</font> MEMO,
M<font size=-1>. </font>O<font size=-1>.</font> CARRUBA,
 <font size=-1>AND</font> P<font size=-1>. </font>F<font size=-1>.</font> SPANO.



Characterization of dopamine receptors associated with aldosterone secretion in rat adrenal glomerulosa.
<I>Endocrinology</I>
119: 2227-2232, 1986<!-- HIGHWIRE ID="78:1:189:308" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=endo&resid=119/5/2227" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B309"><!-- comment for mosaic --></a>
<P>309. &nbsp; 

MISSALE, C<font size=-1>.</font>,
C<font size=-1>.</font> LOMBARDI,
R<font size=-1>.</font> DE COTIIS,
M<font size=-1>.</font> MEMO,
M<font size=-1>. </font>O<font size=-1>.</font> CARRUBA,
 <font size=-1>AND</font> P<font size=-1>. </font>F<font size=-1>.</font> SPANO.



Dopaminergic receptor mechanisms modulating the renin-angiotensin system and aldosterone secretion: an overview.
<I>J. Cardiovasc. Pharmacol.</I>
14, <I>Suppl. </I>8: S29-S39, 1989<!-- HIGHWIRE ID="78:1:189:309" --><A HREF="/cgi/external_ref?access_num=2483440&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B310"><!-- comment for mosaic --></a>
<P>310. &nbsp; 

MISSALE, C<font size=-1>.</font>,
M<font size=-1>.</font> LOSA,
F<font size=-1>.</font> BORONI,
M<font size=-1>.</font> GIOVANELLI,
A<font size=-1>.</font> BALSARI,
 <font size=-1>AND</font> P<font size=-1>. </font>F<font size=-1>.</font> SPANO.



Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.
<I>Br. J.&nbsp;Cancer</I>
72: 1397-1399, 1995<!-- HIGHWIRE ID="78:1:189:310" --><A HREF="/cgi/external_ref?access_num=8519650&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B311"><!-- comment for mosaic --></a>
<P>311. &nbsp; 

MISSALE, C<font size=-1>.</font>,
M<font size=-1>.</font> MEMO,
P<font size=-1>.</font> LIBERINI,
 <font size=-1>AND</font> P<font size=-1>. </font>F<font size=-1>.</font> SPANO.



Dopamine selectively inhibits angiotensin II-induced aldosterone secretion by interacting with D<SUB>2</SUB> receptors.
<I>J. Pharmacol. Exp. Ther.</I>
246: 1137-1143, 1988<!-- HIGHWIRE ID="78:1:189:311" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jpet&resid=246/3/1137" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B312"><!-- comment for mosaic --></a>
<P>312. &nbsp; 

MOISES, H<font size=-1>. </font>M<font size=-1>.</font>,
J<font size=-1>.</font> GELERNTER,
L<font size=-1>. </font>A<font size=-1>.</font> GIUFFRA,
V<font size=-1>.</font> ZARCONE,
L<font size=-1>.</font> WETTERBERG,
O<font size=-1>.</font> CIVELLI,
K<font size=-1>. </font>K<font size=-1>.</font> KIDD,
L<font size=-1>. </font>L<font size=-1>.</font> CAVALLI<font size=-1>-</font>SFORZA,
D<font size=-1>. </font>K<font size=-1>.</font> GRANDY,
 <font size=-1>AND</font> J<font size=-1>. </font>L<font size=-1>.</font> KENNEDY.



No linkage between D<SUB>2</SUB> dopamine receptor gene region and schizophrenia.
<I>Arch. Gen. Psychiatry</I>
48: 643-647, 1991<!-- HIGHWIRE ID="78:1:189:312" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=archpsyc&resid=48/7/643" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B313"><!-- comment for mosaic --></a>
<P>313. &nbsp; 

MONSMA, F<font size=-1>. </font>J<font size=-1>.</font>,
A<font size=-1>. </font>C<font size=-1>.</font> BARTON,
 <font size=-1>AND</font> D<font size=-1>. </font>R<font size=-1>.</font> SIBLEY.



Expression of functional D<SUB>2</SUB> dopamine receptors following differentiation of Y-79 human retinoblastoma cells.
<I>J. Neurochem.</I>
54: 1200-1207, 1990<!-- HIGHWIRE ID="78:1:189:313" --><A HREF="/cgi/external_ref?access_num=1968958&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B314"><!-- comment for mosaic --></a>
<P>314. &nbsp; 

MONSMA, F<font size=-1>. </font>J<font size=-1>.</font>,
L<font size=-1>. </font>C<font size=-1>.</font> MAHAN,
L<font size=-1>. </font>D<font size=-1>.</font> M<font size=-1>C</font>VITTIE,
C<font size=-1>. </font>R<font size=-1>.</font> GERFEN,
 <font size=-1>AND</font> D<font size=-1>. </font>R<font size=-1>.</font> SIBLEY.



Molecular cloning and expression of a D<SUB>1</SUB> dopamine receptor linked to adenylyl cyclase activation.
<I>Proc. Natl. Acad. Sci. USA</I>
87: 6723-6727, 1990<!-- HIGHWIRE ID="78:1:189:314" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=87/17/6723" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B315"><!-- comment for mosaic --></a>
<P>315. &nbsp; 

MONSMA, F<font size=-1>. </font>J<font size=-1>.</font>,
L<font size=-1>. </font>D<font size=-1>.</font> M<font size=-1>C</font>VITTIE,
C<font size=-1>. </font>R<font size=-1>.</font> GERFEN,
L<font size=-1>. </font>C<font size=-1>.</font> MAHAN,
 <font size=-1>AND</font> D<font size=-1>. </font>R<font size=-1>.</font> SIBLEY.



Multiple D<SUB>2</SUB> dopamine receptors produced by alternative RNA splicing.
<I>Nature</I>
342: 926-929, 1989<!-- HIGHWIRE ID="78:1:189:315" --><A HREF="/cgi/external_ref?access_num=2480527&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B316"><!-- comment for mosaic --></a>
<P>316. &nbsp; 

MONTASTRUC, J<font size=-1>. </font>L<font size=-1>.</font>,
G<font size=-1>.</font> GAILLARD,
O<font size=-1>.</font> RASCOL,
M<font size=-1>. </font>A<font size=-1>.</font> TRAN,
 <font size=-1>AND</font> P<font size=-1>.</font> MONTASTRUC.



Effect of apomorphine on adrenal medullary catecholamine levels.
<I>Fundam. Clin. Pharmacol.</I>
3: 665-670, 1989<!-- HIGHWIRE ID="78:1:189:316" --><A HREF="/cgi/external_ref?access_num=2575570&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B317"><!-- comment for mosaic --></a>
<P>317. &nbsp; 

MONTMAYEUR, J<font size=-1>. </font>P<font size=-1>.</font>,
 <font size=-1>AND</font> E<font size=-1>.</font> BORRELLI.



Transcription mediated by a cAMP-responsive promoter element is reduced upon activation of dopamine D<SUB>2</SUB> receptors.
<I>Proc. Natl. Acad. Sci. USA</I>
88: 3135-3139, 1991<!-- HIGHWIRE ID="78:1:189:317" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=88/8/3135" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B318"><!-- comment for mosaic --></a>
<P>318. &nbsp; 

MONTMAYEUR, J<font size=-1>. </font>P<font size=-1>.</font>,
J<font size=-1>.</font> GUIRAMAND,
 <font size=-1>AND</font> E<font size=-1>.</font> BORRELLI.



Preferential coupling between dopamine D<SUB>2</SUB> receptors and G proteins.
<I>Mol. Endocrinol.</I>
7: 161-170, 1993<!-- HIGHWIRE ID="78:1:189:318" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=mend&resid=7/2/161" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B319"><!-- comment for mosaic --></a>
<P>319. &nbsp; 

MRZLJAK, L<font size=-1>.</font>,
C<font size=-1>.</font> BERGSON,
M<font size=-1>.</font> PAPPY,
R<font size=-1>.</font> HUFF,
R<font size=-1>.</font> LEVENSON,
 <font size=-1>AND</font> P<font size=-1>. </font>S<font size=-1>.</font> GOLDMAN<font size=-1>-</font>RAKIC.



Localization of dopamine D<SUB>4</SUB> receptors in GABAergic neurons of the primate brain.
<I>Nature</I>
381: 245-248, 1996<!-- HIGHWIRE ID="78:1:189:319" --><A HREF="/cgi/external_ref?access_num=8622768&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B320"><!-- comment for mosaic --></a>
<P>320. &nbsp; 

MUNEMURA, M<font size=-1>.</font>,
T<font size=-1>. </font>E<font size=-1>.</font> COTE,
K<font size=-1>.</font> TSURUTA,
R<font size=-1>. </font>L<font size=-1>.</font> ESKAY,
 <font size=-1>AND</font> J<font size=-1>. </font>W<font size=-1>.</font> KEBABIAN.



The dopamine receptor in the intermediate lobe of the rat anterior pituitary gland: pharmacological characterization.
<I>Endocrinology</I>
106: 1676-1683, 1980<!-- HIGHWIRE ID="78:1:189:320" --><!-- /HIGHWIRE -->.</P>
<a name="B321"><!-- comment for mosaic --></a>
<P>321. &nbsp; 

MUTO, S<font size=-1>.</font>,
K<font size=-1>.</font> TABEI,
Y<font size=-1>.</font> ASANO,
 <font size=-1>AND</font> M<font size=-1>.</font> IMAI.



Dopaminergic inhibition of the action of vasopressin on the cortical collecting tubule.
<I>Eur. J.&nbsp;Pharmacol.</I>
114: 393-397, 1985<!-- HIGHWIRE ID="78:1:189:321" --><A HREF="/cgi/external_ref?access_num=4065204&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B322"><!-- comment for mosaic --></a>
<P>322. &nbsp; 

NAKAJIMA, T<font size=-1>.</font>,
J<font size=-1>.-</font>L<font size=-1>.</font> DAVAL,
P<font size=-1>. </font>F<font size=-1>.</font> MORGAN,
R<font size=-1>. </font>M<font size=-1>.</font> POST,
 <font size=-1>AND</font> P<font size=-1>. </font>J<font size=-1>.</font> MARAGOS.



Adenosynergic modulation of caffeine-induced c-<I>fos</I> mRNA expression in mouse brain.
<I>Brain Res.</I>
501: 307-314, 1989<!-- HIGHWIRE ID="78:1:189:322" --><A HREF="/cgi/external_ref?access_num=2510904&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B323"><!-- comment for mosaic --></a>
<P>323. &nbsp; 

NAKAJIMA, T<font size=-1>.</font>,
 <font size=-1>AND</font> I<font size=-1>.</font> KURUMA.



Characterization with <SUP>3</SUP>H-haloperidol of the dopamine receptor in the rat kidney particulate preparation.
<I>Jpn. J.&nbsp;Pharmacol.</I>
30: 891-898, 1980<!-- HIGHWIRE ID="78:1:189:323" --><A HREF="/cgi/external_ref?access_num=6113299&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B324"><!-- comment for mosaic --></a>
<P>324. &nbsp; 

NANKO, S<font size=-1>.</font>,
R<font size=-1>.</font> FUKUDA,
M<font size=-1>.</font> HATTORI,
T<font size=-1>.</font> SASAKI,
X<font size=-1>. </font>Y<font size=-1>.</font> DAI,
K<font size=-1>.</font> YAMAGUCHI,
 <font size=-1>AND</font> H<font size=-1>.</font> KAZAMATSURI.



Further evidence of no linkage between schizophrenia and the dopamine D<SUB>3</SUB> receptor gene locus.
<I>Am. J.&nbsp;Med. Genet.</I>
54: 264-267, 1994<!-- HIGHWIRE ID="78:1:189:324" --><A HREF="/cgi/external_ref?access_num=7810586&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B325"><!-- comment for mosaic --></a>
<P>325. &nbsp; 

NANKO, S<font size=-1>.</font>,
M<font size=-1>.</font> HATTORI,
K<font size=-1>.</font> IKEDA,
T<font size=-1>.</font> SASAKI,
H<font size=-1>.</font> KAZAMATSURI,
 <font size=-1>AND</font> S<font size=-1>.</font> KUWATA.



Dopamine D<SUB>3</SUB> and D<SUB>4</SUB> receptor gene polymorphisms and Parkinson's disease.
<I>Lancet</I>
341: 689-690, 1993<!-- HIGHWIRE ID="78:1:189:325" --><A HREF="/cgi/external_ref?access_num=8095589&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B326"><!-- comment for mosaic --></a>
<P>326. &nbsp; 

NASH, S<font size=-1>. </font>R<font size=-1>.</font>,
N<font size=-1>.</font> GODINOT,
 <font size=-1>AND</font> M<font size=-1>. </font>G<font size=-1>.</font> CARON.



Cloning and characterization of the opossum kidney cell D<SUB>1</SUB> dopamine receptor: expression of identical D<SUB>1A</SUB> and D<SUB>1B</SUB> dopamine receptor mRNAs in opossum kidney and brain.
<I>Mol. Pharmacol.</I>
44: 918-925, 1993<!-- HIGHWIRE ID="78:1:189:326" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=44/5/918" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B327"><!-- comment for mosaic --></a>
<P>327. &nbsp; 

NATHANS, J<font size=-1>.</font>,
 <font size=-1>AND</font> D<font size=-1>. </font>S<font size=-1>.</font> HOGNESS.



Isolation, sequence analysis and intron-exon arrangement of the gene encoding bovine rhodopsin.
<I>Cell</I>
34: 807-814, 1983<!-- HIGHWIRE ID="78:1:189:327" --><A HREF="/cgi/external_ref?access_num=6194890&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B328"><!-- comment for mosaic --></a>
<P>328. &nbsp; 

NEVE, K<font size=-1>. </font>A<font size=-1>.</font>,
B<font size=-1>. </font>A<font size=-1>.</font> COX,
A<font size=-1>. </font>R<font size=-1>.</font> HENNINGSEN,
A<font size=-1>.</font> SPANOYANNIS,
 <font size=-1>AND</font> R<font size=-1>. </font>L<font size=-1>.</font> NEVE.



Pivotal role for aspartate-80 in the regulation of dopamine D<SUB>2</SUB> receptor affinity for drugs and inhibition of adenylyl cyclase.
<I>Mol. Pharmacol.</I>
39: 733-739, 1991<!-- HIGHWIRE ID="78:1:189:328" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=39/6/733" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B329"><!-- comment for mosaic --></a>
<P>329. &nbsp; 

NEVE, K<font size=-1>. </font>A<font size=-1>.</font>,
M<font size=-1>. </font>R<font size=-1>.</font> KOZLOWSKI,
 <font size=-1>AND</font> M<font size=-1>. </font>P<font size=-1>.</font> ROSSER.



Dopamine D<SUB>2</SUB> receptor stimulation of Na<SUP>+</SUP>/H<SUP>+</SUP> exchange assessed by quantification of extracellular acidification.
<I>J. Biol. Chem.</I>
267: 25748-25753, 1992<!-- HIGHWIRE ID="78:1:189:329" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=267/36/25748" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B330"><!-- comment for mosaic --></a>
<P>330. &nbsp; 

NGUYEN, T<font size=-1>. </font>V<font size=-1>.</font>,
B<font size=-1>.</font> KOSOFSKY,
R<font size=-1>.</font> BIRNBAUM,
B<font size=-1>. </font>M<font size=-1>.</font> COHEN,
 <font size=-1>AND</font> S<font size=-1>. </font>E<font size=-1>.</font> HYMAN.



Differential expression of c-<I>fos</I> and zif 268&nbsp;in rat striatum after haloperidol, clozapine, and amphetamine.
<I>Proc. Natl. Acad. Sci. USA</I>
89: 4270-4274, 1992<!-- HIGHWIRE ID="78:1:189:330" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=89/10/4270" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B331"><!-- comment for mosaic --></a>
<P>331. &nbsp; 

NISHI, A<font size=-1>.</font>,
A<font size=-1>. </font>M<font size=-1>.</font> BERTORELLO,
 <font size=-1>AND</font> A<font size=-1>.</font> APERIA.



High salt diet down-regulates proximal tubule Na<SUP>+</SUP>,K<SUP>+</SUP>-ATPase activity in Dahl salt-sensitive but not Dahl salt-resistant rats: evidence of defective dopamine regulation.
<I>Acta Physiol. Scand.</I>
144: 263-267, 1992<!-- HIGHWIRE ID="78:1:189:331" --><A HREF="/cgi/external_ref?access_num=1316713&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B332"><!-- comment for mosaic --></a>
<P>332. &nbsp; 

NISHI, A<font size=-1>.</font>,
A<font size=-1>. </font>C<font size=-1>.</font> EKLOF,
A<font size=-1>. </font>M<font size=-1>.</font> BERTORELLO,
 <font size=-1>AND</font> A<font size=-1>.</font> APERIA.



Dopamine regulation of renal Na<SUP>+</SUP>,K<SUP>+</SUP>-ATPase activity is lacking in Dahl salt-sensitive rats.
<I>Hypertension</I>
21: 767-771, 1993<!-- HIGHWIRE ID="78:1:189:332" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=hypertensionaha&resid=21/6/767" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B333"><!-- comment for mosaic --></a>
<P>333. &nbsp; 

NORMAND, E<font size=-1>.</font>,
T<font size=-1>.</font> POPOVICI,
D<font size=-1>.</font> FELLMANN,
 <font size=-1>AND</font> B<font size=-1>.</font> BLOCH.



Anatomical study of enkephalin gene expression in the rat forebrain following haloperidol treatment.
<I>Neurosci. Lett.</I>
83: 232-236, 1987<!-- HIGHWIRE ID="78:1:189:333" --><A HREF="/cgi/external_ref?access_num=3441305&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B334"><!-- comment for mosaic --></a>
<P>334. &nbsp; 

NOTH, R<font size=-1>. </font>H<font size=-1>.</font>,
R<font size=-1>. </font>W<font size=-1>.</font> M<font size=-1>C</font>CALLUM,
C<font size=-1>.</font> CONTINO,
 <font size=-1>AND</font> J<font size=-1>.</font> MAVELIK.



Tonic dopaminergic suppression of plasma aldosterone.
<I>J. Clin. Endocrinol. Metab.</I>
51: 64-69, 1980<!-- HIGHWIRE ID="78:1:189:334" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jcem&resid=51/1/64" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B335"><!-- comment for mosaic --></a>
<P>335. &nbsp; 

OATES, N<font size=-1>. </font>S<font size=-1>.</font>,
S<font size=-1>. </font>G<font size=-1>.</font> BALL,
C<font size=-1>. </font>M<font size=-1>.</font> PERKINS,
 <font size=-1>AND</font> M<font size=-1>. </font>R<font size=-1>.</font> LEE.



Plasma and urine dopamine in man given sodium chloride in the diet.
<I>Clin. Sci. Mol. Med.</I>
56: 261-264, 1979<!-- HIGHWIRE ID="78:1:189:335" --><!-- /HIGHWIRE -->.</P>
<a name="B336"><!-- comment for mosaic --></a>
<P>336. &nbsp; 

O<font size=-1>'</font>CONNELL, D<font size=-1>. </font>P<font size=-1>.</font>,
S<font size=-1>. </font>J<font size=-1>.</font> BOTKIN,
S<font size=-1>. </font>I<font size=-1>.</font> RAMOS,
D<font size=-1>. </font>R<font size=-1>.</font> SIBLEY,
M<font size=-1>. </font>A<font size=-1>.</font> ARIANO,
R<font size=-1>. </font>A<font size=-1>.</font> FELDER,
 <font size=-1>AND</font> R<font size=-1>. </font>M<font size=-1>.</font> CAREY.



Localization of dopamine D<SUB>1A</SUB> receptor protein in rat kidneys.
<I>Am. J.&nbsp;Physiol.</I>
268(<I>Renal Fluid Electrolyte Physiol.</I> 37): F1185-F1197, 1995<!-- HIGHWIRE ID="78:1:189:336" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=268/6/F1185" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B337"><!-- comment for mosaic --></a>
<P>337. &nbsp; 

O<font size=-1>'</font>DOWD, B<font size=-1>. </font>F<font size=-1>.</font>.



Structure of dopamine receptors.
<I>J. Neurochem.</I>
60: 804-816, 1993<!-- HIGHWIRE ID="78:1:189:337" --><A HREF="/cgi/external_ref?access_num=8436971&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B338"><!-- comment for mosaic --></a>
<P>338. &nbsp; 

O<font size=-1>'</font>DOWD, B<font size=-1>. </font>F<font size=-1>.</font>,
M<font size=-1>.</font> HNATOWICH,
M<font size=-1>. </font>G<font size=-1>.</font> CARON,
R<font size=-1>. </font>J<font size=-1>.</font> LEFKOWITZ,
 <font size=-1>AND</font> R<font size=-1>. </font>J<font size=-1>.</font> BOUVIER.



Palmitoylation of the human <IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BASELINE ALT="beta "><SUB>2</SUB> adrenergic receptor: mutation of CYS 341&nbsp;in the carboxy tail leads to an uncoupled, non-palmitoylated form of the receptor.
<I>J. Biol. Chem.</I>
264: 7564-7569, 1989<!-- HIGHWIRE ID="78:1:189:338" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=264/13/7564" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B339"><!-- comment for mosaic --></a>
<P>339. &nbsp; 

OHBU, K<font size=-1>.</font>,
 <font size=-1>AND</font> R<font size=-1>. </font>A<font size=-1>.</font> FELDER.



DA<SUB>1</SUB> dopamine receptors in renal cortical collecting duct.
<I>Am. J.&nbsp;Physiol.</I>
261(<I>Renal Fluid Electrolyte Physiol.</I> 30): F890-F895, 1991<!-- HIGHWIRE ID="78:1:189:339" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=261/5/F890" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B340"><!-- comment for mosaic --></a>
<P>340. &nbsp; 

OHBU, K<font size=-1>.</font>,
 <font size=-1>AND</font> R<font size=-1>. </font>A<font size=-1>.</font> FELDER.



Nephron specificity of dopamine receptor-adenylyl cyclase defect in spontaneous hypertension.
<I>Am. J.&nbsp;Physiol.</I>
264(<I>Renal Fluid Electrolyte Physiol.</I> 33): F274-F279, 1993<!-- HIGHWIRE ID="78:1:189:340" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=264/2/F274" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B341"><!-- comment for mosaic --></a>
<P>341. &nbsp; 

OHBU, K<font size=-1>.</font>,
F<font size=-1>. </font>J<font size=-1>.</font> KASKEL,
S<font size=-1>.</font> KINOSHITA,
 <font size=-1>AND</font> R<font size=-1>. </font>A<font size=-1>.</font> FELDER.



Dopamine-1 receptors in the proximal convoluted tubule of Dahl rats: defective coupling to adenylate cyclase.
<I>Am. J.&nbsp;Physiol.</I>
268(<I>Regulatory Integrative Comp. Physiol.</I> 37): R231-R235, 1995<!-- HIGHWIRE ID="78:1:189:341" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajpregu&resid=268/1/R231" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B342"><!-- comment for mosaic --></a>
<P>342. &nbsp; 

OLSEN, N<font size=-1>. </font>V<font size=-1>.</font>,
J<font size=-1>. </font>M<font size=-1>.</font> HANSEN,
S<font size=-1>. </font>D<font size=-1>.</font> LADEFORD,
N<font size=-1>.</font> FOGH<font size=-1>-</font>ANDERSEN,
 <font size=-1>AND</font> P<font size=-1>. </font>P<font size=-1>.</font> LEYSSAC.



Renal tubular reabsorption of sodium and water during infusion of low-dose dopamine in normal man.
<I>Clin. Sci.</I>
78: 503-507, 1990<!-- HIGHWIRE ID="78:1:189:342" --><A HREF="/cgi/external_ref?access_num=2162278&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B343"><!-- comment for mosaic --></a>
<P>343. &nbsp; 

O<font size=-1>'</font>MALLEY, K<font size=-1>. </font>L<font size=-1>.</font>,
S<font size=-1>.</font> HARMON,
L<font size=-1>.</font> TANG,
 <font size=-1>AND</font> R<font size=-1>. </font>D<font size=-1>.</font> TODD.



The rat dopamine D<SUB>4</SUB> receptor: sequence, gene structure, and demonstration of expression in the cardiovascular system.
<I>New Biologist</I>
4: 137-146, 1992<!-- HIGHWIRE ID="78:1:189:343" --><A HREF="/cgi/external_ref?access_num=1554689&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B344"><!-- comment for mosaic --></a>
<P>344. &nbsp; 

ONALI, P<font size=-1>. </font>L<font size=-1>.</font>,
M<font size=-1>. </font>C<font size=-1>.</font> OLIANAS,
 <font size=-1>AND</font> G<font size=-1>. </font>L<font size=-1>.</font> GESSA.



Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum.
<I>Mol. Pharmacol.</I>
28: 138-145, 1985<!-- HIGHWIRE ID="78:1:189:344" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=28/2/138" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B345"><!-- comment for mosaic --></a>
<P>345. &nbsp; 

ONALI, P<font size=-1>. </font>L<font size=-1>.</font>,
J<font size=-1>. </font>P<font size=-1>.</font> SCHWARTZ,
 <font size=-1>AND</font> E<font size=-1>.</font> COSTA.



Dopaminergic modulation of adenylate cyclase stimulation by vasoactive intestinal peptide (VIP) in anterior pituitary.
<I>Proc. Natl. Acad. Sci. USA</I>
78: 6531-6534, 1981<!-- HIGHWIRE ID="78:1:189:345" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=78/10/6531" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B346"><!-- comment for mosaic --></a>
<P>346. &nbsp; 

OSIPENKO, O<font size=-1>. </font>N<font size=-1>.</font>,
P<font size=-1>.</font> VARNAI,
A<font size=-1>.</font> MIKE,
A<font size=-1>.</font> SPAT,
 <font size=-1>AND</font> E<font size=-1>. </font>S<font size=-1>.</font> VIZI.



Dopamine blocks T-type calcium channels in cultured rat adrenal glomerulosa cells.
<I>Endocrinology</I>
134: 511-514, 1994<!-- HIGHWIRE ID="78:1:189:346" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=endo&resid=134/1/511" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B347"><!-- comment for mosaic --></a>
<P>347. &nbsp; 

OVCHINNIKOV, Y<font size=-1>.</font>,
N<font size=-1>.</font> ABDULAEV,
 <font size=-1>AND</font> A<font size=-1>.</font> BOGACHUK.



Two adjacent cysteine residues in the C-terminal cytoplasmic fragment of bovine rhodopsin are palmitoylated.
<I>FEBS Lett.</I>
230: 1-5, 1988<!-- HIGHWIRE ID="78:1:189:347" --><A HREF="/cgi/external_ref?access_num=3350146&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B348"><!-- comment for mosaic --></a>
<P>348. &nbsp; 

PACKARD, M<font size=-1>. </font>G<font size=-1>.</font>,
 <font size=-1>AND</font> N<font size=-1>. </font>M<font size=-1>.</font> WHITE.



Dissociation of hippocampus and caudate nucleus memory systems by post-training intracerebral injection of dopamine agonists.
<I>Behav. Neurosci.</I>
105: 295-306, 1991<!-- HIGHWIRE ID="78:1:189:348" --><A HREF="/cgi/external_ref?access_num=1675062&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B349"><!-- comment for mosaic --></a>
<P>349. &nbsp; 

PARSONS, L<font size=-1>. </font>H<font size=-1>.</font>,
S<font size=-1>. </font>B<font size=-1>.</font> CAINE,
P<font size=-1>.</font> SOKOLOFF,
J<font size=-1>.-</font>C<font size=-1>.</font> SCHWARTZ,
G<font size=-1>. </font>F<font size=-1>.</font> KOOB,
 <font size=-1>AND</font> F<font size=-1>.</font> WEISS.



Neurochemical evidence that postsynaptic nucleus accumbens D<SUB>3</SUB> receptor stimulation enhances cocaine reinforcement.
<I>J. Neurochem.</I>
67: 1078-1089, 1996<!-- HIGHWIRE ID="78:1:189:349" --><A HREF="/cgi/external_ref?access_num=8752115&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B350"><!-- comment for mosaic --></a>
<P>350. &nbsp; 

PAUL, M<font size=-1>. </font>L<font size=-1>.</font>,
A<font size=-1>. </font>M<font size=-1>.</font> GRAYBIEL,
J<font size=-1>.-</font>C<font size=-1>.</font> DAVID,
 <font size=-1>AND</font> H<font size=-1>. </font>A<font size=-1>.</font> ROBERTSON.



D<SUB>1</SUB>-like and D<SUB>2</SUB>-like dopamine receptors synergistically activate rotation and c-<I>fos</I> expression in the dopamine-depleted striatum in a rat model of Parkinson's disease.
<I>J. Neurosci.</I>
12: 3729-3742, 1992<!-- HIGHWIRE ID="78:1:189:350" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jneuro&resid=12/10/3729" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B351"><!-- comment for mosaic --></a>
<P>351. &nbsp; 

PEDERSEN, U<font size=-1>. </font>B<font size=-1>.</font>,
B<font size=-1>.</font> NORBY,
A<font size=-1>. </font>A<font size=-1>.</font> JENSEN,
M<font size=-1>.</font> SCHI<font size=-1>&Oslash;</font>DT,
A<font size=-1>.</font> HANSEN,
P<font size=-1>.</font> SUHR<font size=-1>-</font>JESSEN,
M<font size=-1>.</font> SCHEIDELER,
O<font size=-1>.</font> THASTRUP,
 <font size=-1>AND</font> P<font size=-1>. </font>H<font size=-1>.</font> ANDERSEN.



Characteristics of stably expressed D<SUB>1a</SUB> and D<SUB>1b</SUB> receptors: atypical behaviour of the dopamine D<SUB>1b</SUB> receptor.
<I>Eur. J.&nbsp;Pharmacol.</I>
267: 85-93, 1994<!-- HIGHWIRE ID="78:1:189:351" --><A HREF="/cgi/external_ref?access_num=8206133&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B352"><!-- comment for mosaic --></a>
<P>352. &nbsp; 

PELLEGRINI, I<font size=-1>.</font>,
R<font size=-1>.</font> ROSLONJANAHARY,
G<font size=-1>.</font> GUNZ,
P<font size=-1>.</font> BERTRAND,
S<font size=-1>.</font> DELIVET,
C<font size=-1>. </font>P<font size=-1>.</font> JEDYNAK,
C<font size=-1>.</font> KORDON,
F<font size=-1>.</font> PEILLON,
P<font size=-1>.</font> JAQUET,
 <font size=-1>AND</font> A<font size=-1>.</font> ENJALBERT.



Resistance to bromocriptine in prolactinomas.
<I>J. Clin. Endocrinol. Metab.</I>
69: 500-509, 1989<!-- HIGHWIRE ID="78:1:189:352" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jcem&resid=69/3/500" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B353"><!-- comment for mosaic --></a>
<P>353. &nbsp; 

PENDLETON, R<font size=-1>. </font>G<font size=-1>.</font>,
 <font size=-1>AND</font> S<font size=-1>. </font>S<font size=-1>.</font> SHERMAN.



Studies concerning dopamine diuresis in the rat.
<I>Arch. Int. Pharmacodyn. Ther.</I>
222: 94-102, 1976<!-- HIGHWIRE ID="78:1:189:353" --><A HREF="/cgi/external_ref?access_num=10862&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B354"><!-- comment for mosaic --></a>
<P>354. &nbsp; 

PHILLIPS, G<font size=-1>. </font>D<font size=-1>.</font>,
T<font size=-1>. </font>W<font size=-1>.</font> ROBBINS,
 <font size=-1>AND</font> B<font size=-1>. </font>J<font size=-1>.</font> EVERITT.



Bilateral intra-accumbens self-administration of <I>d</I>-amphetamine: antagonism with intra-accumbens SCH 23390&nbsp;and sulpiride.
<I>Psychopharmacology</I>
114: 477-485, 1994<!-- HIGHWIRE ID="78:1:189:354" --><A HREF="/cgi/external_ref?access_num=7855206&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B355"><!-- comment for mosaic --></a>
<P>355. &nbsp; 

PILON, C<font size=-1>.</font>,
D<font size=-1>.</font> L<font size=-1>&Eacute;</font>VESQUE,
V<font size=-1>.</font> DIMITRIADOU,
N<font size=-1>.</font> GRIFFON,
M<font size=-1>.-</font>P<font size=-1>.</font> MARTRES,
J<font size=-1>.-</font>C<font size=-1>.</font> SCHWARTZ,
 <font size=-1>AND</font> P<font size=-1>.</font> SOKOLOFF.



Functional coupling of the human dopamine D<SUB>3</SUB> receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line.
<I>Eur. J.&nbsp;Pharmacol.</I>
268: 129-139, 1994<!-- HIGHWIRE ID="78:1:189:355" --><A HREF="/cgi/external_ref?access_num=7957635&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B356"><!-- comment for mosaic --></a>
<P>356. &nbsp; 

PIOMELLI, D<font size=-1>.</font>,
C<font size=-1>.</font> PILON,
B<font size=-1>.</font> GIROS,
P<font size=-1>.</font> SOKOLOFF,
M<font size=-1>.-</font>P<font size=-1>.</font> MARTRES,
 <font size=-1>AND</font> J<font size=-1>.-</font>C<font size=-1>.</font> SCHWARTZ.



Dopamine activation of the arachidonic acid cascade as a basis for D<SUB>1</SUB>/D<SUB>2</SUB> receptor synergism.
<I>Nature</I>
353: 164-167, 1991<!-- HIGHWIRE ID="78:1:189:356" --><A HREF="/cgi/external_ref?access_num=1909771&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B357"><!-- comment for mosaic --></a>
<P>357. &nbsp; 

PIZZI, M<font size=-1>.</font>,
A<font size=-1>.</font> VALERIO,
M<font size=-1>.</font> BENARESE,
C<font size=-1>.</font> MISSALE,
M<font size=-1>. </font>O<font size=-1>.</font> CARRUBA,
M<font size=-1>.</font> MEMO,
 <font size=-1>AND</font> P<font size=-1>. </font>F<font size=-1>.</font> SPANO.



Selective stimulation of a subtype of dopamine D<SUB>2</SUB> receptors by the azepine derivative BHT920 in rat pituitary.
<I>Mol. Neuropharmacol.</I>
1: 37-42, 1990.<!-- HIGHWIRE ID="78:1:189:357" --><!-- /HIGHWIRE --></P>
<a name="B358"><!-- comment for mosaic --></a>
<P>358. &nbsp; 

PORTER, I<font size=-1>. </font>D<font size=-1>.</font>,
B<font size=-1>. </font>J<font size=-1>.</font> WHITEHOUSE,
G<font size=-1>. </font>M<font size=-1>.</font> PRICE,
J<font size=-1>. </font>P<font size=-1>.</font> HINSON,
 <font size=-1>AND</font> G<font size=-1>. </font>P<font size=-1>.</font> VINSON.



Effects of dopamine, high potassium concentration and field stimulation on the secretion of aldosterone by the perfused rat adrenal gland.
<I>J. Endocrinol.</I>
133: 257-282, 1992<!-- HIGHWIRE ID="78:1:189:358" --><!-- /HIGHWIRE -->.</P>
<a name="B359"><!-- comment for mosaic --></a>
<P>359. &nbsp; 

PORTER, T<font size=-1>. </font>E<font size=-1>.</font>,
C<font size=-1>. </font>D<font size=-1>.</font> WILES,
 <font size=-1>AND</font> S<font size=-1>.</font> FRAWLEY.



Stimulation of lactotrope differentiation in vitro by fibroblast growth factor.
<I>Endocrinology</I>
134: 164-168, 1994<!-- HIGHWIRE ID="78:1:189:359" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=endo&resid=134/1/164" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B360"><!-- comment for mosaic --></a>
<P>360. &nbsp; 

POTENZA, M<font size=-1>. </font>N<font size=-1>.</font>,
G<font size=-1>. </font>F<font size=-1>.</font> GRAMINSKI,
C<font size=-1>.</font> SCHMAUSS,
 <font size=-1>AND</font> M<font size=-1>. </font>R<font size=-1>.</font> LERNER.



Functional expression and characterization of human D<SUB>2</SUB> and D<SUB>3</SUB> dopamine receptors.
<I>J. Neurosci.</I>
14: 1463-1476, 1994<!-- HIGHWIRE ID="78:1:189:360" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jneuro&resid=14/3/1463" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B361"><!-- comment for mosaic --></a>
<P>361. &nbsp; 

PUPILLI, C<font size=-1>.</font>,
R<font size=-1>.</font> LANZILLOTTI,
G<font size=-1>.</font> FIORELLI,
C<font size=-1>.</font> SELLI,
R<font size=-1>. </font>A<font size=-1>.</font> GOMEZ,
R<font size=-1>. </font>M<font size=-1>.</font> CAREY,
M<font size=-1>.</font> SERIO,
 <font size=-1>AND</font> M<font size=-1>.</font> MANNELLI.



Dopamine D<SUB>2</SUB> receptor gene expression and binding sites in adrenal medulla and pheocromocytoma.
<I>J. Clin. Endocrinol. Metab.</I>
79: 56-61, 1994<!-- HIGHWIRE ID="78:1:189:361" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jcem&resid=79/1/56" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B362"><!-- comment for mosaic --></a>
<P>362. &nbsp; 

PROBST, W<font size=-1>. </font>C<font size=-1>.</font>,
L<font size=-1>. </font>A<font size=-1>.</font> SNYDER,
D<font size=-1>. </font>I<font size=-1>.</font> SCHUSTER,
J<font size=-1>.</font> BROSIUS,
 <font size=-1>AND</font> S<font size=-1>. </font>C<font size=-1>.</font> SEALFON.



Sequence alignment of the G-protein coupled receptor superfamily.
<I>DNA Cell Biol.</I>
11: 1-20, 1992<!-- HIGHWIRE ID="78:1:189:362" --><A HREF="/cgi/external_ref?access_num=1310857&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B363"><!-- comment for mosaic --></a>
<P>363. &nbsp; 

RAGSDALE, N<font size=-1>. </font>V<font size=-1>.</font>,
M<font size=-1>.</font> LYND,
R<font size=-1>. </font>L<font size=-1>.</font> CHEVALIER,
R<font size=-1>. </font>A<font size=-1>.</font> FELDER,
M<font size=-1>. </font>J<font size=-1>.</font> PEACH,
 <font size=-1>AND</font> R<font size=-1>. </font>M<font size=-1>.</font> CAREY.



Selective peripheral dopamine-1 receptor stimulation. Differential responses to sodium loading and depletion in humans.
<I>Hypertension</I>
15: 914-921, 1990<!-- HIGHWIRE ID="78:1:189:363" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=hypertensionaha&resid=15/6/914" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B364"><!-- comment for mosaic --></a>
<P>364. &nbsp; 

RAJFER, S<font size=-1>. </font>I<font size=-1>.</font>,
 <font size=-1>AND</font> F<font size=-1>. </font>R<font size=-1>.</font> DAVIS.



Role of dopamine receptors and the utility of dopamine agonists in heart failure.
<I>Circulation</I>
82: 97-102, 1990<!-- HIGHWIRE ID="78:1:189:364" --><!-- /HIGHWIRE -->.</P>
<a name="B365"><!-- comment for mosaic --></a>
<P>365. &nbsp; 

RAMSEY, N<font size=-1>. </font>F<font size=-1>.</font>,
 <font size=-1>AND</font> J<font size=-1>. </font>M<font size=-1>.</font> VAN REE.



Reward and abuse of opiates.
<I>Pharmacol. Toxicol.</I>
71: 81-94, 1992<!-- HIGHWIRE ID="78:1:189:365" --><A HREF="/cgi/external_ref?access_num=1438034&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B366"><!-- comment for mosaic --></a>
<P>366. &nbsp; 

RAPPAPORT, M<font size=-1>. </font>S<font size=-1>.</font>,
S<font size=-1>. </font>C<font size=-1>.</font> SEALFON,
A<font size=-1>.</font> PRIKHOZHAN,
G<font size=-1>. </font>W<font size=-1>.</font> HUNTLEY,
 <font size=-1>AND</font> J<font size=-1>. </font>H<font size=-1>.</font> MORRIS.



Heterogeneous distribution of D<SUB>1</SUB> ,&nbsp;D<SUB>2</SUB> and D<SUB>5</SUB> receptor mRNAs in monkey striatum.
<I>Brain Res.</I>
616: 242-250, 1993<!-- HIGHWIRE ID="78:1:189:366" --><A HREF="/cgi/external_ref?access_num=8358616&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B367"><!-- comment for mosaic --></a>
<P>367. &nbsp; RAVINDRANATHAN A., H.&nbsp;COON, L.&nbsp;DELISI, J.&nbsp;HOLIK, M.&nbsp;HOFF, A.&nbsp;BROWN, G.&nbsp;SHIELDS, T.&nbsp;CROW, <font size=-1>AND</font> W.&nbsp;BYERLEY. Linkage analysis between schizophrenia and a microsatellite polymorphism for the D<SUB>5</SUB> dopamine receptor gene. <I>Psychiatr. Genet.</I> 4: 77-80, 1994.<!-- HIGHWIRE ID="78:1:189:367" --><!-- /HIGHWIRE --></P>
<a name="B368"><!-- comment for mosaic --></a>
<P>368. &nbsp; 

REYNOLDS, G<font size=-1>. </font>P<font size=-1>.</font>.



Beyond the dopamine hypothesis.
<I>Br. J.&nbsp;Psychiatry</I>
155: 305-316, 1989<!-- HIGHWIRE ID="78:1:189:368" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=bjprcpsych&resid=155/3/305" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B369"><!-- comment for mosaic --></a>
<P>369. &nbsp; 

RICCI, A<font size=-1>.</font>,
W<font size=-1>. </font>L<font size=-1>.</font> COLLIER,
I<font size=-1>.</font> ROSSODIVITA,
 <font size=-1>AND</font> F<font size=-1>.</font> AMENTA.



Dopamine receptors mediating inhibition of the cyclic adenosine monophosphate generating system in the rat renal cortex.
<I>J. Auton. Pharmacol.</I>
11: 121-127, 1991<!-- HIGHWIRE ID="78:1:189:369" --><A HREF="/cgi/external_ref?access_num=1675217&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B370"><!-- comment for mosaic --></a>
<P>370. &nbsp; 

RICCI, A<font size=-1>.</font>,
I<font size=-1>.</font> ROSSODIVITA,
 <font size=-1>AND</font> F<font size=-1>.</font> AMENTA.



Dopamine DA-2 receptor sites in the rat renal cortex: a light microscope autoradiographic study.
<I>Naunyn-Schmiedebergs Arch. Pharmacol.</I>
344: 259-261, 1991<!-- HIGHWIRE ID="78:1:189:370" --><A HREF="/cgi/external_ref?access_num=1834952&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B371"><!-- comment for mosaic --></a>
<P>371. &nbsp; 

RIVET, J<font size=-1>. </font>M<font size=-1>.</font>,
V<font size=-1>.</font> AUDINOT,
A<font size=-1>.</font> GOBERT,
J<font size=-1>. </font>L<font size=-1>.</font> PEGLION,
 <font size=-1>AND</font> M<font size=-1>. </font>J<font size=-1>.</font> MILLAN.



Modulation of mesolimbic dopamine release by the selective dopamine D<SUB>3</SUB> receptor antagonist, (+)-S 14297.
<I>Eur. J.&nbsp;Pharmacol.</I>
265: 175-177, 1994<!-- HIGHWIRE ID="78:1:189:371" --><A HREF="/cgi/external_ref?access_num=7875234&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B372"><!-- comment for mosaic --></a>
<P>372. &nbsp; 

ROBERTSON, G<font size=-1>. </font>S<font size=-1>.</font>,
 <font size=-1>AND</font> H<font size=-1>. </font>C<font size=-1>.</font> FIBIGER.



Neuroleptics increase c-<I>fos</I> expression in the forebrain: contrasting effects of haloperidol and clozapine.
<I>Neuroscience</I>
46: 315-328, 1992<!-- HIGHWIRE ID="78:1:189:372" --><A HREF="/cgi/external_ref?access_num=1347406&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B373"><!-- comment for mosaic --></a>
<P>373. &nbsp; 

ROBERTSON, G<font size=-1>. </font>S<font size=-1>.</font>,
 <font size=-1>AND</font> M<font size=-1>.</font> JIAN.



D<SUB>1</SUB> and D<SUB>2</SUB> dopamine receptors differentially increase Fos-like immunoreactivity in accumbal projections to the ventral pallidum and midbrain.
<I>Neuroscience</I>
64: 1019-1034, 1995<!-- HIGHWIRE ID="78:1:189:373" --><A HREF="/cgi/external_ref?access_num=7753373&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B374"><!-- comment for mosaic --></a>
<P>374. &nbsp; 

ROBERTSON, G<font size=-1>. </font>S<font size=-1>.</font>,
S<font size=-1>. </font>R<font size=-1>.</font> VINCENT,
 <font size=-1>AND</font> H<font size=-1>. </font>C<font size=-1>.</font> FIBIGER.



D<SUB>1</SUB> and D<SUB>2</SUB> dopamine receptors differentially regulate c-<I>fos</I> expression in striatonigral and striatopallidal neurons.
<I>Neuroscience</I>
49: 285-296, 1992<!-- HIGHWIRE ID="78:1:189:374" --><A HREF="/cgi/external_ref?access_num=1359451&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B375"><!-- comment for mosaic --></a>
<P>375. &nbsp; 

ROBERTSON, H<font size=-1>. </font>A<font size=-1>.</font>.



Immediate-early genes, neuronal plasticity and memory.
<I>Biochem. Cell Biol.</I>
70: 729-737, 1992<!-- HIGHWIRE ID="78:1:189:375" --><A HREF="/cgi/external_ref?access_num=1482550&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B376"><!-- comment for mosaic --></a>
<P>376. &nbsp; 

ROBERTSON, H<font size=-1>. </font>A<font size=-1>.</font>.



Dopamine receptor interactions: some implications for the treatment of Parkinson's disease.
<I>Trends Neurosci.</I>
15: 201-206, 1992<!-- HIGHWIRE ID="78:1:189:376" --><A HREF="/cgi/external_ref?access_num=1378662&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B377"><!-- comment for mosaic --></a>
<P>377. &nbsp; 

ROBINSON, S<font size=-1>. </font>W<font size=-1>.</font>,
 <font size=-1>AND</font> M<font size=-1>. </font>G<font size=-1>.</font> CARON.



Chimeric D<SUB>2</SUB>/D<SUB>3</SUB> dopamine receptors efficiently inhibit adenylyl cyclase in HEK 293&nbsp;cells.
<I>J. Neurochem.</I>
67: 212-219, 1996<!-- HIGHWIRE ID="78:1:189:377" --><A HREF="/cgi/external_ref?access_num=8666994&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B378"><!-- comment for mosaic --></a>
<P>378. &nbsp; 

ROBINSON, S<font size=-1>. </font>W<font size=-1>.</font>,
K<font size=-1>. </font>R<font size=-1>.</font> JARVIE,
 <font size=-1>AND</font> M<font size=-1>. </font>G<font size=-1>.</font> CARON.



High affinity agonist binding to the dopamine D<SUB>3</SUB> receptor: chimeric receptors delineate a role for intracellular domains.
<I>Mol. Pharmacol.</I>
46: 352-356, 1994<!-- HIGHWIRE ID="78:1:189:378" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=46/2/352" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B379"><!-- comment for mosaic --></a>
<P>379. &nbsp; 

RODRIGUES, P<font size=-1>. </font>S<font size=-1>.</font>,
 <font size=-1>AND</font> J<font size=-1>. </font>E<font size=-1>.</font> DOWLING.



Dopamine induces neurite retraction in retinal horizontal cells via diacylglycerol and protein kinase C.
<I>Proc. Natl. Acad. Sci. USA</I>
87: 9693-9697, 1990<!-- HIGHWIRE ID="78:1:189:379" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=87/24/9693" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B380"><!-- comment for mosaic --></a>
<P>380. &nbsp; 

RUBINSTEIN, J<font size=-1>. </font>E<font size=-1>.</font>,
 <font size=-1>AND</font> R<font size=-1>. </font>J<font size=-1>.</font> HITZEMANN.



Further evidence against the coupling of dopamine receptors to phosphoinositide hydrolysis in rat striatum.
<I>Biochem. Pharmacol.</I>
39: 1965-1970, 1990<!-- HIGHWIRE ID="78:1:189:380" --><A HREF="/cgi/external_ref?access_num=1972328&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B381"><!-- comment for mosaic --></a>
<P>381. &nbsp; 

RUMP, L<font size=-1>. </font>C<font size=-1>.</font>,
E<font size=-1>.</font> SCHWERTFEGER,
M<font size=-1>. </font>J<font size=-1>.</font> SCHUSTER,
U<font size=-1>.</font> SCHAIBLE,
A<font size=-1>.</font> FRANKENSCHMIDT,
 <font size=-1>AND</font> P<font size=-1>. </font>J<font size=-1>.</font> SCHOLLMEYER.



Dopamine DA<SUB>2</SUB>-receptor activation inhibits noradrenaline release in human kidney slices.
<I>Kidney Int.</I>
43: 197-204, 1993<!-- HIGHWIRE ID="78:1:189:381" --><A HREF="/cgi/external_ref?access_num=8094472&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B382"><!-- comment for mosaic --></a>
<P>382. &nbsp; SACKTOR, B.&nbsp;Sodium gradient-dependent transport systems in renal proximal tubule brush border membrane vesicles. In: <I>Membranes and Transport,</I> edited by G.&nbsp;Mortonosi. New York: Plenum, 1982,&nbsp;p. 197-206.<!-- HIGHWIRE ID="78:1:189:382" --><!-- /HIGHWIRE --></P>
<a name="B383"><!-- comment for mosaic --></a>
<P>383. &nbsp; 

SAITO, I<font size=-1>.</font>,
S<font size=-1>.</font> ITSUJI,
E<font size=-1>.</font> TAKESHITA,
H<font size=-1>.</font> KAWABE,
M<font size=-1>.</font> NISHINO,
H<font size=-1>.</font> WAINAI,
C<font size=-1>.</font> HASEGAWA,
T<font size=-1>.</font> SARUTA,
S<font size=-1>.</font> NAGANO,
 <font size=-1>AND</font> T<font size=-1>.</font> SEKIHARA.



Increased urinary dopamine excretion in young patients with essential hypertension.
<I>Clin. Exp. Hypertens.</I>
16: 29-39, 1994<!-- HIGHWIRE ID="78:1:189:383" --><A HREF="/cgi/external_ref?access_num=8136773&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B384"><!-- comment for mosaic --></a>
<P>384. &nbsp; 

SAITO, I<font size=-1>.</font>,
E<font size=-1>.</font> TAKESHITA,
T<font size=-1>.</font> SARUTA,
S<font size=-1>.</font> NAGANO,
 <font size=-1>AND</font> T<font size=-1>.</font> SEKIHARA.



Urinary dopamine excretion in normotensive subjects with or without a family history of hypertension.
<I>J. Hypertens.</I>
4: 57-60, 1986<!-- HIGHWIRE ID="78:1:189:384" --><A HREF="/cgi/external_ref?access_num=3514746&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B385"><!-- comment for mosaic --></a>
<P>385. &nbsp; 

SAKAMOTO, T<font size=-1>.</font>,
C<font size=-1>.</font> CHEN,
 <font size=-1>AND</font> M<font size=-1>. </font>F<font size=-1>.</font> LOCKHANDWALA.



Lack of renal dopamine production during acute volume expansion in Dahl salt-sensitive rats.
<I>Clin. Exp. Hypertens.</I>
16: 197-206, 1994<!-- HIGHWIRE ID="78:1:189:385" --><A HREF="/cgi/external_ref?access_num=8193610&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B386"><!-- comment for mosaic --></a>
<P>386. &nbsp; 

SAMAMA, P<font size=-1>.</font>,
S<font size=-1>.</font> COTECCHIA,
T<font size=-1>.</font> COSTA,
 <font size=-1>AND</font> R<font size=-1>. </font>J<font size=-1>.</font> LEFKOWITZ.



A mutation-induced activated state of the <IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BASELINE ALT="beta "><SUB>2</SUB>-adrenergic receptor. Extending the ternary complex model.
<I>J. Biol. Chem.</I>
268: 4625-4636, 1993<!-- HIGHWIRE ID="78:1:189:386" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=268/7/4625" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B387"><!-- comment for mosaic --></a>
<P>387. &nbsp; 

SATOH, T<font size=-1>.</font>,
H<font size=-1>. </font>T<font size=-1>.</font> COHEN,
 <font size=-1>AND</font> A<font size=-1>. </font>I<font size=-1>.</font> KATZ.



Intracellular signaling in the regulation of renal Na<SUP>+</SUP>,K<SUP>+</SUP>-ATPase. I.&nbsp;Role of cyclic AMP and phospholipase A<SUB>2</SUB> .
<I>J. Clin. Invest.</I>
89: 1496-1500, 1992<!-- HIGHWIRE ID="78:1:189:387" --><A HREF="/cgi/external_ref?access_num=1349027&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B388"><!-- comment for mosaic --></a>
<P>388. &nbsp; 

SATOH, T<font size=-1>.</font>,
H<font size=-1>. </font>T<font size=-1>.</font> COHEN,
 <font size=-1>AND</font> A<font size=-1>. </font>I<font size=-1>.</font> KATZ.



Different mechanisms of renal Na-K-ATPase regulation by protein kinases in proximal and distal nephron.
<I>Am. J.&nbsp;Physiol.</I>
265(<I>Renal Fluid Electrolyte Physiol.</I> 34): F399-F405, 1993<!-- HIGHWIRE ID="78:1:189:388" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=265/3/F399" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B389"><!-- comment for mosaic --></a>
<P>389. &nbsp; 

SATOH, T<font size=-1>.</font>,
H<font size=-1>. </font>T<font size=-1>.</font> COHEN,
 <font size=-1>AND</font> A<font size=-1>. </font>I<font size=-1>.</font> KATZ.



Intracellular signalling in the regulation of renal Na<SUP>+</SUP>,K<SUP>+</SUP>-ATPase. II. Role of eicosanoids.
<I>J. Clin. Invest.</I>
91: 409-415, 1993<!-- HIGHWIRE ID="78:1:189:389" --><A HREF="/cgi/external_ref?access_num=8381820&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B390"><!-- comment for mosaic --></a>
<P>390. &nbsp; 

SAWAGUCHI, T<font size=-1>.</font>,
 <font size=-1>AND</font> P<font size=-1>. </font>S<font size=-1>.</font> GOLDMAN<font size=-1>-</font>RAKIC.



D<SUB>1</SUB> dopamine receptors in prefrontal cortex: involvement in working memory.
<I>Science</I>
251: 947-950, 1991<!-- HIGHWIRE ID="78:1:189:390" --><A HREF="/cgi/external_ref?access_num=1825731&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B391"><!-- comment for mosaic --></a>
<P>391. &nbsp; 

SAWAGUCHI, T<font size=-1>.</font>,
 <font size=-1>AND</font> P<font size=-1>. </font>S<font size=-1>.</font> GOLDMAN<font size=-1>-</font>RAKIC.



The role of D<SUB>1</SUB> dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task.
<I>J. Neurophysiol.</I>
71: 515-528, 1994<!-- HIGHWIRE ID="78:1:189:391" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jn&resid=71/2/515" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B392"><!-- comment for mosaic --></a>
<P>392. &nbsp; 

SCHINELLI, S<font size=-1>.</font>,
M<font size=-1>.</font> PAOLILLO,
 <font size=-1>AND</font> G<font size=-1>. </font>L<font size=-1>.</font> CORONA.



Opposing actions of D<SUB>1</SUB>- and D<SUB>2</SUB>-dopamine receptors on arachidonic acid release and cyclic AMP production in striatal neurons.
<I>J. Neurochem.</I>
62: 944-949, 1994<!-- HIGHWIRE ID="78:1:189:392" --><A HREF="/cgi/external_ref?access_num=8113815&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B393"><!-- comment for mosaic --></a>
<P>393. &nbsp; 

SCHOORS, D<font size=-1>. </font>F<font size=-1>.</font>,
 <font size=-1>AND</font> A<font size=-1>. </font>G<font size=-1>.</font> DUPONT.



Increased dopamine-induced nephrogenous cAMP formation in hypertension.
<I>Am. J.&nbsp;Hypertens.</I>
4: 494-49, 1991<!-- HIGHWIRE ID="78:1:189:393" --><A HREF="/cgi/external_ref?access_num=1651737&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B394"><!-- comment for mosaic --></a>
<P>394. &nbsp; 

SCHULTZ, W<font size=-1>.</font>,
P<font size=-1>.</font> APICELLA,
 <font size=-1>AND</font> T<font size=-1>.</font> LJUNGBERG.



Responses of monkey dopamine neurons to reward and conditioned stimuli during successive steps of learning a delayed response task.
<I>J. Neurosci.</I>
13: 900-913, 1993<!-- HIGHWIRE ID="78:1:189:394" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jneuro&resid=13/3/900" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B395"><!-- comment for mosaic --></a>
<P>395. &nbsp; 

SEABROOK, G<font size=-1>. </font>R<font size=-1>.</font>,
J<font size=-1>. </font>A<font size=-1>.</font> KEMP,
S<font size=-1>. </font>B<font size=-1>.</font> FREEDMAN,
S<font size=-1>.</font> PATEL,
H<font size=-1>. </font>A<font size=-1>.</font> SINCLAIR,
 <font size=-1>AND</font> G<font size=-1>.</font> M<font size=-1>C</font>ALLISTER.



Functional expression of human D<SUB>3</SUB> dopamine receptors in differentiated neuroblastoma&nbsp;&#215;&nbsp;glioma NG108-15 cells.
<I>Br. J.&nbsp;Pharmacol.</I>
111: 391-393, 1994<!-- HIGHWIRE ID="78:1:189:395" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=brjpharmacol&resid=111/2/391" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B396"><!-- comment for mosaic --></a>
<P>396. &nbsp; 

SEABROOK, G<font size=-1>. </font>R<font size=-1>.</font>,
M<font size=-1>.</font> KNOWLES,
N<font size=-1>.</font> BROWN,
J<font size=-1>.</font> MYERS,
H<font size=-1>.</font> SINCLAIR,
S<font size=-1>.</font> PATEL,
S<font size=-1>. </font>B<font size=-1>.</font> FREEDMAN,
 <font size=-1>AND</font> G<font size=-1>.</font> M<font size=-1>C</font>ALLISTER.



Pharmacology of high-threshold calcium currents in GH<SUB>4</SUB>C<SUB>1</SUB> pituitary cells and their regulation by activation of human D<SUB>2</SUB> and D<SUB>4</SUB> dopamine receptors.
<I>Br. J.&nbsp;Pharmacol.</I>
112: 728-734, 1994<!-- HIGHWIRE ID="78:1:189:396" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=brjpharmacol&resid=112/3/728" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B397"><!-- comment for mosaic --></a>
<P>397. &nbsp; 

SEABROOK, G<font size=-1>. </font>R<font size=-1>.</font>,
G<font size=-1>.</font> M<font size=-1>C</font>ALLISTER,
M<font size=-1>. </font>R<font size=-1>.</font> KNOWLES,
J<font size=-1>.</font> MYERS,
H<font size=-1>.</font> SINCLAIR,
S<font size=-1>.</font> PATEL,
S<font size=-1>. </font>B<font size=-1>.</font> FREEDMAN,
 <font size=-1>AND</font> J<font size=-1>. </font>A<font size=-1>.</font> KEMP.



Depression of high-threshold calcium currents by activation of human D<SUB>2</SUB> (short) dopamine receptors expressed in differentiated NG108-15 cells.
<I>Br. J.&nbsp;Pharmacol.</I>
111: 1061-1066, 1994<!-- HIGHWIRE ID="78:1:189:397" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=brjpharmacol&resid=111/4/1061" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B398"><!-- comment for mosaic --></a>
<P>398. &nbsp; 

SEEMAN, P<font size=-1>.</font>.



Multiple D<SUB>2</SUB> dopamine receptors.
<I>Clin. Neuropharmacol.</I>
13: 124-125, 1990<!-- HIGHWIRE ID="78:1:189:398" --><!-- /HIGHWIRE -->.</P>
<a name="B399"><!-- comment for mosaic --></a>
<P>399. &nbsp; 

SEEMAN, P<font size=-1>.</font>.



Dopamine receptors sequences. Therapeutic levels of neuroleptics occupy D<SUB>2</SUB> receptors, clozapine occupies D<SUB>4</SUB> .
<I>Neuropsychopharmacology</I>
7: 261-284, 1992<!-- HIGHWIRE ID="78:1:189:399" --><A HREF="/cgi/external_ref?access_num=1362057&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B400"><!-- comment for mosaic --></a>
<P>400. &nbsp; 

SEEMAN, P<font size=-1>.</font>,
H<font size=-1>. </font>C<font size=-1>.</font> GUAN,
 <font size=-1>AND</font> H<font size=-1>. </font>H<font size=-1>.</font><font size=-1>&nbsp;</font>M<font size=-1>.</font> VAN TOL.



Dopamine D<SUB>4</SUB> receptors elevated in schizophrenia.
<I>Nature</I>
365: 441-445, 1993<!-- HIGHWIRE ID="78:1:189:400" --><A HREF="/cgi/external_ref?access_num=8413587&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B401"><!-- comment for mosaic --></a>
<P>401. &nbsp; 

SEEMAN, P<font size=-1>.</font>,
 <font size=-1>AND</font> H<font size=-1>. </font>H<font size=-1>.</font><font size=-1>&nbsp;</font>M<font size=-1>.</font> VAN TOL.



Dopamine receptor pharmacology.
<I>Trends Pharmacol. Sci.</I>
15: 264-270, 1994<!-- HIGHWIRE ID="78:1:189:401" --><A HREF="/cgi/external_ref?access_num=7940991&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B402"><!-- comment for mosaic --></a>
<P>402. &nbsp; 

SEEMAN, P<font size=-1>.</font>,
 <font size=-1>AND</font> H<font size=-1>. </font>H<font size=-1>.</font><font size=-1>&nbsp;</font>M<font size=-1>.</font> VAN TOL.



Dopamine D<SUB>4</SUB>-like receptor elevation in schizophrenia: cloned D<SUB>2</SUB> and D<SUB>4</SUB> receptors cannot be discriminating by raclopride competition against [<SUP>3</SUP>H]nemonapride.
<I>J. Neurochem.</I>
64: 1413-1415, 1995<!-- HIGHWIRE ID="78:1:189:402" --><A HREF="/cgi/external_ref?access_num=7861175&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B403"><!-- comment for mosaic --></a>
<P>403. &nbsp; 

SELF, D<font size=-1>. </font>W<font size=-1>.</font>,
W<font size=-1>. </font>J<font size=-1>.</font> BARNHART,
D<font size=-1>. </font>A<font size=-1>.</font> LEHMAN,
 <font size=-1>AND</font> E<font size=-1>. </font>J<font size=-1>.</font> NESTLER.



Opposite modulation of cocaine-seeking behavior by D<SUB>1</SUB>- and D<SUB>2</SUB>-like dopamine receptor agonists.
<I>Science</I>
271: 1586-1589, 1996<!-- HIGHWIRE ID="78:1:189:403" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=sci&resid=271/5255/1586" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B404"><!-- comment for mosaic --></a>
<P>404. &nbsp; 

SELF, D<font size=-1>. </font>W<font size=-1>.</font>,
 <font size=-1>AND</font> L<font size=-1>.</font> STEIN.



Dopamine receptor subtypes in opioid and stimulant reward.
<I>Pharmacol. Toxicol.</I>
70: 87-94, 1992<!-- HIGHWIRE ID="78:1:189:404" --><A HREF="/cgi/external_ref?access_num=1324497&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B405"><!-- comment for mosaic --></a>
<P>405. &nbsp; 

SENOGLES, S<font size=-1>. </font>E<font size=-1>.</font>.



The D<SUB>2</SUB> dopamine receptor isoforms signal through distinct G<SUB>i</SUB><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "> proteins to inhibit adenylyl cyclase. A study with site-directed mutant G<SUB>i</SUB><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "> proteins.
<I>J. Biol. Chem.</I>
269: 23120-23127, 1994<!-- HIGHWIRE ID="78:1:189:405" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=269/37/23120" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B406"><!-- comment for mosaic --></a>
<P>406. &nbsp; 

SENOGLES, S<font size=-1>. </font>E<font size=-1>.</font>.



The D<SUB>2</SUB> dopamine receptor mediates inhibition of growth in GH<SUB>4</SUB>ZR<SUB>7</SUB> cells: involvement of protein kinase C.
<I>Endocrinology</I>
134: 783-789, 1994<!-- HIGHWIRE ID="78:1:189:406" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=endo&resid=134/2/783" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B407"><!-- comment for mosaic --></a>
<P>407. &nbsp; 

SHAHEDI, M<font size=-1>.</font>,
K<font size=-1>.</font> LABORDE,
S<font size=-1>.</font> AZIMI,
S<font size=-1>.</font> HAMDANI,
 <font size=-1>AND</font> C<font size=-1>.</font> SACHS.



Mechanisms of dopamine effects on Na-K-ATPase activity in Madin-Darby canine kidney (MDCK) epithelial cells.
<I>Pfl&uuml;gers Arch.</I>
429: 832-840, 1995<!-- HIGHWIRE ID="78:1:189:407" --><A HREF="/cgi/external_ref?access_num=7541525&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B408"><!-- comment for mosaic --></a>
<P>408. &nbsp; 

SHIKUMA, R<font size=-1>.</font>,
M<font size=-1>.</font> YOSHIMURA,
S<font size=-1>.</font> KAMBARA,
H<font size=-1>.</font> YAMAZAKI,
R<font size=-1>.</font> TAKASHINA,
H<font size=-1>.</font> TAKAHASHI,
K<font size=-1>.</font> TAKEDA,
 <font size=-1>AND</font> H<font size=-1>.</font> IJICHI.



Dopaminergic modulation of salt sensitivity in patients with essential hypertension.
<I>Life Sci.</I>
38: 915-921, 1986<!-- HIGHWIRE ID="78:1:189:408" --><A HREF="/cgi/external_ref?access_num=3951317&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B409"><!-- comment for mosaic --></a>
<P>409. &nbsp; 

SHINAMOTO, K<font size=-1>.</font>,
N<font size=-1>.</font> URA,
M<font size=-1>.</font> NISHIMURA,
 <font size=-1>AND</font> O<font size=-1>.</font> IIMURA.



Renal kallikrein-kinin, prostaglandin E<SUB>2</SUB> ,&nbsp;and dopamine systems in young normotensive subjects with a family history of hypertension.
<I>Am. J.&nbsp;Med. Sci.</I>
307, <I>Suppl</I>. 1: S70-S74, 1994<!-- HIGHWIRE ID="78:1:189:409" --><A HREF="/cgi/external_ref?access_num=8141169&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B410"><!-- comment for mosaic --></a>
<P>410. &nbsp; 

SHULTZ, P<font size=-1>. </font>J<font size=-1>.</font>,
J<font size=-1>. </font>R<font size=-1>.</font> SEDOR,
 <font size=-1>AND</font> H<font size=-1>. </font>E<font size=-1>.</font> ABBOUD.



Dopaminergic stimulation of cAMP accumulation in cultured rat mesangial cells.
<I>Am. J.&nbsp;Physiol.</I>
253(<I>Heart Circ. Physiol.</I> 22): H358-H364, 1987<!-- HIGHWIRE ID="78:1:189:410" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajpheart&resid=253/2/H358" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B411"><!-- comment for mosaic --></a>
<P>411. &nbsp; 

SIDENBERG, D<font size=-1>. </font>G<font size=-1>.</font>,
N<font size=-1>.</font> KING,
 <font size=-1>AND</font> J<font size=-1>. </font>L<font size=-1>.</font> KENNEDY.



Analysis of new D<SUB>4</SUB> dopamine receptor (DRD<SUB>4</SUB>) coding region variants and TH microsatellite in the Old Amish family.
<I>Psychiatr. Genet.</I>
4: 95-99, 1994<!-- HIGHWIRE ID="78:1:189:411" --><A HREF="/cgi/external_ref?access_num=7914460&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B412"><!-- comment for mosaic --></a>
<P>412. &nbsp; 

SIDHU, A<font size=-1>.</font>,
R<font size=-1>. </font>A<font size=-1>.</font> FELDER,
P<font size=-1>. </font>A<font size=-1>.</font> JOSE,
 <font size=-1>AND</font> P<font size=-1>. </font>H<font size=-1>.</font> FISHMAN.



Comparison of the central and renal dopamine-1 receptor.
<I>Am. J.&nbsp;Hypertens.</I>
3, <I>Suppl.</I>: 37S-39S, 1990<!-- HIGHWIRE ID="78:1:189:412" --><A HREF="/cgi/external_ref?access_num=1974441&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B413"><!-- comment for mosaic --></a>
<P>413. &nbsp; 

SIDHU, A<font size=-1>.</font>,
M<font size=-1>.</font> SULLIVAN,
T<font size=-1>.</font> KOHOUT,
P<font size=-1>.</font> BALEN,
 <font size=-1>AND</font> P<font size=-1>. </font>H<font size=-1>.</font> FISHMAN.



D<SUB>1</SUB> dopamine receptors can interact with both stimulatory and inhibitory guanine nucleotide binding proteins.
<I>J. Neurochem.</I>
57: 1445-1451, 1991<!-- HIGHWIRE ID="78:1:189:413" --><A HREF="/cgi/external_ref?access_num=1832710&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B414"><!-- comment for mosaic --></a>
<P>414. &nbsp; 

SIDHU, A<font size=-1>.</font>,
P<font size=-1>.</font> VACHVANICHSANONG,
P<font size=-1>. </font>A<font size=-1>.</font> JOSE,
 <font size=-1>AND</font> R<font size=-1>. </font>A<font size=-1>.</font> FELDER.



Persistent defective coupling of dopamine-1 receptors to G proteins after solubilization from kidney proximal tubules of hypertensive rats.
<I>J. Clin. Invest.</I>
89: 789-793, 1992<!-- HIGHWIRE ID="78:1:189:414" --><A HREF="/cgi/external_ref?access_num=1531836&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B415"><!-- comment for mosaic --></a>
<P>415. &nbsp; 

SIGMUNDSON, H<font size=-1>. </font>K<font size=-1>.</font>.



Pharmacotherapy of schizophrenia: a review.
<I>Can. J.&nbsp;Psychiatry</I>
39: 70-75, 1994<!-- HIGHWIRE ID="78:1:189:415" --><!-- /HIGHWIRE -->.</P>
<a name="B416"><!-- comment for mosaic --></a>
<P>416. &nbsp; 

SIMMONDS, S<font size=-1>. </font>H<font size=-1>.</font>,
 <font size=-1>AND</font> P<font size=-1>. </font>G<font size=-1>.</font> STRANGE.



Inhibition of inositolphospholipid breakdown by D-2 receptors in dissociated bovine anterior pituitary cells.
<I>Neurosci. Lett.</I>
60: 267-272, 1985<!-- HIGHWIRE ID="78:1:189:416" --><A HREF="/cgi/external_ref?access_num=2415878&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B417"><!-- comment for mosaic --></a>
<P>417. &nbsp; 

SMILEY, J<font size=-1>. </font>F<font size=-1>.</font>,
A<font size=-1>. </font>I<font size=-1>.</font> LEVEY,
B<font size=-1>. </font>J<font size=-1>.</font> CILIAX,
 <font size=-1>AND</font> P<font size=-1>. </font>S<font size=-1>.</font> GOLDMAN<font size=-1>-</font>RAKIC.



D<SUB>1</SUB> dopamine receptor immunoreactivity in human and monkey cerebral cortex: predominant and extrasynaptic localization in dendritic spines.
<I>Proc. Natl. Acad. Sci. USA</I>
91: 5720-5724, 1994<!-- HIGHWIRE ID="78:1:189:417" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=91/12/5720" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B418"><!-- comment for mosaic --></a>
<P>418. &nbsp; 

SNYDER, L<font size=-1>. </font>A<font size=-1>.</font>,
J<font size=-1>. </font>L<font size=-1>.</font> ROBERTS,
 <font size=-1>AND</font> S<font size=-1>. </font>C<font size=-1>.</font> SEALFON.



Alternative transcripts of the rat and human dopamine D<SUB>3</SUB> receptor.
<I>Biochem. Biophys. Res. Commun.</I>
180: 1031-1035, 1991<!-- HIGHWIRE ID="78:1:189:418" --><A HREF="/cgi/external_ref?access_num=1953708&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B419"><!-- comment for mosaic --></a>
<P>419. &nbsp; 

SOARES<font size=-1>-</font>DE<font size=-1>-</font>SILVA, P<font size=-1>.</font>.



Source and handling of renal dopamine: its physiological importance.
<I>News Physiol. Sci.</I>
9: 128-134, 1994.<!-- HIGHWIRE ID="78:1:189:419" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=nips&resid=9/3/128" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --></P>
<a name="B420"><!-- comment for mosaic --></a>
<P>420. &nbsp; 

SOKOLOFF, P<font size=-1>.</font>,
B<font size=-1>.</font> GIROS,
M<font size=-1>. </font>P<font size=-1>.</font> MARTRES,
M<font size=-1>. </font>L<font size=-1>.</font> BARTHENET,
 <font size=-1>AND</font> J<font size=-1>. </font>C<font size=-1>.</font> SCHWARTZ.



Molecular cloning and characterization of a novel dopamine receptor (D-3) as a target for neuroleptics.
<I>Nature</I>
347: 146-151, 1990<!-- HIGHWIRE ID="78:1:189:420" --><A HREF="/cgi/external_ref?access_num=1975644&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B421"><!-- comment for mosaic --></a>
<P>421. &nbsp; 

SOKOLOFF, P<font size=-1>.</font>,
 <font size=-1>AND</font> J<font size=-1>. </font>C<font size=-1>.</font> SCHWARTZ.



Novel dopamine receptors half a decade later.
<I>Trends Pharmacol. Sci.</I>
16: 270-275, 1995<!-- HIGHWIRE ID="78:1:189:421" --><A HREF="/cgi/external_ref?access_num=7482988&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B422"><!-- comment for mosaic --></a>
<P>422. &nbsp; 

SOWERS, J<font size=-1>. </font>R<font size=-1>.</font>,
A<font size=-1>. </font>S<font size=-1>.</font> BRICKMAN,
D<font size=-1>. </font>K<font size=-1>.</font> SOWERS,
 <font size=-1>AND</font> G<font size=-1>.</font> BERG.



Dopaminergic modulation of aldosterone secretion in man is unaffected by glucocorticoids, and angiotensin blockade.
<I>J. Clin. Endocrinol. Metab.</I>
52: 1078-1084, 1981<!-- HIGHWIRE ID="78:1:189:422" --><A HREF="/cgi/external_ref?access_num=7014592&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B423"><!-- comment for mosaic --></a>
<P>423. &nbsp; 

SOWERS, J<font size=-1>. </font>R<font size=-1>.</font>,
M<font size=-1>. </font>L<font size=-1>.</font> TUCK,
M<font size=-1>. </font>S<font size=-1>.</font> GOLUB,
 <font size=-1>AND</font> S<font size=-1>. </font>E<font size=-1>.</font> SOLLARS.



Dopaminergic modulation of aldosterone secretion is independent of alterations in renin secretion.
<I>Endocrinology</I>
107: 937-941, 1980<!-- HIGHWIRE ID="78:1:189:423" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=endo&resid=107/4/937" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B424"><!-- comment for mosaic --></a>
<P>424. &nbsp; 

SPANO, P<font size=-1>. </font>F<font size=-1>.</font>,
S<font size=-1>.</font> GOVONI,
 <font size=-1>AND</font> M<font size=-1>.</font> TRABUCCHI.



Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system.
<I>Adv. Biochem. Psychopharmacol.</I>
19: 155-165, 1978<!-- HIGHWIRE ID="78:1:189:424" --><A HREF="/cgi/external_ref?access_num=358777&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B425"><!-- comment for mosaic --></a>
<P>425. &nbsp; 

STACK, J<font size=-1>.</font>,
 <font size=-1>AND</font> A<font size=-1>.</font> SURPRENANT.



Dopamine actions on calcium currents, potassium currents and hormone release in rat melanotrophs.
<I>J. Physiol. (Lond.)</I>
493: 37-58, 1991<!-- HIGHWIRE ID="78:1:189:425" --><!-- /HIGHWIRE -->.</P>
<a name="B426"><!-- comment for mosaic --></a>
<P>426. &nbsp; 

STRADER, C<font size=-1>. </font>D<font size=-1>.</font>,
M<font size=-1>. </font>R<font size=-1>.</font> CANDELORE,
W<font size=-1>. </font>S<font size=-1>.</font> HILL,
I<font size=-1>. </font>S<font size=-1>.</font> SIGAL,
 <font size=-1>AND</font> R<font size=-1>. </font>A<font size=-1>.</font><font size=-1>&nbsp;</font>F<font size=-1>.</font> DIXON.



Identification of two serine residues involved in agonist activation of the <IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BASELINE ALT="beta ">&nbsp;adrenergic receptor.
<I>J. Biol. Chem.</I>
264: 13572-13478, 1989<!-- HIGHWIRE ID="78:1:189:426" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=264/23/13572" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B427"><!-- comment for mosaic --></a>
<P>427. &nbsp; 

STRADER, C<font size=-1>. </font>D<font size=-1>.</font>,
I<font size=-1>. </font>S<font size=-1>.</font> SIGAL,
M<font size=-1>. </font>R<font size=-1>.</font> CANDELORE,
E<font size=-1>.</font> ROUDS,
W<font size=-1>. </font>S<font size=-1>.</font> HILL,
 <font size=-1>AND</font> R<font size=-1>. </font>A<font size=-1>.</font><font size=-1>&nbsp;</font>F<font size=-1>.</font> DIXON.



Conserved aspartic acid residues 79&nbsp;and 113&nbsp;of the <IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BASELINE ALT="beta ">-adrenergic receptor have different roles in receptor function.
<I>J. Biol. Chem.</I>
263: 10267-10271, 1988<!-- HIGHWIRE ID="78:1:189:427" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=263/21/10267" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B428"><!-- comment for mosaic --></a>
<P>428. &nbsp; 

STUDER, L<font size=-1>.</font>,
C<font size=-1>.</font> SPENGER,
R<font size=-1>. </font>W<font size=-1>.</font> SEILER,
C<font size=-1>. </font>A<font size=-1>.</font> ALTAR,
R<font size=-1>. </font>M<font size=-1>.</font> LINDSAY,
 <font size=-1>AND</font> C<font size=-1>.</font> HYMAN.



Comparison of the effects of the neurotrophins on the morphological structure of dopaminergic neurons in cultures of rat substantia nigra.
<I>Eur. J.&nbsp;Neurosci.</I>
7: 223-233, 1995<!-- HIGHWIRE ID="78:1:189:428" --><A HREF="/cgi/external_ref?access_num=7757259&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B429"><!-- comment for mosaic --></a>
<P>429. &nbsp; 

SU, Y<font size=-1>.</font>,
J<font size=-1>.</font> BURKE,
F<font size=-1>. </font>A<font size=-1>.</font> O<font size=-1>'</font>NEIL,
B<font size=-1>.</font> MURPHY,
L<font size=-1>.</font> NIE,
B<font size=-1>.</font> KIPPS,
J<font size=-1>.</font> BRAY,
R<font size=-1>.</font> SHINKWIN,
 <font size=-1>AND</font> M<font size=-1>.</font> NI.



NUALLAIN, <font size=-1>AND</font> C.&nbsp;J.&nbsp;MACLEAN. Exclusion of linkage between schizophrenia and the D<SUB>2</SUB> dopamine receptor gene region of chromosome 11q in 112&nbsp;Irish multiplex families.
<I>Arch. Gen. Psychiatry</I>
50: 205-211, 1993<!-- HIGHWIRE ID="78:1:189:429" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=archpsyc&resid=50/3/205" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B430"><!-- comment for mosaic --></a>
<P>430. &nbsp; 

SUGAMORI, K<font size=-1>. </font>S<font size=-1>.</font>,
L<font size=-1>. </font>L<font size=-1>.</font> DEMCHYSHYN,
M<font size=-1>.</font> CHUNG,
 <font size=-1>AND</font> H<font size=-1>. </font>B<font size=-1>.</font> NIZNIK.



D<SUB>1A</SUB> ,&nbsp;D<SUB>1B</SUB> ,&nbsp;and D<SUB>1C</SUB> dopamine receptors from <I>Xenopus laevis</I>.
<I>Proc. Natl. Acad. Sci. USA</I>
91: 10536-10540, 1994<!-- HIGHWIRE ID="78:1:189:430" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=91/22/10536" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B431"><!-- comment for mosaic --></a>
<P>431. &nbsp; 

SUNAHARA, R<font size=-1>. </font>K<font size=-1>.</font>,
H<font size=-1>. </font>C<font size=-1>.</font> GUAN,
B<font size=-1>. </font>F<font size=-1>.</font> O<font size=-1>'</font>DOWD,
P<font size=-1>.</font> SEEMAN,
L<font size=-1>. </font>G<font size=-1>.</font> LAURIER,
G<font size=-1>.</font> NG,
S<font size=-1>. </font>R<font size=-1>.</font> GEORGE,
J<font size=-1>.</font> TORCHIA,
H<font size=-1>. </font>H<font size=-1>.</font><font size=-1>&nbsp;</font>M<font size=-1>.</font> VAN TOL,
 <font size=-1>AND</font> H<font size=-1>. </font>B<font size=-1>.</font> NIZNIK.



Cloning of the gene for a human dopamine D<SUB>5</SUB> receptor with higher affinity for dopamine than D<SUB>1</SUB> .
<I>Nature</I>
350: 614-619, 1991<!-- HIGHWIRE ID="78:1:189:431" --><A HREF="/cgi/external_ref?access_num=1826762&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B432"><!-- comment for mosaic --></a>
<P>432. &nbsp; SURMEIER, D.&nbsp;J., J.&nbsp;BARGAS, H.&nbsp;C. HEMMINGS, A.&nbsp;C. NAIRN, <font size=-1>AND</font> P.&nbsp;GREENGARD. Modulation of calcium currents by a D<SUB>1</SUB> dopaminergic protein kinase/phosphatase cascade in rat neostriatal neurons.<I> Neuron</I> 14: 385-397, 1995.<!-- HIGHWIRE ID="78:1:189:432" --><!-- /HIGHWIRE --></P>
<a name="B433"><!-- comment for mosaic --></a>
<P>433. &nbsp; 

SURMEIER, D<font size=-1>. </font>J<font size=-1>.</font>,
J<font size=-1>.</font> EBERWINE,
C<font size=-1>. </font>J<font size=-1>.</font> WILSON,
Y<font size=-1>.</font> CAO,
A<font size=-1>.</font> STEFANI,
 <font size=-1>AND</font> S<font size=-1>. </font>T<font size=-1>.</font> KITAI.



Dopamine receptor subtypes co-localize in rat striatonigral neurons.
<I>Proc. Natl. Acad. Sci. USA</I>
89: 10178-10182, 1992<!-- HIGHWIRE ID="78:1:189:433" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=89/21/10178" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B434"><!-- comment for mosaic --></a>
<P>434. &nbsp; 

SVENSSON, K<font size=-1>.</font>,
A<font size=-1>.</font> CARLSSON,
R<font size=-1>. </font>M<font size=-1>.</font> HUFF,
T<font size=-1>.</font> KLING<font size=-1>-</font>PETERSEN,
 <font size=-1>AND</font> N<font size=-1>.</font> WATERS.



Behavioral and neurochemical data suggest functional differences between dopamine D<SUB>2</SUB> and D<SUB>3</SUB> receptors.
<I>Eur. J.&nbsp;Pharmacol.</I>
263: 235-243, 1994<!-- HIGHWIRE ID="78:1:189:434" --><A HREF="/cgi/external_ref?access_num=7843260&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B435"><!-- comment for mosaic --></a>
<P>435. &nbsp; 

SWARZENSKI, B<font size=-1>. </font>C<font size=-1>.</font>,
L<font size=-1>.</font> TANG,
Y<font size=-1>. </font>J<font size=-1>.</font> OH,
K<font size=-1>. </font>L<font size=-1>.</font> O<font size=-1>'</font>MALLEY,
 <font size=-1>AND</font> R<font size=-1>. </font>D<font size=-1>.</font> TODD.



Morphogenic potentials of D<SUB>2</SUB> ,&nbsp;D<SUB>3</SUB> ,&nbsp;and D<SUB>4</SUB> dopamine receptors revealed in transfected neuronal cell lines.
<I>Proc. Natl. Acad. Sci. USA</I>
91: 649-653, 1994<!-- HIGHWIRE ID="78:1:189:435" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=91/2/649" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B436"><!-- comment for mosaic --></a>
<P>436. &nbsp; 

TAKEMOTO, F<font size=-1>.</font>,
H<font size=-1>. </font>T<font size=-1>.</font> COHEN,
T<font size=-1>.</font> SATOH,
 <font size=-1>AND</font> A<font size=-1>. </font>I<font size=-1>.</font> KATZ.



Dopamine inhibits Na/K-ATPase in single tubules and cultured cells from the distal nephron.
<I>Pfl&uuml;gers Arch.</I>
421: 302-306, 1992<!-- HIGHWIRE ID="78:1:189:436" --><A HREF="/cgi/external_ref?access_num=1357625&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B437"><!-- comment for mosaic --></a>
<P>437. &nbsp; 

TAKEMOTO, F<font size=-1>.</font>,
T<font size=-1>.</font> SATOH,
H<font size=-1>. </font>T<font size=-1>.</font> COHEN,
 <font size=-1>AND</font> A<font size=-1>. </font>I<font size=-1>.</font> KATZ.



Localization of dopamine receptors along the microdissected rat nephron.
<I>Pfl&uuml;gers Arch.</I>
419: 243-249, 1991<!-- HIGHWIRE ID="78:1:189:437" --><A HREF="/cgi/external_ref?access_num=1660593&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B438"><!-- comment for mosaic --></a>
<P>438. &nbsp; 

TANG, L<font size=-1>.</font>,
R<font size=-1>. </font>D<font size=-1>.</font> TODD,
A<font size=-1>.</font> HELLER,
 <font size=-1>AND</font> K<font size=-1>. </font>L<font size=-1>.</font> O<font size=-1>'</font>MALLEY.



Pharmacological and functional characterization of D<SUB>2</SUB> ,&nbsp;D<SUB>3</SUB> and D<SUB>4</SUB> dopamine receptors in fibroblast and dopaminergic cell lines.
<I>J. Pharmacol. Exp. Ther.</I>
268: 495-502, 1994<!-- HIGHWIRE ID="78:1:189:438" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jpet&resid=268/1/495" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B439"><!-- comment for mosaic --></a>
<P>439. &nbsp; 

TANG, L<font size=-1>.</font>,
R<font size=-1>. </font>D<font size=-1>.</font> TODD,
 <font size=-1>AND</font> K<font size=-1>. </font>L<font size=-1>.</font> O<font size=-1>'</font>MALLEY.



Dopamine D<SUB>2</SUB> and D<SUB>3</SUB> receptors inhibit dopamine release.
<I>J. Pharmacol. Exp. Ther.</I>
270: 475-479, 1994<!-- HIGHWIRE ID="78:1:189:439" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jpet&resid=270/2/475" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B440"><!-- comment for mosaic --></a>
<P>440. &nbsp; 

TIBERI, M<font size=-1>.</font>,
 <font size=-1>AND</font> M<font size=-1>. </font>G<font size=-1>.</font> CARON.



High agonist-independent activity is a distinguishing feature of the dopamine D<SUB>1B</SUB> receptor subtype.
<I>J. Biol. Chem.</I>
269: 27925-27931, 1994<!-- HIGHWIRE ID="78:1:189:440" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=269/45/27925" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B441"><!-- comment for mosaic --></a>
<P>441. &nbsp; 

TIBERI, M<font size=-1>.</font>,
K<font size=-1>. </font>R<font size=-1>.</font> JARVIE,
C<font size=-1>.</font> SILVIA,
P<font size=-1>.</font> FALARDEAU,
J<font size=-1>. </font>A<font size=-1>.</font> GINGRICH,
N<font size=-1>.</font> GODINOT,
L<font size=-1>.</font> BERTRAND,
T<font size=-1>. </font>L<font size=-1>.</font> YANG<font size=-1>-</font>FENG,
R<font size=-1>. </font>T<font size=-1>.</font> FREMEAU,
 <font size=-1>AND</font> M<font size=-1>. </font>G<font size=-1>.</font> CARON.



Cloning, molecular characterization, and chromosomal assignment of a gene encoding a second D<SUB>1</SUB> dopamine receptor subtype: differential expression pattern in rat brain compared with the D<SUB>1a</SUB> receptor.
<I>Proc. Natl. Acad. Sci. USA</I>
88: 7491-7495, 1991<!-- HIGHWIRE ID="78:1:189:441" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=88/17/7491" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B442"><!-- comment for mosaic --></a>
<P>442. &nbsp; 

TOMIC, M<font size=-1>.</font>,
P<font size=-1>.</font> SEEMAN,
S<font size=-1>. </font>R<font size=-1>.</font> GEORGE,
 <font size=-1>AND</font> B<font size=-1>.</font> O<font size=-1>'</font>DOWD.



Dopamine D<SUB>1</SUB> receptor mutagenesis: role of amino acids in agonist and antagonist binding.
<I>Biochem. Biophys. Res. Commun.</I>
191: 1020-1027, 1993<!-- HIGHWIRE ID="78:1:189:442" --><A HREF="/cgi/external_ref?access_num=8466481&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B443"><!-- comment for mosaic --></a>
<P>443. &nbsp; 

TRUMPP<font size=-1>-</font>KALLMEYER, S<font size=-1>.</font>,
J<font size=-1>.</font> HOFLACK,
A<font size=-1>.</font> BRUINVELS,
 <font size=-1>AND</font> M<font size=-1>.</font> HIBERT.



Modeling of G protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine and mammalian opsin receptors.
<I>J. Med. Chem.</I>
35: 3448-3462, 1992<!-- HIGHWIRE ID="78:1:189:443" --><A HREF="/cgi/external_ref?access_num=1328638&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B444"><!-- comment for mosaic --></a>
<P>444. &nbsp; 

UNDIE, A<font size=-1>. </font>S<font size=-1>.</font>,
 <font size=-1>AND</font> E<font size=-1>.</font> FRIEDMAN.



Stimulation of a dopamine D<SUB>1</SUB> receptor enhances inositol phosphates formation in rat brain.
<I>J. Pharmacol. Exp. Ther.</I>
253: 987-992, 1990<!-- HIGHWIRE ID="78:1:189:444" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jpet&resid=253/3/987" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B445"><!-- comment for mosaic --></a>
<P>445. &nbsp; 

UNDIE, A<font size=-1>. </font>S<font size=-1>.</font>,
J<font size=-1>.</font> WEINSTOCK,
H<font size=-1>. </font>M<font size=-1>.</font> SARAU,
 <font size=-1>AND</font> E<font size=-1>.</font> FRIEDMAN.



Evidence for a distinct D<SUB>1</SUB>-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain.
<I>J. Neurochem.</I>
62: 2045-2048, 1994<!-- HIGHWIRE ID="78:1:189:445" --><A HREF="/cgi/external_ref?access_num=7908949&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B446"><!-- comment for mosaic --></a>
<P>446. &nbsp; 

VACHVANICHSANONG, P<font size=-1>.</font>,
K<font size=-1>.</font> KIMURA,
 <font size=-1>AND</font> A<font size=-1>.</font> SIDHU.



Differences in photoaffinity labeling of DA<SUB>1</SUB> receptors in the proximal renal tubules from normotensive rat and SHR.
<I>Am. J.&nbsp;Physiol.</I>
268(<I>Renal Fluid Electrolyte Physiol.</I> 37): F1009-F1016, 1995<!-- HIGHWIRE ID="78:1:189:446" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=268/6/F1009" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B447"><!-- comment for mosaic --></a>
<P>447. &nbsp; 

VALENTIJN, J<font size=-1>. </font>A<font size=-1>.</font>,
H<font size=-1>.</font> VAUDRY,
 <font size=-1>AND</font> L<font size=-1>.</font> CAZIN.



Multiple control of calcium channel gating by dopamine D<SUB>2</SUB> receptors in frog pituitary menotrophs.
<I>Ann. NY Acad. Sci.</I>
680: 211-228, 1993<!-- HIGHWIRE ID="78:1:189:447" --><A HREF="/cgi/external_ref?access_num=8390152&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B448"><!-- comment for mosaic --></a>
<P>448. &nbsp; 

VALLAR, L<font size=-1>.</font>,
C<font size=-1>.</font> MUCA,
M<font size=-1>.</font> MAGNI,
P<font size=-1>.</font> ALBERT,
J<font size=-1>.</font> BUNZOW,
J<font size=-1>.</font> MELDOLESI,
 <font size=-1>AND</font> O<font size=-1>.</font> CIVELLI.



Differential coupling of dopaminergic D<SUB>2</SUB> receptors expressed in different cell types. Stimulation of phosphatidylinositol 4,5-bisphosphate hydrolysis in Ltk<SUP><IMG SRC="/math/12pt/normal/scr/minus.gif" ALIGN=BASELINE ALT="-"></SUP> fibroblasts, hyperpolarization, and cytosolic-free Ca<SUP>2+</SUP> concentration decrease in GH<SUB>4</SUB>C<SUB>1</SUB> cells.
<I>J. Biol. Chem.</I>
265: 10320-10326, 1990<!-- HIGHWIRE ID="78:1:189:448" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=265/18/10320" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B449"><!-- comment for mosaic --></a>
<P>449. &nbsp; 

VAN MUISWINKEL, F<font size=-1>. </font>L<font size=-1>.</font>,
B<font size=-1>.</font> DRUKARCH,
H<font size=-1>. </font>W<font size=-1>.</font><font size=-1>&nbsp;</font>M<font size=-1>.</font> STEINBUSCH,
 <font size=-1>AND</font> J<font size=-1>. </font>C<font size=-1>.</font> STOOF.



Chronic dopamine D<SUB>2</SUB> receptor activation does not affect survival and differentiation of cultured dopaminergic neurons: morphological and neurochemical observations.
<I>J. Neurochem.</I>
60: 83-92, 1993<!-- HIGHWIRE ID="78:1:189:449" --><A HREF="/cgi/external_ref?access_num=8093262&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B450"><!-- comment for mosaic --></a>
<P>450. &nbsp; 

VAN TOL, H<font size=-1>. </font>H<font size=-1>.</font><font size=-1>&nbsp;</font>M<font size=-1>.</font>,
J<font size=-1>. </font>R<font size=-1>.</font> BUNZOW,
H<font size=-1>.-</font>C<font size=-1>.</font> GUAN,
R<font size=-1>. </font>K<font size=-1>.</font> SUNAHARA,
P<font size=-1>.</font> SEEMAN,
H<font size=-1>. </font>B<font size=-1>.</font> NIZNIK,
 <font size=-1>AND</font> O<font size=-1>.</font> CIVELLI.



Cloning of the gene for a human dopamine D<SUB>4</SUB> receptor with high affinity for the antipsychotic clozapine.
<I>Nature</I>
350: 610-614, 1991<!-- HIGHWIRE ID="78:1:189:450" --><A HREF="/cgi/external_ref?access_num=1840645&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B451"><!-- comment for mosaic --></a>
<P>451. &nbsp; 

VAN TOL, H<font size=-1>. </font>H<font size=-1>.</font><font size=-1>&nbsp;</font>M<font size=-1>.</font>,
C<font size=-1>. </font>M<font size=-1>.</font> WU,
H<font size=-1>. </font>C<font size=-1>.</font> GUAN,
K<font size=-1>.</font> OHARA,
J<font size=-1>. </font>R<font size=-1>.</font> BUNZOW,
O<font size=-1>.</font> CIVELLI,
J<font size=-1>.</font> KENNEDY,
P<font size=-1>.</font> SEEMAN,
H<font size=-1>. </font>B<font size=-1>.</font> NIZNIK,
 <font size=-1>AND</font> V<font size=-1>.</font> JOVANOVIC.



Multiple dopamine D<SUB>4</SUB> receptor variants in the human population.
<I>Nature</I>
358: 149-152, 1992<!-- HIGHWIRE ID="78:1:189:451" --><A HREF="/cgi/external_ref?access_num=1319557&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B452"><!-- comment for mosaic --></a>
<P>452. &nbsp; 

VERNIER, P<font size=-1>.</font>,
B<font size=-1>.</font> CARDINAUD,
O<font size=-1>.</font> VALDENAIRE,
P<font size=-1>.</font> HERVE,
 <font size=-1>AND</font> J<font size=-1>. </font>D<font size=-1>.</font> VINCENT.



An evolutionary view of drug-receptor interaction: the bioamine receptor family.
<I>Trends Pharmacol. Sci.</I>
16: 375-381, 1995<!-- HIGHWIRE ID="78:1:189:452" --><A HREF="/cgi/external_ref?access_num=8578606&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B453"><!-- comment for mosaic --></a>
<P>453. &nbsp; 

VIZI, E<font size=-1>.</font>.



S,. I.&nbsp;E.&nbsp;TOTH, E.&nbsp;ORSO, K.&nbsp;S.&nbsp;SZALAY, D.&nbsp;SZABO, M.&nbsp;BARANY, <font size=-1>AND</font> G.&nbsp;P.&nbsp;VINSON. Dopamine is taken up from the circulation by, and released from, local noradrenergic varicose axon terminals in zona glomerulosa of the rat: a neurochemical and immunocytochemical study.
<I>J. Endocrinol.</I>
139: 213-226, 1993<!-- HIGHWIRE ID="78:1:189:453" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=joe&resid=139/2/213" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B454"><!-- comment for mosaic --></a>
<P>454. &nbsp; 

VOSS, J<font size=-1>. </font>W<font size=-1>.</font>,
 <font size=-1>AND</font> M<font size=-1>. </font>G<font size=-1>.</font> ROSENFELD.



Anterior pituitary development: short tales from dwarf mice.
<I>Cell</I>
70: 527-530, 1992<!-- HIGHWIRE ID="78:1:189:454" --><A HREF="/cgi/external_ref?access_num=1505020&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B455"><!-- comment for mosaic --></a>
<P>455. &nbsp; 

WADDINGTON, J<font size=-1>. </font>L<font size=-1>.</font>.



Functional interactions between D<SUB>1</SUB> and D<SUB>2</SUB> dopamine receptor systems.
<I>J. Psychopharmacol.</I>
3: 54-63, 1989<!-- HIGHWIRE ID="78:1:189:455" --><!-- /HIGHWIRE -->.</P>
<a name="B456"><!-- comment for mosaic --></a>
<P>456. &nbsp; 

WADDINGTON, J<font size=-1>. </font>L<font size=-1>.</font>,
 <font size=-1>AND</font> K<font size=-1>. </font>M<font size=-1>.</font> O<font size=-1>'</font>BOYLE.



The D<SUB>1</SUB> dopamine receptor and the search for its functional role: from neurochemistry to behaviour.
<I>Rev. Neurosci.</I>
1: 157-184, 1987<!-- HIGHWIRE ID="78:1:189:456" --><!-- /HIGHWIRE -->.</P>
<a name="B457"><!-- comment for mosaic --></a>
<P>457. &nbsp; 

WADDINGTON, J<font size=-1>. </font>L<font size=-1>.</font>,
 <font size=-1>AND</font> K<font size=-1>. </font>M<font size=-1>.</font> O<font size=-1>'</font>BOYLE.



Drugs acting on brain dopamine receptors: a conceptual re-evaluation five years after the first selective D<SUB>1</SUB> agonist.
<I>Pharmacol. Ther.</I>
43: 1-52, 1989<!-- HIGHWIRE ID="78:1:189:457" --><A HREF="/cgi/external_ref?access_num=2675127&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B458"><!-- comment for mosaic --></a>
<P>458. &nbsp; 

WANG, C<font size=-1>. </font>D<font size=-1>.</font>,
M<font size=-1>. </font>A<font size=-1>.</font> BUCK,
 <font size=-1>AND</font> C<font size=-1>. </font>M<font size=-1>.</font> FRASER.



Site-directed mutagenesis of <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BASELINE ALT="alpha "><SUB>2A</SUB> adrenergic receptors: identification of amino acids involved in ligand binding and receptor activation by agonists.
<I>Mol. Pharmacol.</I>
40: 168-179, 1991<!-- HIGHWIRE ID="78:1:189:458" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=40/2/168" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B459"><!-- comment for mosaic --></a>
<P>459. &nbsp; 

WANG, H<font size=-1>.-</font>Y<font size=-1>.</font>,
A<font size=-1>. </font>S<font size=-1>.</font> UNDIE,
 <font size=-1>AND</font> E<font size=-1>.</font> FRIEDMAN.



Evidence for coupling of G<SUB>q</SUB> protein to D<SUB>1</SUB>-like dopamine sites in rat striatum: possible role in dopamine-mediated inositol phosphate formation.
<I>Mol. Pharmacol.</I>
48: 988-994, 1995<!-- HIGHWIRE ID="78:1:189:459" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=48/6/988" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B460"><!-- comment for mosaic --></a>
<P>460. &nbsp; 

WATERS, N<font size=-1>.</font>,
L<font size=-1>.</font> LOFBERG,
S<font size=-1>.</font> HAADSMA<font size=-1>-</font>SVENSSON,
K<font size=-1>.</font> SVENSSON,
C<font size=-1>.</font> SONESSON,
 <font size=-1>AND</font> A<font size=-1>.</font> CARLSSON.



Differential effects of dopamine D<SUB>2</SUB> and D<SUB>3</SUB> receptor antagonists in regard to dopamine release, in vivo receptor displacement and behaviour.
<I>J. Neural Transm. Gen. Sect.</I>
98: 39-55, 1994<!-- HIGHWIRE ID="78:1:189:460" --><A HREF="/cgi/external_ref?access_num=7710738&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B461"><!-- comment for mosaic --></a>
<P>461. &nbsp; 

WATERS, N<font size=-1>.</font>,
K<font size=-1>.</font> SVENSSON,
S<font size=-1>. </font>R<font size=-1>.</font> HAADSMA<font size=-1>-</font>SVENSSON,
M<font size=-1>. </font>W<font size=-1>.</font> SMITH,
 <font size=-1>AND</font> A<font size=-1>.</font> CARLSSON.



The dopamine D<SUB>3</SUB> receptor: a postsynaptic receptor inhibitory on rat locomotor activity.
<I>J. Neural Transm.</I>
94: 11-19, 1993<!-- HIGHWIRE ID="78:1:189:461" --><A HREF="/cgi/external_ref?access_num=8129881&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B462"><!-- comment for mosaic --></a>
<P>462. &nbsp; 

WEBB, R<font size=-1>. </font>L<font size=-1>.</font>,
R<font size=-1>.</font> DELLA<font size=-1>-</font>PUCA,
J<font size=-1>.</font> MANNIELLO,
R<font size=-1>. </font>D<font size=-1>.</font> ROBSON,
M<font size=-1>. </font>B<font size=-1>.</font> ZIMMERMAN,
 <font size=-1>AND</font> R<font size=-1>. </font>D<font size=-1>.</font> GHAI.



Dopaminergic mediation of the diuretic and natriuretic effects of ANF in the rat.
<I>Life Sci.</I>
38: 2319-2327, 1986<!-- HIGHWIRE ID="78:1:189:462" --><A HREF="/cgi/external_ref?access_num=2941632&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B463"><!-- comment for mosaic --></a>
<P>463. &nbsp; 

WEINER, D<font size=-1>. </font>M<font size=-1>.</font>,
A<font size=-1>. </font>I<font size=-1>.</font> LEVEY,
R<font size=-1>. </font>K<font size=-1>.</font> SUNAHARA,
H<font size=-1>. </font>H<font size=-1>.</font> NIZNIK,
B<font size=-1>. </font>F<font size=-1>.</font> O<font size=-1>'</font>DOWD,
 <font size=-1>AND</font> M<font size=-1>. </font>R<font size=-1>.</font> BRANN.



Dopamine D<SUB>1</SUB> and D<SUB>2</SUB> receptor mRNA expression in rat brain.
<I>Proc. Natl. Acad. Sci. USA</I>
88: 1859-1863, 1991<!-- HIGHWIRE ID="78:1:189:463" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=88/5/1859" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B464"><!-- comment for mosaic --></a>
<P>464. &nbsp; 

WEINSHANK, R<font size=-1>. </font>L<font size=-1>.</font>,
N<font size=-1>.</font> ADHAM,
M<font size=-1>.</font> MACCHI,
M<font size=-1>. </font>A<font size=-1>.</font> OLSEN,
T<font size=-1>. </font>A<font size=-1>.</font> BRANCHECK,
 <font size=-1>AND</font> P<font size=-1>. </font>R<font size=-1>.</font> HARTIG.



Molecular cloning and characterization of high affinity dopamine receptor (D<SUB>1<IMG SRC="/math/12pt/normal/scr/beta.gif" ALIGN=BASELINE ALT="beta "></SUB>) and its pseudogene.
<I>J. Biol. Chem.</I>
266: 22427-22435, 1991<!-- HIGHWIRE ID="78:1:189:464" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=266/33/22427" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B465"><!-- comment for mosaic --></a>
<P>465. &nbsp; 

WHITE, N<font size=-1>. </font>M<font size=-1>.</font>,
M<font size=-1>. </font>G<font size=-1>.</font> PACKARD,
 <font size=-1>AND</font> J<font size=-1>.</font> SEAMANS.



Memory enhancement by post-training peripheral administration of low doses of dopamine agonists: possible autoreceptor effect.
<I>Behav. Neural Biol.</I>
59: 230-241, 1993<!-- HIGHWIRE ID="78:1:189:465" --><A HREF="/cgi/external_ref?access_num=8099277&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B466"><!-- comment for mosaic --></a>
<P>466. &nbsp; 

WHITE, N<font size=-1>. </font>M<font size=-1>.</font>,
 <font size=-1>AND</font> M<font size=-1>.</font> VIAUD.



Localized intracaudate dopamine D<SUB>2</SUB> receptor activation during the post-training period improves memory for visual or olfactory conditioned emotional responses in rats.
<I>Behav. Neural Biol.</I>
55: 255-269, 1991<!-- HIGHWIRE ID="78:1:189:466" --><A HREF="/cgi/external_ref?access_num=1676259&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B467"><!-- comment for mosaic --></a>
<P>467. &nbsp; 

WILLIAMS, P<font size=-1>. </font>J<font size=-1>.</font>,
B<font size=-1>. </font>A<font size=-1>.</font> MACVICAR,
 <font size=-1>AND</font> Q<font size=-1>. </font>J<font size=-1>.</font> PITTMAN.



A dopaminergic inhibitory postsynaptic potential mediated by an increased potassium conductance.
<I>Neuroscience</I>
31: 673-681, 1989<!-- HIGHWIRE ID="78:1:189:467" --><A HREF="/cgi/external_ref?access_num=2594196&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B468"><!-- comment for mosaic --></a>
<P>468. &nbsp; 

WILLIAMS, P<font size=-1>. </font>J<font size=-1>.</font>,
B<font size=-1>. </font>A<font size=-1>.</font> MACVICAR,
 <font size=-1>AND</font> Q<font size=-1>. </font>J<font size=-1>.</font> PITTMAN.



Synaptic modulation by dopamine of calcium currents in rat pars intermedia.
<I>J. Neurosci.</I>
10: 757-763, 1990<!-- HIGHWIRE ID="78:1:189:468" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jneuro&resid=10/3/757" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B469"><!-- comment for mosaic --></a>
<P>469. &nbsp; 

WISE, R<font size=-1>. </font>A<font size=-1>.</font>,
 <font size=-1>AND</font> P<font size=-1>. </font>P<font size=-1>.</font> ROMPRE.



Brain dopamine and reward.
<I>Annu. Rev. Psychol.</I>
40: 191-225, 1994<!-- HIGHWIRE ID="78:1:189:469" --><A HREF="/cgi/external_ref?access_num=2648975&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B470"><!-- comment for mosaic --></a>
<P>470. &nbsp; 

WITHFIELD, L<font size=-1>.</font>,
J<font size=-1>. </font>R<font size=-1>.</font> SOWERS,
M<font size=-1>. </font>L<font size=-1>.</font> TUCK,
 <font size=-1>AND</font> M<font size=-1>. </font>S<font size=-1>.</font> GOLUB.



Dopaminergic control of plasma catecholamines and aldosterone responses to acute stimuli in normal man.
<I>J. Clin. Endocrinol. Metab.</I>
51: 724-729, 1980<!-- HIGHWIRE ID="78:1:189:470" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jcem&resid=51/4/724" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B471"><!-- comment for mosaic --></a>
<P>471. &nbsp; 

XU, M<font size=-1>.</font>,
X<font size=-1>.-</font>T<font size=-1>.</font> HU,
D<font size=-1>. </font>C<font size=-1>.</font> COOPER,
R<font size=-1>.</font> MORATALLA,
A<font size=-1>. </font>M<font size=-1>.</font> GRAYBIEL,
F<font size=-1>. </font>J<font size=-1>.</font> WHITE,
 <font size=-1>AND</font> S<font size=-1>.</font> TONEGAWA.



Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine D<SUB>1</SUB> receptor mutant mice.
<I>Cell</I>
79: 945-955, 1994<!-- HIGHWIRE ID="78:1:189:471" --><A HREF="/cgi/external_ref?access_num=8001143&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B472"><!-- comment for mosaic --></a>
<P>472. &nbsp; 

XU, M<font size=-1>.</font>,
R<font size=-1>.</font> MORATALLA,
L<font size=-1>. </font>H<font size=-1>.</font> GOLD,
N<font size=-1>.</font> HIROI,
G<font size=-1>. </font>F<font size=-1>.</font> KOOB,
A<font size=-1>. </font>M<font size=-1>.</font> GRAYBIEL,
 <font size=-1>AND</font> S<font size=-1>.</font> TONEGAWA.



Dopamine D<SUB>1</SUB> receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses.
<I>Cell</I>
79: 729-742, 1994<!-- HIGHWIRE ID="78:1:189:472" --><A HREF="/cgi/external_ref?access_num=7954836&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B473"><!-- comment for mosaic --></a>
<P>473. &nbsp; 

YAMAGUCHI, I<font size=-1>.</font>,
P<font size=-1>. </font>A<font size=-1>.</font> JOSE,
M<font size=-1>. </font>M<font size=-1>.</font> MOURADIAN,
L<font size=-1>. </font>M<font size=-1>.</font> CANESSA,
 <font size=-1>AND</font> F<font size=-1>.</font> MONSMA.



J<font size=-1>R</font>., D.&nbsp;R.&nbsp;SIBLEY, K.&nbsp;TAKEYASU, <font size=-1>AND</font> R.&nbsp;A.&nbsp;FELDER. Expression of dopamine D<SUB>1A</SUB> receptor gene in proximal tubule of rat kidneys.
<I>Am. J.&nbsp;Physiol.</I>
264(<I>Renal Fluid Electrolyte Physiol.</I> 33): F280-F285, 1993<!-- HIGHWIRE ID="78:1:189:473" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajprenal&resid=264/2/F280" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B474"><!-- comment for mosaic --></a>
<P>474. &nbsp; 

YOSHIMURA, M<font size=-1>.</font>,
I<font size=-1>.</font> IKEGAKI,
M<font size=-1>.</font> NISHIMURA,
 <font size=-1>AND</font> H<font size=-1>.</font> TAKAHASHI.



Role of dopaminergic mechanisms in the kidney for the pathogenesis of hypertension.
<I>J. Auton. Pharmacol.</I>
10, <I>Suppl</I>. 1: S62-S67, 1990<!-- HIGHWIRE ID="78:1:189:474" --><!-- /HIGHWIRE -->.</P>
<a name="B475"><!-- comment for mosaic --></a>
<P>475. &nbsp; 

YOSHIMURA, M<font size=-1>.</font>,
S<font size=-1>.</font> KAMBARA,
H<font size=-1>.</font> OKABAYASHI,
H<font size=-1>.</font> TAKAHASHI,
 <font size=-1>AND</font> H<font size=-1>.</font> IJICHI.



Effect of decreased dopamine synthesis on the development of hypertension induced by salt loading in spontaneously hypertensive rats.
<I>Clin. Exp. Hypertens.</I>
9: 1141-1157, 1987<!-- HIGHWIRE ID="78:1:189:475" --><!-- /HIGHWIRE -->.</P>
<a name="B476"><!-- comment for mosaic --></a>
<P>476. &nbsp; 

YOSHIMURA, M<font size=-1>.</font>,
R<font size=-1>.</font> TAKASHIMA,
H<font size=-1>.</font> TAKAHASHI,
 <font size=-1>AND</font> H<font size=-1>.</font> IJICHI.



Role of renal nerves and dopamine on prostaglandin E release from the kidney of rats.
<I>Agents Actions Suppl.</I>
22: 93-100, 1987<!-- HIGHWIRE ID="78:1:189:476" --><A HREF="/cgi/external_ref?access_num=3481215&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B477"><!-- comment for mosaic --></a>
<P>477. &nbsp; 

YU, P<font size=-1>. </font>Y<font size=-1>.</font>,
G<font size=-1>. </font>M<font size=-1>.</font> EISNER,
I<font size=-1>.</font> YAMAGUCHI,
M<font size=-1>. </font>M<font size=-1>.</font> MOURADIAN,
R<font size=-1>. </font>A<font size=-1>.</font> FELDER,
 <font size=-1>AND</font> P<font size=-1>. </font>A<font size=-1>.</font> JOSE.



Dopamine D<SUB>1A</SUB> receptor regulation of phospholipase C isoforms.
<I>J. Biol. Chem.</I>
271: 19503-19508, 1996<!-- HIGHWIRE ID="78:1:189:477" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=271/32/19503" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B478"><!-- comment for mosaic --></a>
<P>478. &nbsp; 

YUN, C<font size=-1>. </font>H<font size=-1>.</font><font size=-1>&nbsp;</font>C<font size=-1>.</font>,
C<font size=-1>.-</font>M<font size=-1>.</font> TSE,
S<font size=-1>. </font>K<font size=-1>.</font> NATH,
S<font size=-1>. </font>A<font size=-1>.</font> LEVINE,
S<font size=-1>. </font>R<font size=-1>.</font> BRANT,
 <font size=-1>AND</font> M<font size=-1>.</font> DONOWITZ.



Mammalian Na<SUP>+</SUP>/H<SUP>+</SUP> exchanger gene family: structure and function studies.
<I>Am. J.&nbsp;Physiol.</I>
269(<I>Gastrointest. Liver Physiol.</I> 32): G1-G11, 1995<!-- HIGHWIRE ID="78:1:189:478" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=ajpgi&resid=269/1/G1" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->.</P>
<a name="B479"><!-- comment for mosaic --></a>
<P>479. &nbsp; 

ZHANG, L<font size=-1>. </font>J<font size=-1>.</font>,
J<font size=-1>. </font>E<font size=-1>.</font> LACHOWICZ,
 <font size=-1>AND</font> D<font size=-1>. </font>R<font size=-1>.</font> SIBLEY.



The D<SUB>2S</SUB> and D<SUB>2L</SUB> dopamine receptor isoforms are differentially regulated in Chinese hamster ovary cells.
<I>Mol. Pharmacol.</I>
45: 878-889, 1994<!-- HIGHWIRE ID="78:1:189:479" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=45/5/878" >[Abstract]</A><!-- /HIGHWIRE -->.</P>
<a name="B480"><!-- comment for mosaic --></a>
<P>480. &nbsp; 

ZHOU, Q<font size=-1>.-</font>Y<font size=-1>.</font>,
D<font size=-1>. </font>K<font size=-1>.</font> GRANDY,
L<font size=-1>.</font> THAMBI,
J<font size=-1>. </font>A<font size=-1>.</font> KUSHNER,
H<font size=-1>. </font>H<font size=-1>.</font><font size=-1>&nbsp;</font>M<font size=-1>.</font> VAN TOL,
R<font size=-1>.</font> CONE,
D<font size=-1>.</font> PRIBNOW,
J<font size=-1>.</font> SALON,
J<font size=-1>. </font>R<font size=-1>.</font> BUNZOW,
 <font size=-1>AND</font> O<font size=-1>.</font> CIVELLI.



Cloning and expression of human and rat D<SUB>1</SUB> dopamine receptors.
<I>Nature</I>
347: 76-80, 1990<!-- HIGHWIRE ID="78:1:189:480" --><A HREF="/cgi/external_ref?access_num=2168520&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>
<a name="B481"><!-- comment for mosaic --></a>
<P>481. &nbsp; 

ZIMMLICHMAN, R<font size=-1>.</font>,
P<font size=-1>. </font>D<font size=-1>.</font> LEVINSON,
G<font size=-1>.</font> KELLY,
R<font size=-1>.</font> STULL,
H<font size=-1>. </font>R<font size=-1>.</font> KEISER,
 <font size=-1>AND</font> D<font size=-1>. </font>S<font size=-1>.</font> GOLDSTEIN.



Derivation of urinary dopamine from plasma dopa.
<I>Clin. Sci. (Lond.)</I>
75: 515-520, 1988<!-- HIGHWIRE ID="78:1:189:481" --><A HREF="/cgi/external_ref?access_num=3151165&link_type=MED" >[Medline]</A><!-- /HIGHWIRE -->.</P>








<HR>
<H5>
0031-9333/98 $15.00 <A HREF="/misc/terms.shtml"> Copyright &#169;1998 The American Physiological Society</A>
</H5>
<!--

   Pages created by the Electronic Press Engine from 

		Atypon Systems, Inc.

   Visit http://www.atypon.com/

-->

</vardef>

		
        
        
	
	
	
	



 




<BR CLEAR=ALL>



  <FONT FACE="">
  
  </FONT>
<BR CLEAR=ALL>
<BR CLEAR=ALL>



<A NAME="otherarticles"><!-- null --></A>
<P>
<FONT SIZE=+2><STRONG>This article has been cited by other articles:</STRONG></FONT>
<P>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jop.sagepub.com"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jop.sagepub.com/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jop.sagepub.com"><IMG ALT="J Psychopharmacol" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/spjop.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	Y. Makihara, H. Yamamoto, M. Inoue, K. Tomiyama, N. Koshikawa, and J. L. Waddington<BR>
	<STRONG>Topographical effects of D1-like dopamine receptor agonists on orofacial         movements in mice and their differential regulation via oppositional versus         synergistic D1-like: D2-like interactions: cautionary observations on SK&F         82958 as an anomalous agent</STRONG><BR>
	
		
			J Psychopharmacol,
		
	
        
        December&nbsp;1,&nbsp;2004;
	18(4):
	484 - 495.
<BR>
<A HREF="http://jop.sagepub.com/cgi/content/abstract/18/4/484">[Abstract]</A>


<A HREF="http://jop.sagepub.com/cgi/reprint/18/4/484">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://molpharm.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Mol Pharmacol" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/molpharm.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	X. Zhen, S. Goswami, S. A. Abdali, M. Gil, K. Bakshi, and E. Friedman<BR>
	<STRONG>Regulation of Cyclin-Dependent Kinase 5 and Calcium/Calmodulin-Dependent Protein Kinase II by Phosphatidylinositol-Linked Dopamine Receptor in Rat Brain</STRONG><BR>
	
		
			Mol. Pharmacol.,
		
	
        
        December&nbsp;1,&nbsp;2004;
	66(6):
	1500 - 1507.
<BR>
<A HREF="http://www.molpharm.org/cgi/content/abstract/66/6/1500">[Abstract]</A>

<A HREF="http://www.molpharm.org/cgi/content/full/66/6/1500">[Full Text]</A>
<A HREF="http://www.molpharm.org/cgi/reprint/66/6/1500">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jhc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jhc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jhc.org"><IMG ALT="J. Histochem. Cytochem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jhc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	A. Nurnberger, M. Rabiger, A. Mack, J. Diaz, P. Sokoloff, B. Muhlbauer, and G. Luippold<BR>
	<STRONG>Subapical Localization of the Dopamine D3 Receptor in Proximal Tubules of the Rat Kidney</STRONG><BR>
	
		
			J. Histochem. Cytochem.,
		
	
        
        December&nbsp;1,&nbsp;2004;
	52(12):
	1647 - 1655.
<BR>
<A HREF="http://www.jhc.org/cgi/content/abstract/52/12/1647">[Abstract]</A>

<A HREF="http://www.jhc.org/cgi/content/full/52/12/1647">[Full Text]</A>
<A HREF="http://www.jhc.org/cgi/reprint/52/12/1647">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.molbiolcell.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.molbiolcell.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.molbiolcell.org"><IMG ALT="Mol. Biol. Cell" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/molbiolcell.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	F. Jeanneteau, O. Guillin, J. Diaz, N. Griffon, and P. Sokoloff<BR>
	<STRONG>GIPC Recruits GAIP (RGS19) To Attenuate Dopamine D2 Receptor Signaling</STRONG><BR>
	
		
			Mol. Biol. Cell,
		
	
        
        November&nbsp;1,&nbsp;2004;
	15(11):
	4926 - 4937.
<BR>
<A HREF="http://www.molbiolcell.org/cgi/content/abstract/15/11/4926">[Abstract]</A>

<A HREF="http://www.molbiolcell.org/cgi/content/full/15/11/4926">[Full Text]</A>
<A HREF="http://www.molbiolcell.org/cgi/reprint/15/11/4926">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jpet.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jpet.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jpet.aspetjournals.org"><IMG ALT="J. Pharmacol. Exp. Ther." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jpet.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	A. Hsu, D. M. Togasaki, E. Bezard, P. Sokoloff, J. W. Langston, D. A. Di Monte, and M. Quik<BR>
	<STRONG>Effect of the D3 Dopamine Receptor Partial Agonist BP897 [N-[4-(4-(2-Methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-Dihydroxyphenylalanine-Induced Dyskinesias and Parkinsonism in Squirrel Monkeys</STRONG><BR>
	
		
			J. Pharmacol. Exp. Ther.,
		
	
        
        November&nbsp;1,&nbsp;2004;
	311(2):
	770 - 777.
<BR>
<A HREF="http://www.jpet.org/cgi/content/abstract/311/2/770">[Abstract]</A>

<A HREF="http://www.jpet.org/cgi/content/full/311/2/770">[Full Text]</A>
<A HREF="http://www.jpet.org/cgi/reprint/311/2/770">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	T.-S. Tang and I. Bezprozvanny<BR>
	<STRONG>Dopamine Receptor-mediated Ca2+ Signaling in Striatal Medium Spiny Neurons</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        October&nbsp;1,&nbsp;2004;
	279(40):
	42082 - 42094.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/279/40/42082">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/279/40/42082">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/279/40/42082">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jpet.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jpet.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jpet.aspetjournals.org"><IMG ALT="J. Pharmacol. Exp. Ther." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jpet.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	S. S. Saklayen, O. S. Mabrouk, and E. A. Pehek<BR>
	<STRONG>Negative Feedback Regulation of Nigrostriatal Dopamine Release: Mediation by Striatal D1 Receptors</STRONG><BR>
	
		
			J. Pharmacol. Exp. Ther.,
		
	
        
        October&nbsp;1,&nbsp;2004;
	311(1):
	342 - 348.
<BR>
<A HREF="http://www.jpet.org/cgi/content/abstract/311/1/342">[Abstract]</A>

<A HREF="http://www.jpet.org/cgi/content/full/311/1/342">[Full Text]</A>
<A HREF="http://www.jpet.org/cgi/reprint/311/1/342">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jcem.endojournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jcem.endojournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jcem.endojournals.org"><IMG ALT="J Clin Endocrinol Metab" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jcem.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	R. Pivonello, D. Ferone, W. W. de Herder, R. R. de Krijger, M. Waaijers, D. M. Mooij, P. M. van Koetsveld, A. Barreca, M. L. Del Basso De Caro, G. Lombardi, A. Colao, S. W. J. Lamberts, and L. J. Hofland<BR>
	<STRONG>Dopamine Receptor Expression and Function in Human Normal Adrenal Gland and Adrenal Tumors</STRONG><BR>
	
		
			J. Clin. Endocrinol. Metab.,
		
	
        
        September&nbsp;1,&nbsp;2004;
	89(9):
	4493 - 4502.
<BR>
<A HREF="http://jcem.endojournals.org/cgi/content/abstract/89/9/4493">[Abstract]</A>

<A HREF="http://jcem.endojournals.org/cgi/content/full/89/9/4493">[Full Text]</A>
<A HREF="http://jcem.endojournals.org/cgi/reprint/89/9/4493">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.ebmonline.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.ebmonline.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.ebmonline.org"><IMG ALT="Exp Biol Med" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/psebm.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	M. Pourcyrous, H. S. Bada, K. E. Blaho, M. M. Randolph, H. Parfenova, T. D. Mandrell, K. Arheart, S. B. Korones, and C. W. Leffler<BR>
	<STRONG>Chronic Prenatal Exposure to Cocaine Alters Cerebrovascular Responses in Newborn Pigs</STRONG><BR>
	
		
			Experimental Biology and Medicine,
		
	
        
        September&nbsp;1,&nbsp;2004;
	229(8):
	819 - 825.
<BR>
<A HREF="http://www.ebmonline.org/cgi/content/abstract/229/8/819">[Abstract]</A>

<A HREF="http://www.ebmonline.org/cgi/content/full/229/8/819">[Full Text]</A>
<A HREF="http://www.ebmonline.org/cgi/reprint/229/8/819">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jn.physiology.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jn.physiology.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jn.physiology.org"><IMG ALT="J. Neurophysiol." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jn.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	M. A. Madriaga, L. C. McPhee, T. Chersa, K. J. Christie, and P. J. Whelan<BR>
	<STRONG>Modulation of Locomotor Activity by Multiple 5-HT and Dopaminergic Receptor Subtypes in the Neonatal Mouse Spinal Cord</STRONG><BR>
	
		
			J Neurophysiol,
		
	
        
        September&nbsp;1,&nbsp;2004;
	92(3):
	1566 - 1576.
<BR>
<A HREF="http://jn.physiology.org/cgi/content/abstract/92/3/1566">[Abstract]</A>

<A HREF="http://jn.physiology.org/cgi/content/full/92/3/1566">[Full Text]</A>
<A HREF="http://jn.physiology.org/cgi/reprint/92/3/1566">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.pnas.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.pnas.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.pnas.org"><IMG ALT="Proc. Natl. Acad. Sci. U. S. A." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/pnas.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	Z. Liu, B. J. Richmond, E. A. Murray, R. C. Saunders, S. Steenrod, B. K. Stubblefield, D. M. Montague, and E. I. Ginns<BR>
	<STRONG>DNA targeting of rhinal cortex D2 receptor protein reversibly blocks learning of cues that predict reward</STRONG><BR>
	
		
			PNAS,
		
	
        
        August&nbsp;17,&nbsp;2004;
	101(33):
	12336 - 12341.
<BR>
<A HREF="http://www.pnas.org/cgi/content/abstract/101/33/12336">[Abstract]</A>

<A HREF="http://www.pnas.org/cgi/content/full/101/33/12336">[Full Text]</A>
<A HREF="http://www.pnas.org/cgi/reprint/101/33/12336">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://clincancerres.aacrjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://clincancerres.aacrjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://clincancerres.aacrjournals.org"><IMG ALT="Clin Cancer Res" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/clincanres.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	D. Chakroborty, C. Sarkar, R. B. Mitra, S. Banerjee, P. S. Dasgupta, and S. Basu<BR>
	<STRONG>Depleted Dopamine in Gastric Cancer Tissues: Dopamine Treatment Retards Growth of Gastric Cancer by Inhibiting Angiogenesis</STRONG><BR>
	
		
			Clin. Cancer Res.,
		
	
        
        July&nbsp;1,&nbsp;2004;
	10(13):
	4349 - 4356.
<BR>
<A HREF="http://clincancerres.aacrjournals.org/cgi/content/abstract/10/13/4349">[Abstract]</A>

<A HREF="http://clincancerres.aacrjournals.org/cgi/content/full/10/13/4349">[Full Text]</A>
<A HREF="http://clincancerres.aacrjournals.org/cgi/reprint/10/13/4349">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	S. Beom, D. Cheong, G. Torres, M. G. Caron, and K.-M. Kim<BR>
	<STRONG>Comparative Studies of Molecular Mechanisms of Dopamine D2 and D3 Receptors for the Activation of Extracellular Signal-regulated Kinase</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        July&nbsp;2,&nbsp;2004;
	279(27):
	28304 - 28314.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/279/27/28304">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/279/27/28304">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/279/27/28304">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://molpharm.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Mol Pharmacol" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/molpharm.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	E. A. Gay, J. D. Urban, D. E. Nichols, G. S. Oxford, and R. B. Mailman<BR>
	<STRONG>Functional Selectivity of D2 Receptor Ligands in a Chinese Hamster Ovary hD2L Cell Line: Evidence for Induction of Ligand-Specific Receptor States</STRONG><BR>
	
		
			Mol. Pharmacol.,
		
	
        
        July&nbsp;1,&nbsp;2004;
	66(1):
	97 - 105.
<BR>
<A HREF="http://www.molpharm.org/cgi/content/abstract/66/1/97">[Abstract]</A>

<A HREF="http://www.molpharm.org/cgi/content/full/66/1/97">[Full Text]</A>
<A HREF="http://www.molpharm.org/cgi/reprint/66/1/97">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jneurosci.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jneurosci.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jneurosci.org"><IMG ALT="J. Neurosci." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jneuro.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	C. D. Paspalas and P. S. Goldman-Rakic<BR>
	<STRONG>Microdomains for Dopamine Volume Neurotransmission in Primate Prefrontal Cortex</STRONG><BR>
	
		
			J. Neurosci.,
		
	
        
        June&nbsp;9,&nbsp;2004;
	24(23):
	5292 - 5300.
<BR>
<A HREF="http://www.jneurosci.org/cgi/content/abstract/24/23/5292">[Abstract]</A>

<A HREF="http://www.jneurosci.org/cgi/content/full/24/23/5292">[Full Text]</A>
<A HREF="http://www.jneurosci.org/cgi/reprint/24/23/5292">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jeb.biologists.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jeb.biologists.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jeb.biologists.org"><IMG ALT="J Exp Biol" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jexbio.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	S. T. Mukai, L. Kiehn, and A. S. M. Saleuddin<BR>
	<STRONG>Dopamine stimulates snail albumen gland glycoprotein secretion through the activation of a D1-like receptor</STRONG><BR>
	
		
			J. Exp. Biol.,
		
	
        
        June&nbsp;15,&nbsp;2004;
	207(14):
	2507 - 2518.
<BR>
<A HREF="http://jeb.biologists.org/cgi/content/abstract/207/14/2507">[Abstract]</A>

<A HREF="http://jeb.biologists.org/cgi/content/full/207/14/2507">[Full Text]</A>
<A HREF="http://jeb.biologists.org/cgi/reprint/207/14/2507">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://nro.sagepub.com"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://nro.sagepub.com/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://nro.sagepub.com"><IMG ALT="Neuroscientist" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/spnro.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	A. Abi-Dargham and H. Moore<BR>
	<STRONG>Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia</STRONG><BR>
	
		
			Neuroscientist,
		
	
        
        October&nbsp;1,&nbsp;2003;
	9(5):
	404 - 416.
<BR>
<A HREF="http://nro.sagepub.com/cgi/content/abstract/9/5/404">[Abstract]</A>


<A HREF="http://nro.sagepub.com/cgi/reprint/9/5/404">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://nro.sagepub.com"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://nro.sagepub.com/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://nro.sagepub.com"><IMG ALT="Neuroscientist" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/spnro.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	F.-M. Zhou, C. Wilson, and J. A. Dani<BR>
	<STRONG>Muscarinic and Nicotinic Cholinergic Mechanisms in the Mesostriatal Dopamine Systems</STRONG><BR>
	
		
			Neuroscientist,
		
	
        
        February&nbsp;1,&nbsp;2003;
	9(1):
	23 - 36.
<BR>
<A HREF="http://nro.sagepub.com/cgi/content/abstract/9/1/23">[Abstract]</A>


<A HREF="http://nro.sagepub.com/cgi/reprint/9/1/23">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jcem.endojournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jcem.endojournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jcem.endojournals.org"><IMG ALT="J Clin Endocrinol Metab" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jcem.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	R. Pivonello, D. Ferone, W. W. de Herder, J. M. Kros, M. L. Del Basso De Caro, M. Arvigo, L. Annunziato, G. Lombardi, A. Colao, L. J. Hofland, and S. W. J. Lamberts<BR>
	<STRONG>Dopamine Receptor Expression and Function in Corticotroph Pituitary Tumors</STRONG><BR>
	
		
			J. Clin. Endocrinol. Metab.,
		
	
        
        May&nbsp;1,&nbsp;2004;
	89(5):
	2452 - 2462.
<BR>
<A HREF="http://jcem.endojournals.org/cgi/content/abstract/89/5/2452">[Abstract]</A>

<A HREF="http://jcem.endojournals.org/cgi/content/full/89/5/2452">[Full Text]</A>
<A HREF="http://jcem.endojournals.org/cgi/reprint/89/5/2452">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.pnas.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.pnas.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.pnas.org"><IMG ALT="Proc. Natl. Acad. Sci. U. S. A." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/pnas.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	J. D. Brioni, R. B. Moreland, M. Cowart, G. C. Hsieh, A. O. Stewart, P. Hedlund, D. L. Donnelly-Roberts, M. Nakane, J. J. Lynch III, T. Kolasa, J. S. Polakowski, M. A. Osinski, K. Marsh, K.-E. Andersson, and J. P. Sullivan<BR>
	<STRONG>Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats</STRONG><BR>
	
		
			PNAS,
		
	
        
        April&nbsp;27,&nbsp;2004;
	101(17):
	6758 - 6763.
<BR>
<A HREF="http://www.pnas.org/cgi/content/abstract/101/17/6758">[Abstract]</A>

<A HREF="http://www.pnas.org/cgi/content/full/101/17/6758">[Full Text]</A>
<A HREF="http://www.pnas.org/cgi/reprint/101/17/6758">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jcem.endojournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jcem.endojournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jcem.endojournals.org"><IMG ALT="J Clin Endocrinol Metab" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jcem.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	R. Pivonello, C. Matrone, M. Filippella, L. M. Cavallo, C. Di Somma, P. Cappabianca, A. Colao, L. Annunziato, and G. Lombardi<BR>
	<STRONG>Dopamine Receptor Expression and Function in Clinically Nonfunctioning Pituitary Tumors: Comparison with the Effectiveness of Cabergoline Treatment</STRONG><BR>
	
		
			J. Clin. Endocrinol. Metab.,
		
	
        
        April&nbsp;1,&nbsp;2004;
	89(4):
	1674 - 1683.
<BR>
<A HREF="http://jcem.endojournals.org/cgi/content/abstract/89/4/1674">[Abstract]</A>

<A HREF="http://jcem.endojournals.org/cgi/content/full/89/4/1674">[Full Text]</A>
<A HREF="http://jcem.endojournals.org/cgi/reprint/89/4/1674">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.pnas.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.pnas.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.pnas.org"><IMG ALT="Proc. Natl. Acad. Sci. U. S. A." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/pnas.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	J.-M. Beaulieu, T. D. Sotnikova, W.-D. Yao, L. Kockeritz, J. R. Woodgett, R. R. Gainetdinov, and M. G. Caron<BR>
	<STRONG>Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade</STRONG><BR>
	
		
			PNAS,
		
	
        
        April&nbsp;6,&nbsp;2004;
	101(14):
	5099 - 5104.
<BR>
<A HREF="http://www.pnas.org/cgi/content/abstract/101/14/5099">[Abstract]</A>

<A HREF="http://www.pnas.org/cgi/content/full/101/14/5099">[Full Text]</A>
<A HREF="http://www.pnas.org/cgi/reprint/101/14/5099">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jneurosci.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jneurosci.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jneurosci.org"><IMG ALT="J. Neurosci." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jneuro.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	L. Zhang, D. Lou, H. Jiao, D. Zhang, X. Wang, Y. Xia, J. Zhang, and M. Xu<BR>
	<STRONG>Cocaine-Induced Intracellular Signaling and Gene Expression Are Oppositely Regulated by the Dopamine D1 and D3 Receptors</STRONG><BR>
	
		
			J. Neurosci.,
		
	
        
        March&nbsp;31,&nbsp;2004;
	24(13):
	3344 - 3354.
<BR>
<A HREF="http://www.jneurosci.org/cgi/content/abstract/24/13/3344">[Abstract]</A>

<A HREF="http://www.jneurosci.org/cgi/content/full/24/13/3344">[Full Text]</A>
<A HREF="http://www.jneurosci.org/cgi/reprint/24/13/3344">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://hyper.ahajournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://hyper.ahajournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://hyper.ahajournals.org"><IMG ALT="Hypertension" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/hypertensionaha.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	C. Zeng, D. Wang, Z. Yang, Z. Wang, L. D. Asico, C. S. Wilcox, G. M. Eisner, W. J. Welch, R. A. Felder, and P. A. Jose<BR>
	<STRONG>Dopamine D1 Receptor Augmentation of D3 Receptor Action in Rat Aortic or Mesenteric Vascular Smooth Muscles</STRONG><BR>
	
		
			Hypertension,
		
	
        
        March&nbsp;1,&nbsp;2004;
	43(3):
	673 - 679.
<BR>
<A HREF="http://www.hypertensionaha.org/cgi/content/abstract/43/3/673">[Abstract]</A>

<A HREF="http://www.hypertensionaha.org/cgi/content/full/43/3/673">[Full Text]</A>
<A HREF="http://www.hypertensionaha.org/cgi/reprint/43/3/673">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://mend.endojournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://mend.endojournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://mend.endojournals.org"><IMG ALT="Mol Endocrinol" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/mend.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	S. J. Kim, M. Y. Kim, E. J. Lee, Y. S. Ahn, and J.-H. Baik<BR>
	<STRONG>Distinct Regulation of Internalization and Mitogen-Activated Protein Kinase Activation by Two Isoforms of the Dopamine D2 Receptor</STRONG><BR>
	
		
			Mol. Endocrinol.,
		
	
        
        March&nbsp;1,&nbsp;2004;
	18(3):
	640 - 652.
<BR>
<A HREF="http://mend.endojournals.org/cgi/content/abstract/18/3/640">[Abstract]</A>

<A HREF="http://mend.endojournals.org/cgi/content/full/18/3/640">[Full Text]</A>
<A HREF="http://mend.endojournals.org/cgi/reprint/18/3/640">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://embojournal.npgjournals.com"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://embojournal.npgjournals.com/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://embojournal.npgjournals.com"><IMG ALT="EMBO J." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/emboj.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	S. Sanyal, R. F Wintle, K. S Kindt, W. M Nuttley, R. Arvan, P. Fitzmaurice, E. Bigras, D. C Merz, T. E Hebert, D. van der Kooy, W. R Schafer, J. G Culotti, and H. H M Van Tol<BR>
	<STRONG>Dopamine modulates the plasticity of mechanosensory responses in Caenorhabditis elegans</STRONG><BR>
	
		
			EMBO J.,
		
	
        
        January&nbsp;28,&nbsp;2004;
	23(2):
	473 - 482.
<BR>
<A HREF="http://embojournal.npgjournals.com/cgi/content/abstract/23/2/473">[Abstract]</A>

<A HREF="http://embojournal.npgjournals.com/cgi/content/full/23/2/473">[Full Text]</A>
<A HREF="http://embojournal.npgjournals.com/cgi/reprint/23/2/473">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jneurosci.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jneurosci.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jneurosci.org"><IMG ALT="J. Neurosci." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jneuro.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	L. Pei, F. J. S. Lee, A. Moszczynska, B. Vukusic, and F. Liu<BR>
	<STRONG>Regulation of Dopamine D1 Receptor Function by Physical Interaction with the NMDA Receptors</STRONG><BR>
	
		
			J. Neurosci.,
		
	
        
        February&nbsp;4,&nbsp;2004;
	24(5):
	1149 - 1158.
<BR>
<A HREF="http://www.jneurosci.org/cgi/content/abstract/24/5/1149">[Abstract]</A>

<A HREF="http://www.jneurosci.org/cgi/content/full/24/5/1149">[Full Text]</A>
<A HREF="http://www.jneurosci.org/cgi/reprint/24/5/1149">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jneurosci.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jneurosci.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jneurosci.org"><IMG ALT="J. Neurosci." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jneuro.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	N. Chuhma, H. Zhang, J. Masson, X. Zhuang, D. Sulzer, R. Hen, and S. Rayport<BR>
	<STRONG>Dopamine Neurons Mediate a Fast Excitatory Signal via Their Glutamatergic Synapses</STRONG><BR>
	
		
			J. Neurosci.,
		
	
        
        January&nbsp;28,&nbsp;2004;
	24(4):
	972 - 981.
<BR>
<A HREF="http://www.jneurosci.org/cgi/content/abstract/24/4/972">[Abstract]</A>

<A HREF="http://www.jneurosci.org/cgi/content/full/24/4/972">[Full Text]</A>
<A HREF="http://www.jneurosci.org/cgi/reprint/24/4/972">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.molbiolcell.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.molbiolcell.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.molbiolcell.org"><IMG ALT="Mol. Biol. Cell" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/molbiolcell.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	F. Jeanneteau, J. Diaz, P. Sokoloff, and N. Griffon<BR>
	<STRONG>Interactions of GIPC with Dopamine D2, D3 but not D4 Receptors Define a Novel Mode of Regulation of G Protein-coupled Receptors</STRONG><BR>
	
		
			Mol. Biol. Cell,
		
	
        
        February&nbsp;1,&nbsp;2004;
	15(2):
	696 - 705.
<BR>
<A HREF="http://www.molbiolcell.org/cgi/content/abstract/15/2/696">[Abstract]</A>

<A HREF="http://www.molbiolcell.org/cgi/content/full/15/2/696">[Full Text]</A>
<A HREF="http://www.molbiolcell.org/cgi/reprint/15/2/696">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	S. E. Senogles, T. L. Heimert, E. R. Odife, and M. W. Quasney<BR>
	<STRONG>A Region of the Third Intracellular Loop of the Short Form of the D2 Dopamine Receptor Dictates Gi Coupling Specificity</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        January&nbsp;16,&nbsp;2004;
	279(3):
	1601 - 1606.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/279/3/1601">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/279/3/1601">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/279/3/1601">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	M. K. Ali and C. Bergson<BR>
	<STRONG>Elevated Intracellular Calcium Triggers Recruitment of the Receptor Cross-talk Accessory Protein Calcyon to the Plasma Membrane</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        December&nbsp;19,&nbsp;2003;
	278(51):
	51654 - 51663.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/278/51/51654">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/278/51/51654">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/278/51/51654">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://pharmrev.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://pharmrev.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://pharmrev.aspetjournals.org"><IMG ALT="Pharmacological Reviews" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/pharmrev.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	L. F. Agnati, S. Ferre, C. Lluis, R. Franco, and K. Fuxe<BR>
	<STRONG>Molecular Mechanisms and Therapeutical Implications of Intramembrane Receptor/Receptor Interactions among Heptahelical Receptors with Examples from the Striatopallidal GABA Neurons</STRONG><BR>
	
		
			Pharmacol. Rev.,
		
	
        
        September&nbsp;1,&nbsp;2003;
	55(3):
	509 - 550.
<BR>
<A HREF="http://pharmrev.aspetjournals.org/cgi/content/abstract/55/3/509">[Abstract]</A>

<A HREF="http://pharmrev.aspetjournals.org/cgi/content/full/55/3/509">[Full Text]</A>
<A HREF="http://pharmrev.aspetjournals.org/cgi/reprint/55/3/509">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jn.physiology.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jn.physiology.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jn.physiology.org"><IMG ALT="J. Neurophysiol." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jn.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	K. Azdad, R. Piet, D. A. Poulain, and S. H. R. Oliet<BR>
	<STRONG>Dopamine D4 Receptor-Mediated Presynaptic Inhibition of GABAergic Transmission in the Rat Supraoptic Nucleus</STRONG><BR>
	
		
			J Neurophysiol,
		
	
        
        August&nbsp;1,&nbsp;2003;
	90(2):
	559 - 565.
<BR>
<A HREF="http://jn.physiology.org/cgi/content/abstract/90/2/559">[Abstract]</A>

<A HREF="http://jn.physiology.org/cgi/content/full/90/2/559">[Full Text]</A>
<A HREF="http://jn.physiology.org/cgi/reprint/90/2/559">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	H. Fang, J. Chartier, C. Sodja, A. Desbois, M. Ribecco-Lutkiewicz, P. R. Walker, and M. Sikorska<BR>
	<STRONG>Transcriptional Activation of the Human Brain-derived Neurotrophic Factor Gene Promoter III by Dopamine Signaling in NT2/N Neurons</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        July&nbsp;18,&nbsp;2003;
	278(29):
	26401 - 26409.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/278/29/26401">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/278/29/26401">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/278/29/26401">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jneurosci.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jneurosci.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jneurosci.org"><IMG ALT="J. Neurosci." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jneuro.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	F. W. Hopf, M. G. Cascini, A. S. Gordon, I. Diamond, and A. Bonci<BR>
	<STRONG>Cooperative Activation of Dopamine D1 and D2 Receptors Increases Spike Firing of Nucleus Accumbens Neurons via G-Protein {beta}{gamma} Subunits</STRONG><BR>
	
		
			J. Neurosci.,
		
	
        
        June&nbsp;15,&nbsp;2003;
	23(12):
	5079 - 5087.
<BR>
<A HREF="http://www.jneurosci.org/cgi/content/abstract/23/12/5079">[Abstract]</A>

<A HREF="http://www.jneurosci.org/cgi/content/full/23/12/5079">[Full Text]</A>
<A HREF="http://www.jneurosci.org/cgi/reprint/23/12/5079">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	C. Fiorentini, F. Gardoni, P. Spano, M. Di Luca, and C. Missale<BR>
	<STRONG>Regulation of Dopamine D1 Receptor Trafficking and Desensitization by Oligomerization with Glutamate N-Methyl-D-aspartate Receptors</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        May&nbsp;30,&nbsp;2003;
	278(22):
	20196 - 20202.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/278/22/20196">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/278/22/20196">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/278/22/20196">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.annalsnyas.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.annalsnyas.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.annalsnyas.org"><IMG ALT="Annals NYAS Online" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/anny.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	S. K. LEONARD, J. M. PETITTO, C. M. ANDERSON, D. H. MOONEY, J. E. LACHOWICZ, D. W. SCHULZ, C. D. KILTS, and R. B. MAILMAN<BR>
	<STRONG>D1 Dopamine Receptors in the Amygdala Exhibit Unique Properties</STRONG><BR>
	
		
			Ann. N.Y. Acad. Sci.,
		
	
        
        April&nbsp;1,&nbsp;2003;
	985(1):
	536 - 539.
<BR>


<A HREF="http://www.annalsnyas.org/cgi/content/full/985/1/536">[Full Text]</A>
<A HREF="http://www.annalsnyas.org/cgi/reprint/985/1/536">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://ajp.psychiatryonline.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://ajp.psychiatryonline.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://ajp.psychiatryonline.org"><IMG ALT="Am. J. Psychiatry" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/ajp.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	J. Tong, B. M. Ross, G. A. Schmunk, F. J. Peretti, K. S. Kalasinsky, Y. Furukawa, L. C. Ang, S. S. Aiken, D. J. Wickham, and S. J. Kish<BR>
	<STRONG>Decreased Striatal Dopamine D1 Receptor- Stimulated Adenylyl Cyclase Activity in Human Methamphetamine Users</STRONG><BR>
	
		
			Am. J. Psychiatry,
		
	
        
        May&nbsp;1,&nbsp;2003;
	160(5):
	896 - 903.
<BR>
<A HREF="http://ajp.psychiatryonline.org/cgi/content/abstract/160/5/896">[Abstract]</A>

<A HREF="http://ajp.psychiatryonline.org/cgi/content/full/160/5/896">[Full Text]</A>
<A HREF="http://ajp.psychiatryonline.org/cgi/reprint/160/5/896">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jneurosci.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jneurosci.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jneurosci.org"><IMG ALT="J. Neurosci." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jneuro.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	B. J. Aragona, Y. Liu, J. T. Curtis, F. K. Stephan, and Z. Wang<BR>
	<STRONG>A Critical Role for Nucleus Accumbens Dopamine in Partner-Preference Formation in Male Prairie Voles</STRONG><BR>
	
		
			J. Neurosci.,
		
	
        
        April&nbsp;15,&nbsp;2003;
	23(8):
	3483 - 3490.
<BR>
<A HREF="http://www.jneurosci.org/cgi/content/abstract/23/8/3483">[Abstract]</A>

<A HREF="http://www.jneurosci.org/cgi/content/full/23/8/3483">[Full Text]</A>
<A HREF="http://www.jneurosci.org/cgi/reprint/23/8/3483">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	C.-Y. Lin, M. G. Varma, A. Joubel, S. Madabushi, O. Lichtarge, and D. L. Barber<BR>
	<STRONG>Conserved Motifs in Somatostatin, D2-dopamine, and alpha 2B-Adrenergic Receptors for Inhibiting the Na-H Exchanger, NHE1</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        April&nbsp;25,&nbsp;2003;
	278(17):
	15128 - 15135.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/278/17/15128">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/278/17/15128">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/278/17/15128">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://ajrccm.atsjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://ajrccm.atsjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://ajrccm.atsjournals.org"><IMG ALT="Am J Respir Crit Care Med" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/ajrccm.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	Y. S. Lin, Q. Gu, and L.-Y. Lee<BR>
	<STRONG>Activation of Dopamine D2-like Receptors Attenuates Pulmonary C-Fiber Hypersensitivity in Rats</STRONG><BR>
	
		
			Am. J. Respir. Crit. Care Med.,
		
	
        
        April&nbsp;15,&nbsp;2003;
	167(8):
	1096 - 1101.
<BR>
<A HREF="http://ajrccm.atsjournals.org/cgi/content/abstract/167/8/1096">[Abstract]</A>

<A HREF="http://ajrccm.atsjournals.org/cgi/content/full/167/8/1096">[Full Text]</A>
<A HREF="http://ajrccm.atsjournals.org/cgi/reprint/167/8/1096">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	K. Tumova, R. M. Iwasiow, and M. Tiberi<BR>
	<STRONG>Insight into the Mechanism of Dopamine D1-like Receptor Activation. EVIDENCE FOR A MOLECULAR INTERPLAY BETWEEN THE THIRD EXTRACELLULAR LOOP AND THE CYTOPLASMIC TAIL</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        March&nbsp;7,&nbsp;2003;
	278(10):
	8146 - 8153.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/278/10/8146">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/278/10/8146">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/278/10/8146">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://ajpcell.physiology.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://ajpcell.physiology.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://ajpcell.physiology.org"><IMG ALT="Am. J. Physiol." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/ajpcell.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	G. Liu, M. H. Ghahremani, B. Banihashemi, and P. R. Albert<BR>
	<STRONG>Diacylglycerol and ceramide formation induced by dopamine D2S receptors via Gbeta gamma -subunits in Balb/c-3T3 cells</STRONG><BR>
	
		
			Am J Physiol Cell Physiol,
		
	
        
        March&nbsp;1,&nbsp;2003;
	284(3):
	C640 - 648.
<BR>
<A HREF="http://ajpcell.physiology.org/cgi/content/abstract/284/3/C640">[Abstract]</A>

<A HREF="http://ajpcell.physiology.org/cgi/content/full/284/3/C640">[Full Text]</A>
<A HREF="http://ajpcell.physiology.org/cgi/reprint/284/3/C640">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://ajpheart.physiology.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://ajpheart.physiology.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://ajpheart.physiology.org"><IMG ALT="Am. J. Physiol." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/ajpheart.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	K.-H. Huemer, G. Garhofer, C. Zawinka, E. Golestani, B. Litschauer, L. Schmetterer, and G. T. Dorner<BR>
	<STRONG>Effects of dopamine on human retinal vessel diameter and its modulation during flicker stimulation</STRONG><BR>
	
		
			Am J Physiol Heart Circ Physiol,
		
	
        
        January&nbsp;1,&nbsp;2003;
	284(1):
	H358 - 363.
<BR>
<A HREF="http://ajpheart.physiology.org/cgi/content/abstract/284/1/H358">[Abstract]</A>

<A HREF="http://ajpheart.physiology.org/cgi/content/full/284/1/H358">[Full Text]</A>
<A HREF="http://ajpheart.physiology.org/cgi/reprint/284/1/H358">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://ajprenal.physiology.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://ajprenal.physiology.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://ajprenal.physiology.org"><IMG ALT="Am. J. Physiol." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/ajprenal.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	N. Pizzinat, S. Marchal-Victorion, A. Maurel, C. Ordener, G. Bompart, and A. Parini<BR>
	<STRONG>Substrate-dependent regulation of MAO-A in rat mesangial cells: involvement of dopamine D2-like receptors</STRONG><BR>
	
		
			Am J Physiol Renal Physiol,
		
	
        
        January&nbsp;1,&nbsp;2003;
	284(1):
	F167 - 174.
<BR>
<A HREF="http://ajprenal.physiology.org/cgi/content/abstract/284/1/F167">[Abstract]</A>

<A HREF="http://ajprenal.physiology.org/cgi/content/full/284/1/F167">[Full Text]</A>
<A HREF="http://ajprenal.physiology.org/cgi/reprint/284/1/F167">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jn.physiology.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jn.physiology.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jn.physiology.org"><IMG ALT="J. Neurophysiol." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jn.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	D. D. Kline, K. N. Takacs, E. Ficker, and D. L. Kunze<BR>
	<STRONG>Dopamine Modulates Synaptic Transmission in the Nucleus of the Solitary Tract</STRONG><BR>
	
		
			J Neurophysiol,
		
	
        
        November&nbsp;1,&nbsp;2002;
	88(5):
	2736 - 2744.
<BR>
<A HREF="http://jn.physiology.org/cgi/content/abstract/88/5/2736">[Abstract]</A>

<A HREF="http://jn.physiology.org/cgi/content/full/88/5/2736">[Full Text]</A>
<A HREF="http://jn.physiology.org/cgi/reprint/88/5/2736">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jneurosci.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jneurosci.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jneurosci.org"><IMG ALT="J. Neurosci." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jneuro.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	C. A. Cornil, J. Balthazart, P. Motte, L. Massotte, and V. Seutin<BR>
	<STRONG>Dopamine Activates Noradrenergic Receptors in the Preoptic Area</STRONG><BR>
	
		
			J. Neurosci.,
		
	
        
        November&nbsp;1,&nbsp;2002;
	22(21):
	9320 - 9330.
<BR>
<A HREF="http://www.jneurosci.org/cgi/content/abstract/22/21/9320">[Abstract]</A>

<A HREF="http://www.jneurosci.org/cgi/content/full/22/21/9320">[Full Text]</A>
<A HREF="http://www.jneurosci.org/cgi/reprint/22/21/9320">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jp.physoc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jp.physoc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jp.physoc.org"><IMG ALT="J Physiol" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jphysiol.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	C. Ribelayga, Y. Wang, and S. C. Mangel<BR>
	<STRONG>Dopamine mediates circadian clock regulation of rod and cone input to fish retinal horizontal cells</STRONG><BR>
	
		
			J. Physiol.,
		
	
        
        November&nbsp;1,&nbsp;2002;
	544(3):
	801 - 816.
<BR>
<A HREF="http://jp.physoc.org/cgi/content/abstract/544/3/801">[Abstract]</A>

<A HREF="http://jp.physoc.org/cgi/content/full/544/3/801">[Full Text]</A>
<A HREF="http://jp.physoc.org/cgi/reprint/544/3/801">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.pnas.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.pnas.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.pnas.org"><IMG ALT="Proc. Natl. Acad. Sci. U. S. A." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/pnas.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	M. G. Hearn, Y. Ren, E. W. McBride, I. Reveillaud, M. Beinborn, and A. S. Kopin<BR>
	<STRONG>A Drosophila dopamine 2-like receptor: Molecular characterization and identification of multiple alternatively spliced variants</STRONG><BR>
	
		
			PNAS,
		
	
        
        October&nbsp;29,&nbsp;2002;
	99(22):
	14554 - 14559.
<BR>
<A HREF="http://www.pnas.org/cgi/content/abstract/99/22/14554">[Abstract]</A>

<A HREF="http://www.pnas.org/cgi/content/full/99/22/14554">[Full Text]</A>
<A HREF="http://www.pnas.org/cgi/reprint/99/22/14554">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.pnas.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.pnas.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.pnas.org"><IMG ALT="Proc. Natl. Acad. Sci. U. S. A." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/pnas.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	C. Iaccarino, T. A. Samad, C. Mathis, H. Kercret, R. Picetti, and E. Borrelli<BR>
	<STRONG>Control of lactotrop proliferation by dopamine: Essential role of signaling through D2 receptors and ERKs</STRONG><BR>
	
		
			PNAS,
		
	
        
        October&nbsp;29,&nbsp;2002;
	99(22):
	14530 - 14535.
<BR>
<A HREF="http://www.pnas.org/cgi/content/abstract/99/22/14530">[Abstract]</A>

<A HREF="http://www.pnas.org/cgi/content/full/99/22/14530">[Full Text]</A>
<A HREF="http://www.pnas.org/cgi/reprint/99/22/14530">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://mend.endojournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://mend.endojournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://mend.endojournals.org"><IMG ALT="Mol Endocrinol" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/mend.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	B. Banihashemi and P. R. Albert<BR>
	<STRONG>Dopamine-D2S Receptor Inhibition of Calcium Influx, Adenylyl Cyclase, and Mitogen-Activated Protein Kinase in Pituitary Cells: Distinct G{alpha} and G{beta}{gamma} Requirements</STRONG><BR>
	
		
			Mol. Endocrinol.,
		
	
        
        October&nbsp;1,&nbsp;2002;
	16(10):
	2393 - 2404.
<BR>
<A HREF="http://mend.endojournals.org/cgi/content/abstract/16/10/2393">[Abstract]</A>

<A HREF="http://mend.endojournals.org/cgi/content/full/16/10/2393">[Full Text]</A>
<A HREF="http://mend.endojournals.org/cgi/reprint/16/10/2393">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://ajpregu.physiology.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://ajpregu.physiology.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://ajpregu.physiology.org"><IMG ALT="Am. J. Physiol." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/ajpregu.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	S. O. Fetissov, M. M. Meguid, T. Sato, and L.-H. Zhang<BR>
	<STRONG>Expression of dopaminergic receptors in the hypothalamus of lean and obese Zucker rats and food intake</STRONG><BR>
	
		
			Am J Physiol Regulatory Integrative Comp Physiol,
		
	
        
        October&nbsp;1,&nbsp;2002;
	283(4):
	R905 - 910.
<BR>
<A HREF="http://ajpregu.physiology.org/cgi/content/abstract/283/4/R905">[Abstract]</A>

<A HREF="http://ajpregu.physiology.org/cgi/content/full/283/4/R905">[Full Text]</A>
<A HREF="http://ajpregu.physiology.org/cgi/reprint/283/4/R905">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jneurosci.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jneurosci.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jneurosci.org"><IMG ALT="J. Neurosci." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jneuro.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	K.-W. Lee, J.-H. Hong, I. Y. Choi, Y. Che, J.-K. Lee, S.-D. Yang, C.-W. Song, H. S. Kang, J.-H. Lee, J. S. Noh, H.-S. Shin, and P.-L. Han<BR>
	<STRONG>Impaired D2 Dopamine Receptor Function in Mice Lacking Type 5 Adenylyl Cyclase</STRONG><BR>
	
		
			J. Neurosci.,
		
	
        
        September&nbsp;15,&nbsp;2002;
	22(18):
	7931 - 7940.
<BR>
<A HREF="http://www.jneurosci.org/cgi/content/abstract/22/18/7931">[Abstract]</A>

<A HREF="http://www.jneurosci.org/cgi/content/full/22/18/7931">[Full Text]</A>
<A HREF="http://www.jneurosci.org/cgi/reprint/22/18/7931">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jpet.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jpet.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jpet.aspetjournals.org"><IMG ALT="J. Pharmacol. Exp. Ther." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jpet.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	G. Cai, H.-Y. Wang, and E. Friedman<BR>
	<STRONG>Increased Dopamine Receptor Signaling and Dopamine Receptor-G Protein Coupling in Denervated Striatum</STRONG><BR>
	
		
			J. Pharmacol. Exp. Ther.,
		
	
        
        September&nbsp;1,&nbsp;2002;
	302(3):
	1105 - 1112.
<BR>
<A HREF="http://jpet.aspetjournals.org/cgi/content/abstract/302/3/1105">[Abstract]</A>

<A HREF="http://jpet.aspetjournals.org/cgi/content/full/302/3/1105">[Full Text]</A>
<A HREF="http://jpet.aspetjournals.org/cgi/reprint/302/3/1105">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://molpharm.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Mol Pharmacol" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/molpharm.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	A. V. Binda, N. Kabbani, R. Lin, and R. Levenson<BR>
	<STRONG>D2 and D3 Dopamine Receptor Cell Surface Localization Mediated by Interaction with Protein 4.1N</STRONG><BR>
	
		
			Mol. Pharmacol.,
		
	
        
        September&nbsp;1,&nbsp;2002;
	62(3):
	507 - 513.
<BR>
<A HREF="http://molpharm.aspetjournals.org/cgi/content/abstract/62/3/507">[Abstract]</A>

<A HREF="http://molpharm.aspetjournals.org/cgi/content/full/62/3/507">[Full Text]</A>
<A HREF="http://molpharm.aspetjournals.org/cgi/reprint/62/3/507">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://ajprenal.physiology.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://ajprenal.physiology.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://ajprenal.physiology.org"><IMG ALT="Am. J. Physiol." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/ajprenal.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	M. Zelenina, S. Zelenin, A. A. Bondar, H. Brismar, and A. Aperia<BR>
	<STRONG>Water permeability of aquaporin-4 is decreased by protein kinase C and dopamine</STRONG><BR>
	
		
			Am J Physiol Renal Physiol,
		
	
        
        August&nbsp;1,&nbsp;2002;
	283(2):
	F309 - 318.
<BR>
<A HREF="http://ajprenal.physiology.org/cgi/content/abstract/283/2/F309">[Abstract]</A>

<A HREF="http://ajprenal.physiology.org/cgi/content/full/283/2/F309">[Full Text]</A>
<A HREF="http://ajprenal.physiology.org/cgi/reprint/283/2/F309">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jneurosci.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jneurosci.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jneurosci.org"><IMG ALT="J. Neurosci." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jneuro.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	L. Ding and D. J. Perkel<BR>
	<STRONG>Dopamine Modulates Excitability of Spiny Neurons in the Avian Basal Ganglia</STRONG><BR>
	
		
			J. Neurosci.,
		
	
        
        June&nbsp;15,&nbsp;2002;
	22(12):
	5210 - 5218.
<BR>
<A HREF="http://www.jneurosci.org/cgi/content/abstract/22/12/5210">[Abstract]</A>

<A HREF="http://www.jneurosci.org/cgi/content/full/22/12/5210">[Full Text]</A>
<A HREF="http://www.jneurosci.org/cgi/reprint/22/12/5210">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	T. S. Kostic, M. Tomic', S. A. Andric, and S. S. Stojilkovic<BR>
	<STRONG>Calcium-independent and cAMP-dependent Modulation of Soluble Guanylyl Cyclase Activity by G Protein-coupled Receptors in Pituitary Cells</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        May&nbsp;10,&nbsp;2002;
	277(19):
	16412 - 16418.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/277/19/16412">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/277/19/16412">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/277/19/16412">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://ajp.psychiatryonline.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://ajp.psychiatryonline.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://ajp.psychiatryonline.org"><IMG ALT="Am. J. Psychiatry" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/ajp.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	P. Karlsson, L. Farde, C. Halldin, and G. Sedvall<BR>
	<STRONG>PET Study of D1 Dopamine Receptor Binding in Neuroleptic-Naive Patients With Schizophrenia</STRONG><BR>
	
		
			Am. J. Psychiatry,
		
	
        
        May&nbsp;1,&nbsp;2002;
	159(5):
	761 - 767.
<BR>
<A HREF="http://ajp.psychiatryonline.org/cgi/content/abstract/159/5/761">[Abstract]</A>

<A HREF="http://ajp.psychiatryonline.org/cgi/content/full/159/5/761">[Full Text]</A>
<A HREF="http://ajp.psychiatryonline.org/cgi/reprint/159/5/761">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://mend.endojournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://mend.endojournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://mend.endojournals.org"><IMG ALT="Mol Endocrinol" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/mend.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	A. Ozawa, M. Yamada, T. Satoh, T. Monden, K. Hashimoto, H. Kohga, Y. Hashiba, T. Sasaki, and M. Mori<BR>
	<STRONG>Transcriptional Regulation of the Human PRL-Releasing Peptide (PrRP) Receptor Gene by a Dopamine 2 Receptor Agonist: Cloning and Characterization of the Human PrRP Receptor Gene and Its Promoter Region</STRONG><BR>
	
		
			Mol. Endocrinol.,
		
	
        
        April&nbsp;1,&nbsp;2002;
	16(4):
	785 - 798.
<BR>
<A HREF="http://mend.endojournals.org/cgi/content/abstract/16/4/785">[Abstract]</A>

<A HREF="http://mend.endojournals.org/cgi/content/full/16/4/785">[Full Text]</A>
<A HREF="http://mend.endojournals.org/cgi/reprint/16/4/785">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	M. Lamey, M. Thompson, G. Varghese, H. Chi, M. Sawzdargo, S. R. George, and B. F. O'Dowd<BR>
	<STRONG>Distinct Residues in the Carboxyl Tail Mediate Agonist-induced Desensitization and Internalization of the Human Dopamine D1 Receptor</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        March&nbsp;15,&nbsp;2002;
	277(11):
	9415 - 9421.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/277/11/9415">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/277/11/9415">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/277/11/9415">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://endo.endojournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://endo.endojournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://endo.endojournals.org"><IMG ALT="Endocrinology" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/endo.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	P. R. Albert<BR>
	<STRONG>Editorial: Dopamine-D2-Mediated Inhibition of TRH-Induced PLC Activation in Pituitary Cells--Direct or Indirect?</STRONG><BR>
	
		
			Endocrinology,
		
	
        
        March&nbsp;1,&nbsp;2002;
	143(3):
	744 - 746.
<BR>


<A HREF="http://endo.endojournals.org/cgi/content/full/143/3/744">[Full Text]</A>
<A HREF="http://endo.endojournals.org/cgi/reprint/143/3/744">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://endo.endojournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://endo.endojournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://endo.endojournals.org"><IMG ALT="Endocrinology" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/endo.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	R. Rasolonjanahary, C. Gerard, M. N. Dufour, V. Homburger, A. Enjalbert, and G. Guillon<BR>
	<STRONG>Evidence for a Direct Negative Coupling between Dopamine-D2 Receptors and PLC by Heterotrimeric Gi1/2 Proteins in Rat Anterior Pituitary Cell Membranes</STRONG><BR>
	
		
			Endocrinology,
		
	
        
        March&nbsp;1,&nbsp;2002;
	143(3):
	747 - 754.
<BR>
<A HREF="http://endo.endojournals.org/cgi/content/abstract/143/3/747">[Abstract]</A>

<A HREF="http://endo.endojournals.org/cgi/content/full/143/3/747">[Full Text]</A>
<A HREF="http://endo.endojournals.org/cgi/reprint/143/3/747">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jn.physiology.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jn.physiology.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jn.physiology.org"><IMG ALT="J. Neurophysiol." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jn.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	P. Congar, A. Bergevin, and L.-E. Trudeau<BR>
	<STRONG>D2 Receptors Inhibit the Secretory Process Downstream From Calcium Influx in Dopaminergic Neurons: Implication of K+ Channels</STRONG><BR>
	
		
			J Neurophysiol,
		
	
        
        February&nbsp;1,&nbsp;2002;
	87(2):
	1046 - 1056.
<BR>
<A HREF="http://jn.physiology.org/cgi/content/abstract/87/2/1046">[Abstract]</A>

<A HREF="http://jn.physiology.org/cgi/content/full/87/2/1046">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://mend.endojournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://mend.endojournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://mend.endojournals.org"><IMG ALT="Mol Endocrinol" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/mend.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	C. Fiorentini, N. Guerra, M. Facchetti, A. Finardi, L. Tiberio, L. Schiaffonati, P. Spano, and C. Missale<BR>
	<STRONG>Nerve Growth Factor Regulates Dopamine D2 Receptor Expression in Prolactinoma Cell Lines via p75NGFR-Mediated Activation of Nuclear Factor-{kappa}B</STRONG><BR>
	
		
			Mol. Endocrinol.,
		
	
        
        February&nbsp;1,&nbsp;2002;
	16(2):
	353 - 366.
<BR>
<A HREF="http://mend.endojournals.org/cgi/content/abstract/16/2/353">[Abstract]</A>

<A HREF="http://mend.endojournals.org/cgi/content/full/16/2/353">[Full Text]</A>
<A HREF="http://mend.endojournals.org/cgi/reprint/16/2/353">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	M. R. Walters, M. Dutertre, and C. L. Smith<BR>
	<STRONG>SKF-82958 Is a Subtype-selective Estrogen Receptor-alpha  (ERalpha ) Agonist That Induces Functional Interactions between ERalpha  and AP-1</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        January&nbsp;18,&nbsp;2002;
	277(3):
	1669 - 1679.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/277/3/1669">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/277/3/1669">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/277/3/1669">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jneurosci.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jneurosci.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jneurosci.org"><IMG ALT="J. Neurosci." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jneuro.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	E. C. Cooper, E. Harrington, Y. N. Jan, and L. Y. Jan<BR>
	<STRONG>M Channel KCNQ2 Subunits Are Localized to Key Sites for Control of Neuronal Network Oscillations and Synchronization in Mouse Brain</STRONG><BR>
	
		
			J. Neurosci.,
		
	
        
        December&nbsp;15,&nbsp;2001;
	21(24):
	9529 - 9540.
<BR>
<A HREF="http://www.jneurosci.org/cgi/content/abstract/21/24/9529">[Abstract]</A>

<A HREF="http://www.jneurosci.org/cgi/content/full/21/24/9529">[Full Text]</A>
<A HREF="http://www.jneurosci.org/cgi/reprint/21/24/9529">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://edrv.endojournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://edrv.endojournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://edrv.endojournals.org"><IMG ALT="Endocr Rev" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/edrv.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	N. Ben-Jonathan and R. Hnasko<BR>
	<STRONG>Dopamine as a Prolactin (PRL) Inhibitor</STRONG><BR>
	
		
			Endocr. Rev.,
		
	
        
        December&nbsp;1,&nbsp;2001;
	22(6):
	724 - 763.
<BR>
<A HREF="http://edrv.endojournals.org/cgi/content/abstract/22/6/724">[Abstract]</A>

<A HREF="http://edrv.endojournals.org/cgi/content/full/22/6/724">[Full Text]</A>
<A HREF="http://edrv.endojournals.org/cgi/reprint/22/6/724">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jn.physiology.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jn.physiology.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jn.physiology.org"><IMG ALT="J. Neurophysiol." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jn.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	C. Gonzalez-Islas and J. J. Hablitz<BR>
	<STRONG>Dopamine Inhibition of Evoked IPSCs in Rat Prefrontal Cortex</STRONG><BR>
	
		
			J Neurophysiol,
		
	
        
        December&nbsp;1,&nbsp;2001;
	86(6):
	2911 - 2918.
<BR>
<A HREF="http://jn.physiology.org/cgi/content/abstract/86/6/2911">[Abstract]</A>

<A HREF="http://jn.physiology.org/cgi/content/full/86/6/2911">[Full Text]</A>
<A HREF="http://jn.physiology.org/cgi/reprint/86/6/2911">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jcs.biologists.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jcs.biologists.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jcs.biologists.org"><IMG ALT="J Cell Sci" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/joces.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	D. Prou, W.-J. Gu, S. Le Crom, J.-D. Vincent, J. Salamero, and P. Vernier<BR>
	<STRONG>Intracellular retention of the two isoforms of the D2 dopamine receptor promotes endoplasmic reticulum disruption</STRONG><BR>
	
		
			J. Cell Sci.,
		
	
        
        January&nbsp;10,&nbsp;2001;
	114(19):
	3517 - 3527.
<BR>
<A HREF="http://jcs.biologists.org/cgi/content/abstract/114/19/3517">[Abstract]</A>

<A HREF="http://jcs.biologists.org/cgi/content/full/114/19/3517">[Full Text]</A>
<A HREF="http://jcs.biologists.org/cgi/reprint/114/19/3517">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	Q. Wang, J. P. Jolly, J. D. Surmeier, B. M. Mullah, M. S. Lidow, C. M. Bergson, and J. D. Robishaw<BR>
	<STRONG>Differential Dependence of the D1 and D5 Dopamine Receptors on the G Protein gamma 7 Subunit for Activation of Adenylylcyclase</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        October&nbsp;19,&nbsp;2001;
	276(42):
	39386 - 39393.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/276/42/39386">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/276/42/39386">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/276/42/39386">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	K.-M. Kim, K. J. Valenzano, S. R. Robinson, W. D. Yao, L. S. Barak, and M. G. Caron<BR>
	<STRONG>Differential Regulation of the Dopamine D2 and D3 Receptors by G Protein-coupled Receptor Kinases and beta -Arrestins</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        October&nbsp;5,&nbsp;2001;
	276(40):
	37409 - 37414.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/276/40/37409">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/276/40/37409">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/276/40/37409">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://hyper.ahajournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://hyper.ahajournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://hyper.ahajournals.org"><IMG ALT="Hypertension" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/hypertensionaha.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	J. Christopher, V. Velarde, and A. A. Jaffa<BR>
	<STRONG>Induction of B1-Kinin Receptors in Vascular Smooth Muscle Cells: Cellular Mechanisms of MAP Kinase Activation</STRONG><BR>
	
		
			Hypertension,
		
	
        
        September&nbsp;1,&nbsp;2001;
	38(3):
	602 - 605.
<BR>
<A HREF="http://hyper.ahajournals.org/cgi/content/abstract/38/3/602">[Abstract]</A>

<A HREF="http://hyper.ahajournals.org/cgi/content/full/38/3/602">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://molpharm.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Mol Pharmacol" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/molpharm.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	X. Zhen, J. Zhang, G. P. Johnson, and E. Friedman<BR>
	<STRONG>D4 Dopamine Receptor Differentially Regulates Akt/Nuclear Factor-kappa B and Extracellular Signal-Regulated Kinase Pathways in D4MN9D Cells</STRONG><BR>
	
		
			Mol. Pharmacol.,
		
	
        
        October&nbsp;1,&nbsp;2001;
	60(4):
	857 - 864.
<BR>
<A HREF="http://molpharm.aspetjournals.org/cgi/content/abstract/60/4/857">[Abstract]</A>

<A HREF="http://molpharm.aspetjournals.org/cgi/content/full/60/4/857">[Full Text]</A>
<A HREF="http://molpharm.aspetjournals.org/cgi/reprint/60/4/857">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jcem.endojournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jcem.endojournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jcem.endojournals.org"><IMG ALT="J Clin Endocrinol Metab" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jcem.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	K.-D. Wu, Y.-M. Chen, T.-S. Chu, S.-C. Chueh, M.-H. Wu, and H. Bor-Shen<BR>
	<STRONG>Expression and Localization of Human Dopamine D2 and D4 Receptor mRNA in the Adrenal Gland, Aldosterone-Producing Adenoma, and Pheochromocytoma</STRONG><BR>
	
		
			J. Clin. Endocrinol. Metab.,
		
	
        
        September&nbsp;1,&nbsp;2001;
	86(9):
	4460 - 4467.
<BR>
<A HREF="http://jcem.endojournals.org/cgi/content/abstract/86/9/4460">[Abstract]</A>

<A HREF="http://jcem.endojournals.org/cgi/content/full/86/9/4460">[Full Text]</A>
<A HREF="http://jcem.endojournals.org/cgi/reprint/86/9/4460">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jn.physiology.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jn.physiology.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jn.physiology.org"><IMG ALT="J. Neurophysiol." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jn.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	C. J. Price and Q. J. Pittman<BR>
	<STRONG>Dopamine D4 Receptor Activation Inhibits Presynaptically Glutamatergic Neurotransmission in the Rat Supraoptic Nucleus</STRONG><BR>
	
		
			J Neurophysiol,
		
	
        
        September&nbsp;1,&nbsp;2001;
	86(3):
	1149 - 1155.
<BR>
<A HREF="http://jn.physiology.org/cgi/content/abstract/86/3/1149">[Abstract]</A>

<A HREF="http://jn.physiology.org/cgi/content/full/86/3/1149">[Full Text]</A>
<A HREF="http://jn.physiology.org/cgi/reprint/86/3/1149">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.psychosomaticmedicine.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.psychosomaticmedicine.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.psychosomaticmedicine.org"><IMG ALT="Psychosom Med" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/psychmed.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	G. Torres and J. M. Horowitz<BR>
	<STRONG>Drugs of Abuse and Brain Gene Expression</STRONG><BR>
	
		
			Psychosom Med,
		
	
        
        September&nbsp;1,&nbsp;1999;
	61(5):
	630 - 650.
<BR>
<A HREF="http://www.psychosomaticmedicine.org/cgi/content/abstract/61/5/630">[Abstract]</A>

<A HREF="http://www.psychosomaticmedicine.org/cgi/content/full/61/5/630">[Full Text]</A>
<A HREF="http://www.psychosomaticmedicine.org/cgi/reprint/61/5/630">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jneurosci.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jneurosci.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jneurosci.org"><IMG ALT="J. Neurosci." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jneuro.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	C. L. Parish, D. I. Finkelstein, J. Drago, E. Borrelli, and M. K. Horne<BR>
	<STRONG>The Role of Dopamine Receptors in Regulating the Size of Axonal Arbors</STRONG><BR>
	
		
			J. Neurosci.,
		
	
        
        July&nbsp;15,&nbsp;2001;
	21(14):
	5147 - 5157.
<BR>
<A HREF="http://www.jneurosci.org/cgi/content/abstract/21/14/5147">[Abstract]</A>

<A HREF="http://www.jneurosci.org/cgi/content/full/21/14/5147">[Full Text]</A>
<A HREF="http://www.jneurosci.org/cgi/reprint/21/14/5147">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://molinterv.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://molinterv.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://molinterv.aspetjournals.org"><IMG ALT="Mol Interv" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/molint.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	K. P. Minneman<BR>
	<STRONG>Splice Variants of GPCRs</STRONG><BR>
	
		
			Mol. Interv.,
		
	
        
        June&nbsp;1,&nbsp;2001;
	1(2):
	108 - 116.
<BR>
<A HREF="http://molinterv.aspetjournals.org/cgi/content/abstract/1/2/108">[Abstract]</A>

<A HREF="http://molinterv.aspetjournals.org/cgi/content/full/1/2/108">[Full Text]</A>
<A HREF="http://molinterv.aspetjournals.org/cgi/reprint/1/2/108">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://ajprenal.physiology.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://ajprenal.physiology.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://ajprenal.physiology.org"><IMG ALT="Am. J. Physiol." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/ajprenal.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	O. Saito, Y. Ando, E. Kusano, and Y. Asano<BR>
	<STRONG>Functional characterization of basolateral and luminal dopamine receptors in rabbit CCD</STRONG><BR>
	
		
			Am J Physiol Renal Physiol,
		
	
        
        July&nbsp;1,&nbsp;2001;
	281(1):
	F114 - 122.
<BR>
<A HREF="http://ajprenal.physiology.org/cgi/content/abstract/281/1/F114">[Abstract]</A>

<A HREF="http://ajprenal.physiology.org/cgi/content/full/281/1/F114">[Full Text]</A>
<A HREF="http://ajprenal.physiology.org/cgi/reprint/281/1/F114">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jp.physoc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jp.physoc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jp.physoc.org"><IMG ALT="J Physiol" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jphysiol.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	T. Momiyama and E. Koga<BR>
	<STRONG>Dopamine D2-like receptors selectively block N-type Ca2+ channels to reduce GABA release onto rat striatal cholinergic interneurones</STRONG><BR>
	
		
			J. Physiol.,
		
	
        
        June&nbsp;1,&nbsp;2001;
	533(2):
	479 - 492.
<BR>
<A HREF="http://jp.physoc.org/cgi/content/abstract/533/2/479">[Abstract]</A>

<A HREF="http://jp.physoc.org/cgi/content/full/533/2/479">[Full Text]</A>
<A HREF="http://jp.physoc.org/cgi/reprint/533/2/479">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://pharmrev.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://pharmrev.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://pharmrev.aspetjournals.org"><IMG ALT="Pharmacological Reviews" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/pharmrev.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	E. S. Vizi<BR>
	<STRONG>Role of High-Affinity Receptors and Membrane Transporters in Nonsynaptic Communication and Drug Action in the Central Nervous System</STRONG><BR>
	
		
			Pharmacol. Rev.,
		
	
        
        March&nbsp;1,&nbsp;2000;
	52(1):
	63 - 90.
<BR>
<A HREF="http://pharmrev.aspetjournals.org/cgi/content/abstract/52/1/63">[Abstract]</A>

<A HREF="http://pharmrev.aspetjournals.org/cgi/content/full/52/1/63">[Full Text]</A>
<A HREF="http://pharmrev.aspetjournals.org/cgi/reprint/52/1/63">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jpet.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jpet.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jpet.aspetjournals.org"><IMG ALT="J. Pharmacol. Exp. Ther." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jpet.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	P. J. Pauwels, F. Finana, S. Tardif, T. Wurch, and F. C. Colpaert<BR>
	<STRONG>Dynamic Dopamine-Antagonist Interactions at Recombinant Human Dopamine D2short Receptor: Dopamine-Bound versus Antagonist-Bound Receptor States</STRONG><BR>
	
		
			J. Pharmacol. Exp. Ther.,
		
	
        
        April&nbsp;1,&nbsp;2001;
	297(1):
	133 - 140.
<BR>
<A HREF="http://www.jpet.org/cgi/content/abstract/297/1/133">[Abstract]</A>

<A HREF="http://www.jpet.org/cgi/content/full/297/1/133">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.pnas.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.pnas.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.pnas.org"><IMG ALT="Proc. Natl. Acad. Sci. U. S. A." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/pnas.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	N. Stella<BR>
	<STRONG>How might cannabinoids influence sexual behavior?</STRONG><BR>
	
		
			PNAS,
		
	
        
        January&nbsp;30,&nbsp;2001;
	98(3):
	793 - 795.
<BR>


<A HREF="http://www.pnas.org/cgi/content/full/98/3/793">[Full Text]</A>
<A HREF="http://www.pnas.org/cgi/reprint/98/3/793">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://physrev.physiology.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://physrev.physiology.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://physrev.physiology.org"><IMG ALT="Physiol. Rev" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/physrev.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	E. F&eacute;raille and A. Doucet<BR>
	<STRONG>Sodium-Potassium-Adenosinetriphosphatase-Dependent Sodium Transport in the Kidney: Hormonal Control</STRONG><BR>
	
		
			Physiol Rev,
		
	
        
        January&nbsp;1,&nbsp;2001;
	81(1):
	345 - 418.
<BR>
<A HREF="http://physrev.physiology.org/cgi/content/abstract/81/1/345">[Abstract]</A>

<A HREF="http://physrev.physiology.org/cgi/content/full/81/1/345">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.pnas.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.pnas.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.pnas.org"><IMG ALT="Proc. Natl. Acad. Sci. U. S. A." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/pnas.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	W.-J. Gao, L. S. Krimer, and P. S. Goldman-Rakic<BR>
	<STRONG>Presynaptic regulation of recurrent excitation by D1 receptors in prefrontal circuits</STRONG><BR>
	
		
			PNAS,
		
	
        
        January&nbsp;2,&nbsp;2001;
	98(1):
	295 - 300.
<BR>
<A HREF="http://www.pnas.org/cgi/content/abstract/98/1/295">[Abstract]</A>

<A HREF="http://www.pnas.org/cgi/content/full/98/1/295">[Full Text]</A>
<A HREF="http://www.pnas.org/cgi/reprint/98/1/295">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://molpharm.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Mol Pharmacol" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/molpharm.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	A. S. Gordon, L. Yao, Z. Jiang, C. S. Fishburn, S. Fuchs, and I. Diamond<BR>
	<STRONG>Ethanol Acts Synergistically with a D2 Dopamine Agonist to Cause Translocation of Protein Kinase C</STRONG><BR>
	
		
			Mol. Pharmacol.,
		
	
        
        January&nbsp;1,&nbsp;2001;
	59(1):
	153 - 160.
<BR>
<A HREF="http://www.molpharm.org/cgi/content/abstract/59/1/153">[Abstract]</A>

<A HREF="http://www.molpharm.org/cgi/content/full/59/1/153">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jn.physiology.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jn.physiology.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jn.physiology.org"><IMG ALT="J. Neurophysiol." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jn.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	D. A. Henze, G. R. Gonz&aacute;lez-Burgos, N. N. Urban, D. A. Lewis, and G. Barrionuevo<BR>
	<STRONG>Dopamine Increases Excitability of Pyramidal Neurons in Primate Prefrontal Cortex</STRONG><BR>
	
		
			J Neurophysiol,
		
	
        
        December&nbsp;1,&nbsp;2000;
	84(6):
	2799 - 2809.
<BR>
<A HREF="http://jn.physiology.org/cgi/content/abstract/84/6/2799">[Abstract]</A>

<A HREF="http://jn.physiology.org/cgi/content/full/84/6/2799">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://ajpcell.physiology.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://ajpcell.physiology.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://ajpcell.physiology.org"><IMG ALT="Am. J. Physiol." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/ajpcell.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	S. Nowicki, M. S. Kruse, H. Brismar, and A. Aperia<BR>
	<STRONG>Dopamine-induced translocation of protein kinase C isoforms visualized in renal epithelial cells</STRONG><BR>
	
		
			Am J Physiol Cell Physiol,
		
	
        
        December&nbsp;1,&nbsp;2000;
	279(6):
	C1812 - 1818.
<BR>
<A HREF="http://ajpcell.physiology.org/cgi/content/abstract/279/6/C1812">[Abstract]</A>

<A HREF="http://ajpcell.physiology.org/cgi/content/full/279/6/C1812">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://endo.endojournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://endo.endojournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://endo.endojournals.org"><IMG ALT="Endocrinology" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/endo.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	Y. Lee and J. L. Voogt<BR>
	<STRONG>Feedback Effects of Placental Lactogens on Prolactin Levels and Fos-Related Antigen Immunoreactivity of Tuberoinfundibular Dopaminergic Neurons in the Arcuate Nucleus during Pregnancy in the Rat</STRONG><BR>
	
		
			Endocrinology,
		
	
        
        May&nbsp;1,&nbsp;1999;
	140(5):
	2159 - 2166.
<BR>
<A HREF="http://endo.endojournals.org/cgi/content/abstract/140/5/2159">[Abstract]</A>

<A HREF="http://endo.endojournals.org/cgi/content/full/140/5/2159">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.brjpharmacol.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.brjpharmacol.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.brjpharmacol.org"><IMG ALT="Br. J. Pharmacol." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/brjpharmacol.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	G. L. Alberts, J. F. Pregenzer, and W. B. Im<BR>
	<STRONG>Advantages of heterologous expression of human D2long dopamine receptors in human neuroblastoma SH-SY5Y over human embryonic kidney 293 cells</STRONG><BR>
	
		
			Br. J. Pharmacol.,
		
	
        
        October&nbsp;3,&nbsp;2000;
	131(3):
	514 - 520.
<BR>
<A HREF="http://www.brjpharmacol.org/cgi/content/abstract/131/3/514">[Abstract]</A>

<A HREF="http://www.brjpharmacol.org/cgi/content/full/131/3/514">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://molpharm.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Mol Pharmacol" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/molpharm.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	K. D. Karpa, R. Lin, N. Kabbani, and R. Levenson<BR>
	<STRONG>The Dopamine D3 Receptor Interacts with Itself and the Truncated D3 Splice Variant D3nf: D3-D3nf Interaction Causes Mislocalization of D3 Receptors</STRONG><BR>
	
		
			Mol. Pharmacol.,
		
	
        
        October&nbsp;1,&nbsp;2000;
	58(4):
	677 - 683.
<BR>
<A HREF="http://www.molpharm.org/cgi/content/abstract/58/4/677">[Abstract]</A>

<A HREF="http://www.molpharm.org/cgi/content/full/58/4/677">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jpet.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jpet.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jpet.aspetjournals.org"><IMG ALT="J. Pharmacol. Exp. Ther." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jpet.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	J. F. M. Vanhauwe, K. Josson, W. H. M. L. Luyten, A. J. Driessen, and J. E. Leysen<BR>
	<STRONG>G-Protein Sensitivity of Ligand Binding to Human Dopamine D2 and D3 Receptors Expressed in Escherichia coli: Clues for a Constrained D3 Receptor Structure</STRONG><BR>
	
		
			J. Pharmacol. Exp. Ther.,
		
	
        
        October&nbsp;1,&nbsp;2000;
	295(1):
	274 - 283.
<BR>
<A HREF="http://www.jpet.org/cgi/content/abstract/295/1/274">[Abstract]</A>

<A HREF="http://www.jpet.org/cgi/content/full/295/1/274">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://hyper.ahajournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://hyper.ahajournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://hyper.ahajournals.org"><IMG ALT="Hypertension" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/hypertensionaha.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	M. Sato, M. Soma, T. Nakayama, and K. Kanmatsuse<BR>
	<STRONG>Dopamine D1 Receptor Gene Polymorphism Is Associated With Essential Hypertension</STRONG><BR>
	
		
			Hypertension,
		
	
        
        August&nbsp;1,&nbsp;2000;
	36(2):
	183 - 186.
<BR>
<A HREF="http://hyper.ahajournals.org/cgi/content/abstract/36/2/183">[Abstract]</A>

<A HREF="http://hyper.ahajournals.org/cgi/content/full/36/2/183">[Full Text]</A>
<A HREF="http://hyper.ahajournals.org/cgi/reprint/36/2/183">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jneurosci.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jneurosci.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jneurosci.org"><IMG ALT="J. Neurosci." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jneuro.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	
	<STRONG></STRONG><BR>
	
		
			J. Neurosci.,
		
	
        
        August&nbsp;15,&nbsp;2000;
	20(16):
	91R - 91.
<BR>
<A HREF="http://www.jneurosci.org/cgi/content/abstract/20/16/RC91">[Abstract]</A>

<A HREF="http://www.jneurosci.org/cgi/content/full/20/16/RC91">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jneurosci.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jneurosci.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jneurosci.org"><IMG ALT="J. Neurosci." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jneuro.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	M. J. Thomas, R. C. Malenka, and A. Bonci<BR>
	<STRONG>Modulation of Long-Term Depression by Dopamine in the Mesolimbic System</STRONG><BR>
	
		
			J. Neurosci.,
		
	
        
        August&nbsp;1,&nbsp;2000;
	20(15):
	5581 - 5586.
<BR>
<A HREF="http://www.jneurosci.org/cgi/content/abstract/20/15/5581">[Abstract]</A>

<A HREF="http://www.jneurosci.org/cgi/content/full/20/15/5581">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	L. L. Demchyshyn, F. McConkey, and H. B. Niznik<BR>
	<STRONG>Dopamine D5 Receptor Agonist High Affinity and Constitutive Activity Profile Conferred by Carboxyl-terminal Tail Sequence</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        July&nbsp;28,&nbsp;2000;
	275(31):
	23446 - 23455.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/275/31/23446">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/275/31/23446">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/275/31/23446">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://ajpgi.physiology.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://ajpgi.physiology.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://ajpgi.physiology.org"><IMG ALT="Am. J. Physiol." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/ajpgi.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	J. K. L. Walker, R. R. Gainetdinov, A. W. Mangel, M. G. Caron, and M. A. Shetzline<BR>
	<STRONG>Mice lacking the dopamine transporter display altered regulation of distal colonic motility</STRONG><BR>
	
		
			Am J Physiol Gastrointest Liver Physiol,
		
	
        
        August&nbsp;1,&nbsp;2000;
	279(2):
	G311 - 318.
<BR>
<A HREF="http://ajpgi.physiology.org/cgi/content/abstract/279/2/G311">[Abstract]</A>

<A HREF="http://ajpgi.physiology.org/cgi/content/full/279/2/G311">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://molpharm.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Mol Pharmacol" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/molpharm.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	S. E. Senogles<BR>
	<STRONG>The D2s Dopamine Receptor Stimulates Phospholipase D Activity: A Novel Signaling Pathway for Dopamine</STRONG><BR>
	
		
			Mol. Pharmacol.,
		
	
        
        August&nbsp;1,&nbsp;2000;
	58(2):
	455 - 462.
<BR>
<A HREF="http://www.molpharm.org/cgi/content/abstract/58/2/455">[Abstract]</A>

<A HREF="http://www.molpharm.org/cgi/content/full/58/2/455">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jpet.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jpet.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jpet.aspetjournals.org"><IMG ALT="J. Pharmacol. Exp. Ther." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jpet.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	M. J. Millan, A. Gobert, A. Newman-Tancredi, F. Lejeune, D. Cussac, J.-M. Rivet, V. Audinot, T. Dubuffet, and G. Lavielle<BR>
	<STRONG>S33084, a Novel, Potent, Selective, and Competitive Antagonist at Dopamine D3-Receptors: I. Receptorial, Electrophysiological and Neurochemical Profile Compared with GR218,231 and L741,626</STRONG><BR>
	
		
			J. Pharmacol. Exp. Ther.,
		
	
        
        June&nbsp;1,&nbsp;2000;
	293(3):
	1048 - 1062.
<BR>
<A HREF="http://www.jpet.org/cgi/content/abstract/293/3/1048">[Abstract]</A>

<A HREF="http://www.jpet.org/cgi/content/full/293/3/1048">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jpet.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jpet.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jpet.aspetjournals.org"><IMG ALT="J. Pharmacol. Exp. Ther." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jpet.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	M. J. Millan, A. Dekeyne, J.-M. Rivet, T. Dubuffet, G. Lavielle, and M. Brocco<BR>
	<STRONG>S33084, a Novel, Potent, Selective, and Competitive Antagonist at Dopamine D3-Receptors: II. Functional and Behavioral Profile Compared with GR218,231 and L741,626</STRONG><BR>
	
		
			J. Pharmacol. Exp. Ther.,
		
	
        
        June&nbsp;1,&nbsp;2000;
	293(3):
	1063 - 1073.
<BR>
<A HREF="http://www.jpet.org/cgi/content/abstract/293/3/1063">[Abstract]</A>

<A HREF="http://www.jpet.org/cgi/content/full/293/3/1063">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.sciencemag.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.sciencemag.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.sciencemag.org"><IMG ALT="Science" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/sci.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	M. Rocheville, D. C. Lange, U. Kumar, S. C. Patel, R. C. Patel, and Y. C. Patel<BR>
	<STRONG>Receptors for Dopamine and Somatostatin: Formation of Hetero-Oligomers with Enhanced Functional Activity</STRONG><BR>
	
		
			Science,
		
	
        
        April&nbsp;7,&nbsp;2000;
	288(5463):
	154 - 157.
<BR>
<A HREF="http://www.sciencemag.org/cgi/content/abstract/288/5463/154">[Abstract]</A>

<A HREF="http://www.sciencemag.org/cgi/content/full/288/5463/154">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://physrev.physiology.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://physrev.physiology.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://physrev.physiology.org"><IMG ALT="Physiol. Rev" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/physrev.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	J. C. Rekling, G. D. Funk, D. A. Bayliss, X.-W. Dong, and J. L. Feldman<BR>
	<STRONG>Synaptic Control of Motoneuronal Excitability</STRONG><BR>
	
		
			Physiol Rev,
		
	
        
        April&nbsp;1,&nbsp;2000;
	80(2):
	767 - 852.
<BR>
<A HREF="http://physrev.physiology.org/cgi/content/abstract/80/2/767">[Abstract]</A>

<A HREF="http://physrev.physiology.org/cgi/content/full/80/2/767">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://embojournal.npgjournals.com"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://embojournal.npgjournals.com/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://embojournal.npgjournals.com"><IMG ALT="EMBO J." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/emboj.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	Y.-F. Lin, Y. N. Jan, and L. Y. Jan<BR>
	<STRONG>Regulation of ATP-sensitive potassium channel function by protein kinase A-mediated phosphorylation in transfected HEK293 cells</STRONG><BR>
	
		
			EMBO J.,
		
	
        
        March&nbsp;1,&nbsp;2000;
	19(5):
	942 - 955.
<BR>
<A HREF="http://embojournal.npgjournals.com/cgi/content/abstract/19/5/942">[Abstract]</A>

<A HREF="http://embojournal.npgjournals.com/cgi/content/full/19/5/942">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://molpharm.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Mol Pharmacol" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/molpharm.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	M. Li, J. C. Bermak, Z. W. Wang, and Q. Y. Zhou<BR>
	<STRONG>Modulation of Dopamine D2 Receptor Signaling by Actin-Binding Protein (ABP-280)</STRONG><BR>
	
		
			Mol. Pharmacol.,
		
	
        
        March&nbsp;1,&nbsp;2000;
	57(3):
	446 - 452.
<BR>
<A HREF="http://www.molpharm.org/cgi/content/abstract/57/3/446">[Abstract]</A>

<A HREF="http://www.molpharm.org/cgi/content/full/57/3/446">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jp.physoc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jp.physoc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jp.physoc.org"><IMG ALT="J Physiol" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jphysiol.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	E. Koga and T. Momiyama<BR>
	<STRONG>Presynaptic dopamine D2-like receptors inhibit excitatory transmission onto rat ventral tegmental dopaminergic neurones</STRONG><BR>
	
		
			J. Physiol.,
		
	
        
        February&nbsp;15,&nbsp;2000;
	523(1):
	163 - 173.
<BR>
<A HREF="http://jp.physoc.org/cgi/content/abstract/523/1/163">[Abstract]</A>

<A HREF="http://jp.physoc.org/cgi/content/full/523/1/163">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://mcb.asm.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://mcb.asm.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://mcb.asm.org"><IMG ALT="Mol. Cell. Biol." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/mcb.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	M. H. Ghahremani, C. Forget, and P. R. Albert<BR>
	<STRONG>Distinct Roles for Galpha i2 and Gbeta gamma  in Signaling to DNA Synthesis and Galpha i3 in Cellular Transformation by Dopamine D2S Receptor Activation in BALB/c 3T3 Cells</STRONG><BR>
	
		
			Mol. Cell. Biol.,
		
	
        
        March&nbsp;1,&nbsp;2000;
	20(5):
	1497 - 1506.
<BR>
<A HREF="http://mcb.asm.org/cgi/content/abstract/20/5/1497">[Abstract]</A>

<A HREF="http://mcb.asm.org/cgi/content/full/20/5/1497">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jpet.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jpet.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jpet.aspetjournals.org"><IMG ALT="J. Pharmacol. Exp. Ther." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jpet.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	M. J. Millan, A. Gobert, A. Newman-Tancredi, F. Lejeune, D. Cussac, J.-M. Rivet, V. Audinot, A. Adhumeau, M. Brocco, J.-P. Nicolas, J. A. Boutin, N. Despaux, and J.-L. Peglion<BR>
	<STRONG>S18327 (1-{2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a Novel, Potential Antipsychotic Displaying Marked Antagonist Properties at alpha 1- and alpha 2-Adrenergic Receptors: I. Receptorial, Neurochemical, and Electrophysiological Profile</STRONG><BR>
	
		
			J. Pharmacol. Exp. Ther.,
		
	
        
        January&nbsp;1,&nbsp;2000;
	292(1):
	38 - 53.
<BR>
<A HREF="http://www.jpet.org/cgi/content/abstract/292/1/38">[Abstract]</A>

<A HREF="http://www.jpet.org/cgi/content/full/292/1/38">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	R. M. Iwasiow, M.-F. Nantel, and M. Tiberi<BR>
	<STRONG>Delineation of the Structural Basis for the Activation Properties of the Dopamine D1 Receptor Subtypes</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        November&nbsp;5,&nbsp;1999;
	274(45):
	31882 - 31890.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/274/45/31882">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/274/45/31882">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/274/45/31882">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://molpharm.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Mol Pharmacol" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/molpharm.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	D. Cussac, A. Newman-Tancredi, V. Pasteau, and M. J. Millan<BR>
	<STRONG>Human Dopamine D3 Receptors Mediate Mitogen-Activated Protein Kinase Activation Via a Phosphatidylinositol 3-Kinase and an Atypical Protein Kinase C-Dependent Mechanism</STRONG><BR>
	
		
			Mol. Pharmacol.,
		
	
        
        November&nbsp;1,&nbsp;1999;
	56(5):
	1025 - 1030.
<BR>
<A HREF="http://www.molpharm.org/cgi/content/abstract/56/5/1025">[Abstract]</A>

<A HREF="http://www.molpharm.org/cgi/content/full/56/5/1025">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jpet.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jpet.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jpet.aspetjournals.org"><IMG ALT="J. Pharmacol. Exp. Ther." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jpet.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	E. H. Chartoff, R. P. Ward, and D. M. Dorsa<BR>
	<STRONG>Role of Adenosine and N-Methyl-D-aspartate Receptors in Mediating Haloperidol-Induced Gene Expression and Catalepsy</STRONG><BR>
	
		
			J. Pharmacol. Exp. Ther.,
		
	
        
        November&nbsp;1,&nbsp;1999;
	291(2):
	531 - 537.
<BR>
<A HREF="http://www.jpet.org/cgi/content/abstract/291/2/531">[Abstract]</A>

<A HREF="http://www.jpet.org/cgi/content/full/291/2/531">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	M.-Y. Jung and C. Schmauss<BR>
	<STRONG>Decreased c-fos Responses to Dopamine D1 Receptor Agonist Stimulation in Mice Deficient for D3 Receptors</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        October&nbsp;8,&nbsp;1999;
	274(41):
	29406 - 29412.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/274/41/29406">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/274/41/29406">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/274/41/29406">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://physrev.physiology.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://physrev.physiology.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://physrev.physiology.org"><IMG ALT="Physiol. Rev" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/physrev.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	A. J. Morris and C. C. Malbon<BR>
	<STRONG>Physiological Regulation of G Protein-Linked Signaling</STRONG><BR>
	
		
			Physiol Rev,
		
	
        
        October&nbsp;1,&nbsp;1999;
	79(4):
	1373 - 1430.
<BR>
<A HREF="http://physrev.physiology.org/cgi/content/abstract/79/4/1373">[Abstract]</A>

<A HREF="http://physrev.physiology.org/cgi/content/full/79/4/1373">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jn.physiology.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jn.physiology.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jn.physiology.org"><IMG ALT="J. Neurophysiol." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jn.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	A. Y. Hsia, J.-D. Vincent, and P.-M. Lledo<BR>
	<STRONG>Dopamine Depresses Synaptic Inputs Into the Olfactory Bulb</STRONG><BR>
	
		
			J Neurophysiol,
		
	
        
        August&nbsp;1,&nbsp;1999;
	82(2):
	1082 - 1085.
<BR>
<A HREF="http://jn.physiology.org/cgi/content/abstract/82/2/1082">[Abstract]</A>

<A HREF="http://jn.physiology.org/cgi/content/full/82/2/1082">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jpet.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jpet.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jpet.aspetjournals.org"><IMG ALT="J. Pharmacol. Exp. Ther." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jpet.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	J. F. M. Vanhauwe, N. Fraeyman, B. J. B. Francken, W. H. M. L. Luyten, and J. E. Leysen<BR>
	<STRONG>Comparison of the Ligand Binding and Signaling Properties of Human Dopamine D2 and D3 Receptors in Chinese Hamster Ovary Cells</STRONG><BR>
	
		
			J. Pharmacol. Exp. Ther.,
		
	
        
        August&nbsp;1,&nbsp;1999;
	290(2):
	908 - 916.
<BR>
<A HREF="http://www.jpet.org/cgi/content/abstract/290/2/908">[Abstract]</A>

<A HREF="http://www.jpet.org/cgi/content/full/290/2/908">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	F. D. Smith, G. S. Oxford, and S. L. Milgram<BR>
	<STRONG>Association of the D2 Dopamine Receptor Third Cytoplasmic Loop with Spinophilin, a Protein Phosphatase-1-interacting Protein</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        July&nbsp;9,&nbsp;1999;
	274(28):
	19894 - 19900.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/274/28/19894">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/274/28/19894">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/274/28/19894">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.pnas.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.pnas.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.pnas.org"><IMG ALT="Proc. Natl. Acad. Sci. U. S. A." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/pnas.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	C. Klein, M. F. Brin, P. Kramer, M. Sena-Esteves, D. de Leon, D. Doheny, S. Bressman, S. Fahn, X. O. Breakefield, and L. J. Ozelius<BR>
	<STRONG>Association of a missense change in the D2 dopamine receptor with myoclonus dystonia</STRONG><BR>
	
		
			PNAS,
		
	
        
        April&nbsp;27,&nbsp;1999;
	96(9):
	5173 - 5176.
<BR>
<A HREF="http://www.pnas.org/cgi/content/abstract/96/9/5173">[Abstract]</A>

<A HREF="http://www.pnas.org/cgi/content/full/96/9/5173">[Full Text]</A>
<A HREF="http://www.pnas.org/cgi/reprint/96/9/5173">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://jn.physiology.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://jn.physiology.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://jn.physiology.org"><IMG ALT="J. Neurophysiol." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jn.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	F.-M. Zhou and J. J. Hablitz<BR>
	<STRONG>Dopamine Modulation of Membrane and Synaptic Properties of Interneurons in Rat Cerebral Cortex</STRONG><BR>
	
		
			J Neurophysiol,
		
	
        
        March&nbsp;1,&nbsp;1999;
	81(3):
	967 - 976.
<BR>
<A HREF="http://jn.physiology.org/cgi/content/abstract/81/3/967">[Abstract]</A>

<A HREF="http://jn.physiology.org/cgi/content/full/81/3/967">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://molpharm.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Mol Pharmacol" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/molpharm.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	A. Newman-Tancredi, D. Cussac, V. Audinot, V. Pasteau, S. Gavaudan, and M. J. Millan<BR>
	<STRONG>G Protein Activation by Human Dopamine D3 Receptors in High-Expressing Chinese Hamster Ovary Cells: A Guanosine-5'-O-(3-[35S]thio)-Triphosphate Binding and Antibody Study</STRONG><BR>
	
		
			Mol. Pharmacol.,
		
	
        
        March&nbsp;1,&nbsp;1999;
	55(3):
	564 - 574.
<BR>
<A HREF="http://www.molpharm.org/cgi/content/abstract/55/3/564">[Abstract]</A>

<A HREF="http://www.molpharm.org/cgi/content/full/55/3/564">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jneurosci.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jneurosci.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jneurosci.org"><IMG ALT="J. Neurosci." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jneuro.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	E. V. Kuzhikandathil and G. S. Oxford<BR>
	<STRONG>Activation of Human D3 Dopamine Receptor Inhibits P/Q-Type Calcium Channels and Secretory Activity in AtT-20 Cells</STRONG><BR>
	
		
			J. Neurosci.,
		
	
        
        March&nbsp;1,&nbsp;1999;
	19(5):
	1698 - 1707.
<BR>
<A HREF="http://www.jneurosci.org/cgi/content/abstract/19/5/1698">[Abstract]</A>

<A HREF="http://www.jneurosci.org/cgi/content/full/19/5/1698">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://hyper.ahajournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://hyper.ahajournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://hyper.ahajournals.org"><IMG ALT="Hypertension" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/hypertensionaha.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	Z.-Q. Wang, R. A. Felder, and R. M. Carey<BR>
	<STRONG>Selective Inhibition of the Renal Dopamine Subtype D1A Receptor Induces Antinatriuresis in Conscious Rats</STRONG><BR>
	
		
			Hypertension,
		
	
        
        January&nbsp;1,&nbsp;1999;
	33(1):
	504 - 510.
<BR>
<A HREF="http://hyper.ahajournals.org/cgi/content/abstract/33/1/504">[Abstract]</A>

<A HREF="http://hyper.ahajournals.org/cgi/content/full/33/1/504">[Full Text]</A>
<A HREF="http://hyper.ahajournals.org/cgi/reprint/33/1/504">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jcb.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jcb.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jcb.org"><IMG ALT="J. Cell Biol." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jcb.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	R. G. Vickery and M. von Zastrow<BR>
	<STRONG>Distinct Dynamin-dependent and -independent Mechanisms Target Structurally Homologous Dopamine Receptors to Different Endocytic Membranes</STRONG><BR>
	
		
			J. Cell Biol.,
		
	
        
        January&nbsp;11,&nbsp;1999;
	144(1):
	31 - 43.
<BR>
<A HREF="http://www.jcb.org/cgi/content/abstract/144/1/31">[Abstract]</A>

<A HREF="http://www.jcb.org/cgi/content/full/144/1/31">[Full Text]</A>

<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	











<BR CLEAR=ALL>


	
	 
		
		  
			
	
		<table class="content_box_outer_table"
		 
			
				
					
						align="right"
					
				
			
		>
			<tr>
			<td>
	

<!-- beginning of inner table -->
	<table class="content_box_inner_table">
<!-- citation -->

	
		




	

	

	
		
			
<tr><td class="content_box_title_highlight" colspan="2">This Article</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr>
				
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				
				<strong><a href="/cgi/content/abstract/78/1/189">
				Abstract</a></strong>
				 					<img alt="" width="32" height="7" border="0" src="/icons/shared/toc/free.gif">
				
	
				</td></tr>
			
		
		
	

	
	
	

	
	
	


	
	
	

	
	
	

	
	
	

	
	
	

	
		
	

	

	
		
			
		
	

	

	
	 

	
	 

		
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
		<strong>
		
		
		
			
				
				
					<a href="/cgi/reprint/78/1/189">
		<strong>Full Text</strong> (PDF)</a>
				
			
		
		</strong>
		</td></tr>
	
	

	
	
	

	
	
	

	
	





	
		

	
		

	
		
		

			


	

			

			
		
	

			
	  
	

			

			

			
	
	

	
		
	









	
		
	





	

	 

	

	
	
		  
    

	







		
	
		
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/alerts/ctalert?alertType=citedby&addAlert=cited_by&saveAlert=no&cited_by_criteria_resid=physrev;78/1/189&return_type=article&return_url=http%3A%2F%2Fphysrev.physiology.org%2Fcgi%2Fcontent%2Ffull%2F78%2F1%2F189">
				Alert me when this article is cited</a></strong>
			</td></tr>
	

		
		

		
		

		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/alerts/ctalert?alertType=correction&addAlert=correction&saveAlert=no&correction_criteria_value=78/1/189&return_type=article&return_url=http%3A%2F%2Fphysrev.physiology.org%2Fcgi%2Fcontent%2Ffull%2F78%2F1%2F189">
				Alert me if a correction is posted</a></strong>
			</td></tr>
		










			
		
			
			
			
				
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
					<strong><a href="/cgi/citemap?id=physrev;78/1/189">
					Citation Map</a></strong>
				</td></tr>
		
	

			
			
<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr><tr><td class="content_box_title" colspan="2">Services</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr>
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/mailafriend?url=http%3A%2F%2Fphysrev.physiology.org%2Fcgi%2Fcontent%2Ffull%2F78%2F1%2F189&title=Dopamine+Receptors%3A+From+Structure+to+Function">
				Email this article to a friend</a></strong>
			</td></tr>
			
			


	

	

		
		



			
			
			
		
	

		
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
		<strong>
		<a href="/cgi/search?qbe=physrev;78/1/189&journalcode=physrev&minscore=5000">
		Similar articles in this journal</a>
		</strong>
		</td></tr>

		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/external_ref?access_num=9457173&link_type=MED_NBRS">
				Similar articles in PubMed</a></strong>
			</td></tr>
		
	


		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/alerts/etoc">
				Alert me to new issues of the journal</a></strong>
			</td></tr>
		

		
		
	

		
		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
			<strong><a href="/cgi/citmgr?gca=physrev;78/1/189">
			Download to citation manager</a></strong>
			</td></tr>
		
		
	


	
		
	

	


	

	

		


	
	
	
		

	

	






	
		
<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr><tr><td class="content_box_title" colspan="2">PubMed</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr>
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/external_ref?access_num=9457173&link_type=PUBMED">
				PubMed Citation</a></strong>
			</td></tr>
		
	

	
		
		
			
				

						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="/cgi/external_ref?access_num=MISSALE+C&link_type=AUTHORSEARCH">
							Articles by MISSALE, C.</a></strong>
						</td></tr>
				
			
				

						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="/cgi/external_ref?access_num=CARON+MG&link_type=AUTHORSEARCH">
							Articles by CARON, M. G.</a></strong>
						</td></tr>
				
			
		

		
	






	






	
		

	

		
			
		











	




	</td></tr></table>
</td></tr></table> 

					
					
	

<BR CLEAR=ALL>









        
                
	<P>
	<HR NOSHADE ALIGN=LEFT WIDTH=450>
	
	<TABLE CELLPADDING=2 CELLSPACING=2 WIDTH=450>
	<TR>
		<TD ALIGN=CENTER VALIGN=TOP BGCOLOR=003399 NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/"><FONT SIZE=-2 COLOR=FFFFFF FACE="arial,helvetica">HOME</FONT></A></TD>
	    <TD ALIGN=CENTER VALIGN=TOP BGCOLOR=003399 NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/help/"><FONT SIZE=-2 COLOR=FFFFFF FACE="arial,helvetica">HELP</FONT></A></FONT></TD>
	    <TD ALIGN=CENTER VALIGN=TOP BGCOLOR=003399 NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/cgi/feedback"><FONT SIZE=-2 COLOR=FFFFFF FACE="arial,helvetica">FEEDBACK</FONT></A></TD>
	    <TD ALIGN=CENTER VALIGN=TOP BGCOLOR=003399 NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/subscriptions"><FONT SIZE=-2 COLOR=FFFFFF FACE="arial,helvetica">SUBSCRIPTIONS</FONT></A></TD>
	    <TD ALIGN=CENTER VALIGN=TOP BGCOLOR=003399 NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/contents-by-date.0.shtml"><FONT SIZE=-2 COLOR=FFFFFF FACE="arial,helvetica">ARCHIVE</FONT></A></TD>
	    <TD ALIGN=CENTER VALIGN=TOP BGCOLOR=003399 NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/search.dtl"><FONT SIZE=-2 COLOR=FFFFFF FACE="arial,helvetica">SEARCH</FONT></A></TD>
	    


<TD ALIGN=CENTER VALIGN=TOP BGCOLOR=003399 NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/content/vol78/issue1/"><FONT SIZE=-2 COLOR=FFFFFF FACE="arial,helvetica">TABLE OF CONTENTS</FONT></A></TD>




	</TR>
	</TABLE>
	
	
        <TABLE CELLPADDING=2 CELLSPACING=2 WIDTH=


500


>
        <TR>
                <TD ALIGN=CENTER VALIGN=TOP BGCOLOR=003399 NOWRAP><A STYLE="text-decoration: none" HREF="http://www.physiology.org"><FONT SIZE=-2 COLOR=FFFFFF FACE="arial,helvetica">Visit Other APS Journals Online</A></TD>
        </TR>
        </TABLE>

	
        



</BODY>
</HTML>

<script language="JavaScript">
<!--
var SymRealOnLoad;
var SymRealOnUnload;

function SymOnUnload()
{
  window.open = SymWinOpen;
  if(SymRealOnUnload != null)
     SymRealOnUnload();
}

function SymOnLoad()
{
  if(SymRealOnLoad != null)
     SymRealOnLoad();
  window.open = SymRealWinOpen;
  SymRealOnUnload = window.onunload;
  window.onunload = SymOnUnload;
}

SymRealOnLoad = window.onload;
window.onload = SymOnLoad;

//-->
</script>

